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ABSTRACT  
Otitis Media (OM) is the most common paediatric disease and a leading cause of 
conductive hearing impairment. This multifactorial disease shows significant involvement 
of innate immunity genes and epithelial abnormalities are also commonly implicated. 
BPIFA1, a member of BPI fold containing family of putative innate defence proteins, is one 
of the most abundant secretory proteins in the upper airways and SNPs in BPIFA1 have 
been associated with OM susceptibility. Recent studies suggest that BPIFA1 plays a 
pleiotropic host defense role. This thesis describes experiments aimed at investigating the 
role of BPIFA1 in protection of the middle ear and in the development of OM.  
Bpifa1-/- mice do not spontaneously develop OM and do not demonstrate increased 
nasopharyngeal carriage of the human otopathogen, NTHi. However, deletion of Bpifa1 in 
Junbo (Evi1Jbo/+) mice, an established model of chronic OM, leads to significant exacerbation 
of OM severity and ME mucosal thickness. This thesis also describes the development of a 
novel in vitro model of the murine middle ear epithelium. Using a combination of 
transcriptional and proteomic approaches, I demonstrate that the model closely mimics the 
native middle ear epithelium and differentiates into ciliated cells, goblet cells and secretory 
cells and also supports infection by NTHi. Attempts were made to recapitulate the OM 
phenotype in vitro using this culture system. 
Overall, the data from this thesis indicate that BPIFA1 is involved in maintaining 
homeostasis within the middle ear under steady state conditions through nonspecific 
defence of the middle ear mucosa. Loss of BPIFA1 in presence of infection or inflammation 
increases the sensitivity of the epithelium and leads to an exacerbated host defence 
response and excessive epithelial remodelling. Furthermore, the novel in vitro culture 
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system can be applied as an effective tool to study the interaction between the middle ear 
epithelium and various otopathogens. 
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CHAPTER 1:  GENERAL INTRODUCTION  
  
2  
 
1.1 Structure and function of the ear 
The mammalian ear is the sensory organ of hearing and balance. Different parts of the ear 
co-ordinate to convert sound waves from the external environment into the electrical 
impulses transmitted to the brain. The ear can be divided into three parts: the external or 
outer ear, the middle ear and the inner ear (Fig 1.1). The outer ear is composed of the 
pinna, which gathers environmental sounds and the ear canal, which funnels them towards 
the eardrum or the tympanic membrane (Tm) of the middle ear. The sound waves hit the 
Tm and cause it to vibrate (Carola et al 1992). 
The middle ear is an air-filled chamber, with an average volume of 2cm3 in humans. It 
contains a chain of 3 ossicles or auditory bones called malleus, incus and stapes, extending 
from the Tm to the oval window of the inner ear. The mechanical energy of the vibrations 
from the comparatively large area of the Tm is transmitted to the first ossicle, the malleus, 
followed by the incus and finally concentrated at the small footplate of the last ossicle, the 
stapes, which presses against the oval window of the inner ear. This results in an increase 
in the energy of the waves transmitted from the outer ear to the inner ear. The middle ear 
cavity is also connected to the Nasopharynx (NP) through a narrow tube called the 
Eustachian tube (ET) that opens intermittently to maintain atmospheric pressure within the 
middle ear cavity. Maintenance of optimal pressure within the middle ear ensures maximal 
vibration of the Tm (Emanuel et al 2009, Straetemans et al 2001).  
The inner ear is the final part of the ear and is made up of a fluid-filled bony structure 
called the labyrinth. Pressure transferred from the stapes onto the round window displaces 
the fluid inside the cochlea, the auditory component of the labyrinth. This causes deflection 
of the stereocilia of the sensory cells or hair cells that line the cochlear membrane and 
generation of electrical impulses, which are transmitted to and recognised by the brain. 
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The inner ear also contains the vestibular system, which is maintains equilibrium and 
spatial orientation (Carola et al 1992, Emanuel et al 2009). 
 
Figure 1.1 Structure of the ear  
The ear is divided into three main parts: the outer ear, middle ear and the inner ear. The middle ear 
cavity comprises of the three ossicles, the (i) malleus, (ii) incus and (iii) stapes. The Tm separates the 
outer ear from the middle ear cavity. The ET connects the middle ear to the nasopharynx. Image 
reused with permission from (Schilder et al 2016), copyright 2016 Nature publishing group. 
 
 
1.2 The burden of hearing loss 
Around 360 million people globally suffer from partial or complete deafness, making 
hearing loss the most common sensory disorder (WHO 2015). Within the UK, more than 11 
million people are affected by disabling hearing loss and this number has been estimated 
to reach 14.5 million by 2035 (Action On Hearing Loss 2015). Hearing loss can result due to 
various factors such as ototoxic drugs, genetic defects, persistent ear infections or 
exposure to loud noises. Hearing loss resulting from defects in or damage to the inner ear 
hair cells is termed as sensorineural hearing loss. Age related hearing loss is known as 
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presbycusis, whereas loss of hearing due to reduced transmission of sound through the 
outer and middle ear is called conductive hearing loss.  
One of the major common causes of conductive hearing loss is Otitis Media (OM) or 
inflammation of the middle ear. It is the most prevalent childhood disease and the most 
common cause of paediatric deafness, surgery and antibiotic prescription in developed 
countries (Monasta et al 2012). 80% children suffer from at least one episode of OM by 
three years of age (Bakaletz 2010, Woodfield & Dugdale 2008). Severe and recurrent forms 
of the disease can cause perforation of the Tm and more than 50% of the affected children 
are at a risk of suffering from conductive hearing loss (Monasta et al 2012). OM is an 
enormous socio-economic burden. In the United States of America, annual diagnosis and 
management costs account for 2.3 billion dollars (Streubel & Ross 2013). Moreover, 
paediatric deafness hampers behaviour, language development and communication 
abilities and thus affects educational and social development (Rye et al 2011a). OM can 
also lead to life threatening complications such as brain abscesses, mastoiditis and bacterial 
meningitis (Geyik et al 2002, Schilder et al 2016) with an estimated paediatric mortality 
rate of 21,000 reported deaths per year (Monasta et al 2012). 
 
1.3 Otitis media – a spectrum of middle ear diseases  
OM is the most prevalent cause of paediatric surgery (insertion of tympanosomy tubes or 
grommets in the Tm) and conductive hearing loss in children. OM is often a combination of 
overlapping conditions, which are classified in the following categories, based on their 
symptoms and chronicity: 
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1.3.1 Acute suppurative Otitis media (ASOM) or acute Otitis media (AOM) 
This is the most prevalent type of OM with over 709 million cases of AOM reported per 
year (Monasta et al 2012). It is characterised by rapid onset of symptoms such as otalgia 
(ear pain), otorrhea (discharge of pus or fluid from the ear), irritability and fever (Bakaletz 
2010). It is sometimes associated with bulging of the tympanum and cholesteatoma. OM is 
classified as rAOM when the child suffers from AOM more than three times in 6 months or 
more than 4 times a year (Rye et al 2011a). 
 
1.3.2 Otitis Media with Effusion (OME) 
OME is usually sequelae of AOM and presents with ottorhea, without the signs of 
inflammation and through an intact Tm. It is often attributed to ET dysfunction and is also 
commonly known as ‘glue ear’ (Bakaletz 2010). When chronic, OME is termed as Chronic 
Otitis media with effusion (COME) (Rye et al 2011a). 
 
1.3.3 Chronic suppurative Otitis media (CSOM) 
If untreated, rAOM and COME can lead to development of CSOM, which is characterized by 
persistent inflammation, perforation of the Tm and continuous ear discharge for over 2 
weeks (Bluestone 1998). CSOM can reduce hearing capacity by up to 30 decibels (db) and 
thus cause conductive hearing loss (Straetemans et al 2001).  
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Figure 1.2 Interplay between types of OM 
AOM, the commonest form of OM can lead to the development of rAOM as well as CSOM. 
Recurrent episodes of OM can cause OME, which in turn gives rise to its chronic form, COME. The 
persistence of rAOM and COME for long periods leads to perforation of the tympanum and 
development of CSOM. CSOM leads to conductive hearing loss.  
 
1.4 The aetiology of OM 
The upper airways consist of the trachea, NP, ET, middle ear and mastoid cells surrounding 
the middle ear. The middle ear epithelium is continuous throughout the upper airways 
(Fireman 1997). Therefore, the physiology and immune defences of the upper respiratory 
tract (URT) are very similar to that of middle ear and ET.  
The middle ear is relatively sterile and this sterility is conferred as a combined result of the 
structure and physiology of the ET, and the immunological defence mechanisms of the 
mucociliary lining (Straetemans et al 2001). 
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1.4.1 Structure and function of the Eustachian tube 
The middle ear is an isolated organ, separated from the outer ear by the Tm on one end 
and connected to the NP via the ET at the other end. The mucociliary epithelium of the 
middle ear and the ET comprises of, secretory, goblet and ciliated cells, plasma cells, blood 
vessels, and mast cells. (Ishii et al 1980). Both the middle ear and ET are involved in the 
development of OM. The ET plays an analogous role in relation to the NP and the middle 
ear as the bronchial tree performs in relation to the lung and the upper airways (Fireman 
1997).  
The ET performs three main functions: protection, ventilation and clearance. 
Protection: The nasopharyngeal end of the ET is closed at rest, thus preventing the 
pathogens present the nasal secretions from entering into the middle ear cavity. It opens 
actively during actions like swallowing, sneezing, and yawning. Goblet cells of the 
mucociliary epithelium secrete a viscous substance called mucus which obscures epithelial 
attachment sites for bacteria, preventing bacterial colonization and thus protecting the 
middle ear from infections (Kubba et al 2000). The ET in children is narrower, shorter and 
more horizontal being  inclined at an angle of 10◦ in children as compared to 45◦ in adults 
(Corbeel 2007). It is also more compliant (Bakaletz 2010) and sometimes patent i.e. more 
open (Straetemans et al 2001). Therefore, children are more prone to ET dysfunction. 
Ventilation: Ventilation is provided due to intermittent opening of the ET. Surfactant 
components present in the ET lower the surface tension and aid in its opening (McGuire 
2002). This facilitates equilibration of pressure between the middle ear and NP. Defects in 
the opening mechanism of the ET or its physical obstruction, can cause negative pressure 
to develop in the middle ear in comparison to the nasopharynx and leads to aspiration of 
nasal fluid (Robinson et al 1992, Straetemans et al 2001). Also, gaseous exchange between 
the middle ear and surrounding mastoid cells creates hypoxic conditions in the middle ear. 
Opening of the ET restores oxygen levels in the middle ear (Corbeel 2007).  
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Clearance: The goblet cells of the mucociliary epithelium continuously secrete mucus and 
the ciliated cells beat in a unidirectional manner, transporting this mucus from the middle 
ear into the NP, through the Eustachian tube. As a result, nasopharyngeal pathogens are 
physically prevented from ascending into the middle ear (Sade 1967).  
 
1.4.2 Pathogens involved in OM  
The three most commonly isolated pathogens from middle ear effusions of OM patients 
are Streptococcus pneumoniae (S.pneumoniae), non-typeable Haemophilus influenzae 
(NTHi), and Moraxella catarrhalis (M.catarrhalis) (Faden 2001). Of these, S.pneumoniae is 
more commonly associated with AOM, while NTHi is more commonly associated with the 
chronic forms. Apart from the 3 major bacterial species, other bacteria in middle ear 
effusions include Alloiococcus otitidis, Pseudomonas aeruginosa (P.aeruginosa), 
Streptococcus pyogenes, Staphylococcus aureus, Klebsiella pneumoniae (K. pneumoniae) 
and Escherichia coli (Ngo et al 2016). Most of these bacteria are a part of the normal flora 
of the NP and upper airways. AOM is often preceded by a viral URT infection, which 
compromises local immunity, increases the cell surface receptors for bacterial adhesion 
and increases the possibility of secondary infection by the normal flora of the NP (Bakaletz 
2010). For example, infection by Respiratory Syncytial Virus (RSV) is shown to promote 
ascending infection of the middle ear by M. catarrhalis in chinchilla models of OM 
(Brockson et al 2012). The most common viral species causing URT infections include RSV, 
influenza, rhinovirus, coronavirus and adenovirus. 5% of middle ear effusions from AOM 
patients contain virus alone (Schilder et al 2016). 
This thesis focuses on the role of NTHi in the pathogenesis of OM. NTHi is a Gram-negative 
non-encapsulated bacterium commensal to the NP. Globally, it is responsible for 25%-30% 
cases of AOM and is the most commonly isolated pathogen in COME (Giebink 1991).  
Colonisation of the URT with NTHi during the first year of life increases the chances of OM 
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development four fold (Faden 2001). A study monitoring colonisation of the NP by NTHi in 
children for the first two years of life showed that acquisition of this bacterial species was 
higher in the first year. Children carried one strain of NTHi at a time but were colonised by 
up to 7 different strains, distinguished by changes in the outer membrane protein of NTHi 
(Faden et al 1996). Currently a conjugate vaccine against 7 serotypes of S.pneumoniae 
(PCV7) is commonly administered to children (Shinefield et al 2002). The advent of this 
pneumococcal vaccine has caused a shift in the frequency of detection of NTHi in AOM 
patients, with the frequency surpassing that of S.pneumoniae in developed countries (Ngo 
et al 2016). Thus, NTHi is gaining more importance as the causative pathogen in OM. 
 
1.4.3 Immunological defence mechanisms of the middle ear 
Immunological defense is a key factor in maintaining sterility of the middle ear. Immunity is 
classified as innate immunity and adaptive immunity. Adaptive immunity requires prior 
sensitization of lymphocytes (B cells, T cells and natural killer cells) in order to elicit an 
antibody- and T-cell mediated response. Since the healthy middle ear does not harbor 
many lymphocytes, a well-developed innate immune system  is essential in preventing 
infection and promoting  resolution (Leichtle et al 2011).  
Innate immunity does not require prior contact with antigenic epitopes. It provides the first 
line of defense against invading pathogens and in the ear, is comprised of the middle ear 
epithelium which acts as a physical barrier, epithelial secretions and resident macrophages, 
mast cells and dendritic cells in the peripheral tissue. The goblet cells of the mucociliary 
epithelium secrete high molecular glycoproteins called mucins which increase the viscosity 
of epithelial secretions and are important in trapping pathogens. MUC5AC and MUC5B are 
the major secreted gel forming mucins in the human middle ear (Kerschner et al 2010b, Lin 
et al 2001) and OM is associated with upregulation of these two proteins (Kerschner et al 
2010b, Preciado et al 2010). The middle ear epithelium also produces antimicrobial 
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molecules such as Lysozyme, Lactotransferrin, components of complement system (Jeep 
1990, Lim et al 2000) and broad-spectrum bactericidal molecules called β-defensins (Mittal 
et al 2014). β-defensins are involved in bactericidal activities like perforation of bacterial 
membranes, inhibition of bacteriotoxins, and promotion of inflammation. (Bakaletz 2009, 
Underwood & Bakaletz 2011). Moreover, surfactant proteins  secreted by the mucosal 
lining of the ET and the middle ear and phosphatidylcholine promote dispersal of bacterial 
biofilms (McGuire 2002). It has recently been shown that the middle ear epithelium also 
secretes BPIFA1, a putative multifunctional host defense protein of the URT (Bartlett et al 
2011). 
The epithelial cells and sentinel cells such as dendritic cells and macrophages express 
receptors, known as pattern recognition receptors (PRRs), that recognize the invariant 
features of microbes known as pathogen associated molecular markers (PAMPs). PAMPs 
include characteristics such as flagella, Lipopolysaccharide (LPS) of Gram-negative bacteria 
and Lipotechoic acid of Gram-positive organisms, that are common to multiple organisms 
(Iwasaki & Medzhitov 2010). PRRs include Toll like receptors (TLRs), Retinoic acid inducible 
gene I like receptors (RLRs) and Nucleotide-binding oligomerization domain (NODs) (Mittal 
et al 2014). Of these, TLRs are the most widely studied. Thirteen TLRs are present in 
mammals, of which TLR2 and TLR4 have the best studied roles in OM pathogenesis. Upon 
ligand recognition, most TLRs activate the nuclear factor kappa-light-chain-enhancer of 
activated B cells (NFκβ). NFκβ signaling triggers the release of chemokines such as such as 
macrophage inflammatory protein 1α (MIP1α)/CCL3 and macrophage inflammatory 
protein 2 (MIP 2)/CXCL2 and pro-inflammatory cytokines, such as Interleukin (IL) 1β (IL1β), 
IL10, IL6, IL8, and Tumor necrosis factor α (TNFα)  (Juhn et al 2008, Leichtle et al 2011). A 
concentration gradient of TLR4 expression exists in the ET with a higher concentration 
towards the middle ear cavity and a lower concentration towards the nasopharynx (Akashi-
Takamura & Miyake 2008). Since, the nasopharynx is home to a wide range of normal flora, 
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low numbers of TLRs near the nasopharynx avert unnecessary elicitation of immune 
response whereas the higher concentration near the middle ear facilitates stringent control 
of immune response in the event of infection (Bakaletz 2010). 
Middle ear fluids also show presence of antibodies such as antigen specific IgG and IgA. T-
cells may also play a role in middle ear inflammation, however further research is 
warranted to fully explore the role of adaptive immunity in the aetiology of OM (Schilder et 
al 2016). 
  
1.5 A model for the pathophysiology of OM 
Failure of the structural defense mechanisms, such as ET dysfunction, coupled with 
impairment of the mucociliary apparatus, or failure of the innate immune system to 
prevent an infection or clear pathogens leads to the development of OM (Casselbrant & 
Mandel 2001). A pre-requisite in the disease pathogenesis is presence of bacteria in the 
nasopharynx. A preceding viral infection compromises the immunity of the URT, modifies 
the mucosa and enables greater adhesion of bacteria leading to colonization. It also 
induces a pro-inflammatory response, impairing  mucociliary clearance which leads to ET 
dysfunction and development of negative pressure in the middle ear cavity (Schilder et al 
2016). This in turn facilitates ascent of the normal flora of the NP into the middle ear 
(Bakaletz 2010).  
The pathogens in the middle ear cavity are detected by TLRs, which trigger production of 
cytokines chemokines and antimicrobial peptides. Inflammatory cells such as neutrophils 
and macrophages infiltrate the middle ear cavity and add to the production of the 
inflammatory mediators (Leichtle et al 2011). Mounting such an inflammatory response is 
crucial for clearance of invading pathogens. However, persistent inflammation can have 
pathological implications as seen in chronic forms of OM. Over production of cytokines up 
regulates mucin genes, leading to excessive production of mucus, which obstructs the 
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movement of cilia (Hunter et al 1999). The inflammatory fluid is therefore retained in the 
middle ear cavity and also blocks the ET. This enhances inflammation further and leads to 
epithelial tissue remodeling, often characterized by a reduction in the number of ciliated 
cells, increases in the number of secretory or goblet cells (goblet cell hyperplasia) and 
conversion of other cell types to goblet cells (goblet cell metaplasia) (Straetemans et al 
2001). The mucosal epithelium thickens and the single layer of squamous epithelium is 
converted into multiple layers of pseudostratified respiratory epithelium with copious 
amounts of underlying stroma. The oxygen requirements of bacteria and inflammatory 
cells, along with reduced ventilation in the middle ear, leads to development of hypoxia, 
which activates the Hypoxia inducible factor (HIFα). HIFα induces angiogenesis and 
activates other genes, which help in restoring homeostasis in the hypoxic tissues. However, 
prolonged activity of HIFα leads to further tissue remodeling and overactive inflammation. 
(Cheeseman et al 2011). Consequently, a vicious cycle of inflammation, mucus production 
and decreased ciliary function commences, which if persistent for extended periods of 
time, can lead to major complications like Mastoiditis - spread of infection to the temporal 
bone and damage to the Tm leading to conductive hearing loss (Schilder et al 2016). 
Thus, the pathophysiology of OM is highly complex and a wide variety of factors may 
contribute to disease development (Fig 1.3). 
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Figure 1.3 Pathophysiology of OM 
Viral infection of the URT predisposes secondary infection by the normal flora of the NP and leads to ET dysfunction. Bacteria migrate from the NP 
through the ET and enter the middle ear cavity (MEC) where they activate PRRs such as TLRs. This causes recruitment of inflammatory cells and release 
of inflammatory mediators, like cytokines which subsequently up regulates mucous production. The viscous mucous contr ibutes to ciliary dysfunction, 
leading to blocking of the MEC and ET. As a result, ET dysfunction increases and leads to further inflammation and epithelial remodel ing. Hypoxia also 
contributes to epithelial remodeling. Thus, a vicious cycle sets in leading to the development of chronic OM. 
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1.6 Risk factors and candidate genes for OM 
Epidemiological studies indicate that race is an important susceptibility factor for 
development of OM. Prevalence of OM is more common in American Indians and 
Australian aborigines. The occurrence of OM amongst Caucasians is relatively low 
(Bluestone 1998). Many other factors such as the male sex, lack of breast feeding, 
attendance at day care centres, immaturity of the immune system, prolonged URT 
inflammation, presence of affected siblings, exposure to cigarette smoke also. increase 
susceptibility to OM (Schilder et al 2016, Straetemans et al 2001). 
Although OM is largely perceived as an infectious disease, the fact that some children 
suffer from these infections more frequently and some fail to resolve it in comparison to 
others, suggest a strong genetic basis, especially for rAOM, CSOM and COME (Parkinson et 
al 2006). Twin and triplet studies suggested that the children with siblings having a history 
of rAOM and COME demonstrated 1.6-4.2 higher fold higher susceptibility to the disease 
(Rasmussen 1993, Sipila et al 1988, Teele et al 1989). Based on these studies, it was 
determined that the genetic contribution to OM is between 45% - 75% (Casselbrant et al 
2004). Two genome wide linkage studies (GWLS) have been performed to date (Casselbrant 
et al 2009, Daly et al 2004). Both studies have identified several susceptibility loci for OM 
including chemokine genes, surfactant genes, inflammasome genes and genes involved in 
allergy. However the studies were confounded by large size of the linkage loci, low 
statistical power and discrepancy between OM phenotypes recruited and the specific 
genes were not mapped (Casselbrant et al 2009, Daly et al 2004). 
However, several other studies have identified candidate genes for susceptibility to OM. 
Majority of these genes are associated with dysfunction of the ET and other craniofacial 
structures, impairment of mucociliary defence or the innate immune system (Rye et al 
2011a). For example, OM occurs in 92- 97% children with cleft palate, due to abnormally 
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structured ETs (Robinson et al 1992) and children with, Primary Ciliary Dyskinesia (PCD), 
which results in abnormal functioning cilia (leading to failure of mucociliary clearance,  are 
also predisposed to OM (Campbell et al 2009). Mice deficient in Myd88 (a key regulatory 
innate defence protein) have delayed recruitment of inflammatory cells and more 
persistent OM (Hernandez et al 2008). Polymorphisms in TLR2, TLR4, TLR9, PA11, EVI1, 
FBXO11, mucin genes (MUC2, MUC5B, MUC5AC) as well as various cytokine genes 
(including interleukins, TNFα and Transforming growth factorβ (TGFβ), have also been 
linked to OM susceptibility (Patel et al 2006, Roy et al 2014, Rye et al 2012a, Schilder et al 
2016, Segade et al 2006). 
The largest GWAS study to date identified BPIFA1 and BPIFA3 on chromosome 20q11 and 
CALPN14 and GALNT14 on chromosome 2p23 as the top candidate genes for OM 
susceptibility (Rye et al 2012b). Interestingly, loss of Bpifa1 has recently been shown to 
increase OM susceptibility in aged mice (Bartlett et al 2015) 
As outlined above, OM is a multifactorial; polymicrobial disease associated with a large 
number of susceptibility genes. Identifying genes involved in the development of the OM is 
key to the better understanding of its complex etiology and for the development of 
therapeutic approaches. Innate immunity is of particular importance in OM 
pathophysiology. In this thesis, I have investigated a role for the putative URT innate 
immunity gene, BPIFA1 in the development of OM.   
 
1.7 An introduction to PLUNCS or BPIF proteins 
The Palate Lung and Nasal Epithelial Clone (Plunc) gene was first identified whilst studying 
proteins participating in closure of the embryonic mouse palate (Weston et al 1999). Whole 
mount in situ hybridisation showed that the gene was highly expressed during embryonic 
development of murine nasal epithelium. In adult mice, the gene was strongly expressed in 
the nasal passages and proximal trachea, but expression decreased towards the bifurcation 
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of the bronchi and disappeared in the peripheral lung. (Weston et al 1999). Following this 
study, multiple human PLUNC genes were soon identified on chromosome 20q11 using 
sequence analysis and bioinformatics approaches (Bingle & Bingle 2000, Bingle & Craven 
2002, LeClair et al 2001).  
1.7.1 Nomenclature and types of PLUNCS/BPIF proteins 
PLUNCS have been previously known by various names, such as Secretory protein in the 
upper respiratory tract (Spurt), Lung specific X protein (Lunx) and YY1 (Barnes et al 2008, 
He et al 2000). Modelling studies suggest that PLUNC proteins are structurally similar to the 
antimicrobial and anti-inflammatory Bacterial permeability increasing protein (BPI), which 
is composed of two domains connected by a β sheet (Bingle & Craven 2002). BPI is also 
similar in structure to Lipopolysaccharide binding protein (LBP), Phospholipid transfer 
protein (PLTP) and, Cholesterol ester transfer protein (CETP), together forming the BPI/LBP 
superfamily (Bingle & Craven 2004). PLUNCS belong to, and form the largest branch of, the 
BPI/LBP superfamily and therefore were recently renamed as BPI-Fold containing proteins 
or BPIF proteins. This nomenclature was based on phylogenetic analysis of 102 sequences 
across different species and has been approved by the HUGO Gene Nomenclature 
Committee. Under the new system, PLUNC proteins containing a single BPI structural 
domain (previously known as SPLUNCs) have been renamed BPI fold containing A proteins 
(BPIFA) and PLUNC proteins containing structural similarity to both domains of BPI 
(previously known as LPLUNCs) have been renamed BPI fold containing B proteins (BPIFB) 
(Bingle et al 2011b).  
BPIF orthologs are present in all air-breathing vertebrates and their gene loci have been 
characterised in mice (on chromosome 2) rats (on chromosome 3), cattle (on chromosome 
13) and chickens (on chromosome 20) (Bingle et al 2004, Chiang et al 2011, Wheeler et al 
2011). BPIF genes form a cluster in a 200-300kb region on the genome, and currently 
consist of 11 members in humans, and 14 in mice, including a number of pseudogenes (Fig 
17 
 
1.4) (Bingle et al 2011a).  These adjacent genes, which are also positioned in close 
proximity to BPI and LBP, are suggested to have evolved through a number of duplication 
events (Bingle & Craven 2002, Bingle et al 2004).  
Among the different BPIF proteins, BPIFA1 and BPIFB1 are the most expressed proteins 
within the upper respiratory tract. This thesis focuses on the role of BPIFA1 in development 
of OM. 
 
Figure1.4 Genomic organisation of the human and mouse BPIF genes 
Human BPIF cluster is located on chromosome 20 (top) and mouse cluster on chromosome 2 
(bottom). Arrows indicate orthologs for individual genes. The position of the locus on the 
chromosome (Chr) is indicated by the arrowheads. BPIFA (SPLUNC) genes are shown as grey boxes, 
BPIFB (LPLUNC) genes are shown as white boxes and pseudogenes are shown as shaded boxes. 
SPA4L and CDK5RAP1 are unrelated genes flanking the locus. Our gene of interest, BPIFA1 is circled 
in red. Scale bar, 200 kb. Image reused with permission from (Bingle et al 2011a), copyright 2011 
Portland press.  
 
 
1.8. Normal expression and localisation of BPIFA1  
BPIFA1 is the founding member of the BPIF family, originally identified as “Plunc” in 
embryonic mouse palate (Weston et al 1999) and is the most extensively studied family 
member. The sequence identities between the mouse and human BPIFA1 orthologs is 72% 
(Britto & Cohn 2015). The product of the BPIFA1 gene is a secreted protein with a mass of 
28.6kDa in mice and 26.6 kDa in humans (Britto & Cohn 2015, Chu et al 2007). The crystal 
structure of BPIFA1 was recently published by two independent groups (Garland et al 2013, 
18 
 
Ning et al 2014). As predicted by modelling studies, both studies reveal a 256 amino acid 
monomer, consisting of 6 alpha helices (α1-6), flanking a central beta sheet and together 
enclosing a leucine rich hydrophobic core. The structure of BPIFA1 is largely homologous to 
the N-terminal domain of BPI except for the 2 helices, α4 and α6 (Fig 1.5). BPIFA1 is also 
structurally similar to the single domain proteins, equine surfactant Latherin and dust mite 
allergen Derp7 (Garland et al 2013, Ning et al 2014, Walton et al 2016).  
 
Figure1.5 Crystal structure of BPIFA1 showing structural homology to BPI Human BPIFA1 (blue) demonstrates structural homology with the N-terminal domain of BPI (yellow). Residues 43–254 of BPIFA1 were superimposed on residues 1–194 of BPI and share 
only 12% sequence identity. The labelling is shown for the 6 α-helices of BPIFA1. Image reused with permission from (Garland et al 2013), copyright 2013 by National Academy of Sciences 
 
 
1.8.1 Normal Expression and localisation of BPIFA1 in the upper airways and oral 
cavities 
The expression of BPIFA1 is highly tissue specific. BPIFA1 is mainly expressed in the 
epithelium of nasal passages, oropharynx, trachea and bronchi (Bingle & Bingle 2000, 
Bingle & Bingle 2011). BPIFA1 localises to non-goblet, non-ciliated population of secretory 
cells of the upper airways (Bingle et al 2005). In humans, it is found also the minor glands of 
the nose, tongue, tonsils and sinuses (Barnes et al 2008, Bingle et al 2005) as well as in the 
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mucous cells of the sub-mucosal, sub-lingual and sub-mandibular glands (Bingle & Bingle 
2011). In mice, expression of Bpifa1 is largely restricted to the oral, nasopharyngeal and 
respiratory tissue. This expression pattern is shown by the murine tissue microarray 
expression dataset on the BioGPS data portal (http://biogps.org (Su et al 2004)), which 
shows expression of Bpifa1 at high levels in the parts of the nasal passages and trachea and 
to a lower extent in the lung (Fig 1.6).  
 
Figure 1.6 Tissue restricted expression of BPIFA1 
Adult mouse tissue microarray data of Bpifa1 demonstrated restricted sites of expression. Bpifa1 
expression was restricted to parts of the nasal cavity, trachea and lung (upper airways). The image 
was recovered from the BioGPS portal and is based on data from (Su et al 2004)  
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A previous study for our lab  extensively studied localisation of BPIFA1 in coronal sections 
of the adult mouse head (Musa et al 2012). BPIFA1 was shown to localised to the non-
ciliated cells of the respiratory epithelium in various parts of the nasal cavity. Additionally, 
it was present in the Bowman’s glands and gland ducts. BPIFA1 staining was also seen in 
the sub-mucosal cells of the ducts in the larynx but unlike humans, BPIFA1 was absent in 
the parotid and submandibular salivary glands (Musa et al 2012). Glycosylated forms of 
secreted BPIFA1 can be identified in nasal lavage, saliva, sputum and Bronchi alveolar 
lavage (BAL). They are also secreted in large quantities into the apical surface lining fluid 
from air liquid interface (ALI) cultures of differentiated tracheobronchial epithelial (TBE) 
cells (Britto & Cohn 2015, Campos et al 2004) 
There are limited reports of presence of human and mouse BPIFA1 outside the respiratory 
tract for example in the kidney, colon and stomach (Garcia-Caballero et al 2009, Hou et al 
2004, LeClair et al 2004, Sentani et al 2008). However other reports, including studies from 
own lab failed to detect expression at these sites (Bingle & Bingle 2000, Gally et al 2011, Liu 
et al 2013b, Musa et al 2012). Indeed, extensive analysis of tissues from the GI tract and 
renal system failed to show the protein in any of these tissues (Musa et al 2012).  
 
1.8.2 Normal expression of BPIFA1 in the middle ear 
Since, the middle ear is an extension of the URT, in a preliminary study I investigated the 
localisation of the protein in the middle ear cavity of adult mice (Mulay MSc thesis 2011). I 
observed abundant staining for BPIFA1 along the middle ear epithelium and occasionally, in 
the layer of Tm facing the middle ear cavity (Fig 1.7). Subsequently, a report was published 
showing the presence of BPIFA1 in the murine middle ear as well as its involvement in OM 
(Bartlett et al 2015). BPIFA1 has also been reported to be present in the middle ears of 
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chinchillas (McGillivary & Bakaletz 2010) and in middle ear effusion of OM patients 
(Preciado et al 2010, Val et al 2016).  
 
Figure 1.7 Expression of BPIFA1 in the Wt middle ear 
Low magnification (A) and high magnification (B) images showing strong staining for BPIFA1 in the 
middle ear epithelium. BPIFA1 also occasionally localised to cells of the Tm towards the middle ear 
cavity. n=3. Image taken from (Mulay MSc thesis 2011). 
 
  
 1.9 BPIFA1 is a multifunctional host defence protein 
BPIF genes and particularly the BPIFA subfamily of genes are amongst the most rapidly 
evolving mammalian genes and have undergone various duplication and deletion events 
over the course of evolution (Bingle et al 2011a). This has led to the development of a large 
number of orthologues and paralogues with low sequence similarities (an average of 16-
28% for paralogues and 45-76% for orthologues), a feature that is typical of genes involved 
in host defence (Bingle & Craven 2003, Emes et al 2003). Moreover due to its structural 
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similarity with BPI and LBP and its expression at sites of immediate pathogen interaction, 
BPIFA1 has been published to be an innate immunity protein (Bingle & Craven 2004, Bingle 
et al 2011b). The literature suggests an antimicrobial, surfactant and immunomodulatory 
role for BPIFA1, as well as a role an involvement in regulation of the airway surface liquid 
(ASL) (Britto & Cohn 2015). However, despite an increasing number of published studies, 
mechanistic evidence to validate these functions has only recently started to arise. 
Following the solving of the crystal structure of BPIFA1, site-specific mutations in the 
protein have indicated that specific structural components of BPIFA1 may be responsible 
for specific host pathogen functions of the protein (Walton et al 2016). 
 
1.9.1 Antimicrobial role 
The most widely studied function of BPIFA1 is its antimicrobial role against Gram-negative 
respiratory bacteria. Both in vitro and in vivo studies have shown that BPIFA1 demonstrates 
an antimicrobial activity against Gram-negative bacteria such as K. pneumoniae, P. 
aeruginosa, NTHi and more recently, Burkholderia cepacia (B.cepacia)(Ahmad et al 2016, 
Liu et al 2013a, Liu et al 2013b, Lukinskiene et al 2011, McGillivary & Bakaletz 2010, Sayeed 
et al 2013, Walton et al 2016). For example, silencing or ablation of Bpifa1 in mice has been 
associated with increased susceptibility and higher pulmonary bacterial counts upon 
challenge with K.pneumoniae and P.aeruginosa (Liu et al 2013a, Liu et al 2013b). On the 
other hand, transgenic mice overexpressing BPIFA1 showed improved pulmonary bacterial 
clearance (Lukinskiene et al 2011). In another study, recombinant chinchilla BPIFA1 showed 
increased killing activity against NTHi (McGillivary & Bakaletz 2010). However, some studies 
have suggested that BPIFA1 inhibits the growth of P.aeruginosa and B.cepacia and is thus 
bacteriostatic rather than bactericidal (Ahmad et al 2016, Sayeed et al 2013). 
The mechanism proposed for the antimicrobial activity of BPIFA1 against Gram-negative 
bacteria is through binding and neutralising the endotoxin, LPS in a manner similar to BPI 
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(Chu et al 2010). However, the evidence regarding direct binding of BPIFA1 with LPS, is 
conflicting. Some groups reported binding whereas others reported either a lack of direct 
binding or a lack of competition with LBP (Britto & Cohn 2015, Campos et al 2004, Di 2011, 
Ning et al 2014, Sayeed et al 2013). However, a recent study have suggested that the α4 
helix of BPIFA1 is responsible for binding to LPS and the bacteriostatic activity against 
P.aeruginosa and B.cepacia (Ahmad et al 2016, Walton et al 2016). 
Besides, Gram-negative bacteria, BPFIA1 was also shown to inhibit growth and decrease 
susceptibility to pulmonary infections by the atypical bacterium, Mycoplasma pneumoniae 
(M.pneumoniae) (Chu et al 2007, Gally et al 2011) and also to inhibit replication of Epstein-
Barr virus (Zhou et al 2008).  
 
1.9.2 Surfactant role 
Another proposed function for BPIFA1 is the ability to act as a surfactant. The surfactant 
role of BPIFA1 was first suggested by Gakhar and colleagues when they identified sequence 
homology between BPIFA1 and the equine surfactant protein, Latherin. Using in vitro 
assays they showed that BPIFA1 reduced the surface tension at the air liquid interface (ALI) 
and disrupted biofilm formation by P. aeruginosa (Gakhar et al 2010). Subsequently, two 
other studies demonstrated that ALI TBE cultures from Bpifa1-/- mice showed increased 
biofilm formation by P. aeruginosa and K. pneumoniae (Liu et al 2013a, Liu et al 2013b). 
Moreover, knocking down Bpifa1 in vitro in chinchillas led to impaired mucociliary 
clearance through the ET, indicating a reduction in surface tension affecting the water 
content in the ASL (McGillivary & Bakaletz 2010). A recently published study shows the 
leucine residues of the α4 helix of BPIFA1 are essential for it to function as a surfactant but 
not for biofilm disruption in P. aeruginosa and B.cepacia (Walton et al 2016). However, 
another group that studied the potential lipid ligands of BPIFA1 demonstrated that the 
protein binds pulmonary surfactants such as dipalmitoylphosphatidylcholine (DPPC) (Ning 
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et al 2014). Thus it is possible that BPIFA1 functions to sequester surfactants rather than 
act as a surfactant itself and thus, works in concert with other host defence components of 
the ASL in order to prevent fluid accumulation and to disperse bacterial biofilms. 
 
1.9.3 Immunomodulatory role 
Serum LBP (predominantly produced by the liver) binds to LPS to transfer it to Cluster of 
differentiation (CD)-14, in turn activating TLRs and a pro-inflammatory response whereas 
BPI (secreted by the neutrophils), binds to LPS at the site of infection and plays an anti- 
inflammatory role by making it unavailable for LBP (Weiss 2003). Due to its structural 
similarity with BPI and LBP, BPIFA1 was initially suggested to play either a pro-inflammatory 
or an anti-inflammatory role in response to pathogens (LeClair 2003).  
Loss of Bpifa1 was also associated with increased infiltration of inflammatory cells and 
expression of pro-inflammatory mediators compared to controls in P.aeruginosa and LPS 
induced pulmonary inflammation in mice (Di 2011, Lukinskiene et al 2011), whereas 
overexpression of the protein attenuated the pro-inflammatory response (Di 2011). This 
indicates an anti-inflammatory role for BPIFA1 in inflammation induced by Gram-negative 
bacteria. BPIFA1 deficient mice demonstrated higher levels of TH2 cytokines and increased 
eosinophilic inflammation in an allergic model of inflammation compared to Wt mice. On 
the other hand, over expression of BPIFA1 complimented this effect, thus indicating an 
anti-inflammatory role for BPIFA1 in allergic inflammation (Wright et al 2010). In contrast, 
BPIFA1 demonstrated a pro-inflammatory function in the case of non-infectious 
inflammation induced by inhaled sterile carbon nanotubules. Here, transgenic mice 
overexpressing BPIFA1 showed increase in pulmonary neutrophil infiltration and up 
regulation of pro-inflammatory mediators (Di et al 2013).  
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1.9.4 Role in airway surface liquid regulation 
The surface of the airway epithelium is lined by the ASL. ASL consists of a periciliary fluid 
layer which underlies the mucous layer, and consists of antimicrobial proteins such as 
lysozyme, proteases and protease inhibitors as well as BPIFA1 (Tarran 2004). The ASL 
covers cilia and adequate ASL height is essential for effective mucociliary clearance. The 
epithelial sodium channel, ENaC is a heterotrimer of the α, β and γ subunits and is 
activated by proteolytic cleavage by epithelial and inflammatory proteases leading to 
increased absorption of sodium and resorption of water by the epithelium (Tarran & 
Redinbo 2014). BPIFA1 was shown to act as a negative regulator of ENaC, thus contributing 
to the maintenance of ASL height (Garcia-Caballero et al 2009). The proposed mechanism 
for BPIFA1 mediated inhibition of ENAC function is through the extracellular binding to 
ENaC and prevention its cleavage by proteases (Garcia-Caballero et al 2009, Garland et al 
2013, Hobbs et al 2013). A sequence of 18 amino acids (S18 peptide) at the N-terminus of 
BPIFA1 is responsible for ENaC binding (Hobbs et al 2013). The recent crystal structure of 
BPIFA1 has enabled site-specific mutagenesis studies, which demonstrated that the ENaC-
regulatory motif (S18) is functionally independent of the surfactant and anti-biofilm motif 
(α4 helix) (Ahmad et al 2016, Walton et al 2016). It is also suggested that BPIFA1 regulates 
ENaC activity by maintenance of ENaC in a low opening state (Hobbs et al 2013) and 
reduction of ENaC expression on the epithelium (Rollins et al 2010).  
Regulation of ASL volume is particularly important in pulmonary diseases such as Cystic 
fibrosis (CF), where dehydration of the mucosa leads to mucostasis and impaired 
mucociliary clearance. It has been shown that the ability of BPIFA1 to inhibit ENaC is 
impaired in the acidic microenvironment of CF lungs, resulting in mucosal hyper-absorption 
and depletion of the ASL, whereas addition of the S18 peptide increased ASL height 
(Garland et al 2013). Thus a loss of BPIFA1 function may contribute to CF development. 
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1.10 Alteration of BPIFA1 during infections and diseases of the URT  
BPIFA1 is expressed at high concentrations in the steady state. BPIFA1 is tightly regulation 
by both pathogens and inflammation and the direction of alteration depends upon the 
stimulus. For example, Bpifa1 was reported to be down regulated in a study of acute 
murine pulmonary infection with P.aeruginosa, Influenza A and S.pneumoniae (Britto et al 
2013) whereas, other studies reported an upregulation in Bpifa1 expression upon infection 
with K.pneumoniae and M.pneumoniae. Bpifa1 was downregulated in mice following 
treatment with cytokines IFNγ and in mouse tracheal epithelial cells (mTECs) upon 
treatment with TNFα and IL1β whereas, IL13 upregulated Bpifa1 expression in mTECs 
(Britto & Cohn 2015, Britto et al 2013). 
BPFIA1 is also altered in various inflammatory diseases of the URT. For example, BPIFA1 
levels were reduced in subjects with perennial rhinitis and in nasal polyp tissues of patients 
with chronic rhinosinusitis compared to healthy controls (Irander et al 2014, Seshadri et al 
2012). The expression of BPIFA1 in Chronic obstructive pulmonary disease (COPD) was 
variable and the studies were confounded by the relatively small number of subjects. The 
levels of BPIFA1 were reduced, elevated or unaffected in different studies that employed 
different sampling locations (Bingle et al 2007, Britto & Cohn 2015, Di et al 2003). BPIFA1 
was elevated in CF lungs (Bingle et al 2007). As mentioned before, elevation in levels of 
BPIFA1 may serve as a defence mechanism to rehydrate the airway mucosa and assist in 
clearance of bacteria. However this function of BPIFA1 may be hampered due the low pH 
and increased proteolytic enzymes in the CF lungs (Garland et al 2013). 
In addition, changes in expression levels of BPIFA1 have also been implicated in head and 
neck cancers. BPIFA1 may serve as a marker for non-small cell lung carcinoma (NSCLC) 
(Bingle et al 2005, Vargas et al 2008). Levels of BPIFA1 are also altered in adenocarcinoma, 
nasopharyngeal cancer, mucoepidermoid carcinoma, salivary gland tumours, 
bronchoalveolar carcinoma, etc. (Bingle & Bingle 2011).  
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Thus, it is evident that BPIFA1 is involved in several diseases of the URT. 
 
 1.11 Evidence for involvement of BPIFA1 in Pathogenesis of OM 
As described above, BPIFA1 is highly expressed in the epithelium of the URT of both 
humans and mice (Bingle & Bingle 2011, Musa et al 2012) and has a proposed role in the 
immune defence mechanisms at these sites (Barnes et al 2008). The middle ear epithelium 
is a continuation of the URT epithelium and therefore the physiology of the middle ear is 
comparable to that of the URT. Thus, BPIFA1 may also serve as innate immunity molecule 
in the middle ear. OM is commonly preceded by an URT infection and is characterized by 
epithelial remodelling. Therefore, it can be postulated that OM is accompanied and 
affected by alterations in the levels of BPIFA1. Indeed, evidence regarding expression of 
BPIFA1 in the middle ear and its role in OM pathogenesis has started to emerge. A study in 
chinchillas showed that knocking down Bpifa1 in vivo using siRNA led to impaired 
mucociliary clearance, due to reduction in the surface tension of the tubotympanum, 
plausibly affecting the ASL water content and ion transport and thereby contributing to the 
pathogenesis of OM (McGillivary & Bakaletz 2010). A more compelling indication of the 
involvement of BPIFA1 in OM is the Western Australian GWAS which identified BPIFA1 
gene as one of the top candidate genes associated with OM susceptibility (Rye et al 2012b). 
A recently published report also shows that aged Bpifa1-/- mice show increased 
susceptibility to OM (Bartlett et al 2015). Thus, recent literature has identified BPIFA1 as a 
strong determinant for predisposition to OM. 
 
1.12 Mouse models for OM 
One of the ways to better understand the pathogenesis of OM in vivo is to study the 
disease in an animal model which exhibits the OM phenotype. The mouse serves as a 
classic model for various human diseases. Mice can be bred in large numbers and have a 
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relatively short lifespan of 2 years in laboratory conditions. The sequence of the entire 
mouse genome is known since the Mouse Genome Consortium, 2002 and 90% of the genes 
are conserved between humans and mice (Waterston et al 2002). It is also comparatively 
easy to manipulate genes in mice. The advent of the clustered regularly interspaced short 
palindromic repeats (CRISPR) gene editing technology has further reduced the time 
required for generating mouse mutants considerably (Yin et al 2014).  
The mouse is an excellent model of OM owing to significant functional and anatomical 
similarity between the ears of humans and mice (Brown et al 2008). Several disease 
susceptibility genes, thought to be involved in OM have been disrupted in mice, in an 
attempt to study their role in the pathogenesis of the disease. Table 1.1 gives a summary of 
some of the mouse models of OM. The two major approaches adopted to develop murine 
models of OM as follows: 
x Targeted genes are disrupted to produce gene driven models 
x Random mutations are induced to develop phenotype driven models (Rye et al 
2011a). 
  
29 
 
 
Table 1.1 Mouse models of Otitis media. 
This table has been adopted and modified by permission from (Rye et al 2011a), copyright Springer 
2010 
Gene 
mutated 
Chromosome 
 
phenotypic 
alterations 
Type of OM Reference 
Tlr2 3 Immune 
deficiencies 
AOM 
(induced) 
(Leichtle et al 2009) 
Tlr4 4 Immune 
deficiencies 
AOM 
(induced) 
(Hirano et al 2007) 
Evi1 3 Rhinitis, presence 
of extra digits on 
both limbs 
CSOM 
(spontaneous) 
(Parkinson et al 2006) 
Fbxo11 17 Bent ET, 
craniofacial 
abnormalities, 
deafness 
COME 
(spontaneous) 
(Hardisty et al 2003, 
Hardisty-Hughes et al 
2006) 
MyD88 9 Immune 
deficiencies 
AOM 
(induced) 
(Hernandez et al 
2008) 
Tgif 17 Craniofacial 
defects, placental 
defects 
CSOM 
(spontaneous) 
(Tateossian et al 
2013) 
Fas 19 Autoimmune 
syndrome 
AOM 
(Induced) 
 
(Rivkin et al 2005) 
Dnahc5 15 Immotile cilia, early 
death 
CSOM. AOM 
(spontaneous) 
(Ibanez-Tallon et al 
2002) 
Cby1 15 Lack of motile cilia CSOM 
(spontaneous) 
(Voronina et al 2009) 
Plg 17 Fibrin deposition 
across wide range 
of organs 
CSOM 
(spontaneous) 
(Eriksson et al 1995) 
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1.12.1 Junbo mouse- a model of chronic OM 
This thesis utilises the Junbo mouse model of chronic OM. 
 
1.12.1.1 Generation of Junbo mice 
Junbo is a phenotype driven mouse model identified through a large scale N-Ethyl 
Nitrosourea (ENU) mutagenesis screen at the Medical Research Council (MRC), Harwell 
(Parkinson et al 2006). ENU is a powerful chemical mutagen that introduces random point 
mutations in the genome by transferring its ethyl group to the oxygen or nitrogen radicals 
of DNA (Noveroske et al 2000). To perform this screen, spermatogonial stem cells of 
BALB/c males were mutagenized and the mice mated with female C3H/HeH mice. 
Dominant phenotypes were identified by screening of generation 1 (G1) progeny, whereas 
recessive phenotypes were identified by screening the G3 progeny. G1 Junbo 
heterozygotes had elevated hearing thresholds. A more detailed analysis of the phenotype 
revealed that these mice suffer from conductive hearing loss due to development of OM 
(Parkinson et al 2006).  
 
1.12.1.2 OM development in Junbo mice 
The Junbo mouse is a model of conductive hearing loss following development of 
spontaneous, chronic OM. Heterozygote Junbo (Evi1Jbo/+) mice develop OM after birth, 
which transforms into CSOM by post-natal day 28 (P28) in specific pathogen free 
conditions. Evi1Jbo/+ mice also develop OM in germ free conditions by P54, indicating a 
genetic predisposition to OM development (Rye et al 2011a). Evi1Jbo/+ middle ears are 
characterised by development of cellular fluid and thickening of the mucoperiosteum (Fig 
1.8) (Parkinson et al 2006). Recent studies in our lab have also shown that both the 
mucoperiosteum and middle ear fluid of Evi1Jbo/+ mice are markedly hypoxic (Fig 1.9) 
compared to Wt mice (Cheeseman et al 2011). OM development in Evi1Jbo/+ mice is non-
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syndromic i.e. there is an absence of phenotype outside the middle ear and no systemic 
immune defects (Parkinson et al 2006). Moreover, intranasal (IN) inoculation of Evi1Jbo/+ 
mice with the otopathogen, NTHi leads to high rates of middle colonisation by the 
bacterium (Hood et al 2016) Therefore, Evi1Jbo/+ is a good model of OM development in 
humans. 
 
 
Figure 1.8 OM phenotype in Evi1Jbo/+ mice 
Images on the left show clear middle ear cavities (MEC) of Wt mice and a thin layer of the 
epithelium (E). Evi1Jbo/+ mice (right) develop CSOM marked by build-up of inflammatory exudate in 
the MEC and thickening of the middle ear epithelium. Image reused with permission from (Brown et 
al 2008), copyright 2008 Nature publishing group 
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Figure 1.9 Middle ears of Evi1Jbo/+ mice are hypoxic 
Thickened mucosa and foamy macrophages in Evi1Jbo/+ middle ears stained positive for the hypoxia 
marker, Pimonidazole, PIMO (A). Wt mice did not demonstrate mucosal thickening or hypoxia (B) 
Negative control for Evi1Jbo/+ middle ear (C) ex: exudate, tm: temporomandibular bone; ep: epithelial 
cells, mϕ: macrophage, m= mucosa, * histological artifact. Image reused with permission from 
(Cheeseman et al 2011), copyright 2011 Plos genetics.  
 
The causative mutation in Evi1Jbo/+ mice is a single nucleotide polymorphism (SNP) in the 
ecotropic viral integration site-1 (Evi1) gene, also known as MECOM, located on 
chromosome 3, which encodes a 145 kDa transcription factor. Homozygote Junbo 
(Evi1Jbo/Jbo) mutation is post-natal lethal (Parkinson et al 2006). EVI1 plays a role in normal 
development and overexpression of the gene due to chromosomal rearrangements in 
humans is implicated in myeloid leukaemia (Goyama & Kurokawa 2010, Hirai 1999, 
Kurokawa et al 2000).  EVI1 is made up of 2 Zinc Finger (ZnF) domains connected by a 
proline rich repressor domain and also consists of a C-terminus acidic region. The first ZnF 
domain contains 7 ZnF motifs and the second ZnF domain contains 3 ZnF motifs (Goyama & 
Kurokawa 2009). The first ZnF domain directly binds and regulates GATA2 promoter, a gene 
critically involved in proliferation of definitive haematopoietic stem cells (Yuasa et al 2005). 
The genes directly regulated by the second domain if EVI1 have not yet been identified. 
However, each domain interacts of EVI1 has been shown to interact with different co-
repressors and co-activators and form larger regulatory complexes (Goyama & Kurokawa 
2010). The Evi1Jbo/+ mutation is in the second motif of the second ZnF domain and is three 
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amino acids away from a conserved contact residue. It causes an adenine to thymidine 
transversion, changing the 763rd amino from asparagine to isoleucine. Previous studies 
have shown that alterations in any of the contact residues led to total loss of the DNA 
binding capacity of the transcription factor. It is not known whether the Evi1Jbo/+ mutation 
can alters the binding capacity of the first ZnF domain (Parkinson et al 2006).  
The first ZnF domain of EVI1 directly binds to and inactivates SMAD3, a key signalling 
molecule of the TGFβ signalling pathway. Quenching of SMAD3 prevents the SMAD3/ 
SMAD4 complex from activating transcription of target genes and leads to inhibition of the 
anti-proliferative effect of the TGFβ signalling pathway (Kurokawa et al 1998a, Kurokawa et 
al 1998b, Sood et al 1999). In addition, the proline rich repressor domain, immediately 
preceding the second ZnF domain of EVI1 is involved in recruitment of C-terminal binding 
protein (CtBP), a co-repressor of TGFβ signalling (Izutsu et al 2001). The first ZnF domain of 
EVI1 also directly binds to and inactivates phosphorylated c-Jun N-terminal kinase (JNK), a 
subtype of mitogen-activated protein (MAP) kinases which plays a role in cellular response 
to environmental stress. Binding of EVI1 to JNK prevents phosphorylation of its target, c-
JUN and the activation of genes involved in stress induced apoptosis (Kurokawa et al 2000). 
Thus, normally functional EVI1 is involved in repression of cellular hyper-proliferation and 
in cell survival.  
The second ZnF domain of EVI1 trans-activates cFOS and increases activity of the 
transcription factor, Activator protein 1 (AP-1). AP-1 is a homodimer of cFOS or a 
heterodimer of cFOS/cJUN and converts extracellular signals into changes in gene 
expression. Changes in AP-1 activity are associated cellular proliferation and differentiation 
(Tanaka et al 1994). More recently, the second ZnF domain of EVI1 has also been shown to 
be involved in inflammation through negative feedback regulation of NFκβ signalling 
pathway (Xu et al 2012). This study showed that the otopathogen, NTHi and the pro-
inflammatory cytokine, TNFα induced expression of EVI1. EVI1 directly binds to the p65 
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subunit of transcription factor, NFκβ and inhibits its acetylation. This results in a decrease 
in the biological activity of NFκβ and inhibition of expression of subsequent inflammatory 
mediators and adhesion molecules. The study also shows that NTHi infection of Evi1Jbo/+ 
mice results in a pulmonary inflammatory phenotype. Thus, the second ZnF domain of EVI1 
is involved in cellular proliferation and differentiation as well as prevention an overactive 
inflammatory response. Fig 1.10 summarises the biological functions of the different EVI1 
domains. 
 
Figure 1.10 Biological functions of EVI1 
The first ZnF domain of EVI1 directly binds to GATA2 promoter and activates proliferation of 
haematopoietic stem cells (HSCs). It is also involved in repression of the anti-proliferative properties 
of the TGFβ signalling pathway and inhibiting stressed induced apoptosis through the JNK pathway. 
The repressor domain also participates in blocking TGFβ signalling. The second domain of ZnF 
activates AP-1 and promotes cellular proliferation. It is also a negative regulator of the NFκβ 
signalling pathway. There is no known role for the acidic domain.  
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EVI1 is involved in control of inflammatory responses through repression of both TGFβ and 
NFκβ signalling pathways. These pathways interact with one another and regulate mucin 
production (Jono et al 2002, Jono et al 2003), a key-contributing factor to the 
pathophysiology of OM. Moreover, recent studies in our lab have shown that hypoxia plays 
an important role in the development of OM in Evi1Jbo/+ mice (Cheeseman et al 2011). There 
is significant crosstalk between TGFβ signalling pathway and hypoxia signalling (Sanchez-
Elsner et al 2001). The interaction between different pathways and their potential role of 
EVI1 in their regulation has been described in further detail in Chapter 5. 
Polymorphisms in human EVI1 have not been identified in OM association studies; 
however, the current evidence suggests that EVI1 may be involved in OM development 
through an effect on regulation of mucin production as well as on cellular inflammation, 
proliferation and differentiation.  
In this project, I chose to utilise Evi1Jbo/+ mice as a model for OM because it is one of the 
most well characterised mouse models of non-syndromic OM i.e. these mice develop OM 
without any major phenotype outside the middle ear and without any systemic immune 
defects (Parkinson et al 2006). The network of inflammatory and hypoxia induced genes 
upregulated in the Evi1Jbo/+ exudates (Cheeseman et al 2011) are very similar to those 
effusions from chronic OM patients (Mood et al, Low oxygen in OM study, unpublished). 
Thus Evi1Jbo/+ mice closely mimic the human OM phenotype. 
 
1.12.2 Other mouse models of Otitis media at MRC Harwell 
1.12.2.1 Jeff mouse 
The Jeff mouse was also identified through the Harwell ENU mutagenesis scheme. 
Heterozygote Jeff mice (Fbxo11Jf/+) develop COME by P28 and demonstrate craniofacial 
abnormalities like facial contortions, a narrower and bent ET, collapsed middle ear cavity, 
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and cleft palate (Hardisty et al 2003). Fbxo11Jf/Jf mice have defects in eyelid, lung and palate 
development. The causative mutation is a SNP in the Fbxo11 gene which encodes a 
member of the F-box family of proteins. Polymorphisms in human FBXO11 have been 
associated with human OM (Rye et al 2011b, Segade et al 2006). FBXO11 is implicated in 
TGFβ/SMAD signalling through its ability to regulate of phosphoSmad2 in epithelial cells of 
airways, palatal shelves and eyelids (Rye et al 2011b, Tateossian et al 2015). Moreover, OM 
development in Fbxo11Jf/+ middle ears is characterised by development of hypoxia, similar 
to Evi1Jbo/+ mice (Cheeseman et al 2011, Tateossian et al 2015).  
1.12.2.2 Tgif mice 
The most recent mouse mutant studied at MRC Harwell was the Tgif-/- model (Tateossian et 
al 2013), a knockout mouse model for the Transforming growth inhibitory factor 1 (TGIF) 
gene which is a known regulator of the TGFβ signalling pathway through inhibition of 
SMAD2 activity (Melhuish & Wotton 2000, Seo et al 2004). Tgif-/- mice are characterised by 
middle ear mucosal inflammation, middle ear effusion and elevated hearing thresholds 
from P21. Tgif-/- middle ears also demonstrated goblet cell hyperplasia, presence of hypoxia 
and elevation in pro-inflammatory cytokines (Tateossian et al 2013).  
The Evi1Jbo/+, Fbxo11Jf/+ and Tgif-/- models highlight the involvement of the TGFβ signalling 
pathway in OM susceptibility. 
 
1.13 Preliminary studies from our lab showing involvement of BPIFA1 in OM 
development 
During my Masters project, I performed preliminary experiments in order to characterise 
alterations in the levels of BPIFA1 during the development of OM in Evi1Jbo/+ mice (Mulay 
MSc thesis 2011). Using IHC, I found that the intensity of BPIFA1 staining was reduced in 
the middle ear epithelium of Evi1Jbo/+ mice compared to their age matched Wt littermate 
controls (Fig 1.11). Also, the intensity appeared to reduce with OM progression in Evi1Jbo/+ 
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mice from P21 to P56, but BPIFA1 localised to the inflammatory ear exudate in these mice 
(Fig 1.12).  
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Figure 1.11 BPIFA1 staining in Evi1Jbo/+ middle ears is reduced compared to Wt mice 
Immunohistochemistry for P21, P28 and P56 Wt (A, C, E) and Evi1Jbo/+ (B, D, F) middle ears shows 
lower intensity of staining in Evi1Jbo/+ mice compared to age matched Wt mice. BPIFA1 staining also 
localises to the inflammatory exudates of Evi1Jbo/+ mice. Wt Negative control is BPIFA1 negative (G). 
Scale bar 100μM. Image taken from (Mulay MSc thesis 2011). 
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Figure 1.12 BPIFA1 staining reduces with OM progression in Evi1Jbo/+ mice 
Immunohistochemistry for BPIFA1 indicates intense staining in P21DAB Evi1Jbo/+ mice (A) and P28 
Evi1Jbo/+ with unilateral OM (ear without OM, B). However staining intensity reduces in P28 Evi1Jbo/+ 
mice with bilateral OM (C) and 56DAB Evi1Jbo/+ mice with OM progression (D) Scale bar =50μM 
Negative control is clear of staining (E) Image taken from (Mulay MSc thesis 2011). 
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Using western blots, I identified abundant BPIFA1 (25kDa) in Evi1Jbo/+ exudates. However, 
smaller bands suggested a partial degradation of the protein (Fig 1.13). These observations 
indicated that decrease levels of BPIFA1 or a loss of its function due to proteolytic 
degradation might contribute to OM pathogenesis.  
 
Figure 1.13 Detection of Bpifa1 in ear exudates of Evi1Jbo/+ mice 
Western Blots readily detected BPIFA1 in ear effusions of Evi1Jbo/+ mice. Ear exudates from two 
different P105 and P59 animals showed presence of the full-length protein (25kDa) along partially 
degraded peptides. The control (BAL fluid from transgenic mice) showed presence of only the full-
length proteins. Image taken from (Mulay MSc thesis 2011) 
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1.14 Hypothesis 
BPIFA1 is one of the most abundant secretory proteins in the upper airways. It appears to 
possess pleiotropic roles in innate immune defence of the URT through its antimicrobial, 
surfactant and immunomodulatory functions as well by regulation of ASL height, thus 
ensuring efficient mucociliary clearance. The middle ear epithelium is a continuation of the 
upper airways and shares many physiological and immunological mechanisms with the 
URT. Otitis media is a disease with a complex pathophysiology, that is characterised by 
severe epithelial remodelling. SNPs in BPIFA1 have been associated with OM. Preliminary 
data from my Masters project has shown that BPIFA1 is robustly expressed in middle ears 
of Wt mice and its expression decreases with OM development in the Evi1Jbo+/- mouse 
model of chronic OM.  Based on this evidence, it can be hypothesized that BPIFA1 plays a 
role in the protection of the middle ear and the loss of BPIFA1 is associated with OM 
development. 
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1.15 Aims and objectives 
The overall aim of this thesis was to characterize a role for BPIFA1 in the middle ear and 
study the effect of its loss on the development of OM as well as in middle ear infection by 
the human otopathogen, NTHi in vivo, using mouse models and in vitro, using a novel 
system for culture of primary middle ear epithelial cells. 
In order to achieve this aim Bpifa1-/- mice and Bpifa1-/-Evi1Jbo+/- compound mice were 
generated. Also, a novel in vitro model of murine middle ear epithelium was developed. 
 
More specifically, the objectives of this thesis were as follows: 
1. To determine whether deletion of Bpifa1 leads to spontaneous development of 
OM.  
2. To determine whether deletion of Bpifa1 causes increased carriage of the human 
otopathogen, NTHi from the NP into the middle ear. 
3. To develop a novel in vitro model of the murine middle ear epithelium and 
systematically characterise the epithelial sub-populations.  
4. To utilise the in vitro culture system to study the effect of loss of Bpifa1 on cellular 
differentiation and infection by NTHi. 
5. To investigate whether Bpifa1 deletion exacerbates the OM phenotype in Evi1Jbo+/- 
mice. 
6. To recapitulate the OM phenotype of Evi1Jbo+/- mice using the novel in vitro culture 
system. 
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CHAPTER 2:  MATERIALS AND METHOD S   
45 
 
2.1 Mouse lines 
2.1.1 Maintenance of mouse stock  
This project involves the use of 3 main mouse lines: 
1)  Bpifa1-/- line: Straight knockouts for Bpifa1 wherein exons 2 and 3 of the Bpifa1 
gene have been deleted. Bpifa1-/- mice were originally obtained from University of 
Hawaii on a C57BL/6J background and re-derived at MRC Harwell. Generation of 
these mice is detailed in Section 2.1.2 
2) Evi1Jbo/+ line: Junbo heterozygotes, wherein the Evi1 gene contains a SNP as 
mentioned before (Section 1.12.1). Evi1Jbo/+ mice were identified through the 
Harwell ENU mutagenesis program and were maintained on a C3H/HeH 
background. 
3) Bpifa1-/-Evi1Jbo/+ line: Compound mutants, which bear mutations both from the 
straight knockouts as well as Junbo heterozygotes. In order to generate compound 
mutants with Evi1Jbo/+ mice, Bpifa1-/- mice were transferred onto the C3H/HeH 
background, in addition to being maintained on the original C57BL/6J background. 
The breeding strategy is discussed in depth in Section 2.1.3  
All mice were housed in individually ventilated cages (Techniplast UK Ltd.) in specific 
pathogen free (SPF) conditions. Mice were fed on an irradiated diet (Special Diets 
Service, UK) and water containing 25-ppm chlorine. The cages were supplied with 
grade 6 sawdust bedding (Datesand, UK Ltd.) and maintained in a 12-hour light/dark 
cycle at 21°C (±2°C) and 55% (±10%) humidity. Mice were inspected daily and all animal 
procedures were carried out in accordance to the ‘Responsibility in the Use of Animals 
for Medical Research (July 2003)’, issued by the Medical Research Council, adhering to 
the procedures enlisted under the Home Office project and personal licenses. 
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2.1.2 Generation of transgenic mice deficient in Bpifa1  
Bpifa1-/- mice were generated at University of Hawaii by Professor Ralph Shohet. These 
mice are unpublished A conditional targeting vector for Bpifa1, used for the transfection of 
C57BL/6J mouse embryonic stem cells was constructed by InGenious Targeting Laboratory 
Inc. (Ronkonkoma, NY). The targeted region on the Bpifa1 gene includes exons 2-3 (Fig 2.1). 
Confirmed targeted embryonic stem cells were microinjected into BALB/c blastocysts. 
Resulting chimeras with a high percentage black coat colour were mated to wild-type 
C57BL/6J mice to generate F1 heterozygous offspring. Correctly targeted F1 mice contained 
a Neo-selection cassette, three lox-P sites and two FRT sites. Deletion of the Neo-cassette 
was achieved by breeding with a heterozygous C57BL/6J FLP+/- mouse (Jackson Lab, stock# 
003800). Since these FLP mice are heterozygotes (homozygotes are embryonic lethal), the 
resulting F2 mosaic mice were screened for presence of the FLP transgene and deletion of 
the Neo cassette (Neo-/-). After breeding with C57BL/6J mice, the resulting F3 generation 
was screened for absence of FLP transgene as well as deletion of the Neo cassette and such 
a mouse was bred with another heterozygous FLP+/- and Neo-/- F3 offspring to produce a 
homozygously floxed F4 mouse without the FLP transgene and without the Neo cassette 
(Bpifa1loxP).  
To generate a systemic, straight Bpifa1 knockout mouse (Bpifa1-/-), Bpifa1loxP mice 
were mated with a mouse containing the Cre-recombinase transgene under the control of 
hCMV IE promoter (CMV-Cre, formally B6.C-Tg (Tg (CMV-cre)1Cgn/J; Jackson Lab Stock 
No: 006054).  
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Figure 2.1(Parkinson et al 2006) Generation of Bpifa1-/- mice 
The targeted region on wild type Bpifa1 locus containing exon 2 and 3 (A) Mice were targeted with a 
vector containing a loxP site upstream of exon 2 and a neomycin resistance cassette flanked by a 
loxP site and an FRT region, downstream of exon 3 (B) Bpifa1loxP mice were generated through FLP-
mediated deletion of the neomycin resistance cassette. (C) Straight Bpifa1-/- mice were generated by 
mating the floxed mice with C57BL/6JCre+/- mice to delete exons 2 and 3 (D). 
 
 
 
2.1.3 Breeding strategy 
 
Previous studies in our lab have revealed that Evi1Jbo/+ mice exhibit strain variability in the 
severity of OM. The phenotype is most severe in C57BL/6J strain, followed by C3H/HeH and 
then the BALB/c strain. Due to better viability ratios on the C3H/HeH background Evi1Jbo/+ 
have been maintained on this background (Tyrer PhD thesis 2013). Hence, in order to 
generate Bpifa1-/-Evi1Jbo/+ compound mutants, the founder C57BL/6J Bpifa1-/- mice were 
transferred to a C3H/HeH background. This was achieved by backcrossing Bpifa1+/- 
heterozygotes at each generation with wildtype (Wt) C3H/HeH females until generation 6 
(G6), at which point their genome is estimated to be 96.9% C3H/HeH. Bpifa1+/- females 
were outcrossed with Evi1Jbo/+ males to generate double heterozygotes in which one allele 
of the Bpifa1 gene was deleted and one copy of the Evi1 gene was mutated (Bpifa1+/-
Evi1Jbo/+) in a proportion of the progeny. This was because Evi1Jbo/+ females have a high rate 
of abortion (Parkinson et al 2006). Bpifa1+/-Evi1Jbo/+ mice were then backcrossed with 
Bpifa1+/- to generate the compound mutants Bpifa1-/-Evi1Jbo/+ in which both alleles of Bpifa1 
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were deleted and one copy of the Evi1 gene was mutated and other control genotypes. The 
breeding strategy is depicted in Figure 2.2 
Backcrossing to congenicity is a lengthy process. Therefore, the initial experiments 
performed with Bpifa1-/- mice on a C57BL/6 background well as Bpifa1-/- mice on a mixed 
C57BL/6J-C3H/HeH background (intercrossed at Backcross 2). The strains are mentioned 
where relevant throughout the thesis.   
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Figure 2.2 Breeding strategy for generation of compound mutants 
Bpifa1-/- mice on a C57BL/6J re-derived at MRC Harwell were mated with Wt C3H/HeH mice to 
produce Bpifa1+/- progeny, which were repeatedly backcrossed with Wt C3H/HeH mice. G6 Bpifa1+/- 
females were mated with Evi1Jbo/+ males to generate four different genotypes: Bpifa1+/+Evi1+/+ (Wt), 
Bpifa1+/-Evi1Jbo/+, Evi1Jbo/+ and Bpifa1+/-. Bpifa1+/-Evi1Jbo/+ males were subsequently backcrossed to 
Bpifa1+/- females (blue arrow) to generate the six experimental genotypes (blue box): test genotype, 
Bpifa1-/-Evi1Jbo/+ (red) and the control genotypes Bpifa1-/-, Wt, Bpifa1+/-Evi1Jbo/+, Evi1Jbo/+ and Bpifa1+/-. 
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2.2 Genotyping 
2.2.1 DNA Extraction Using Qiagen DNeasy Blood and Tissue Kit 
DNA for the gel based genotyping assay was extracted using the Dneasy Blood and Tissue 
Kit (Qiagen). Ear biopsies were incubated overnight at 56°C in 20μL Proteinase K and 180μL 
buffer ATL. The following day, samples were vortexed and a mixture of 200μL Buffer AL and 
200μL of absolute ethanol was added to each sample. Samples were thoroughly vortexed 
and centrifuged through a DNeasy mini spin column fitted in a 2ml collection tube at 8000 
rpm for a minute to bind the DNA to the column. The column was transferred to a new 
collection tube, 500μL Buffer AW1 was added to it and centrifuged for 1 minute at 
8000rpm. The column was again transferred to a new collection tube, 500μL Buffer AW2 
was added to it and spun at 14,000 rpm for 3 minutes. The column was then placed into a 
fresh 1.5ml eppendorf and incubated with 100μL of Buffer AE for 1 minute. DNA was eluted 
in the flow-through by spinning the column at 8000 rpm for a minute and either used 
directly for gel based genotyping or stored at -20°C for long term use.   
 
2.2.2 DNA Extraction Using Sample-to-SNP Kit 
DNA for qPCR and Light scanner based genotyping assays was extracted using the TaqMan 
Sample-to-SNP Kit (Applied Biosystems). 50μL lysis solution from the kit was added to the 
ear biopsies contained in 96 well micro titre plates (one biopsy per well). Plates were 
sealed with transparent plastic PCR plate lids (Thermoscientific), centrifuged briefly at 2000 
rpm to ensure that all samples were submerged in the solution and incubated at 95°C using 
G-storm thermocycler (GRI) for 3 minutes. Samples were cooled to room temperature, 
50μL stabilising solution was added to each well and centrifuged briefly at 2000 rpm to give 
the crude lysate. 1:10 dilution of the crude lysate was used for genotyping. 
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2.2.3 Polymerase Chain reaction 
The next step in genotyping the different lines was amplification of the extracted genomic 
DNA using a polymerase chain reaction (PCR). Details of the primer sequences for the gel 
based assay and the primer and probe sequences used for quantitative PCR (qPCR) and 
LightScanner assays are given in Table 2.1. 
For gel-based genotyping, PCR was carried out in 96 well PCR plates (Thermoscientific) in a 
total volume of 10.5μL using the BioRad tetrad thermocycler and the Qiagen multiplex PCR 
kit master mix (Table 2.2A). For qPCR based genotyping, the reaction was carried out in a 
total volume of 10μL in 96 well PCR plates (Thermoscientific) using the 7500 Fast Q-PCR 
cycler (Applied Biosystems) and GTX Taqman master mix (Applied Biosystems) (Table 2.2B).  
For LightScanner based genotyping, a 10μL reaction (Idaho technologies) (Table 2.2C) was 
overlaid with 20μL of mineral oil (Sigma) was run in Frame Star plates (Client Life Science) 
using a G-Storm thermocycler (GRI). Full details of the different PCR master mix contents 
are given in in Tables 2.2A, B and C. Cycling conditions used for the various assays are 
mentioned in Table 2.3 
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Table 2.1 Primer sequences for gel based, LightScanner and qPCR based genotyping assays 
Genotyping Assay Primer type Sequence 5’-3’ 
Agarose gel assay 
 
Forward 
Reverse 
CATGATGGCCTGAAAACAGA 
CTCAGGCTTGGGTATGTGGT 
LightScanner assay Forward 
Reverse 
Probe 
ACTGTGATAGATCATTCAGCATTTC 
CTTCAGGTGTCTGTCAAGATT 
GCTTCTCCTTGTTGTGGATGATGCG 
WT qPCR assay Forward 
Reverse 
FAM labelled Probe 
GGCCTGCTGGGAAAACTGA 
GCTGCCTAGGACTTCTGTTGTTAG 
CGTCATCAGTTCCTCTCCTGAACAACA 
KO Mutant qPCR 
assay 
Forward 
Reverse 
FAM labelled Probe 
ACCGGTACCTGCAGAATTCATG 
CTCAGGCACAGGTGATACAGA 
CGTTCTTCGGACGCCTCGTCAA 
Internal control qPCR 
assay 
Forward 
Reverse 
VIC labelled Probe 
TAGTTGGCATCCTTATGCTTCATC 
GCCCCAGCACGACCATT 
CCAGCTCTCAAGTCG 
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Table 2.2A PCR master mix details for gel based genotyping 
Gel based PCR Master mix components Volume (µl) 
Hotstart Master Mix  5 Q-Solution  2  Forward primer (10 µM)  0.5  Reverse primer (10 µM)  0.5  Nuclease free H2O  1.5 DNA (Qiagen Blood & Tissue Kit) 1   
Table 2.2B PCR master mix details for qPCR based genotyping 
qPCR Master mix components Volume (µl) 
GTX Taqman master mix  5 
Primers Dot1L_2F (20uM) 0.225  Primers Dot1L_R  (20uM) 0.225 
Probe DotL_2M     (5μM) 0.2  Biosearch Wt/ Mutant FAM Assay  (Probe at 5μM & primers at 
15μM each) 0.3 
Nuclease free H2O 1.55 
DNA (1:10 dilution of the ABI Sample-to-SNP crude lysate) 2.5    
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x 40 x 40 x 44 
 
Table 2.2C PCR master mix details for LightScanner based genotyping 
LightScanner PCR Master mix components Volume (µl) 
HotShot master mix  5 LC Green dye  1  Forward primer (20uM)  0.5 Reverse primer(20uM)  0.1  Probe 
 
0.5 
Nuclease free H2O 0.9 
DNA (1:10 dilution of the ABI Sample-to-SNP crude lysate) 2   
 
Table 2.3 PCR cycling conditions for genotyping of Bpifa1-/- line using gel based and qPCR assays 
and Evi1Jbo/+ line using LightScanner assay 
 Gel based assay qPCR assay LightScanner assay 
Step Temperature Time Temperature Time Temperature Time 
1 95°C 15 min 95°C 20 secs 95°C 2 mins 
2 94°C 1 min 95°C 30 secs 95°C 30 secs 
3 60°C 1.30 min 60°C 30 sec 60°C 30 sec 
4 72°C 3 min 72°C 3 min 72°C 3 min 
5 72°C 10 min   95°C 30 secs 
6 18°C hold   25°C 30 secs 
7     15°C 30 secs 
 
2.2.4 Agarose gel based genotyping assay 
To begin with, an agarose gel based genotyping assay was set up to differentiate between 
Wt and Bpifa1+/- mice during the initial backcrossing period. Post PCR, plates were briefly 
centrifuged and 2µl Orange-G loading dye was added to each sample. The plates were 
sealed and re-centrifuged to mix the dye well. 1% Agarose gel was prepared using 1 gm 
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Agarose powder (Sigma, UK Ltd.) in 100ml of 1% Tris- acetate- EDTA (TAE) buffer and 
1mg/ml of Ethidium Bromide. 10µl of the PCR product was loaded in each well against a 
standard marker (100bp ladder- New England Bioloabs Ltd.). The gel was run at 150V for 30 
mins and visualised using the Bio-Rad UV Illuminator and Quantity One v7-6.3 software.  
The genotyping strategy was based on the principle that using a single set of primers, the 
Wt and mutant sequences yielded two different sized products on the agarose gel. The Wt 
sequence yielded a single band larger than 1kb while the Bpifa1+/- sequence showed two 
bands: a higher band corresponding to the Wt allele of >1kb and a lower corresponding to 
the mutant allele of 500bps, due to the loss of exons 2 and 3 from the sequence. An 
example of a gel for genotyping Wt and Bpifa1+/- animals is shown in Figure 2.3. A Bpifa1-/- 
sequence would have an expected single band at 500bps. However, the gel based assay 
was used in the initial stages of back crossing when no Bpifa1-/-  mice had yet been 
generated. 
 
 
Figure 2.3: Gel based genotyping for Wt and Bpifa1+/- mice 
The above image represents the results for the gel based genotyping assay used to differentiate  
Bpifa1+/- mice and Wts. A single higher band indicates a Wt animal whereas, a sample showing both 
higher and lower bands indicate a Bpifa1+/- mouse.  The Wt control is mouse a random line Wt for 
the Bpifa1 gene and the Bpifa1+/- control is the G1 mouse from the cross between the founder 
Bpifa1-/- male and a Wt female. 
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2.2.5 Quantitative PCR based genotyping  
In order to facilitate genotyping of a large number of ear biopsies in a single run, the 
genotyping of the Bpifa1-/- line was transferred to a qPCR system. The qPCR assay was 
designed with the help of Adele Austin in the Genotyping Core facility (GEMS) at MRC 
Harwell. qPCR is a modification of the standard PCR method to continually monitor the 
progression of the reaction. It employs the use of a TaqMan probe complementary to a 
sequence between the forward and reverse primers. The probe is attached with a 
fluorescent reporter at its 5’ end and a quencher at its 3’ end. As long as they remain in 
close association, the emitted fluorescence is quenched. As the forward primer extends 
and reaches the probe, the reporter is cleaved and moves away from the quencher and the 
emitted fluorescence is detected and quantified by the qPCR software. The CT value of the 
product (the number of cycles required to reach a set threshold) is indicative of and 
inversely correlated to the amount of template DNA present in the sample. The CT value 
can also be used to determine the number of copies of a particular allele present in a 
sample. 
Two separate assays were designed for the Wt and mutant Bpifa1 sequence and each 
sample was run twice, once with the Wt assay and once with the mutant assay, thus 
allowing reconfirmation of the genotype. A representative graph showing the results from 
a genotyping experiment analysed using the ABI copy-caller software is shown in Figure 
2.4. The Bpifa1-/- samples showed two copies of the mutant allele while the Wt samples 
showed two copies of the Wt allele. Bpifa1+/- samples demonstrated a copy number of one 
for both the Wt and the mutant sequence. A Wt copy number of 2 corresponded with a 
mutant copy number of 0 and vice-versa thus validating the results. 
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Figure 2.4: qPCR genotyping for the Bpifa1-/- line 
The figure is an example of a qPCR assay performed for genotyping the Bpifa1-/- line. Each sample 
was run twice, once for the Wt assay and once for the mutant assay and the results for the two 
assays are shown adjacently for each sample. Green bars with a copy number of 2 denote Bpifa1-/-  
mice whereas the blue bars with a copy number of 2 denote Wts. For each Bpifa1-/-   sample, the Wt 
copy number is 0 and vice-versa. Bpifa1+/- mice are denoted by 1 copy of both the Wt and the 
mutant allele. 
 
 
 
 
2.2.6 LightScanner genotyping 
A LightScanner assay was used for genotyping of the Evi1Jbo/+ line and was developed by 
Deen Quwailid, GEMS core at MRC Harwell. Post PCR, the plates were centrifuged for 3 
minutes at 1700 xg and analysed using the LightScanner HR/96 (Idaho Technology) along 
with the LightScanner Call-It software v2.0. This genotyping strategy exploits the variability 
in the melting temperatures of different DNA sequences to differentiate between various 
amplicons. The LC green dye in the master mix binds to the double stranded PCR product. 
During the final hybridisation step, this double stranded DNA is heated causing melting of 
the DNA and consequent release of the fluorescent dye which is detected by the system. 
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The method also uses a small probe that spans the SNP in the Evi1Jbo/+ mutation. In the 
mutant allele (Evi1Jbo/ Jbo), the probe perfectly anneals to the SNP and emits the most 
fluorescence and does so at a higher temperature. The Wt allele has a mismatch between 
the probe and its complimentary DNA strand and thus emits less fluorescence. The melting 
profile for Evi1Jbo/+ is intermediate between the two. This method was used to differentiate 
between Wts and Evi1Jbo/+ mice (Evi1Jbo/Jbo mice are post-natal lethal). An example of the 
genotyping results is shown in Figure 2.5 
 
Figure 2.5: LightScanner genotyping for the Evi1Jbo/+ line 
The figure shows LightScanner analysis results for genotyping of the Evi1Jbo/+ line. The melt profile 
for the Wt DNA strands is denoted in grey and that for the Evi1Jbo/+ DNA strands is denoted in red. 
For genotyping the Bpifa1-/-Evi1Jbo/+ line, each DNA sample was analysed for the Bpifa1-/- allele using 
the qPCR assay and the Evi1Jbo/+ allele using the LightScanner assay. 
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2.3 Auditory Brainstem response 
Determination of Auditory Brainstem Response (ABR) thresholds is routinely used as a 
phenotypic test for identification of hearing loss in mice. In this study, the Click evoked ABR 
method was used in which a broad-spectrum sound of progressively reducing intensities 
from 70 decibels (dB) to 5 dB in decrements of 5 dB is played to the mouse’s ear. Animals 
were weighed and intra-peritoneally injected with 1ml Ketamine (Ketaset®, Fort Dodge 
Animal Health) and 0.5 ml Xylazine (Sedaxylan®, Ceva Animal Health) in 8.5 ml sterile water 
(Dechra Veterinary products), at a dose of 0.1ml/10gm body weight using a 25-gauge 
syringe (Scientific Laboratory Supplies) and placed in a hot box at 35°C till deeply 
anaesthetised. Mice were then transferred onto a hot mat in a sound proof booth and a 
generous amount of Viscotears (Novartis AG) was applied to their eyes to avoid 
dehydration. Three electrodes were positioned sub-dermally in the following order: (a) The 
ground electrode behind the right mastoid (b) The reference (-) electrode at the midline or 
the cranial vertex and (c) the positive electrode behind the left mastoid. A sound emitting 
speaker was positioned 1.5 cm away from the pinna, directly facing the auditory canal. The 
booth was closed and a click stimulus was generated by TDT SigGen RP Software (TDT 
system III). The auditory response was recorded and analysed using the Intelligent Hearing 
Systems Opti amp 8002 software. The normal hearing response appears in the form of a 
graph trace with 5 peaks, each one indicating a different region of the auditory circuit. A 
typical ABR graph trace is shown in Figure 2.6. On completion of the test, mice were 
recovered in the hot box by subcutaneous administration of 0.1 ml/10gm body weight of 
the antidote, containing 0.1 ml Atipamezole hydrochloride (Antisedan, Pfizer Animal 
Health) in 9.9ml water. After full recovery the mice were returned to their home cages. For 
terminal ABRs, mice were culled according to Schedule 1 of the Home Office guidelines 
post ABR measurements and sent for histological analysis.  
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Figure 2.6: Auditory brainstem response measurement 
The figure shows the measurement of ABR thresholds in mice.  Sub dermal placement of electrodes 
– adapted from MLC standard operating procedure 1219 (A) A representative click-evoked ABR 
graph trace from a wild type mouse showing the 5 auditory peaks (P1- P5). Hearing threshold for the 
mouse was detected at 25dB (asterisk), which is the minimum intensity for which a reproducible 
graph trace can be obtained (B). 
 
 
 
2.4 Histology 
All samples unless otherwise mentioned were processed, embedded, sectioned and H&E 
stained by the necropsy and histology teams at MRC Harwell. 
  
2.4.1 Decalcification, paraffin embedding and sectioning 
Mice were culled by intraperitoneal overdose of sodium pentobarbital (Pentoject 
Animalcare, UK). Samples were fixed in 10% paraformaldehyde (Surgipath Europe) for 48 
hours at room temperature and decalcified in Kristenson D.F.B agent (Pioneer Scientific) for 
72 hours. Using the Shandon Pathcentre machine (Thermoscientific), samples were 
dehydrated through increasing concentrations of ethanol (70, 90 and 100%), cleared in 
Xylene and embedded in liquid paraffin wax and left to set. The paraffin blocks were cut 
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into 4μm transverse sections on the Finesse™ ME+ microtome (Thermoscientific), floated 
onto clean water to remove creases at 50°C and transferred to charged slides 
(Thermoscientific).  
 
2.4.2 Haematoxylin and eosin staining  
At least one paraffin embedded sections from each mouse was placed on Shandon 
Varistain 24 (Thermoscientific) for haematoxylin and eosin (H&E) staining. Sections were 
deparaffinised with Sub-X (a substitute for xylene), rehydrated through 100% and 70% 
isopropanol (Fischer Scientific) and rinsed under running water. The slides were then 
stained for 6 minutes with Haematoxylin (Shandon Gill 3, Thermo Scientific) which stains 
basophilic structures such as nuclei and differentiated in acid alcohol (hydrochloric acid 
diluted to 1%  in 70% industrial methyl spirit ) to clear background staining . Sections were 
then submerged in 1% lithium carbonate (Fischer Scientific), which makes nuclei appear 
blue and counter-stained for 3 minutes with Eosin (Thermoscientific) which stains 
eosinophilic structures such as the cytoplasm pink. The slides were rinsed briefly under 
running tap water between each step. Sections were finally dehydrated in 70% and 100% 
isopropanol and mounted with Clearium (Surgipath Europe). H&E stained sections were 
scanned using the NanoZoomer Digital Pathology system. 
Bullae samples before and after pronase treatment were embedded, sectioned and H&E 
stained by the Histology core facility in the School of Clinical Dentistry at University of 
Sheffield. 
 
2.5 Histological analysis of H&E sections 
 
I accessed the scanned H&E stained sections of middle ears at Sheffield using Scan-srv NDP 
NanoZoomer software (Hamamatsu).  Thickness of the middle ear mucosa was measured in 
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a defined 1mm area in the promontory region opposite the tympanic membrane. Average 
mucosal thickness was calculated using 5 measurements taken at a distance of 250 μM 
within this region. 
Analysis of H&E slides of the tissue sections from the complete histology screen of Bpifa1-/- 
mice at 6 months of age was performed by Professor Michael Cheeseman at the Roslin 
Institute, Edinburgh. A total of 42 target tissues were analysed for morphological 
abnormalities. 
 
2.6 Immunohistochemistry 
2.6.1 Blocking and antigen retrieval 
Tissue sections were deparaffinised and dewaxed by two 5 minute changes in 100% Xylene 
(Sigma) and rehydrated through 100% and 95% Ethanol (Fischer Scientific). Endogenous 
peroxidase activity was blocked with 0.3 % H2O2- Methanol (Fischer Scientific) for 20 
minutes. High temperature antigen retrieval was performed for all primary antibodies 
except anti-BPIFA1 by microwaving the sections in 0.01M tribasic Sodium citrate (Sigma) 
for 8 minutes. This allows unmasking of antigens by breaking the methylene bridges or co-
ordinate calcium bonds that are formed between some antigen peptides during the fixation 
process. Non-specific binding of secondary antibodies was blocked by incubating the 
sections in 100% normal serum from the animal used to raise the secondary antibody for 
30 minutes at room temperature.  
 
2.6.2 Detection and analysis 
Sections were washed in PBS for 5 minutes and incubated overnight with the appropriate 
primary antibody in serum in a humified chamber at 4◦C. Details of the antibodies used for 
Immunohistochemistry (IHC) are given in Table 2.4. For negative controls, no primary 
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antibody was added. The following day, sections were incubated in 0.5% biotinylated 
secondary antibody from the Vectastain® Elite® ABC kit for 30 minutes at room 
temperature. This was followed by incubation with the AB Complex (ABC) reagent for 30 
minutes and brief incubation with NovaRed mixture from the VECTOR NovaRed kit (SK 
4800) for colour development. Sections were washed twice in PBS for 5 minutes between 
each step. The ABC reagent is a pre-formed complex of the homotertramer, avidin and 
biotinylated horse radish peroxidase enzyme. The AB complex binds to the biotin of the 
secondary antibody. HRP oxidizes a chromogen in presence of H2O2, both of which are 
components of the NovaRed kit to form a dark red colour. Details for preparation of ABC 
reagent and Novared mixture are given in Appendix I. Sections were counterstained on the 
Leica ST4020 autostainer using Harris’ haematoxylin (Thermoscientific), differentiated in 
acid alcohol, treated with Scott’s tap water to change the colour of the nuclei to blue, 
dehydrated in 95 % to absolute ethanol and cleared in Xylene (Leica, Cat No- ST 4020). 
Sections were mounted using Di-N-Butyl Phthalate in Xylene (DPX, Leica Biosystems) and 
visualized and imaged using a light microscope (Olympus BX61) for analysis. 
 
Table 2.4: Antibodies used for Immunohistochemistry (IHC) 
Primary 
Antibody 
 
Type 
 
Dilution Manufacturer 
 
Anti- BPIFA1 Rabbit polyclonal 1:750 Prepared in lab (Musa et al 2012) 
 
Anti- 
Lactotransferrin 
Rabbit antisera 1:500 Milipore (07- 685) 
Anti- αSMA Rabbit polyclonal 1:200 Abcam (5694) 
NB: IHC for comparison of protein expression between Wt, Bpifa1-/-, Evi1Jbo/+ and Bpifa1-/-Evi1Jbo/+ 
middle ears was performed by Catherine Russell, an undergraduate placement student in the lab 
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2.7 Collagen staining 
Picrosirius red stain kit (Polysciences Inc) was used to chemically stain collagen I and III 
fibres in middle ear sections tissue sections. Picrosirius Red Stain binds to collagen fibrils of 
varying diameter. The kit contains 3 solutions: A (phosphomolybdic acid), B (Picrosirius red 
stain) and C (1N hydrochloric acid). Briefly, tissue sections were deparaffinised and 
dewaxed by two 5 minute changes in 100% Xylene (Sigma) and rehydrated through 100% 
and 95% Ethanol as mentioned in Section 2.6.1. 500μL of Weigert’s haematoxylin (details in 
Appendix I) was added and the sections were stained for 8 minutes. Sections were briefly 
rinsed in distilled water and placed in solution A from the kit for 2 minutes. Sections were 
rinsed again with distilled water and stained with solution B for 60 minutes, followed by 
solution C for 2 minutes.  Sections were placed in 70% ethanol for 45 seconds, dehydrated 
in 95 % to absolute ethanol, cleared in Xylene, mounted using DPX and visualised under 
Olympus BX61 light microscope as mentioned in Section 2.6.2. 
 
2.8 Cell culture 
2.8.1 Primary culture of mouse nasal and middle ear epithelial cells 
I performed all cell culture work and subsequent treatments on cultured cells at University 
of Sheffield. The dissection of mouse nasal cavities, nasal septae and middle ears is detailed 
in Figure 2.7. 
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Figure 2.7 Dissection of mouse nasal cavity, nasal septum and middle ear cavity 
Wild type C57BL/6J or C3HeH mice (A) were decapitated (B). The head was skinned (C) and skullcap 
removed (D). Dorsal view of the head after removing the brain. The nasal cavity was dissected along 
the dotted lines to separate it from the lateral maxillary walls (E). Dorsal (F) and ventral (G) view of 
the harvested nasal cavity, showing the nasal septum, NS. Under dissecting microscope, the nasal 
cavity was cleaned from the surrounding tissue (H). The nasal septum was gripped and separated 
from the dorsal nasal bone (I). Ventral aspect of the remaining head, after dissecting out the nasal 
cavity showing the bullae or middle ear cavities, MECs (J). Bisected head showing the outer ear, OE 
(K). Under dissecting microscope, the bullae were separated from surrounding tissue (L). The MEC is 
attached to the outer ear cavity, OEC, at the tympanic membrane, Tm and tapers towards the 
opening of the Eustachian tube, ET near its posterior end (M). Removal of the OEC and the Tm along 
the dotted lines reveals the cochlea of the inner ear on the ventral side of the MEC (N) The cup 
shaped MEC was detached from the inner ear (O)  
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2.8.1.1 Harvesting of nasal cavities and nasal septae 
Mice were euthanized by terminal intra-peritoneal injection of 100μL pentobarbital 
(50mg/ml, Henry Schein®) and exsanguinated by cutting the inferior vana cava. The 
method for dissection of nasal cavities and the nasal septum was adopted from 
(Woodworth et al 2007) and is shown in Figures (2.7A- 2.7I). Under direct visualization, 
mice were decapitated; the skin at the nape of the neck was incised, bisected anteriorly 
and removed entirely to expose the bony surface of the skull and the nose. The mandible 
was detached with a pair of blunt scissors. The head was placed under a dissecting 
microscope (Olympus SZx10), with the nares facing away and the skullcap was gently 
opened with a pair of fine forceps and the brain was removed. Removal of the brain 
exposes the anterior most part of the skull base, which is attached to the posterior most 
part of the nasal cavity (Figure 2.7E). In order to obtain entire nasal cavities, a pair of fine 
dissecting scissors was inserted at this boundary and nasal cavity was incised out 
bilaterally, along the dotted line (Figure 2.7E) to separate it from the lateral maxillary walls 
and the tip of the nose was severed (Figure 2.7F). The nasal cavity was inverted (Figure 
2.7G); remnants of the upper palate were removed and any extraneous tissue and hairs 
were cleaned.  
Inversion of the dissected nasal cavity enables clear visualization of the nasal septum 
(Figure 2.7H). Individual septae were harvested by grasping them with bent forceps, close 
to the floor of the nasal cavities to carefully pull them away from the nasal ridge bones 
(Figure 2.7I). 
 
2.8.1.2 Harvesting of middle ear cavities 
All initial steps including euthanisation of mice till the removal of brain from the skull cavity 
were performed as mentioned in section Section 2.8.1.1. The heads were then bisected at 
the midline (Figure 2.7J) and each half was oriented with the opening of the opening of the 
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ear facing upwards (Figure 2.7K) under a dissecting microscope (Olympus SZx10). Any 
muscle, soft tissue and remnant hair surrounding the ear were removed using fine 
dissecting scissors and forceps, leaving the middle ear cavity (bulla), still attached to the 
outer ear canal and the inner ear (IE; Figure 2.7L). The bony shell of the bulla was further 
cleaned free of any attached extraneous tissue. The Outer ear canal, which appears a shade 
lighter than the middle ear cavity, was gently broken away from the bulla using stork bill 
forceps (Figure 2.7M). The Tm and the ossicles usually detach from the bulla along 
with the outer ear canal. Alternatively, they were physically removed using fine stork 
bill forceps. Lastly, the cup-shaped bulla was carefully lifted away from the inner 
ear (Figure 2.7N and 2.7O).  
 
2.8.1.3 Isolation of epithelial cells from the harvested tissue 
The protocol for isolation, culture and differentiation of mouse middle ear epithelial cells 
(mMECs) and nasal epithelial cells (mNECs) was adapted from a method for isolation of 
mouse tracheal epithelial cells (mTECs) (You & Brody 2013, You et al 2002). For each batch 
of cells, harvested tissue (nasal cavities, nasal septae or bullae) from approximately six 
mice were pooled in a tube containing pronase (1.5 mg/ml) in ‘mMEC basic media’: 
DMEM/F-12 HAMs media (Life Technology) supplemented with penicillin (100 µg /ml) and 
streptomycin (100 µg/ml) (Life Technology) and subjected to overnight proteolysis at 4°C. 
The next day, the pronase was neutralised by the addition of 10% foetal bovine serum 
(FBS) and the samples were gently agitated by inverting the tube 25 times. The samples 
were then transferred to 2ml of fresh mMEC basic 10% FBS media, the tube was inverted 
again 25 times and this process was repeated 3 times. The combined proteolytic and 
mechanical actions led to dissociation of the epithelial cells from the tissue (Figure 2.8). 
Media from the three tubes was combined and centrifuged at 500 xg for 10 minutes at 
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10°C. The pelleted cells were re-suspended in 1ml of media containing 1 mg/ml bovine 
serum albumin (BSA) and 0.5 mg/ml DNase I (Sigma-Aldrich). Cell viability and number 
were assessed using trypan blue staining and a haemocytometer. Cells were centrifuged at 
500 xg for 5 minutes at 10°C and the pellets re-suspended in 5ml of mMEC basic 10% FBS 
media. In order to remove contaminating fibroblasts from epithelial cells, a differential 
adherence step was performed by plating the cells on 60mm surface treated tissue culture 
dishes (Nunclon®, Sigma-Aldrich) at 370C in a 5% CO2 incubator for 3-4 hours. Fibroblasts 
attached to the plastic whilst the non-adherent epithelial cells were collected, centrifuged 
at 500g for 5 minutes at 10°C and re-suspended in 1ml of ‘mMEC plus’ media: mMEC basic 
media supplemented with 5% FBS, 30 µg/ml bovine pituitary extract (Life Technology), 10 
µg/ml of insulin (Sigma-Aldrich), 25 ng/ml of mouse epidermal growth factor (BD 
Biosciences), 5 µg/ml of transferrin (Sigma-Aldrich), 0.1 µg/ml of cholera toxin (Sigma-
Aldrich) and 0.01 µM of freshly added retinoic acid (Sigma-Aldrich).  
 
Figure 2.8 Effect of pronase treatment on middle ear epithelial cells 
Haematoxylin and eosin staining of dissected middle ear cavities showing intact middle ear 
epithelium before proteolytic treatment with pronase (A) and loss of the epithelial lining after 
treatment with pronase and mechanical agitation (B) during the cell isolation process suggesting 
that our isolation protocol successfully dissociates middle ear epithelial cells for culture. Scale bar = 
200 μm 
 
 
69 
 
2.8.1.4 Optimisation of culture conditions 
For determination of optimal culture conditions for the growth of mMECs and mNECs and 
formation of a confluent monolayer, cells were plated on either tissue culture plastic (2.5 x 
104cells/well) or sterile, 0.4μm pore sized transparent PET (Polyethylene Terephthalate) 
membranes coated with 150μL (50μg/ml) of rat-tail collagen type I (BD Biosciences) in a 24-
well supported transwell format (Falcon) 1. On transwells, mMECs were seeded at an initial 
density of 1 x 104 and 2 x 104 cells/well in the presence or absence of 10 μM of Rho Kinase 
inhibitor Y-27632 dihydrochloride (ROCKi, Tocris bioscience) and 5 x 104 cells/well without 
ROCKi. mNECs obtained from whole nasal cavities were seeded at an initial density of 5 x 
104 and 1 x 105  and 2 x 105 without ROCKi and at 3 x 104 cells/well with ROCKi. mNECs 
isolated from nasal septae were seeded at 5 x 104 cells/well without ROCKi. 
The total number of cells obtained from the nasal septum was very low. Hence, all batches 
of mNECs described in this thesis were isolated from whole nasal cavities. A seeding density 
of 1 x 104 cells/well with ROCKi for mMECs and 3 x 104 cells/well with ROCKi for mNECs, 
both grown on transwell membranes was identified as optimum and therefore used for 
culturing all subsequent batches of cells. 
  
2.8.1.5 Air liquid interface culture of mouse middle ear and nasal epithelial cells 
mMEC and mNEC cells were plated on collagen coated transwell membranes placed in 24 
well plates. Cells were initially cultured, submerged, in ‘mMEC plus-proliferation media’ 
with 300 μL of media in the top chamber and 700 μL in the bottom chamber.  Media was 
changed every 48 hours, until the cells were completely confluent, whereafter media from 
the top chamber was removed and media in the bottom chamber was replaced with 
‘mMEC SF- differentiation media’: DMEM/F-12HAMs media supplemented with 1 mg/ml 
BSA (Life Technology), 5 µg/ml insulin, 30 µg/ml bovine pituitary extract, 5 µg/ml 
transferrin, 5 ng/ml mouse epidermal growth factor, 0.025 µg/ml cholera toxin and freshly 
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added 0.01 µM retinoic acid. This system of culture, with media in the bottom culture and 
apical surfaces of cells exposed to air is known as ALI (Air liquid interface) culture and it 
promotes maximal differentiation of cells by mimicking the in vivo physiology. Cells were 
grown at ALI for 14 days. Media was changed and apical surfaces of cells were washed with 
200µL of sterile, warm HBSS every 48 hours to clear any cellular secretions and mucous 
deposition. Cells were lysed in 250 µL of Trizol reagent (Sigma- Aldrich) for RNA extraction 
and apical washes were collected in 200 µL of sterile HBSS at ALI Day 0 (submerged Day 
10), Day 3, Day 7 and Day 14. Figure 2.9 gives a brief summary of the cell culture system.  
 
Figure 2.9 Timeline and method for ALI culture of mMEC and mNEC cells 
Timeline for culture of mMECs and mNECs is shown above. Bullae were dissected, treated with 
pronase for dissociation of the middle ear epithelial cells and fibroblasts excluded from culture by 
differential adherence to plastic. ALI was induced upon confluence. Samples for transcriptional and 
proteomic analysis were collected at regular time points (A). Establishment of air liquid interface 
(ALI) cultures. Cells were initially grown in submerged culture on 0.4μM semipermeable transwell 
membranes up to confluence in a proliferation medium. Most cells are undifferentiated basal cells 
at this point (blue). At confluence, basal chamber is replenished with a differentiation medium and 
apical surface of cells is exposed to air. This promotes differentiation into ciliated cells (green) and 
various secretory cell types (red) (B)  
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2.8.2 Fibroblast culture 
The principle of separation of fibroblasts from mMEC and mNEC cells using the differential 
adherence is explained in Section 2.8.1.3. Fibroblasts have higher affinity to plastic than 
epithelial cells and were separated by incubating the mixed population of epithelial cells 
plus fibroblasts on 60mm plastic petri dishes for 3-4 hours and collecting the non-adherant 
epithelial cells. Adherent fibroblasts were cultured by adding 5 ml of mMEC basic 10% FBS 
media to the tissue culture dish and incubating at 370C in a 5% CO2 incubator till confluent. 
Upon confluence, cells were washed with warm HBSS and sub cultured twice to obtain a 
pure fibroblast population. For passage 3, 3mls of Trypsin-EDTA solution (Sigma) was added 
to the dish and incubated in the incubator for a minute to dislodge the cells. Trypsin was 
neutralised by addition of 3ml neutralising medium (mMEC basic 10% FBS) and cells were 
centrifuged at 500 xg for 5 minutes. Cell pellets were resuspend in 5mls of fresh mMEC 
basic 10% FBS and split into 5 T25 flaks for expansion of the fibroblast cultures. 4 ml of 
media was added to each flask and cells were cultured 370C in a 5% CO2 till confluence. 
Confluent fibroblasts from 3 flasks were lysed in 250 μL TRI reagent each for RNA 
extraction. 
  
2.8.3 Freezing down fibroblasts 
Fibroblasts from the remaining two T25 flasks were dislodged by trypsinisation, pelleted at 
500 xg for 5 minutes and resuspend in 1 ml of mMEC plus media +10% DMSO in cryovials. 
Cells were frozen at -800C overnight and then transferred to liquid nitrogen. 
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2.9 Calculation of population doubling time for mMECs and middle ear fibroblasts 
For calculation of population doubling time (PD), mMECs were seeded at 5 x 104 cells/well 
in mMEC- Plus media without ROCKi in submerged culture. Middle ear fibroblasts were 
seeded at 5 x 104 cells/well in mMEC basic 10% FBS media in tissue culture grade 6 well 
plastic plates (Falcon). Media was changed every 48 hours. mMECs were harvested every 
48 hours by trypsinisation and quantified using a haemocytometer from day 2 to day 10. 
Fibroblasts were harvested every 24 hours from days 1-3. 
 Population doubling time was determined using the formula:  
   
         
              
Where, PD = Population doubling, T= time (24 hours for fibroblasts and 48 hours for 
mMECs), Log =Log10, C1 = initial cell count, C2 = final cell count]. 
 
2.10 Fluorescence Immunocytochemistry 
Fluorescence Immunocytochemistry (IFC) was used for the localisation of proteins 
produced by mMECs and mNECs. Transwell membranes at ALI Day 0 and Day 14 were fixed 
with 10% phosphate buffered formalin at 370C for 30 minutes. Cells were permeabilised 
using 0.5% Triton X-100. Non-specific binding of the secondary antibodies was blocked 
using 10% normal serum from the animal used to raise the secondary antibody for 1 hour 
at 80rpm on an orbital shaker at room temperature. The membranes were washed 3 times 
with PBS for 5 minutes at 150 rpm and incubated with the appropriate primary antibody 
overnight at 4◦C at 80rpm on the shaker. Details of the primary antibodies used are given in 
Table 2.5. For negative controls, no primary antibody was added. The following day, 
membranes were washed as previously described and bound primary antibodies detected 
using 1:200 dilutions of the appropriate fluorophore-tagged secondary antibody: 568 Goat 
anti-rabbit antibody or 488 Goat anti-mouse antibody (Alexa Fluor) and incubated for 1 
hour at 80 rpm at room temperature in the dark. Excess antibody was removed by washing 
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the membrane 3 times in PBS. The membranes were carefully detached from the transwell 
support using a fine scalpel and placed on a glass microscope slide with the cells facing 
upwards. Nuclei were counterstained using Vectashield DAPI mounting medium (Vector 
laboratories) and the cells visualised and imaged using an Olympus Fluoview 1000 Confocal 
microscope. 
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Table 2.5 Antibody details for IFC 
Primary 
Antibody 
 
Type 
 
Dilution Manufacturer 
 
Anti- BPIFA1 Rabbit polyclonal 1:200 Prepared in lab (Musa et al 2012) 
 
Anti- FOXJ1 Mouse monoclonal 1:300 Affymetrix eBioscience (2A5) 
Anti- MUC5B Rabbit polyclonal 1:200 Santa Cruz Biotechnology (H-300) 
Anti- P63 Mouse monoclonal 1:100 Santa Cruz Biotechnology (4A4) 
Anti- 
Lactotransferrin 
Rabbit antisera 1:200 Milipore (07- 685) 
Anti- REG3γ Rabbit polyclonal 1:200 Kindly provided by Professor Lora 
Hooper (Cash et al 2006) 
Anti ZO-1 Rabbit polyclonal 1:100 Life Technologies (40-2200) 
 
 
2.11 Quantification of intracellular localization of epithelial proteins  
ALI Day 14 mMEC membranes immunostained for BPIFA1, FoxJ1 and MUC5B as mentioned 
in Section 2.10 were visualized using the Olympus Fluoview 1000 Confocal microscope. 8 – 
10 adjacent fields at 20x magnification, spanning one half of the membrane were imaged. Z 
stacks were analysed and merged using Photoshop elements editor 8 to obtain a single 
image. The amount of protein expression in each field was quantified by measuring the 
mean integrated fluorescence using Image J software.  The percentage of cells expressing a 
specific protein was quantified using Image J as follows: 
 
                                              
                                         
 
The amount of BPIFA1 expression post bacterial infection was quantified at 60x 
magnification by measuring the mean integrated intensity of 5 fields per membrane using 
Image J software. Three individual batches were analysed for all quantification. 
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2.12 Electron Microscopy 
All post fixation processing for both scanning electron microscopy (SEM) and transmission 
electron microscopy (TEM) and imaging for TEM were performed by Dr Christopher Jill in 
the Department of Biomedical Science, University of Sheffield.  
 
2.12.1 Sample preparation and fixation 
For SEM and TEM of mMEC ALI cultures, media was removed from the bottom chamber of 
the transwells. Cells were washed 3 times with 200μl of warm sterile HBSS (Gibco) and the 
transwell membranes were transferred to a fresh 24 well plate. Membranes were 
immediately fixed by adding 3% Glutaraldehyde in 0.1M Sodium Cacodylate buffer to the 
top chamber and incubated overnight at 4◦C. Following day, membranes were washed 2 
times with 0.1M Cacodylate buffer for 5 minutes each and detached from their transwell 
support as mentioned before Section 2.10. 
For SEM of native middle ear epithelium, whole bullae were dissected as mention in 
Section 2.8.1.2. Bullae were rinsed in in sterile HBSS and immediately fixed overnight in 3% 
Glutaraldehyde in 0.1M Sodium Cacodylate buffer at 4◦C. The following day, bullae were 
washed in buffer as mentioned above. 
 
2.12.2 Scanning electron microscopy 
Samples were post fixed in 2% aqueous Osmium tetroxide for 2 hour at room temperature, 
washed 2 times with 0.1M Cacodylate buffer for 5 minutes each. Samples were then 
dehydrated by passing through a series of ethanols of increasing strength (75%, 95%, 100% 
and 100%) for 15 minutes each and then dried twice for 15 mins at room temperature in 
100% ethanol over anhydrous Copper sulphate. Samples were placed in a 1:1 mixture of 
Hexamethyldisilazane (HEX) and absolute ethanol for 20 minutes before being finally 
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transferred to 100% HEX for 20 minutes and air dried overnight, in a fume hood. Samples 
were mounted onto a pin-stub using Leit-C sticky tabs and coated with gold using the 
Edwards sputter coater and examined using a Philips XL-20 SEM at 15kV operating voltage. 
 
2.12.3 Transmission electron microscopy 
Samples were post fixed in 2% Osmium Tetroxide, washed briefly in water and dehydrated 
through a graded series of ethanols as mentioned in Section 2.12.2. Samples were then 
cleared in two changes of Epoxypropane (EPP) for 15 minutes and infiltrated in 1:1 mixture 
of araldite resin and EPP overnight on a rotating mixture at room temperature. This 
mixture was replaced in two changes with full strength araldite resin over an 8 hour period, 
embedded in fresh resin and cured at 60◦C in an oven for 48-72 hours. Ultrathin sections of 
the embedded samples (approximately 85nm thick) were cut on a Leica UC6 ultra-
microtome onto 200 mesh copper grids, stained for 30 minutes with saturated aqueous 
Uranyl Acetate followed by Reynold’s Lead Citrate for 5 minutes. Sections were examined 
using a FEI Tecnai Transmission Electron Microscope at an accelerating voltage of 80Kv. 
Electron micrographs were recorded using a Gatan Orius 1000 digital camera and Digital 
Micrograph.  
 
2.13 Non Typeable Haemophilus influenzae challenge experiments 
All in vivo challenge experiments with the human otopathogen, NTHi  were performed at 
MRC Harwell and all in vitro NTHi challenge experiments on mMEC ALI cultures were 
performed at University of Sheffield. 
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2.13.1 NTHi strains 
For in vivo intranasal and baro-inoculation of mice, genomically sequenced, streptomycin 
resistant strains of (NTHi) #162 (NTHi 162SR) and NTHi #375 (NTHi375SR) were used. Both 
NTHi #162 and #375 are clinical isolates from a Finnish pneumococcal vaccine study on 
children undergoing tympanocentesis during the year 1994-95 (Cody et al 2003). For NTHi 
infection of mMECs, a GFP tagged strain of NTHi375SR (NTHi 375SR-GFP) was used. All 
streptomycin resistant strains were generated and supplied by Dr. Derek Hood, MRC 
Harwell. 
 
2.13.2 Preparation of bacterial inoculums 
For in vivo experiments, bacteria were grown from glycerol stocks on brain heart infusion 
(BHI) agar plates supplemented with Levinthals (LEV) and streptomycin sulphate (Melford 
Laboratories) (BHI-LEV). For in vitro experiments, bacteria were streaked onto BHI plates 
supplemented with 2μg/ml Nicotinamide adenine dinucleotide hydrate (NAD, Sigma 
Aldrich), 2μg/ml hemin (Sigma Aldrich) and 200μg/ml streptomycin sulphate (Melford 
Laboratories) (BHI-NAD-Hm). Plates were incubated at 37°C, 5% CO2 overnight. The 
following day, a few colonies were transferred into BHI-LEV or BHI-NAD-Hm broth and 
incubated for 3 hr at 37°C, 5% CO2, at 250 rpm. An optical density (OD490) of 1ml liquid 
culture was spectrophotometrically determined (Jenway 6300) and calibrated against 1 ml 
of uninoculated broth. 1ml of the culture was centrifuged at 13,000 rpm for 2 minutes and 
resuspended in required volume of PBS to give an inoculum containing 1x1010 bacteria/ml, 
by using the equation (OD490/0.4) x 2 x109. For in vivo NTHi challenge experiments, the PBS 
was supplemented with 1% gelatin to increase the viscosity of the inoculum. Purity and 
colony forming units (CFU)/ml of bacteria were checked by plating the inoculum on BHI-LEV 
or BHI-NAD-Hm plates before and after infection to ensure that bacteria remained viable 
through the infection process.  
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2.13.3 Intranasal inoculation of mice with NTHi 
Mice were removed from their home cage and placed into a gas anaesthetic chamber 
containing isoflurane. The isoflurane flow rate was set at 2.5- 3 litres/ min and oxygen flow 
rate at 2 litres/min. Once deeply anaesthetised, mice were removed from the chamber and 
5μl of inoculum (1x1010 CFU/ml) was placed into each nostril using a pipette tip, thus 
inoculating each mouse with a total of 1x108 bacteria. Animals were returned to their cage 
to recover. Mice are obligate nose breathers, hence the inoculum entered their nasal 
passages as they sniffed during the recovery process.  
 
2.13.4 Baro-inoculation of mice  
2.13.4.1 Baro-inoculation pilot study  
Baro-inoclutaion is a modification of the intranasal inoculation protocol in which mice are 
inoculated under the effect of increased pressure. In theory, this serves to open the ET and 
improves the efficiency of bacterial ascension from the nasopharynx into the middle ear 
cavity. The protocol was adapted from previously published studies in mice (Stol et al 2009) 
and rats (Tonnaer et al 2003). Since this was the first baro-inoculation experiment 
conducted at MRC Harwell, a pilot study was performed as proof of principle before 
inoculating mice with NTHi. A pressure chamber was developed at the Scientific Workshop 
at MRC, Harwell. 2 Wt mice were anaesthetized and intranasally inoculated with 10μl of 
0.1% Evans blue dye in 1% Methyl cellulose-PBS solution in manner similar to Section 
2.13.3 and then placed in the pressure chamber on a cardboard bed on their backs and the 
lid was secured tightly. The entire process took about 30 secs. Immediately, the pressure in 
the baro-inoculation chamber was raised to approximately 1.4 pounds per square inch (Psi) 
by puffing air in through the inlet. Thereafter, the pressure was increased by approximately 
0.7 PSI every 15 secs, such that a maximum pressure of 5.8 Psi was achieved by the end of 
2 minutes. The pressure in the chamber was then decreased by puffing air out at an 
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interval of 30 secs to return it to atmospheric pressure. The mice were closely observed for 
30 minutes to identify any adverse effects of the procedure, after which they sacrificed and 
their middle ears, nasal passages and lungs were analysed for traces of the blue dye. The 
middle ears and nasal passages were rinsed 3 times with 2μl PBS to recover any dye. This 
solution was diluted to 1 ml and its absorbance was compared with 1ml of 0.1% solution of 
the dye, to quantitate the amount of dye entering the MECs of mice. Even though the 
maximum translocation of the dye from the nasopharynx to the middle ear was found to 
be 0.3-0.9%, this ratio was deemed to be sufficient to cause colonisation of the middle ear 
with the routinely used live bacterial inoculum of 1x1010 CFU/ml. Hence, based on this pilot 
study Ethical Review Process (ERP) approval was obtained to carry out baro-inoculation 
with NTHi. 
 
2.13.4.2 Baroinoculation with NTHi 
After receiving the ERP approval, mice were anaesthetised with isoflurane as mentioned in 
Section 2.13.3. Following this, mice were baroinocluated with 5 μl of 1x1010 CFU/ml NTHi 
into each nostril in accordance to method described in 2.13.4.1. Animals were returned to 
their home cage after completion of the procedure. 
 
2.13.5 Determination of NTHi colonization of middle ears  
At specific time points, intranasally or baroinoculated mice were sacrificed using an 
intraperitoneal overdose of Sodium pentobarbital. Mice were decapitated, their heads 
were skinned and mandibles detached. Their ears were examined under a dissecting 
microscope (Leica M50) to determine the appearance of the Tm. Clear ears without fluid 
have a transparent tympanum, where the malleus is easily visible whereas fluid filled ears 
have a cloudy tympanum where the malleus is not clearly visible. Previous studies in our 
lab have shown that clear ears rinsed with PBS do not culture positive for NTHi and 
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therefore no clear ears were plated. Cloudy TMs were gently pierced and the ossicles were 
removed with fine forceps. 0.5μl of ear fluid was collected and added to 500 μl of sterile 
PBS, at a time. Each fluid containing bulla was collected as a separate sample. Samples 
were thoroughly vortexed to obtain a homogenous solution and then the sample was 
diluted 10-fold twice. 50μl of the dilutions were plated on streptomycin containing BHI-LEV 
plates. Plates were incubated overnight at 37°C, 5% CO2. Following day, plates were 
examined for NTHi growth and the number of colonies was counted. The presence of NTHi 
was confirmed by examining wet mounts of representative colonies in PBS by phase 
contrast microscopy at 100x magnification using an oil immersion lens.  
 
2.13.6 NTHi infection of mMEC cultures in vitro 
 
mMECs were cultured in antibiotic free mMEC-SF media for 48 hours prior to infection. The 
number of mMECs at ALI Day 14 was determined by trypsining the membrane and counting 
the cells on a haemocytometer (n=3). NTHi375SR-GFP inoculum was prepared as mentioned in 
2.13.2. An appropriate amount of the bacterial inoculum in antibiotic free mMEC-SF media 
was added to the apical chamber of ALI Day 14 mMEC cultures such that the membranes 
were infected at a multiplicity of infection (MOI) of 1:100 and 1:1000 (mMECs: bacteria). 
An equal volume of sterile PBS was added instead of the bacterial cultures to generate 
MOCK infected controls. The membranes were incubated at 37°C, 5% CO2 for 1 hr and 
washed 3 times with sterile HBSS to remove non-adherent bacteria. Media was replaced in 
the basal chamber and the cultures were incubated at 37°C, 5% CO2 for 4, 24, 48 and 72 
hours post infection (hpi). At the desired time points, apical washes were collected in 200μl 
sterile HBSS, cells were lysed in Trizol reagent for gene expression studies and membranes 
were fixed for IFC as previously described.  
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2.13.7 Determination of infection of mMECs by NTHi 
Two approaches were utilised for determination and quantification of infection of mMECs 
by NTHi. 
2.13.7.1 Quantification of infection using IFC 
ALI Day 14 mMEC membranes infected with NTHi375SR-GFP for 24, 48 and 72 hpi at MOI 100 
and MOI 1000 were visualized using the Olympus Fluoview 1000 Confocal microscope 
along with their MOCK infected controls. Four central fields on every membrane were 
imaged at 10x magnification at each time point to define a constant area for quantification. 
The amount of infection in this area was quantified by measuring the mean integrated 
intensity for green using Image J software.  
 
Figure 2.10 Quantification of NTHi infection in mMEC cultures using IFC 
Selection of 4 central 10x fields on each ALI Day 14 mMEC cells infected NTHI-375SR-GFP to define a 
constant area for quantification of infection, spanning approximately 50% of the membrane (A). A 
representative image showing progression of NTHi infection in the selected fields at 24 hpi, 48hpi 
and 72 hpi (B). The amount of infection at each time point was quantified as a measure of the mean 
integrated intensity for green fluorescence in these panels from 3 independent batches of 
infections. 
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2.13.7.2 Quantification of infection using bacterial viable counts 
ALI Day 14 mMEC cultures were infected with NTHi375SR-GFP for 48 and 72 hpi at MOI 100 as 
described in Section 2.13.6. At the desired time point, 250μl of 2% Saponin (Sigma Aldrich) 
was added to the apical chambers of 3 MOCK and 3 infected wells and the cells incubated 
for 12 minutes at 37°C, 5% CO2. Following incubation, cells were lysed by vigorously 
scraping the membrane and repeatedly pipetting up and down. The volume was made up 
to 1ml with sterile PBS, serially diluted and required dilutions were plated on BHI-NAD-Hm 
plates using the Miles Misra technique (Miles et al 1938). The plates were incubated 
overnight at 37°C, 5% CO2 and the numbers of colonies were enumerated the following 
day. 
 
2.14 Bacterial Association Assay 
ALI Day 14 mMEC cultures were infected with NTHi375SR-GFP at MOI 100 for 1 hr as described 
in Section 2.13.6. Cells were washed 3 times with sterile PBS to remove unbound bacteria. 
200μl of 1% Saponin was added to the top chamber and cells incubated at 370C, 5% CO2 for 
10 minutes. Cells were lysed by vigorously scraping the membrane and repeatedly 
pipetting up and down, serially diluted and plated on BHI-NAD-Hm agar plates using the 
Miles Misra method. The plates were incubated overnight at 37°C, 5% CO2 and the 
numbers of bacteria were enumerated the following day. Association of bacteria to mMEC 
cultures was calculated as follows:  
% Association =       
⁄                               
                                      x 100 
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2.15 Secretome analysis of mMEC cultures by Mass Spectrometry  
Mass Spectrometry (MS) was performed on apical wash secretions pooled from 6 batches 
of ALI Day 14 mMEC cultures by Stuart Armstrong at the Institute of Infection and Global 
Health, University of Liverpool, Liverpool, UK. 
 
2.15.1 Sample preparation for Mass Spectrometry  
50 µg of soluble proteins were precipitated by adding an equal volume of ice-cold 30% 
(w/v) TCA in acetone and incubating for 2 hours at -20°C. Proteins were pelleted at 12,000 
xg for 10 minutes at 4°C; pellets washed 3 times with ice-cold acetone, air dried and re-
suspended in 50 mM ammonium bicarbonate, 0.1% (w/v) RapiGest SF (waters). Samples 
were heated at 80°C for 10 minutes, reduced with 3 mM DTT at 60°C for 10 minutes, 
cooled and alkylated with 9 mM iodoacetamide (Sigma) for 30 minutes. All steps were 
performed with intermittent vortexing. Proteomic-grade trypsin (Sigma) was added at a 
50:1 ratio of protein: trypsin and incubated at 37°C overnight. Samples were precipitated 
using 1% TFA at 37°C for 2 hr to remove and centrifuged at 12,000 g for 1 hr at 4°C to 
remove RapiGest SF. The peptide supernatant was desalted using C18 reverse-phase stage 
tips (Thermo Scientific Pierce) according to the manufacturer’s instructions, dried and re-
suspended in 3% (v/v) acetonitrile, 0.1% (v/v) TFA for analysis by MS.  
 
2.15.2 NanoLC-MS ESI MS/MS analysis 
Peptides were analysed by on-line nanoflow LC using the Thermo EASY-nLC 1000 LC system 
(ThermoFisher Scientific) coupled with Q-Exactive mass spectrometer (ThermoFisher 
Scientific). Samples were loaded onto an Easy-Spray C18 column (50cm, i.d. 75 µm), fused to 
a silica nano-electrospray emitter (ThermoFisher Scientific). Chromatography was 
performed at 35°C using a buffer system consisting of 0.1 % formic acid (buffer A) and 80% 
84 
 
acetonitrile in 0.1 % formic acid (buffer B). The peptides were separated over a 97-minute 
linear gradient of 3.8-50% buffer B at a flow rate of 300nl/min. The Q-Exactive was 
operated in data-dependent mode with dynamic exclusion (20s) and survey scans acquired 
at a resolution of 70,000. Up to 10 of the most abundant isotope patterns with charge 
states +2, +3 and/or +4 from the survey scan were selected with an isolation window of 
2.0Th and fragmented by higher energy collisional dissociation with normalized collision 
energies of 30. The maximum ion injection times for the survey scan and the MS/MS scans 
were 250 and 100ms, respectively, and the ion target value was set to 1E6 for survey scans 
and 1E4 for the MS/MS scans. 
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2.15.3 Protein Identification and Quantification 
Thermo RAW files were imported into Progenesis LC–MS (version 4.1, Nonlinear Dynamics) 
and only peaks with a charge state between +2 and +7 were picked. Spectral data 
converted into mascot generic files (.mgf) and exported for peptide identification using the 
Mascot (version 2.3.02, Matrix Science) search engine. Tandem MS data were searched 
against translated ORFs from the mouse genome (Uniprot release 2015_02; 16,868 
sequences; 9,451,355 residues). The search parameters were as follows: precursor mass 
tolerance was set to 10 ppm and fragment mass tolerance was set to 0.8 or 0.01Da and 
two missed tryptic cleavages were permitted. Carbamidomethylation (cysteine) was set as 
a fixed modification and oxidation (methionine) set as variable modification. Mascot search 
results were further validated using the machine-learning algorithm Percolator embedded 
within Mascot. The Mascot decoy database function was utilised and the false discovery 
rate was <1%, while individual percolator ion scores> 13 indicated identities or extensive 
homology (p <0.05). Mascot search results were imported into Progenesis LC–MS as XML 
files for relative quantification using non- conflicting peptides.  
 
2.16 Western blotting 
Two types of samples were used for Western blotting: 
1. Apical washes from uninfected mMEC and mNEC ALI cultures. 
2. Apical washes from NTHi infected mMEC ALI cultures 
2.16.1 Protein quantification using Bradford assay 
Total protein concentrations of apical washes from NTHi infected mMEC ALI cultures were 
determined using the Bradford assay (Sigma Aldrich) in accordance to the manufacturer’s 
guidelines. Briefly, bovine serum albumin (BSA) standards were prepared in the dilution 
range of 1.4mg/ml to 0.0625mg/ml. 5 μl of all standards and samples was added to 250μl 
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of the Bradford reagent in 96 well micro-titre plates in triplicates. Samples were incubated 
for 1 minute at room temperature. Protein concentrations of samples were determined by 
measurement of absorbance at 595nm on a plate reader. 
  
2.16.2 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Appropriate percentage resolving gels (12% or 15%, depending on the band size of the 
protein) of interest were poured and allowed to set, followed by 4% stacking gels.  300ng of 
total protein from NTHi infected mMEC apical washes was combined with an appropriate 
amount of 2X SDS lysis buffer and the volume was made up to 40 µL. For all other studies, 
where the main purpose of western blotting was to detect proteins rather than 
quantification of their amount across samples, equal amounts of sample and 2X SDS lysis 
buffer was loaded onto the gels. Samples were denatured at 90˚C for 5 minutes and run 
alongside 10µl of marker (New England BioLabs #P7711S) in 1X Running Buffer at 150 Volts 
(for approximately 1 hour), till the dye reached the bottom on the gel. 
 
2.16.3 Transfer of proteins  
Stacking gels were discarded and resolving gels were placed in 1X Transfer Buffer. A 
transfer cassette was prepared by placing the various components in the following order 
from the cathode to the anode of the semi dry blotting system (Biorad Trans-blot turbo): 3 
layers of Whatmann paper; resolving gel; methanol activated PVDF membrane; 3 layers 
Whatmann paper. All components were soaked in 1X Transfer buffer before assembly. 
Excess buffer was squeezed out and air bubbles were eliminated from the cassette using a 
plastic roller. Proteins were transferred at 25V for 12 minutes.  
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2.16.4 Immuno- detection of proteins 
PVDF membranes were blocked using 5% Marvel in 1X Tris Buffered Saline-TWEEN (TBS-
TWEEN) for 1 hour on an orbital shaker. Membranes were washed for 5 minutes in 1X TBS 
and probed with the appropriate primary antibody diluted in 5ml blocking buffer overnight, 
at 4˚C on a rolling platform. The primary antibodies and their concentrations used for 
Western blotting are given in Table 2.6. The following day, membranes were washed 3 
times in 1X TBS-TWEEN for 5 minutes each. The primary antibody was detected using a 
polyclonal goat anti-rabbit secondary antibody (Dako P0448) conjugated with HRP (1:2000) 
for 1 hour at room temperature on a rolling platform. The membranes were washed 1X 
TBS-TWEEN as described before. The enhanced chemiluminescence (ECL) western blotting 
detection kit (Geneflow) was used to detect the secondary antibody. Membranes were 
placed in a plastic sleeve and 1 ml of ECL solution, prepared by mixing equal volumes of 
solution A (contains the substrate, luminol) and solution B (contains H2O2) was added to 
them. The plastic sleeve was sealed and placed in a light-proof cassette. Photographic X-ray 
films (GE Healthcare) were exposed to the membranes for an appropriate period of time in 
a dark room. In presence of H2O2, luminol is oxidised by HRP its electrons and transferred to 
an excited state. When the luminol electrons return to the ground state they emit light as a 
by-product which is captured by the Xray film. The films were developed, rinsed under tap 
water and fixed.  
Preparation of all stock solutions used for Western blotting are detailed in Appendix I. 
 
Table 2.6 Antibodies used for Western blotting 
Primary 
Antibody 
 
Type 
 
Dilution Manufacturer 
 
Anti- BPIFA1 Rabbit polyclonal 1:200 Prepared in lab (Musa et al 2012) 
 
Anti- 
Lactotransferrin 
Rabbit antisera 1:2000 Milipore (07- 685) 
Anti- Reg3γ Rabbit polyclonal 1:5000 Kindly provided by Professor Lora 
Hooper (Cash et al 2006) 
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NB: Hannah Armes, a summer student in the lab, performed western blotting for Lactotransferrin 
and Reg3γ. 
2.16.5 Quantification of western blots by Densitometry 
For quantification of secreted BPIFA1 in apical washes from NTHi infected mMEC cultures, 
western blot bands were quantified using Image J software. The intensity of the infected 
bands was compared to that of the MOCK infected bands. Statistics was performed using a 
two tailed students t-test and p values <0.05 were considered significant.  
 
2.17 RNA extraction  
Total RNA was extracted from cells using Trizol reagent (Sigma- Aldrich), in accordance to 
the manufacturer’s guidelines. Briefly, cells were lysed in 250μl of TRI reagent. 50μl 
Chloroform (Fisher Scientific) was added to the lysate, vortexed vigorously for 15 secs and 
incubated at room temperature for 15 minutes. Samples were spun at 13,000 rpm at 8˚C 
for 15 minutes to enable phase separation. The top aqueous phase containing RNA was 
transferred to a fresh Eppendorf. 125μl of Isopropanol (Fisher Scientific) and 1μl of 
Glycoblue dye (Ambion) were added to the tube. Glycoblue increases the visibility of RNA 
pellets during the later steps. Samples were left to stand at room temperature for 10 
minutes and then centrifuged at 13,000 rpm at 8˚C for 10 minutes to obtain RNA pellets. 
The pellets were washed with 75% ethanol (Fisher Scientific) and centrifuged again as 
mentioned previously. The ethanol was removed, pellets were air dried and re-suspended 
in 20μl of nuclease free water. RNA samples were stored at -20˚C. 
  
2.18 End Point Reverse Transcription PCR (RT-PCR) 
2.18.1 RNA quantification and DNAse I treatment 
RNA concentration and quality were determined by measurement of absorbance of 1μl of 
the extracted RNA (Section 2.17) using NanoDrop ND-1000 (Thermoscientific). The 260nm: 
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280nm ratio was > 1.7 in all cases. Any residual genomic DNA was digested by DNase I 
treatment (Promega). Briefly, 1μl each of RQ1 RNase free 10x Reaction Buffer and RQ1 
RNase free DNase enzyme from the kit were added to 200 ng of extracted RNA and the 
total reaction volume was made up to 10μl with nuclease free water. Samples were 
incubated at 37˚C for 30 mins. The reaction was terminated by addition of 1µl of RQ1 
DNase Stop Solution and incubation at 65˚C for 10 minutes using a thermal cycler (MJ 
Research PTC-200).  
 
2.18.2 cDNA synthesis  
RNA was reverse transcribed into complementary DNA (cDNA) using the AMV Reverse 
Transcriptase kit (Promega). 0.5μl each of OligoDT (Sigma) and random primers (Promega) 
were added to the DNase digested RNA solution (Section 2.18.1). The total volume was 
made up to 19μl with nuclease free water and samples were heated at 70˚C for 5 minutes. 
6μl of master mix containing 5x AMV buffer, 100μM dNTPs, 0.25μl AMV RT enzyme and 
0.25μl RNasin was added to the samples and cDNA was synthesised on the thermal cycler 
according to the recommended program: 42˚C for 1 hour; 95˚C for 5 minutes. Samples 
were either used immediately for RT-PCR or stored long term at -20˚C. 
 
2.18.3 RT- PCR 
End-point RT-PCR was performed to detect the expression of various genes. 1µl of 
template cDNA was amplified using Maxima Hot Start Green PCR Master 
Mix (ThermoFisher Scientific). Information regarding primer pairs used for RT-PCR is 
described in Table 2.7 and details of the master mix contents and cycling conditions for the 
reactions are mentioned in Table 2.8. The reaction was run for 35 cycles for all genes 
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expect Bpifa1 (25 cycles). Oaz1 was used as the endogenous control for all end point RT-
PCR experiments. 
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x 35 
 
Table 2.7 Primer sequences and amplicon sizes for end point RT- PCR 
Assay Primer type Sequence (5’-3’) Product 
size (bp) 
Bpifa1 Forward 
Reverse 
ACAGAGGAGCCGACGTCTAA 
CCAAGAAAGCTGAAGGTTC 
127 
Tekt1 Forward 
Reverse 
CAGTGCGAAGTGGTAGACG 
TTCACCTGGATTTCCTCCTG 
373 
Muc5B Forward 
Reverse 
ATGGTGACCAAGAGCCAAAA 
CAGGACTGTTCACCCAGGTT 
178 
Muc5AC Forward 
Reverse 
GCACCAAAGACAGCAGATCA 
CTGAGAGGTTTGCAGCTCCT 
167 
Lactotransferrin Forward 
Reverse 
TCTGTCCCTGTGTATTGGT 
GTTTCCGGGTGTCATCAAGG 
237 
Sftpd Forward 
Reverse 
AAGCAGGGGAACATAGGACC 
GCCTTTTGCCCCTGTAGATC 
109 
Bpifb1 Forward 
Reverse 
CCCTGACCAAGATCCTTGAA 
GAGGCTGGAGTGAGCTTGAG 
148 
Keratin 5 Forward 
Reverse 
ACCTTCGAAACACCAAGCAC 
TGACTGGTCCAACTCCTTCC 
337 
Vimentin Forward 
Reverse 
CAAGCAGGAGTCAAACGAG 
CCTGTAGGTGGCGATCTCAA 
273 
Reg3ᵞ Forward 
Reverse 
CCTGTCCTCCATGATCAAAGC 
GCAGACATAGGGTAACTCTAAGT 
250 
Oaz1 Forward 
Reverse 
ACAGAGGAGCCGACGTCTAA 
CCAAGAAAGCTGAAGGTTC 
274 
 
Table 2.8 Master Mix details and cycling conditions for end point RT-PCR 
RT-PCR master mix  (Total volume 20 μl) RT-PCR cycling conditions 
Reagent Volume 
(μl) 
Step Temperature Time 
Maxima hot start mix  (5x) 10 Hot start 950C 5 
mins Nuclease H2O 7 Denaturation 940C 1 min 
Forward primer (10 µM) 1 Annealing 600C 1 min 
Reverse primer 10 µM 1 Extension 720C 1 min 
Template cDNA 1 Final 
Extension 
720C 7 
mins  
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2.18.4 Agarose gel electrophoresis 
The amplified PCR products were run on a 2% agarose gel containing 0.5µg/ml ethidium 
bromide at 80V (Dutscher scientific) and bands were visualised using Biorad ChemiDoc™ 
XRS+ alongside a 100 base pair ladder (Bioline). 
 
2.19 Quantitative Reverse Transcription PCR  
Quantitative Reverse Transcription PCR (RT-qPCR) was used to study relative gene 
expression using a variety of samples. I performed the following steps with the help of Dr. 
Debbie Williams at GEMS, MRC Harwell. 
 
2.19.1 RNA clean-up 
RNA extracted using Trizol (Section 2.17) was found to be contaminated with components 
from the TRI reagent such as phenol and guanidine salts as indicated by the low 260:230nm 
absorbance ratio. Therefore, RNA was treated with the Ambion DNA-free™ kit (Applied 
Biosystems) to reduce these contaminants and eliminate any residual genomic DNA. 12μl 
master mix containing 1x DNase I buffer, 1μl DNase I enzyme and nuclease free water was 
added to 18μl of total RNA. Samples were incubated at 37˚C for 30 minutes on a heat 
block. 0.1 volume of DNase I inactivation reagent was added and samples were mixed by 
gently flicking the tubes. The inactivation reagent contains beads that bind the degraded 
DNA and contaminants. Samples were centrifuged at 10,000 xg for 1.5 minutes to pellet 
the beads. The supernatant containing the RNA was transferred to a fresh eppendorf. 
 
2.19.2 RNA quantity and quality assessment 
The concentration of cleaned RNA samples was determined by measurement of 
absorbance on NanoDrop ND-8000 (Thermoscientific). RNA quality and integrity were 
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checked on a Bioanalyzer 2100 instrument with the RNA 6000 Nano kit (both Agilent), using 
1μl (1:2 diluted) RNA which had been denatured at 70°C for 2 minutes. This instrument 
provides information about the RNA integrity number (RIN), absorbance ratios as well as 
produces RNA gel-like electropherograms showing the integrity of the 28s and 18s rRNA 
subunits. 
 
2.19.3 cDNA synthesis 
240- 500ng of total RNA was reverse transcribed into cDNA in 20µl reaction volume using 
the Superscript™ III First Strand Synthesis kit (Invitrogen), in accordance to manufacturer’s 
guidelines. Briefly, 12µl of master mix containing 2x RT reaction mix and 2µl of RT enzyme 
mix was added to the RNA samples. Samples were run on the thermal cycler according to 
the recommended program: 25˚C for 10 minutes; 50˚C for 30 minutes and 85˚C for 5 
minutes. Samples were chilled on ice; 1µl of RNase H was added to the tubes and 
incubated at 37˚C for 20 minutes on the thermal cycler. RT-ve samples were generated using 
all components of the master mix expect the RT enzyme mix. The cDNA was either used 
immediately or stored at -20˚C. 
 
2.19.4 Determination of appropriate endogenous controls for RT-qPCR  
2.19.4.1 The Primerdesign geNorm™ assay 
For accurate measurement of gene expression, it was necessary to normalise quantitative 
real time PCR results to reference genes (endogenous controls) which did not vary with the 
experimental conditions such as genotype or NTHi infection of cells. The routinely used 
endogenous controls, GAPDH and β-actin, and the endogenous control used for end point 
RT-PCR, Oaz1, did not show stable expression across samples for the required experimental 
conditions (data not shown). Therefore, the geNormTM Reference Gene Selection Kit 
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(Primerdesign) was used to establish the optimal endogenous controls for use. This kit 
contained primer sets for 12 murine candidate reference genes (Table 2.9) Rpl13a from the 
geNormTM kit was replaced with TaqMan® gene expression assay for Ppia (Peptidylprolyl 
isomerase A), because this gene has previously been used as an endogenous control for 
studying hypoxia signalling in the mouse middle ear by our lab (Cheeseman et al 2011). 
Individual reactions were set up in MicroAmpR Fast Optical 96 well reaction plates with 10 
ng cDNA from representative samples to be used for each experimental condition. 2x 
TaqMan® Fast Universal PCR Master mix (Applied Biosystems, contents detailed in Table 
2.10) was added to each well and the final reaction volume was made up to 20µl with 
nuclease free water. Each sample was run in triplicates for each assay. cDNA was amplified 
on the 7900HT Fast Real-Time PCR System (Applied Biosystems) using the Fast program. 
Cycling conditions are detailed in Table 2.10. 
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Table 2.9 List of candidate reference genes assayed using the geNormTM Reference Gene Selection 
Kit 
Gene Name Gene symbol 
Actin, beta, cytoplasmic Actb 
Glyceraldehyde-3-phosphate dehydrogenase Gapdh 
Ubiquitin C UbC 
Beta-2 microglobulin B2m 
Phospholipase A2 Ywhaz 
Ribosomal protein L13a Rpl13a 
Calnexin Canx 
Cytochrome c-1 Cyc1 
Succinate dehydrogenase complex, subunit A Sdha 
18S rRNA 18S 
Eukaryotic translation initiation factor 4A2 Eif4a2 
ATP synthase subunit ATP5B 
NB: Rpl13a from the geNormTM kit was replaced with TaqMan® gene expression assay for Ppia 
(Mm02342429_g1) 
 
2.19.4.2 geNorm™ assay analysis 
For selection of the best reference genes, data was analysed using the geNorm module on 
the RT-qPCR software, qBasePlus which ranks the candidate reference genes according to 
the stability of their expression across all samples. The software generates two types of 
graphs: 
a) The geNorm M plot indicates the average expression stability value (M) of the 
reference genes across samples at each step and arranges the least stably 
expressed gene on the left and the most stably expressed gene on the right. 
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b) The geNorm V plot helps to determine the ideal number of reference genes that 
should be used for normalisation of target genes. It measures a factor called 
pairwise variation, V(n/n+1) which indicates the successive addition of each 
reference gene beginning with the 2 most stably expressed genes as identified by 
the geNorm M plot and the inclusion of successive genes moving right across the 
plot. The ideal number of reference genes (n) is obtained when the value of 
V(n/n+1) drops below the threshold of 0.15.  
Separate geNorm™ assays were performed to identify optimal reference genes to 
study relative gene expression for each experimental condition in this thesis i.e. for 
original middle ear mucosal cells isolated from bullae from mice of different genotypes, 
for mMECs cultured at ALI from different genotypes and cultured mMECs infected with 
NTHi. An example of geNorm analysis is shown in Figures 2.11 and 2.12. 
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Figure 2.11 geNorm M plot for selection of ideal endogenous controls 
The above figure shows a representative Primerdesign geNorm™ M plot for reference gene 
selection. In this case, the plot indicates that Ppia was the most stably expressed reference gene 
across NTHi infected and Mock infected ALI Day 14 mMECs at various time points, followed by 
ATP5b and Cyc1.  
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Figure 2.12 geNorm V plot for determination of the ideal number of endogenous controls for 
normalisation of target gene expression 
The above figure is a Primerdesign geNorm™ V plot, used in this case, to determine the optimal 
number of endogenous controls (ECs) required for normalisation of target genes in NTHi infected 
and MOCK infected mMEC samples. The plot suggests the use of 2/3 ECs since the pairwise variation 
value is below the minimum threshold of 0.15. Therefore, 3 reference genes, Ppia, ATP5b and Cyc1 
were selected for normalisation or target genes in this study. 
 
 
 
2.19.5 Quantitative real time PCR (RT-qPCR) using mouse TaqMan® assays 
RT-qPCR was performed using Applied Biosystems TaqMan® gene expression assays. As 
mentioned above, 10 ng cDNA was used per well. Master Mix and cycling conditions used 
for RT-qPCR were the same as that used for geNorm assay (Section 2.19.4.1). 15µl of 2x 
TaqMan® Fast Universal PCR Master mix (Applied Biosystems) was added to each well. The 
final reaction volume was made up to 20µl with nuclease free water. Plates were sealed 
using MicroAmp optical adhesive films (Applied Biosystems). Reactions were carried out in 
triplicates for each assay and each sample on the 7500 Fast Real Time PCR system (Applied 
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Biosystems) in the Fast mode. Details of the master mix and cycling conditions are outlined 
in Table 2.10. TaqMan assays used for RT-qPCR are mentioned in Table 2.11.  
 
Table 2.10 2x TaqMan® Fast Universal PCR Master mix details and cycling conditions for 
quantitative RT-PCR and geNorm assay 
RT-qPCR master mix  (Total volume 20 μl) RT-qPCR cycling conditions 
Reagent Volume(μl
) 
Step Temperature Time 
2x TaqMan® Fast Universal 
PCR 
10 Hot start 950C 20secs 
Nuclease H2O 4 Denaturation 950C 3 secs 
20x TaqMan assay 1 Annealing 
and extension 
600C 30 secs 
Diluted cDNA (10ng/well) 5    
NB: Primerdesign geNorm™ primer mix was used instead of 20x TaqMan® assay 
for the geNorm analysis 
 
2.19.6 RT-qPCR analysis 
Each TaqMan® assay consisted of a primer pair for cDNA amplification and a probe 
complementary to a sequence between the two primers, with a FAM fluorophore on the 5’ 
end and a quencher on the 3’ end. During RT-qPCR, the endogenous 5’ nuclease activity of 
the Taq polymerase cleaves the fluorophore, separating it from the quencher. This results 
in emission of fluorescence which is detected and quantified by the software and is directly 
proportional to the amount of cDNA present in the sample. Cycle threshold (CT) value is 
the number of cycles required for this fluorescent signal to reach the threshold level set by 
the software. Samples with more cDNA for a particular gene reach the threshold faster and 
thus, have lower CT values.  
x 40 
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Results were analysed on the SDS software v2.2 (Applied Biosystems) using the 
‘Comparative CT (∆∆CT)’ method where, 
x ∆CT = CT Target gene- CT Endogenous control 
Gene expression of targets was normalised against that of endogenous controls selected    
using the geNormTM Reference Gene Selection Kit as mentioned in Section 2.19.4. 
x ∆∆CT = ∆CT Experimental sample - ∆CT Calibrator sample 
 Relative quantification (RQ) or fold change was calculated using the formula, 
x RQ = 2-∆∆CT 
Error bars were calculated as RQmin and RQmax by the software which is based on the 
calculation of the standard error of mean for each ∆CT value using an automated 
algorithm. However, error bars for individual data points have been calculated manually as 
individual RQ value for each biological replicate ±SEM and this has been mentioned where 
relevant. Statistical analysis was performed using ∆CT values of each biological replicate. 
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Table 2.11 TaqMan® gene expression assays used for quantitative real time PCR experiments  
Gene TaqMan® Gene Expression Assay ID 
BPI fold containing family A, member 1 
(Bpifa1) 
Mm00465064_m1 
Chemokine (C-X-C motif) ligand 2 (Cxcl2) Mm00436450_m1 
EVI1 complex locus (Evi1) Mm00491303_m1 
Forkhead box J1 (FoxJ1) Mm01267279_m1 
Interleukin 6 (IL6) Mm99999064_m1 
Mucin 5, subtype B (Muc5B) Mm00466391_m1 
Mucin 5, subtypes A and C(Muc5AC) Mm01276718_m1 
Transformation related protein 63 (p63) Mm00495793_m1 
Transforming growth factor, beta (TGFβ) Mm01178820_m1 
Tumor necrosis factor alpha (TNFα) Mm99999068_m1 
Vascular endothelial growth factor A (Vegfa) Mm00437304_m1 
 
 
2.20 Cytocentrifugation and staining of middle ear fluids 
Middle ear fluids from Evi1Jbo/+ and Bpifa1-/-Evi1Jbo/+ mice were sampled and diluted in PBS 
as mentioned in Section 2.13.5. 80µl of the sample containing 1- 2 X106 cells were mixed 
with 20µl of 10%FBS, vortexed and transferred to clip-slide-filter-chambers/cytospins in 
duplicates. The cells were placed on the slides by centrifugation in Shandon Cytocentrifuge 
(Shandon Cytospin 3, Thermo Scientific) at 300x g for 3 minutes. Cells were air dried briefly 
and fixed on the slides with a drop of 100% methanol. Cells were stained by placing the 
slides in diff quick stain I (orange dye) (Gentaur) for 1 minute, followed by transfer to diff 
quick stain II (blue dye) (Thermo Fisher Scientific) for 2-3 minutes. Cells were washed 
briefly, dried and mounted in a drop of distrene-80 plasticiser xylene (DPX) (Fisher 
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Scientific). The slides were observed by using Zeiss Axioplan microscope with X100 oil 
immersion lens. 
 
2.21 Statistics 
Variance of experimental groups and parametricity was determined by performing 
Levene’s test prior to the statistical analysis. GraphPad Prism (version 6.0) was used to 
perform all statistical tests. 2 tailed students t-test was used to compare two groups. One 
way or two-way analysis of variance (ANOVA) with Tukey’s posthoc test was used to 
compare more than two groups, for parametric data. Fisher’s exact test was used for 
analysing frequency data such as presence or absence of middle ear fluids or genotype 
ratios (Chi squared analysis if there were more than 3 groups). Significance threshold was 
set at p < 0.05. Data are presented as the mean +/- standard error of the mean (SEM) 
unless otherwise stated. Significance levels represented on graphs are as follows: ns = not 
significant; * = p≤0.05; ** = p≤0.01; *** = p≤0.001; **** = p≤0.0001.  
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CHAPTER 3:  ASSESSMENT OF THE EFFECT OF BPIFA1  DELETION ON 
DEVELOPMENT OF OM  
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3.1.1 Introduction 
 
Otitis media is an opportunistic infection of the middle ear caused by transfer of the 
indigenous nasopharyngeal microflora into the middle ear. Some mice with craniofacial 
abnormalities and defects in innate immunity genes are predisposed to OM, leading to the 
generation of several mouse models of spontaneous OM (Rye et al 2011a). Preliminary IHC 
studies in our lab have shown abundant staining for BPIFA1 in the Wt middle ear 
epithelium and there was a decrease in the staining intensity with progression of OM in the 
Evi1Jbo/+ mice, a model of spontaneous, chronic OM (Sections 1.8.2 and 1.13). Owing to the 
abundant expression of this putative innate host defence gene in the middle ear, I 
postulated that deletion of Bpifa1 might result in spontaneous development of OM. This 
hypothesis is supported by a GWAS study showing association of SNPs in BPIFA1 with OM 
(Rye et al 2012b) and the more recent report suggesting that aged Bpifa1-/- mice show 
increased susceptibility to OM development (Bartlett et al 2015). 
OM can also be induced in animal models by infection with otopathogens. NTHi is one of 
the most common causative organisms of both AOM and COM, responsible for 25- 30% of 
the cases (Giebink 1991). Since the advent of pneumococcal vaccines, it has become 
the most common pathogen in OM (Casey & Pichichero 2004). The chinchilla is the 
most commonly used in vivo model for the study of NTHi induced OM, primarily due to the 
large size and easy accessibility of its middle ear cavity (Bakaletz 2009). However, there has 
been an increase in the number of mouse models of induced OM in the recent years (Ryan 
et al 2006, Sabirov & Metzger 2008). The two routes used for induction of OM in animal 
models using bacteria are, direct injection into the middle ear cavity and IN inoculation. IN 
inoculation mimics the natural route of OM pathogenesis, starting with initial colonisation 
of the NP, followed by transfer of bacteria through the ET and leading to a subsequent 
middle ear infection.  
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BPIFA1 is abundantly expressed in various parts of the nasal passages (Musa et al 2012) 
along with the middle ear epithelium. Several studies advocate a surfactant function for 
BPIFA1 (Bartlett et al 2011, Gakhar et al 2010, Liu et al 2013a, Walton et al 2016). 
Surfactants in the middle ear and ET are important in modulating optimal functioning of 
the ET and promoting mucociliary clearance (McGuire 2002). A previous study in chinchillas 
showed that down regulation of Bpifa1 in vivo leads to ET dysfunction (McGillivary & 
Bakaletz 2010). Moreover, based on its structural homology to BPI, an antimicrobial 
function was originally suggested for BPIFA1 (Bingle & Craven 2002). Mice in which Bpifa1 
was either silenced or ablated, show increased susceptibility and higher pulmonary 
bacterial counts when challenged with K.pneumoniae, P.aeruginosa, and M.pneumoniae 
(Chu et al 2007, Gally et al 2011, Liu et al 2013a, Liu et al 2013b).  
Therefore, owing to its surfactant and antimicrobial properties, I proposed that IN 
challenge of Bpifa1-/- mice might lead to an increased ascension of bacteria from the NP 
into the middle ear, resulting in induction of OM.  
 
3.1.2 Aims of this study 
The first aim of this study was to assess spontaneous development of OM in Bpifa1-/- mice. 
The second aim was to study the effect of the loss of Bpifa1 on the nasopharyngeal 
carriage of the human otopathogen NTHi.  
 
3.1.3 Study design 
Figure 3.1 gives a brief study plan for this chapter. Post-natal localisation of BPIFA1 protein 
in the Wt developing middle ear cavity was studied (Section 3.2.1) and deletion of the gene 
was confirmed in Bpifa1-/- mice using IHC (Section 3.2.2). Bpifa1-/- mice were systematically, 
phenotypically characterised for variety of features such as viability, weight, general 
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behaviour (Section 3.2.2) and organ morphology (Section 3.2.4). Auditory threshold 
measurements and histological analysis were performed to identify signs of early and late 
onset OM in these mice (Section 3.2.3). Transfer of NTHi from the NP to the ME was 
evaluated using two different strains of bacteria and using IN inoculation and 
baroinoculation techniques (Section 3.2.5). Experiments for this chapter were performed in 
the initial period of the breeding pipeline (Section 2.1.3, Fig 2.2). Hence, either Bpifa1-/- 
mice on a C57BL/6 background or on a mixed C57BL/6-C3H/HeH background (inter-crossed 
at Backcross 2) were used throughout this chapter. The strains are mentioned where 
relevant.  
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Figure 3.1: Major steps in planning this chapter. 
 
3.2 Results 
3.2.1 BPIFA1 is expressed in the post-natal developing mouse middle ear cavity 
Preliminary IHC studies in our lab had shown that BPIFA1 localised to the Wt middle ear 
epithelium from P21 to P56 and the intensity of staining decreases with progression of OM 
in Evi1Jbo/+ mice during this time period (Section 1.13). In order to evaluate the onset of 
BPIFA1 production during the post-natal development of the middle ear cavity, I performed 
IHC on middle ear sections of C3H/HeH mice from the day of birth (P0) to P30 at regular 
intervals of 5 days. BPIFA1 staining was seen in the middle ear epithelium throughout this 
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developmental period. In neonates, from P0 to P10, the middle ear space was packed with 
mesenchymal material. BPIFA1 staining was visible in the epithelial cells and submucosal 
glands enclosing this mesenchyme-filled space, in the region where the mesenchyme 
pulled away from the underlying epithelium (Fig 3.2A-C). Occasionally, the mesenchyme 
itself stained positive for BPIFA1 (Fig 3.2C). Retraction of the mesenchyme from the 
epithelium began at P5, starting ventrally and continued towards the attic, until an air filled 
cavity was formed by P15 (Fig 3.2 B-D). Occasionally, the layer of the Tm facing the middle 
ear cavity also stained positive for BPIFA1 (Fig 3.2D). At P15, the middle ear cavity 
demonstrated its adult shape. BPIFA1 was localised to the non-ciliated cells and 
submucosal glands throughout the middle ear epithelium from P15 to P30 (Fig3.2 E-G). It 
must be noted the changes in the staining intensity for BPIFA1 were not quantified during 
this developmental period and no assessment was made for the number of ciliated cells. 
Hence, no assumptions can be made regarding the changes occurring in the cell types from 
the histology sections.  
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Figure 3.2 Localisation of BPIFA1 in the post-natal middle ear cavity 
Low and high magnification images showing IHC for BPIFA1 in the developing middle ear cavity from 
P0 to P30. All sections are orientated with the OEC towards the left-hand side (Iv) and the MEC 
towards the right hand side (i), separated by the Tm (iii). BPIFA1 localises to the non-ciliated 
epithelial cells and submucosal glands (A-G). Middle ear space is filled with mesenchymal material 
until P10 which resorbes to form a fully air filled cavity by P15 (A-D). Negative control for BPIFA1 (H). 
Mesenchymal material (i); Tm (ii); middle ear epithelium (iii); outer ear space (iv); cochlea (v); middle 
ear cavity (asterisk). Images representative of n=3 mice at each time point. Scale bar 500μm for 4x 
images and 50μm for 60x images. 
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3.2.2 Characterisation of Bpifa1-/- mice 
All mice were inspected daily by ward technicians and no abnormalities were seen 
in the gross anatomy and overt behaviour of Bpifa1-/- mice. Successful ablation of 
Bpifa1 was confirmed by IHC of P28 middle ear cavities. As described above BPIFA1 
was localised to the non-ciliated cells of the Wt middle ear epithelium and it coated 
the surfaces of cilia. However, staining was completely absent in the middle ear 
epithelium of the Bpifa1-/-  littermate controls (Fig 3.3). 
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Figure 3.3 Localisation of BPIFA1 in Wt and knockout middle ear cavities 
BPIFA1 expression was detected in the Wt mouse middle ear using IHC. Low magnification image of 
Wt mouse middle ear showing localisation of BPIFA1 along the middle ear epithelium (A). High 
magnification images showing that BPIFA1 is produced by non-ciliated cells of the middle ear 
epithelium (B), but coats the surface of the cilia (C). BPIFA1 staining is absent in the Bpifa1-/- middle 
ear (D, E) and the negative control (F, G). Data is representative of n=3 mice for both genotypes. 
Scale bar 500μm for 4x images and 50μm for 60x images. All 4x images are orientated with the OEC 
towards the upper side and the MEC towards the lower side, separated by the Tm.  
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3.2.2.1 Analysis of genotypic ratios 
The viability of the Bpifa1-/- line was assessed on the original C57BL/6 background (Table 
3.1) and after transfer to C3H/HeH background (Table 3.2) by analysing genotype ratios of 
the progeny obtained from Bpifa1+/- x Bpifa1+/- intercrosses (Fishers exact test). On both 
backgrounds, normal Mendelian ratios were observed at weaning age (P21). 
 
Table 3.1: Numbers of live mice for Bpifa1-/- line on the C57BL/6 background 
Genotype Observed 
numbers 
% Observed  Expected 
numbers 
% Expected P-value 
Bpifa1-/- 60 22.38 67 25 0.172045 
Bpifa1+/- 120 44.74 134 50  
Wt 88 32.83 67 25  
Total 268 100 268 100  
 
Table 3.2: Numbers of live mice for Bpifa1-/- line on the C3H/HeH background 
Genotype Observed 
numbers 
% Observed  Expected 
numbers 
% Expected P-value 
Bpifa1-/- 59 25 59 25 0.657047 
Bpifa1+/- 126 53.3 118 50  
Wt 51 21.6 59 25  
Total 236 100 236 100  
 
 
3.2.2.2 Analysis of body weights 
Body weights of C57BL/6-C3H/HeH Bpifa1-/- and Bpifa1+/-  mice were compared to their Wt 
littermate controls. As expected males weighed more than females. No significant 
differences were found between the three genotypes for either males or females at 8 
weeks (Fig 3.4A) and 12 weeks of age (Fig 3.4B). 
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Figure 3.4 Body weight analysis of Bpifa1-/- mice  
The figure shows that there is no significant difference between mean body weights of male and 
female Bpifa1-/- compared to their Bpifa1+/- and Wt littermate controls at 8 weeks (A) and 12 weeks 
(B). Data presented as box and whisker plots demonstrating minimum to maximum weights and 
horizontal line indicates median weight. Male Bpifa1-/- n=4; male Bpifa1+/- n=5; male Wt n=4; female 
Bpifa1-/- n=4; female Bpifa1+/- n=10; female Wt n=4. p values for all inter-genotype comparisons 
analysed using One-way ANOVA with Tukey’s posthoc test >0.05 
 
 
3.2.3 Bpifa1-/- mice do not spontaneously develop OM  
 
3.2.3.1 Bpifa1-/- mice do not demonstrate altered auditory thresholds  
The first test I used to identify whether the loss of Bpifa1 leads to an OM phenotype, was 
measurement of the ABR thresholds in 8 week (Fig3.5A) and 12 week old (Fig3.5B) Bpifa1-/- 
mice and their littermate controls. Previous studies in our lab have shown that these time 
points can be used to accurately identify early onset OM (Hardisty et al 2003, Parkinson et 
al 2006, Tateossian et al 2013). Hearing thresholds of Bpifa1-/- and  Bpifa1+/- mice were 
within the normal Wt range of 20-30dB and did not differ significantly between the three 
groups at either time point.  
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Figure 3.5 Hearing thresholds of Bpifa1-/- mice 
Hearing thresholds for Bpifa1-/- (n=8) and Bpifa1+/- (n=15) do not differ significantly from those of Wt 
mice (n=7) at 8 weeks of age (A). Hearing thresholds for Bpifa1-/- (n=13) and Bpifa1+/- (n=18) do not 
differ significantly from those of Wt mice (n=9) at 12 weeks of age (B). p>0.05 for One-way ANOVA 
with Tukey’s posthoc test. 
 
 
          3.2.3.2 Bpifa1-/- mice do not exhibit histological signs of early OM 
development  
 
In addition to the ABR measurements, OM phenotype was also evaluated by histological 
assessment of middle ear sections (Fig 3.6). Deletion of one or both alleles of Bpifa1 did not 
lead to any morphological signs of OM development at 12 weeks (n=8). Similar to their Wt 
controls, Bpifa1 mutants on the C57BL/6-C3H/HeH background demonstrated a thin 
mucosal epithelium and no middle ear fluid build-up (Fig 3.6A-C). Additionally, no 
recognizable morphological differences were noted in the nasal passages, trachea and lung, 
the primary sites of BPIFA1 expression at this age (Fig3.6D-I).  
 
3.2.3.3 Bpifa1-/- mice do not exhibit histological signs of late onset OM  
Middle ear sections from Bpifa1-/- mice aged to 6 months were also examined to identify 
signs of late onset OM. Out of the 24 middle ears analyzed, 3 had a small amount of 
115 
 
eosinophilic material but lacked any inflammatory cell components in the middle ear 
cavity. Also, no mucosal thickening was observed in any of the sections assessed (Fig 3.6J). 
These changes were therefore interpreted as an incidental occurring rather than an OM 
phenotype. Moreover, no morphological abnormalities were seen in the nasal passages, 
lungs and trachea at this time point (Fig3.6K-L, Appendix II). 
Taken together, my data suggests that ablation of Bpifa1 does not lead to spontaneous 
development of OM in naïve mice on the C57BL/6-C3H/HeH genetic background. 
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Figure 3.6 Histological analyses of 12 weeks and 6 month old Bpifa1-/- mice 
H&E sections from middle ear (A-C), rostral nasal passages (D-F) and lung (G-I) from Wt, Bpifa1+/- and Bpifa1-/- mice show no histological abnormalities at 12 weeks (n=8) of 
age. H&E sections from middle ear (J), rostral nasal passages (K) and lung (L) from n=13 Bpifa1-/- mice show no histological abnormalities at 6 months of age. Middle ear 
cavity (i); middle ear epithelium (ii); outer ear canal (iii), olfactory epithelium (iv) vomeronasal organ (v); respiratory epithelium (vi); nasal septum (vii). Scale bar 500μm for 
4x images and 50μm for 60x images. 
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3.2.4 Detailed histological analysis of Bpifa1-/- mice 
 
Comprehensive histological screening of Bpifa1-/- mice at 6 months of age was undertaken 
by Professor Michael Cheeseman. H&E stained sections from n=13 (9 female and 4 male) 
mice were analysed to assess the morphology of the major organs including the brain, 
kidney, liver, spleen, heart, ovaries etc. Appendix II gives the details of the full histology 
screen. Overall, no major pathological changes were observed in any of the 42 target 
tissues analysed. 
 
 
3.2.5 Bpifa1 mutants do not demonstrate increased nasopharyngeal NTHi 
carriage  
As Bpifa1 mutants did not develop OM spontaneously, I was interested in studying the 
effect of Bpifa1 deletion on the induction of OM by IN inoculation with the otopathogen, 
NTHi. Mice between 8-10 weeks of age were used for all bacterial challenge experiments.  
 
3.2.5.1 Challenge with NTHi162SR 
 
Initially, Wt Bpifa1+/- and Bpifa1-/- mice on a C57BL/6-C3H/HeH background were 
baroinoculated with NTHi162SR. The streptomycin resistant version of NTHi162 was used in 
order to avoid overgrowth of Proteus, which confounds studies of NTHi growth. Proteus is a 
bacterial species commensal to the nasal passages and is routinely found in a proportion of 
mice maintained under SPF conditions at MRC Harwell (Fray et al 2008). Theoretically, the 
baroinoculation method serves to enhance ascending nasal infection into the middle ear 
(Stol et al 2009). The baroinoculation chamber used in these experiments was built at MRC, 
Harwell and the methodology was optimised as described in Section 2.13.4. OM induction 
was assessed on the basis of the appearance of the Tm and presence of middle ear fluids at 
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day 7-post baroinoculation. Serially diluted middle ear fluids and PBS washes from clear 
ears were incubated on agar plates to evaluate culture positivity. The sampling time point 
was selected based on detailed studies performed with Evi1Jbo/+ mice (Hood et al 2016). 
Only 2/30 Bpifa1-/- ears, and no Bpifa1+/ - (n= 30) or Wt (n=30) ears showed the presence of 
fluid in the middle ears (Fig 3.7A). 1 of the 2 fluid filled Bpifa1-/- ears cultured positive for 
NTHi, whereas none of the clear washes showed any bacterial growth (Fig 3.7B).  
I postulated that the lack of middle ear fluid and bacteria at day 7 was perhaps due to 
resolution of any infection and perhaps the lack of effectiveness of the baroinnoculation 
method in these mice.  Therefore C57BL/6-C3H/HeH Wt (n=5), Bpifa1+/-  (n=9) and Bpifa1-/- 
(n=10) mice were directly intranasally challenged with NTHi162SR and OM development was 
assessed after 3 days. However, irrespective of the genotype of the animals, none of the 
mice in this study showed ear fluids or cultured positive for NTHi (Fig 3.7 C, D). 
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Figure 3.7 Challenge of mice with NTHi162SR 
Histograms showing the percentage Wt, Bpifa1+/- and Bpifa1-/- middle ears with fluid build-up (A) and 
NTHi positive or negative middle ears (B) sampled at day 7-post baroinoculation with NTHi162SR; n=30 
for each genotype. None of the Wt (n=5), Bpifa1+/- (n=9) and Bpifa1-/- (n=10) middle ears showed 
fluid build-up (C) and NTHi positivity (D) when sampled at day 3-post IN inoculation with NTHi162SR.  
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3.2.5.2 Challenge with NTHi375SR 
 
Due to the very low efficiency of infection observed with NTHi162SR, mice were challenged 
with an alternative strain, NTHi375SR which bears a slight modification in the LPS side chain 
compared to the former. Middle ear fluids were sampled at day 1 and day 3-post IN 
inoculation and plated to evaluate NTHi growth. To compare efficiency of baroinoclutaion, 
fluids were also sampled at day 3-post baroinoculation with the same bacterial strain. PBS 
washes from clear ears were also plated. These earlier time points were chosen to increase 
the probability of isolating bacteria and observing fluid development in the ears. 
Percentage of OM development was measured in terms of the numbers of ears 
demonstrating fluid build-up (Fig 3.8). At day 1 post IN inoculation, there was no significant 
difference between the proportions of Wt (6/24), Bpifa1+/- (4/24) and Bpifa1-/- (8/24) ears 
with middle ear fluids. At day 3 post IN inoculation, 2/12 Bpifa1-/-  and 2/8 Bpifa1+/- ears, but 
none of the Wt ears (0/16) retained the middle ear fluid. Baroinoculation did not show a 
significant difference between the number of fluid filled Bpifa1-/- (6/24), Bpifa1+/- (4/20) 
Bpifa1+/-  and Wt (2/22) ears at day 3.  
The percentage of fluid filled ears between the Wts, Bpifa1-/- and Bpifa1+/-  mice did not 
differ significantly at a particular time point using either inoculation technique (IN or 
baroinoculation at day 3). However, the decrease in the percentage of fluid filled ears from 
day 1 to day 3 following IN inoculation (which indicates resolution of OM/ bacterial 
clearance) was significant in the Wts (p= 0.035) but not in Bpifa1-/- and Bpifa1+/-  mice.  
 
121 
 
 
Figure 3.8 Percentage of fluid filled ears on challenge of mice with NTHi375SR 
Comparison of the percentage of ears with fluid build-up, sampled at day 1-post IN inoculation (Wt 
n=12, Bpifa1+/-  n= 12 and  Bpifa1-/- n=12), day 3 post IN inoculation (Wt n=16, mutants, 8 Bpifa1+/-  
n=8  Bpifa1-/- n=12) and day 3 post baroinoculation with NTHi375SR (Wt n=12,  Bpifa1+/-  n=12, Bpifa1-/- 
n=12). Fishers exact test, *p<0.05 
 
Fig 3.9 describes the percentage of middle ears producing culturable NTHi. At day 1 post IN 
inoculation 6/24 Wt ears and 4/24 Bpifa1-/- ears and 5/24 Bpifa1+/- ears cultured positive 
and these included washes from some clear ears. At day 3, baroincoluation 2/24 Bpifa1-/- 
and 1/20 Bpifa1+/- ears were positive. At day 3 post IN inoculations 4/12 Bpifa1-/- ears were 
culture positive of which 2 were washes from clear ears and only 1/8 Bpifa1+/- ears was 
culture positive.  However, Wt mice never produced culturable NTHi at this time point 
using either IN or baroinoculation. The number of fluid positive ears positive for NTHi 
growth was too low to perform a statistical comparison of CFU counts between genotypes. 
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This data suggests that there was no significant difference in the number of culture positive 
ears between Wt, Bpifa1-/- and Bpifa1+/- ears, at a specific time point (at day 1 or day 3 
individually) and between the two bacterial challenge methods (IN and baroinoculation at 
day 3). However, comparison of the two time points after IN inoculation indicated that at 
day 1 bacteria got into the middle ear cavities of both Wt mice and Bpifa1 deficient mice at 
similar rates but they were cleared more effectively in Wts (p=0.004) than in the Bpifa1-/- 
and Bpifa1+/-  mice (p>0.05) by day 3.  
 
 
Figure 3.9 Percentage of culture positive ears on challenge of mice with NTHi375SR 
Comparison of the percentage ears with culture positivity sampled at day 1-post IN inoculation 
(n=12 Wt ,  n= 12 Bpifa1+/-  and n=12 Bpifa1-/-), day 3 post IN inoculation (n=16 Wt n=: 8 Bpifa1+/-  and 
n= 12 Bpifa1-/-) and day 3 post baroinoculation with NTHi375SR (n=12 Wt n=12, n=24  n=12 Bpifa1+/-  n= 
2 Bpifa1-/-). Fishers exact test, *p<0.05 
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3.3 Discussion: 
This chapter describes the in vivo effects of Bpifa1 deletion with regards to spontaneous 
development of OM in Bpifa1-/- mice and induction of OM in Bpifa1 mutants by intranasal 
challenge with the human otopathogen, NTHi. 
 
3.3.1 Localisation of BPIFA1 in the developing middle ear 
Prior to undertaking this work I had shown that BPIFA1 is produced at high basal levels in 
the adult middle ear epithelium (Mulay MSc thesis 2011). It was important to identify the 
point of onset of BPIFA1 expression in the neonatal middle ear. Examination of Wt sections 
of the developing middle ear cavity from P0 to P30 confirmed that the middle ear space is 
initially filled with a loose mesenchymal material and cavitates around P15. This 
developmental anatomy has been described previously suggesting that a tubotympanic 
recess is formed by the extension of the first pharyngeal pouch during gestation (Huangfu 
& Saunders 1983). The endoderm of the first pharyngeal pouch then breaks down filling the 
middle ear space with mesenchyme. The mesenchyme may play a role in epithelial 
differentiation and is slowly resorbed post-natally by day 11 (Huangfu & Saunders 1983, 
Thompson & Tucker 2013). Intriguingly, I detected BPIFA1 staining in the middle ear 
epithelial cells and submucosal glands from the day of birth and staining was abundant 
until the furthest time point which was tested (P56). A previous report has demonstrated 
that ciliated cells, secretory cells and glands develop in the middle ear space between 
embryonic day (e)16 -e18, suggesting that the mucociliary defence system is established 
during foetal growth and ready for use immediately after birth (Lim et al 1973).  
Interestingly, it has previously been noted that Bpifa1 gene expression is seen in the mouse 
nasal passages from e14.5 (LeClair et al 2001, Weston et al 1999) whereas expression in the 
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respiratory tract begins around the time of birth (LeClair et al 2001). The reasons for these 
temporal differences in expression are unresolved.  
 
3.3.2 Bpifa1-/- mice exhibit no phenotypic abnormalities 
The Bpifa1 gene in mice is 7.3kb in length and is composed of 9 exons (LeClair et al 2001). 
Previously, two other groups have generated Bpifa1-/- mice. One of these is an ENU mutant 
on a C3HeB/FeJ background, bearing a point mutation in exon 2 of the Bpifa1 gene (Bartlett 
et al 2015, Liu et al 2013a); while the other is a deletion mutant on a C57BL/6J background, 
generated by removal of exons 2-8 (Gally et al 2011). Bpifa1-/- mice used for this study were 
generated by deleting exons 2 and 3.  
Bpifa1 expression is highly tissue specific. The nasal passages, oropharynx, trachea and 
large airways of the lung are the sites of BPIFA1 protein localisation (Bingle & Bingle 2000, 
Di et al 2003). The previous two studies with Bpifa1-/- models did not report abnormalities 
in the overt appearance and lung histopathology (Gally et al 2011, Liu et al 2013a). Bpifa1 
mRNA has also been reported to be expressed in the kidney and colon, where it has been 
suggested to play a role in the regulation of ENaC (Garcia-Caballero et al 2009). However 
reports from several labs including our own have shown that Bpifa1 is not expressed at 
these sites in humans or mice (Bingle & Bingle 2000, Gally et al 2011, Liu et al 2013a, Musa 
et al 2012). A comprehensive histology screen of Bpifa1-/- mice at 6 months of age spanning 
42 tissues did not detect any specific alterations in the morphology of the major organs, 
viability, body weights and behaviour. This analysis included both kidney and colon. 
 
3.3.3 Loss of Bpifa1 does lead to spontaneous development of OM. 
In this study the loss of Bpifa1 did not lead to the development of OM. Deletion of Bpifa1 
had no effect on click ABR thresholds and did not lead to mucosal thickening and middle 
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ear fluid build-up in 8 and 12-week-old mice, a standard time point used to study OM 
development (Hardisty et al 2003, Parkinson et al 2006, Tateossian et al 2013). To extend 
this study further and to look at an age related effect of Bpifa1 deletion; Bpifa1-/- mice were 
aged to 6 months. Again, comprehensive histological analysis did not uncover evidence of 
later onset OM. During the course of these investigations, a study was published identifying 
an increased susceptibility of aged Bpifa1-/-mice to OM (Bartlett et al 2015). Although this 
study differs from my data, there are some key points that must be considered. Firstly, OM 
being a paediatric disease is typically studied at an early age in mouse models. The Bpifa1-/- 
mice used by the researchers were between 10-18 months of age (Bartlett et al 2015), 
rather late in the timeline of a paediatric disease. The mice exhibited a low penetrance 
phenotype with only 30% of the mice developing OM. Secondly; in the study susceptibility 
to OM was measured on the basis of a histological scoring system suggesting an increased 
trend in the presence of inflammatory cells and cell debris in the middle ear cavity and 
thickened mucosa in the Bpifa1-/- mice compared to Wt mice. However, the number of 
mice developing overt OM (30%) was not significantly higher compared to Wt (5%) mice. 
Lastly, middle ear fluids from the mice affected with OM did not show presence of bacteria 
indicating a sterile inflammation. Studies in our lab have shown that Evi1Jbo/+ mice develop 
OM spontaneously in germ free conditions (Hood et al 2016), possibly due to allergic 
response to environmental stimuli such as bedding material. BPIFA1 has been previously 
implicated in inflammatory responses to airway allergens such as cigarette smoke as well as 
to sterile carbon nanotubules (Britto & Cohn 2015, Di et al 2013). Therefore, the 
development of a low penetrance OM phenotype in these mice may be the result of a 
cumulative effect of loss of Bpifa1 along with an overall compromised immune response 
due to increased age, rather than a specific effect of Bpifa1 deletion alone. Due to lack of 
time, I was unable to set up more matings to age mice longer than 6 months of age. 
However, in future, this aspect needs to be explored on further detail.  
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3.3.4 Intranasal NTHi challenge does not lead to induction of OM in Bpifa1-/- mice. 
NTHi is a common pathogen, isolated from AOM as well as COME patients (Giebink 1991). 
This thesis is the first report to investigate the effect of bacterial infection on OM 
development in Bpifa1-/- mice. NTHi162SR and NTHi375SR are clinical isolates from a Finnish 
pneumococcal vaccine study and differ in the structure of their LPS side-chain structure 
(Cody et al 2003, Hood et al 1999). A screen of 7 NTHi strains previously performed in our 
lab, identified NTHi162SR and NTHi375SR as the most efficient strains for intranasal infection of 
Evi1Jbo/+ mice. (Hood et al 2016). In this study, challenge with NTHi162SR led to no OM 
development in Bpifa1 mutant mice. Infection with NTHi375SR did not lead to a significant 
difference in the frequency of OM or NTHi positive middle ears between Wt, Bpifa1-/-  and 
Bpifa1+/-  mice at individual time points. However, the percentage of fluid filled ears and 
NTHi positive ears significantly decreased in the Wts from day 1 to day 3 but not in the 
mutants. The data suggests that bacteria arrived in the middle ear cavities of both Wt and 
Bpifa1 mutant mice at day 1 leading to fluid build-up, but were cleared more effectively in 
Wts compared to Bpifa1 mutants. This suggests a diminished resolution of infection in 
Bpifa1-/- mice, perhaps due to dampened mucociliary clearance. Indeed, in vivo 
downregulation of chinchilla Bpifa1 using siRNA was shown to alter middle ear pressure 
and cause ET dysfunction during NTHi induced OM. (McGillivary & Bakaletz 2010). Thus, 
BPIFA1 may be involved in maintaining the stability of the epithelium through its surfactant 
properties and its loss may affect mucociliary clearance upon bacterial insult. There was no 
clear effect of haploinsufficiency of BPIFA1 in the heterozygote mice. 
However, it must be noted that this difference in clearance of bacteria between Wts and 
Bpifa1-/-  mice cannot be conclusively interpreted as biologically significant in this context. 
This is because mice sampled on day 1-post IN inoculation and on day 3-post 
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baroinoculation were on a C57BL/6 background, whereas those sampled on day 3-post IN 
inoculation were on a C57BL/6-C3H/HeH background. It is known that OM phenotype is 
influenced by background strain (Melhus & Ryan 2003, Tyrer PhD thesis 2013). Therefore, 
an accurate comparison cannot be made between time points. This discrepancy in 
genotypes was simply owing to the availability of mice at this early stage in the breeding 
pipeline. Also, due to the insufficient numbers of culture positive ears for individual 
genotypes, I could not estimate differences in bacterial titers following infection. The 
bacterial challenge experiments were performed with a relatively large number of mice 
(maximum of 12 mice per genotype) because of the low infection rates observed. It was 
therefore not deemed ethically appropriate to perform more experiments in order to 
standardize the variables.  
The low infection rates in Bpifa1-/- mice can be explained based on recent data from our lab 
showing that the presence of fluid is a prerequisite for bacterial infection of the middle ear. 
Assessment of OM in a large number of mice at day 7 after NTHi challenge showed that Wt 
mice almost never showed ear fluids and PBS washes from Wt middle ears were culture 
negative. On the other hand, the different mouse models of spontaneous OM, Evi1Jbo/+, 
Fbxo11Jf/+ and Tgif-/-, all of which show pre-existing inflammation and middle ear fluids 
facilitated access of NTHi into the middle ears (Hood et al 2016). Also NTHi infection did not 
alter OM frequency in challenged Evi1Jbo/+ mice when compared to unchallenged 
Evi1Jbo/+mice. The hypoxic, inflamed environment containing suppurative fluid in the middle 
ears of the OM models, may promote the entry, colonisation and survival of bacteria 
(Cheeseman et al 2011, Hood et al 2016). This notion is supported by studies which showed 
that a single dose of intranasally inoculated bacteria did not cause middle ear infection in 
chinchillas (Bakaletz 2009) and caused only sporadic infection in mice (Ryan et al 2006). 
However co-infection with respiratory viruses (Bakaletz 2009, Giebink 1981, Short et al 
2013) or use of baroinoculation (Giebink et al 1979, Stol et al 2009) promoted middle ear 
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infection in both species. In this study, an increased effect of baroinoculation on efficiency 
of NTHi infection was not observed. However, repeated bacterial inoculation or a 
coincident viral infection in future may provide a more biologically relevant set up to 
investigate NTHi induced OM development in Bpifa1-/- mice.  
Another important argument that my observations raise is with respect to the variability in 
disease susceptibility of Bpifa1-/-  mice to different NTHi strains with modifications in their 
LPS structures. BPIFA1 is structurally similar to LBP and BPI, both of which bind LPS. There is 
conflicting evidence on binding activity of BPIFA1 to LPS, where some studies showed that 
it bound LPS but others showed that it does not compete for binding with LBP (Ahmad et al 
2016, Campos et al 2004, Ning et al 2014, Walton et al 2016). Perhaps a more systematic 
study to identify the optimal strain for infection would yield higher infection rates.  
Analysis of middle ear fluids does not provide information on bacteria associated with the 
middle ear epithelium. In vitro culture of middle ear epithelial cells would enable 
assessment of a controlled dose of NTHi infection, directly on middle ear cells. It will also 
help to explore the antimicrobial and immunoregulatory roles of BPIFA1 in further detail. 
The development of an in vitro system of middle ear epithelial cells and its utilisation to 
study NTHi infection has been described in Chapter 4. 
Overall, the data from this chapter indicates that loss of Bpifa1 alone does not increase 
susceptibility to spontaneous or NTHi induced OM development. However, upon bacterial 
infection, absence of Bpifa1 may affect the phenotype of the middle ear epithelium, 
leading to altered mucociliary clearance and delayed resolution of infection.  
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3.4 Key experimental conclusions 
x BPIFA1 localises to the non-ciliated epithelial cells and sub-mucosal glands in the 
Wt middle ear since the day of birth. 
x Bpifa1-/- mice exhibit no differences between viability, body weights, morphology 
and overt phenotype compared to Wt mice.  
x Loss of Bpifa1 does not alter the auditory function of Bpifa1-/- mice.  
x Bpifa1-/- mice do not demonstrate histological signs of spontaneous OM 
development, at least up to 6 months of age. 
x Challenge of Bpifa1-/-  mice with the human otopathogen, NTHi demonstrates a 
trend towards decreased clearance of bacteria from the middle ear cavity 
compared to Wt mice, suggestive of altered mucociliary clearance. However, 
deficiency of Bpifa1 does not increase nasopharyngeal carriage of NTHi and 
induction of OM. 
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CHAPTER 4:  DEVELOPMENT OF A NOVEL MODEL OF THE MURINE 
MIDDLE EAR EPITHELIUM AND ITS USE TO STUDY THE EFFECT OF LOSS 
OF BPIFA1   
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4.1.1 Introduction 
The middle ear epithelium is similar to the respiratory epithelium and is composed of 
ciliated cells, secretory cells, non-secretory cells and basal cells. Secretory cells are 
responsible for the production of mucins and various anti-microbial proteins such as 
lactotransferrin, lysozyme, defensins and surfactants (Lim et al 2000, McGuire 2002). The 
epithelium, along with its secretions, is involved in maintaining homeostasis and sterility 
within the middle ear cavity. Epithelial remodelling, characterised by mucociliary 
metaplasia and infiltration of the middle ear cavity with inflammatory cells, is a common 
feature of OM (Straetemans et al 2001).  
In most animals, the middle ear is a relatively inaccessible organ lined by a thin mucociliary 
epithelium and sampling of the mucosa is a terminal procedure. Human middle ear tissue 
can be acquired only during surgical procedures and this limits the amount of sample 
available for study of OM. Culturing of middle ear cells in vitro enables maximisation of the 
available material, allows the effect of modifying culture conditions to be studied more 
easily and also enables studies of host pathogen interactions. Previously, attempts have 
been made to culture middle ear epithelial cells from a number of organisms including rats 
(Toyama et al 2004, Ueyama et al 2001, Vanblitterswijk et al 1986), mice (Tsuchiya et al 
2005),  chinchillas (Amesara et al 1992, Nakamura et al 1991), gerbils (Herman et al 1992, 
Portier et al 2005, Takeno 1990), rabbits (Schousboe et al 1995) and humans (Choi et al 
2002, Chun et al 2002, Moon et al 2000). These studies have included organ and explant 
cultures, primary cell cultures and development of middle ear cell lines.  
However, there remains a lack of a robust in vitro middle ear epithelial model that 
differentiates into the different epithelial cell types of the middle ear and is free of 
fibroblast contamination. This has greatly restricted the ability to identify the function of 
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different cell types and their products within the middle ear and limits our understanding 
of the pathophysiology of OM. 
Pulmonary research has been revolutionised by use of the ALI system for culture of TBE 
cells. The exposure of apical cell surfaces to air and the supply of nutrients from the basal 
compartment mimic the in situ arrangement and promote maximal differentiation. ALI 
cultures of TBE cells have been generated from several species (Clarke et al 1992, Davidson 
et al 2000, Yamaya et al 1992, You et al 2002). More recently, this system has been applied 
to the culture of murine nasal epithelial cells, recapitulating the characteristics of the 
respiratory epithelium of the nasal passages (Woodworth et al 2007). Studies employing 
ALI cultures of TBE and nasal epithelial cells have enhanced our knowledge of airway 
epithelial biology tremendously, by shedding light on various aspects such as cellular 
differentiation and secretion, (Kim et al 2000, Pillai et al 2014), cell-cell communication 
(Yeh et al 2007) inflammatory signalling (Krunkosky et al 2003) and pathogenesis of 
infections (Kesimer et al 2009, Lopez-Souza et al 2009, Wu et al 2005). Applications of 
these cultures have furthered our understanding of drug transport and delivery to these 
sites (Dimova et al 2005, Lee et al 2005), effects of environmental and occupational 
pollutants (Auger et al 2006, Johnson et al 2007) and genetic disorders such as CF (Matsui 
et al 1998) and PCD (Hirst et al 2014). 
The middle ear epithelium can be considered to be an anatomical extension of these 
conductive epithelia by the means of the ET. Therefore, using the ALI system I developed a 
novel in vitro model of the murine middle ear epithelial cells, with the view of 
systematically characterising the different cell types present in the middle ear and studying 
the effect of loss of Bpifa1 in culture.    
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4.1.2 Aims of this study 
This chapter addresses two major aims: 
1. The foremost aim of this chapter was to develop a novel in vitro model of the 
mouse middle ear epithelium and to methodically characterise the different 
epithelial sub-populations in the middle ear.  
2. The second aim of this chapter was to utilise the model to assess the effect of loss 
of Bpifa1 on uninfected middle ear cells and also following infection with NTHi. In 
Chapter 3, I have shown that intranasal carriage of NTHi is not affected by loss of 
Bpifa1. The goal of this chapter was to identify the more subtle effects of NTHi 
infection, specifically on the middle ear epithelial cells. 
4.1.3 Study design 
Figure 4.1 gives a summary of the study design for this chapter. 8- 10 week old Bpifa1-/-
mice on the C57BL/6J background were used for all experiments in this chapter unless 
otherwise mentioned. Briefly, an in vitro model of primary mouse middle ear epithelial cells 
(mMECs) was developed using the ALI culture system. Mouse nasal epithelial cells (mNECs) 
were grown in a similar manner as a comparator due to the similarities between the 
markers of the URT and middle ear (Section 2.8). Prior to performing any major 
experiments, culture conditions were optimised and the characteristic features of cell 
growth were evaluated (Sections 4.2.1 and 4.2.2). For validation of the model and 
systematic characterisation of cell types, mMECs were compared to native mouse middle 
ear epithelium using a variety of approaches. Light microscopy and electron microscopy 
were used for morphological characterisation of mMECs (Section 4.2.3). The expression of 
a selected panel of known and novel airway epithelial genes was analysed using RT-PCR 
(Section 4.2.4). MS was employed to perform a global proteomic analysis of the mMEC 
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secretome. Western blotting and RT-PCR were used to confirm some of the most highly 
expressed proteins detected by the MS analysis (Section 4.2.5).  
The validated model was first utilised to evaluate differences in the expression of selected 
epithelial markers between uninfected Wt and Bpifa1-/- cultures (Sections 4.2.8 and 4.2.9). 
Next, differentiated mMEC cultures were infected with NTHi375SR-GFP, to compare the 
susceptibility of Bpifa1-/- mMECs to Wt cells (Sections 4.2.12). Lastly, RT-qPCR was used to 
study the pleotropic effect of Bpifa1-/- deletion on levels of various inflammatory and 
epithelial markers during the course of infection (Sections 4.2.15).
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Figure 4.1 Study design for this chapter 
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4.2 Results 
4.2.1 Determination of optimal culture conditions for mMECs and mNECs 
Formation of a confluent monolayer during the initial submerged culture is a pre-requisite 
for establishing an ALI. Hence, I seeded Wt mMECs and mNECs at a variety of initial seeding 
densities. I also tested the effect of addition of ROCKi in order to facilitate the use of the 
lowest possible seeding density to form a monolayer. In addition, I evaluated the use of 
plastic and collagen coated semipermeable transwell membranes as growth substrates for 
mMECs. 
The average number of mMECs isolated was 74,667±10,621/bulla (n=12 Wt batches). 
When grown on plastic (2.5 x104 cells/ well), both in absence (Fig 4.2 A) and presence (Fig 
4.2 B) of ROCKi, mMECs did not exhibit the typical epithelial morphology in culture, started 
forming vacuoles, detached from the surface and did not achieve confluence. On transwell 
membranes, in the absence of ROCKi, at 1 x104 cells/ well (Fig 4.2 C) cells grew in small 
epithelial clusters but did not form a confluent monolayer. At 2 x104 cells/ well (Fig4.2 D), a 
proportion of wells formed a confluent monolayer at submerged Day 15 and at 5 x104 
cells/well (Fig 4.2 E) cells formed a confluent monolayer around submerged Day 9. By 
addition of ROCKi, the formation of a confluent monolayer could be achieved within 9 -10 
days of seeding at the lower initial seeding densities of 1 x104 cells/ well (Fig 4.2 F) and 2 
x104 cells/ well (fig 4.2 G). A seeding density of 1 x104 mMECs/ well (Fig 4.2 F), in presence 
of ROCKi was selected in order to increase the number of wells from the small number of 
cells available from the middle ear cavities.  
  
138  
 
Figure 4.2 Optimisation of seeding density for mMEC culture 
Cells did not form a confluent monolayer when grown on plastic, both in absence (A) and presence 
(B) of ROCKi and on transwell membranes at 1 x104 cells in absence of ROCKi (C). The number of days 
required to confluence when seeded on transwell membranes at initial densities of 2 x104 cells (D) 
and 5 x104 cells without ROCKi (E) and at 1x104 (F) and 2 x104 (G) with ROCKi. Formation of a 
confluent monolayer led to successful differentiation at ALI and a typical cobbled stone appearance, 
irrespective of the initial seeding density (H-K). Seeding density of 1 x104 cells/ well with ROCKi was 
selected (red box) Scale bar = 200 μm. White arrowheads indicate elevated clusters of cells with 
actively beating cilia and asterisk denote flatter polygonal cells. RT PCR of ALI Day 14 mMECs (L), 
demonstrating that adding ROCKi to the culture medium did not affect differentiation into secretory 
(Bpifa1) and ciliated (Foxj1) cell types 
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The average number of mNECs isolated from nasal cavities (233,517±27,575/NC; n=11 Wt 
batches) was 2.6 times higher than those isolated from nasal septae (88,333±20,000/NS; 
n=2 Wt batches). mNECs were seeded on collagen coated semipermeable transwell 
membranes. Cells isolated from the nasal septum, seeded at an initial density of 5 x104 
cells/ well in the absence of ROCKi reached confluence at submerged Day 13 (Fig 4.3 A). 
Cells isolated from the nasal cavity took 10, 6 and 5 days to become confluent, when 
seeded at 5 x104 cells/ well (Fig 4.3 C), 1 x105 cells/ well (Fig 4.3 E) and 2 x105 cells/ well (Fig 
4.3 F) respectively in absence of ROCKi. Addition of ROCKi enabled the formation of a 
confluent monolayer at submerged Day 7 at a lower initial seeding density of 3 x104 cells/ 
well (Fig 4.3 D). This seeding density in the presence of ROCKi was selected for culture of all 
mNEC batches from nasal cavities.  
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Figure 4.3 Optimisation of seeding density for mNEC culture 
mNECs isolated from nasal septum took 13 days to reach confluence and differentiated within 14 
days at the ALI (A, B). Number of days required for mNECs from nasal cavity to form a confluent 
monolayer when seeded on transwell membranes at initial densities of 5 x104  (C), 1 x105 cells (E), 2 
x105  (F), without ROCKi and 3 x104 with ROCKi (D) Formation of a confluent monolayer led to 
successful differentiation at ALI and a typical cobbled stone appearance, irrespective of the initial 
seeding density (G-J). Seeding density of 3x104 cells/ well with ROCKi was selected (red box). Scale 
bar = 200 μm. Cultures were homogenous with evenly distributed, actively beating cilia.  
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For both mMECs and mNECs, cells forming a confluent monolayer differentiated 
successfully at ALI and demonstrated a typical cobbled stone appearance, irrespective of 
the initial seeding density (Figures 4.2 H-K, 4.3 B, and G-J). Addition of ROCKi did not appear 
to alter differentiation of cells, as demonstrated by Figure 4.2 L 
The growth characteristics of cells throughout the culture period are detailed the following 
section.  
 
4.2.2 Culture characteristics  
As described previously (Section 2.8.1.5), primary culture of mMECs and mNECs proceeded 
in two phases – a proliferative phase in submerged culture and a differentiation phase at 
air liquid interface (Figure 2.9).   
 
 
4.2.2.1 Culture characteristics of mMECs  
mMECs were seeded at a density of 1x104 cells/ membrane and 3 days after seeding only 
16.8±2.6% cells (n=3) adhered to the membrane and had started forming small epithelial 
islands (Figure 4.4A). The attached cells began to elongate to establish contact with 
neighbouring cells, and proliferated more rapidly from day 5 to day 7 (Figure 4.4B, C). Cells 
formed a confluent monolayer of flat, polygonal cells within 9 to 10 days in submerged 
culture (ALI Day 0) in the presence of ROCKi (Figure 4.4D). The morphology of the cells 
became more complex when transferred to the ALI. At ALI Day 3, cells started changing in 
size and shape (Figure 4.4E) and by ALI Day 7 two distinct sub populations of cells could be 
observed, the majority of which were flat polygonal cells, intersected with clusters of 
slightly elevated, more compactly arranged cells (Figure 4.4F). Around ALI Day 9, ciliary 
beating could be seen in these clusters under phase contrast microscope. ALI Day 14 cells 
(1.2x105cells/membrane; n=3) displayed a cobble-stone appearance with well-defined cell 
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boundaries; and were a combination of flat polygonal cells and compactly clustered 
elevated cells with actively beating ciliated cells. (Figure 4.4G).  
There was no noticeable difference between the growth characteristics of Wt and Bpifa1-/-  
mMEC cultures (Table 4.1). ALI Day 14 Bpifa1-/-  mMECs exhibited a similar heterogeneous 
population of flat polygonal cells and elevated cells with actively beating cilia (Fig 4.4H). No 
cells with fibroblasts-like morphology were seen in mMEC ALI cultures. However, 
fibroblasts isolated through the differential adherence treatment during the cell isolation 
process, were grown separately on plastic culture dishes to obtain pure mouse middle ear 
fibroblasts (Figure 4.4I), which were later utilised as negative controls for transcriptional 
analysis of epithelial markers (Section 4.2.4). 
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Figure 4.4 Growth characteristics of mMECs in culture.  
Phase contrast images showing Wt mMECs in culture under 10x magnification (A-G). In the 
proliferative submerged conditions, a small number of cells attached to form epithelial islands 3 
days after seeding (A) The cells proliferated faster from day 5 (B) through day 7 (C) and formed a 
confluent monolayer at day 9. This was termed as ALI Day 0 (D) Morphology of cells changed from 
ALI Day 3 (E) and clusters of compactly arranged cells started forming at ALI Day 7 (F). ALI Day 14 
cultures were composed of flat polygonal and compactly clustered pseudo stratified cells with active 
cilia. Bpifa1-/- ALI Day 14 mMEC displayed a similar morphology (H). White arrowheads mark 
elevated ciliated cells and asterisk mark flatter polygonal cells. Fibroblasts cultured on plastic plates 
through differential adhesion method (I) Scale bar = 200 μm. 
 
 
4.2.2.1 Culture characteristics of mNECs 
mNECs were seeded at a density of 3x104 cells/ well in presence of ROCKi. After 3 days in 
submerged culture, clusters of epithelial cells attached to the membrane were observed 
(Figure 4.5A). Cells became elongated similar to mMEC cells by day 5 (Figure 4.5B) and 
rapidly proliferated to form a confluent monolayer of flat polygonal cells by day 7 (ALI Day 
0, Figure 4.5C). At ALI Day 3, cells appeared more compactly arranged (Figure 4.4D). Ciliary 
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movement was detected around ALI Day 7 (Figure 4.5E). Unlike mMECs, ALI Day 14 mNECs 
(1.5x105cells/membrane) displayed a homogenous appearance with actively beating 
ciliated cells, interspersed throughout the culture under phase contrast microscope. Cells 
were polygonal, with well-defined cell boundaries, displaying a cobble-stone appearance 
characteristic of epithelial cells (Figure 4.5F). Nasal fibroblasts were cultured through 
differential adherence (Figure 4.5H).  
There was no noticeable alteration in the growth characteristics and appearance of Bpifa1-/- 
mNEC cultures (Figure 4.5G, Table 4.1).  
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Figure 4.5 Growth characteristics of mNECs in culture.  
Phase contrast images showing Wt mNECs in culture under 10x magnification (A-F). In the 
proliferative submerged conditions, a small number of cells attached to form epithelial islands 3 
days after seeding (A) The cells proliferated rapidly through day 5 (B) and formed a confluent 
monolayer at day 9 (C). ALI Day 3 (D) and Day 7 (E) cells were more compactly arranged. ALI Day 14 
cultures were composed of a homogenous layer of flat polygonal cells with active cilia (F). Bpifa1-/- 
ALI Day 14 mNEC displayed a similar morphology (G). Scale bar = 200 μm. 
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Table 4.1 Summary of culture characteristics of mMECs and mNECs 
Characteristic 
feature 
Wt mMECs 
n=12 
KO mMECs 
n=8 
WT mNECs 
n=11 
KO mNECs 
n=6 
No of cells 
isolated 
74667±10621 
 
80127±12439 
 
233517±27574 
 
195214±71773 
 
% Viability of 
isolated cells 
before seeding  
86.4% (n=3) 90.06% (n=3) 83% (n=3) 88.03% (n=3) 
Optimised 
seeding density 
1x 104 cells/ well + 
ROCKi 
1x 104 cells/ well + 
ROCKi 
3x 104 cells/ well 
+ ROCKi 
3x 104 cells/ well 
+ ROCKi 
Confluent 
monolayer 
formation 
Submerged Day 
9/10 
Submerged Day 
9/10 Submerged Day 7 Submerged Day 7 
Ciliated cells 
appear ALI Day 9 ALI Day 9 ALI Day 7 ALI Day 7 
Cell 
morphology by 
LM 
Cobbled stone 
appearance; 
combination of flat 
polygonal and 
tightly clustered 
elevated cells 
Cobbled stone 
appearance; 
combination of 
flat polygonal and 
tightly clustered 
elevated cells 
Homogenous 
cobbled-stone 
appearance 
Homogenous 
cobbled-stone 
appearance 
 
Following optimisation of seeding densities, I first validated Wt mMECs as a suitable model 
for the study of the cell biology of the middle ear epithelium and host pathogen 
interactions within the middle ear as described in Sections 4.2.3 to 4.2.7. 
 
4.2.3 mMECs exhibit an epithelial morphology 
Electron microscopy imaging of Wt ALI Day 14 mMECs revealed a morphology reminiscent 
of the upper airway epithelium (Figure 4.6). At ALI Day 0 (undifferentiated cells), SEM 
showed uniformly flat, large cells with microvilli on the apical surfaces (Figure 4.6A). At ALI 
Day 14, the cells exhibited a dome shaped appearance (Figure 4.6B), areas of flatter 
polygonal and secretory cells with microvilli on the apical surfaces and areas abundant in 
ciliated cells (Figure 4.6C). The morphology of the ALI Day 14 mMEC cultures resembled the 
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in vivo middle ear epithelium (Figure 4.6D). TEM revealed that ALI Day 14 cells were 
polarized with desmosomes on the baso-lateral surfaces suggesting the formation of tight 
junctions, another feature of epithelial cells (Figure 4.6E). The formation of tight junctions 
was further confirmed by uniform expression of zonna occludens, ZO-1 in the cell 
membrane (Figure 4.6F). 
 
 
Figure 4.6 Morphology of mMEC cultures.  
SEM of ALI Day 0 mMEC cultures showing large flat polygonal cells with apical microvilli (A) ALI Day 
14 cultures showing dome shaped cells at higher magnification (B) and combination of interspersed 
flat polygonal and densely ciliated cell populations (C) resembling the morphology of native middle 
ear epithelium (D). Cracks in the membrane are due to processing of samples for SEM. White 
arrowheads mark elevated ciliated cells and asterix mark flatter polygonal cells.  TEM of ALI Day 14 
mMEC cultures showing adjacent ciliated and secretory cells and formation of tight junctions 
demonstrated by presence of desmosomes (asterisk). Arrow shows cilia (E). Immunoconfocal 
microscopy image showing formation of tight junctions marked by ZO1 positive staining. Area 
beyond white lines indicates a cross section through the membrane. (n=3) Scale bar =10 μm (A, C, 
D); 5 μm (B); 1 μm (E); 50 μm (F). 
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4.2.4 Expression of epithelial markers by Wt mMEC cultures 
The expression of a selected panel of genes, known to be expressed by the middle ear 
epithelium and upper airways was assessed by RT- PCR of RNA from the original Wt mMECs 
before seeding (mMEC original) and compared to ALI Days 0 and 14 mMEC cells. Fibroblasts 
isolated by differential adherence were used as a negative control for epithelial markers 
(Figure 4.7A). Bpifa1 was expressed strongly in the original and ALI Day 14 cells, but was 
lower in the undifferentiated ALI Day 0 cells. Bpifb1 was detected only in the original cells, 
not in cultured cells. Tekt1 (a marker of ciliated cells) was detected at ALI Day 14. Analysis 
of Muc5ac and Muc5b expression, markers of goblet cells, suggested that Muc5ac was 
weakly expressed in mMEC original cells but was not detectable in the cultured cells, 
whereas Muc5b was expressed more strongly in the original cells and maintained this 
expression to ALI Day 14. I also studied the mucosal innate immune genes Lactotransferrin, 
Surfactant protein D (Stfpd) and Regenerating islet-derived protein 3 gamma (Reg3ᵞ), which 
were identified through a proteomic study of the mMEC secretome, mentioned later in 
Section 4.2.5. Lactotransferrin and Reg3ᵞ were detected in the mMEC original cells and at 
ALI Days 0 and 14, whereas expression of Stfpd was seen in the cells during ALI 
differentiation. As expected, the expression of Keratin5, a marker of basal cells, was 
reduced as cells differentiated from ALI Day 0 to Day 14. The expression of these epithelial 
markers in the mMEC cultures indicated that the cells differentiated in culture from ALI Day 
0 to ALI Day 14 and the pattern of expression in the differentiated cells was in line with that 
seen in the mMEC original cells isolated from the middle ear. Vimentin is a marker of 
fibroblasts and other mesenchymal cell types. The absence of Vimentin in ALI Day 14 
cultures indicates that the mMEC cultures are devoid of potential fibroblast contamination. 
Oaz1 was used as a housekeeping gene for all RT-PCR experiments.  
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4.2.5 Apical secretome of Wt mMECs 
To complement the gene expression studies, I also performed a global proteomic analysis 
of apical ALI Day 14 secretions of Wt mMECs by Orbitrap MS. Table 4.2 lists the most 
abundant secreted proteins identified classified according to their emPAI score, which is 
the ratio of the number of peptides found for a protein divided by the predicted number of 
peptides that could be potentially seen in the sample. The most abundant secreted protein 
was Lactotransferrin, with Serotransferrin, Reg3ᵞ, Lipocalin2, Ceruloplasmin and BPIFA1 
also being found at high levels. Multiple anti-proteinase and proteinase proteins were also 
found in the secretions including members of the WAP four-disulfide core domain protein 
(WFDC) family, WFDC2, SLPI (WFDC4) and WFDC18 (EXPI) as well as multiple cathepsins. I 
validated the secretion of BPIFA1, Lactotransferrin and Reg3ᵞ in the apical washes from the 
differentiating mMEC cells using western blotting (Fig. 4.7 B, C, D). The list of top 500 
proteins identified is given in Appendix III, Table S5. 
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Figure 4.7 Expression of epithelial markers in mMEC cultures 
End-point RT-PCR showing expression of a selected panel of upper airway associated genes in mMEC 
original cells isolated from the middle ear cavity, ALI D0 cells and ALI D14 cells. Expression profile of 
ALI Day 14 cells was similar to mMEC original cells isolated from the middle ear for most genes (A). 
Detection of BPIFA1 (B), Lactotransferrin (C) and Reg3ϒ (D) in the apical washes from differentiating 
cells using the western blotting technique. Data is representative of results from three independent 
cultures. 
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Table 4.2: Most abundant secreted proteins identified in apical ALI Day 14 washes from Wt mMEC 
cultures 
Accession 
Number Protein 
Peptide 
count 
emPAI 
Score Biological reference 
P08071 Lactotransferrin 47 202.53 Anti-microbial iron chelation 
Q921I1 Serotransferrin 40 29.58 Iron chelation, cell proliferation 
O09049 Regenerating islet-derived protein 3-gamma 8 11.38 Anti-microbial 
P11672 Neutrophil gelatinase-associated lipocalin 9 10.45 Iron trafficking, innate immunity 
Q61147 Ceruloplasmin 55 10.1 Copper transport, antioxidant defense 
P97361 BPI fold-containing family A member 1 9 4.74 Suggested role in innate immunity 
P01027 Complement C3 111 4.68 Activates complement system 
P06797 Cathepsin L1 12 3.11 Lysosomal protein degradation 
Q61805 Lipopolysaccharide-binding protein 19 2.96 
Antimicrobial activity through 
bacterial LPS binding 
P10605 Cathepsin B 15 2.47 Intracellular protein degradation and turnover 
Q61362 Chitinase-3-like protein 1 22 2.16 
Tissue remodeling in response to 
environmental stress, activation of 
NfκB signaling pathway 
P25785 Metalloproteinase inhibitor 2 14 2.08 Inactivates metalloenzymes 
Q9CQV3 Serpin B11 24 1.97 Serine protease inhibitor 
P18242 Cathepsin D 20 1.67 Intracellular protein breakdown 
O88312 Anterior gradient protein 2 homolog 10 1.53 
Regulates giblet cell differentiation 
and mucous secretion. 
P50404 Pulmonary surfactant-associated protein D 23 1.5 
Innate immunity response, 
respiratory gaseous exchange and 
homeostasis 
P10810 Monocyte differentiation antigen CD14 16 1.41 
TLR2 mediated innate immune and 
inflammatory response to 
bacterial LPS in concert with LBP 
Q62426 Cystatin-B 6 1.24 Proteinase inhibitor 
Q9ER10 Brain-specific serine protease 4 15 1.11 Protease activity 
P08905 Lysozyme 10 1.05 Bacteriolytic activity 
Q9DAU7 WAP four-disulfide core domain protein 2 6 0.91 Protease inhibitor 
P11214 Tissue-type plasminogen activator 31 0.89 Tissue remodeling, cell migration 
Q9WUU7 Cathepsin Z 14 0.89 Peptidase activity 
O88593 Peptidoglycan recognition protein 1 10 0.81 
Triggers apoptosis of Gram 
positive bacteria 
Q60854 Serpin B6 23 0.81 Regulation of serine proteases 
P34884 Macrophage migration inhibitory factor 5 0.61 
Pro inflammatory cytokine 
involved in regulation o 
macrophage activity 
Q9R118 Serine protease HTRA1 21 0.54 Cell proliferation and viral response 
P12032 Metalloproteinase inhibitor 1 12 0.49 Cell differentiation and wound healing 
P97430 Antileukoproteinase 11 0.49 Anti microbial host defense 
P61939 Thyroxine-binding globulin 22 0.4 Thyroid hormone transport 
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P25085 Interleukin-1 receptor antagonist protein 7 0.35 Inhibits IL-1 activity 
P70124 Serpin B5 22 0.35 Morphogenesis of epithelium 
Q61703 Inter-alpha-trypsin inhibitor heavy chain H2 48 0.24 Hyaluronan metabolic process 
P97290 Plasma protease C1 inhibitor 25 0.12 Blood coagulation, complement activation. 
NB- Accession numbers and biological functions from the UniProt database 
 
4.2.6 Cytosolic localisation of epithelial markers in Wt mMEC cultures  
I used IFC microscopy to study the localisation of epithelial markers in Wt ALI Day 0 and ALI 
Day 14 cultures, in order confirm the differentiation process at the protein level. ALI Day 0 
cultures showed abundant expression of transformation-related protein 63, p63 (basal cell 
marker), scanty expression of BPIFA1 (Figure 4.8A) and no expression of FOXJ1 (ciliated 
cells) and MUC5B (goblet cells) (Figure 4.8C). However, by ALI Day 14, the cells had 
differentiated into multiple cell types and expressed high levels of BPIFA1, reduced levels of 
p63 (Figure 4.8B) and were populated with ciliated and goblet cells (Figure 4.8D). BPIFA1 
was localised to the non-ciliated population in differentiated mMECs, consistent with that 
seen in the in vivo middle ear epithelium (Section 3.2.2; Fig 3.3). In keeping with proteomic 
and RT-PCR data, I also detected abundant cytosolic staining of Lactotransferrin and Reg3ᵞ 
in the ALI Day 14 cultures (Figures 4.8E, F). Staining of nuclei with DAPI and Z-slice imaging 
using confocal microscopy also demonstrated that the cells formed a flat monolayer at ALI 
Day 0, but showed a more complex reorganisation by ALI Day14 with a combination of flat 
and elevated cells showing 2 or 3 different layers, with nuclei further away from the base of 
the membrane (Figures 4.8G, H). 
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Figure 4.8 Localisation of epithelial markers in Wt mMEC cultures.  
Immunofluorescence confocal images (representative of three independent batches) showing 
abundant expression of the basal cell marker, P63; limited expression of the secretory protein, 
BPIFA1 (A), no expression of goblet cell marker, MUC5B and the ciliated marker, FOXJ1 (C) in 
undifferentiated ALI Day 0 mMEC cultures (A and C). Differentiated mMEC ALI Day 14 (B, D, E, F) 
cultures showing expression of secretory cells positive for BPIFA1 (B), Lactotransferrin (E), Reg3γ (F), 
goblet cells positive for Muc5B and ciliated cells positive for FoxJ1 (D). Area beyond white lines 
indicates a cross section through the membrane. High magnification Z-stack cross sections of nuclei 
stained with DAPI shows that ALI Day 0 cells form a flat monolayer (G) whereas ALI Day 14 cells are a 
combination of pseudostratified elevated cells (arrowheads) and flatter cells (asterisk) (H).  Scale bar 
=50μm. 
 
 
 
4.2.7 Relative abundance of secretory, goblet and ciliated cells 
mMEC cultures displayed a heterogeneous distribution of BPIFA1 positive cells and FOXJ1 
positive ciliated cells. Staining for BPIFA1 was abundant in the cultures, whereas ciliated 
cells appeared in smaller clusters. Low powered phase contrast microscopy (Fig 4.9A) and 
SEM (Fig 4.9B) of mMEC cultures demonstrated that the ALI Day 14 cultures were 
composed of distinct anatomical areas of flat polygonal cells and patches of more elevated 
pseudostratified cells. I further analysed the localisation of secretory, goblet and ciliated 
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markers within the two regions of this cellular morphology. FOXJ1 positive ciliated cells and 
MUC5B positive goblet cells, were restricted to the elevated pseudostratified cell clusters, 
whilst BPIFA1 was more commonly seen in the flatter cells, although some staining was 
seen in the elevated cells, especially near the periphery (Fig. 4.9C, D). This was consistent 
with the observation that ciliated cells could be seen beating in the elevated clusters of 
cells under light microscopy. I also confirmed BPIFA1 and MUC5B positive cells were not 
ciliated (Fig. 4.9E, F).  
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Figure 4.9 Distribution of cell types in mMEC cultures.  
Phase contrast image at 10x magnification (A) and very low powered SEM image (B) reveal that ALI 
Day 14 mMEC cultured are composed of regions of flat and elevated cells. Immunofluorescence 
confocal images showing a similar pattern of flat cells elevated clusters cells at slightly different foci. 
Ciliated cells (FOXJ1) do not co-localise with and goblet cells (MUC5B) (C) and BPIFA1 expressing cells 
(D) High magnification (60x) cross section Z-stack confocal images showing that FOXJ1 and MUC5B 
expression is mostly restricted to the elevated cell types (arrowheads) (E) and BPIFA1 is 
predominantly expressed by flatter cells (asterisk) (F) Scale bar = 200μm (A) 100μm (C,D) 50μm (E,F). 
Images representative of 3 independent batches. 
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The native middle ear epithelium showed tracts of dense cilia near the ET (Figure 4.10A). 
The central part of the bulla however exhibited a combination of areas of ciliated clusters 
and non-ciliated cells and regions of only flat non-ciliated polygonal cells (Figure 4.10B, C), 
much like that shown for mMEC cultures previously (Fig 4.6B, C).  
 
 
Figure 4.10 Distribution of ciliated cells in WT native mouse middle ear cavity 
SEM images showing the distribution of ciliated cells in various parts of the native Wt middle ear 
cavity. Areas near the Eustachian tube were lined with tracts of dense ciliated cells (A). The central 
part of the middle consists of flat polygonal cells interspersed with clusters of short and long ciliated 
cells (B), similar to what is seen in mMEC cultures. Areas towards the Tm exhibit patches similar to 
central part of the middle ear as well as larger patches of flat polygonal cells with apical microvilli 
(C). Scale bar = 10 μm 
 
 
 
The next step following the development of a model that mimicked the in vivo middle ear 
epithelium and the characterisation of the epithelial sub-populations in the middle ear was 
in order to utilise the mMEC culture system to evaluate the effect of Bpifa1 deletion.  
 
4.2.8 Bpifa1-/- mMECs retain the expression profile of epithelial markers 
Using RT-PCR, expression of a subset of epithelial markers identified in (Section 4.2.4) was 
compared between three independent batches of Wt and Bpifa1-/- mMECs, at regular time 
points during differentiation. The rationale behind this experiment was to analyse the 
regulation of these genes from ALI Day 0 to 14, as well as to assess the result of loss of 
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Bpifa1 on expression of other epithelial markers. The genes selected for comparison 
included Bpifa1 (secretory marker and the gene of interest), Tekt1 (a ciliated marker) and 
Muc5b and Muc5ac (goblet cell markers). Bpifa1 was either faintly detectable in Wt mMECs 
at ALI Day 0 as shown earlier in Fig 4.7A or at ALI Day 3 (Fig 4.11A). In both Wt and Bpifa1-/- 
mMEC cultures, Muc5b and Tekt1 expression was switched on at ALI Day 3 and continued 
throughout the differentiation period, up to ALI Day 14. Muc5ac was faintly detected in the 
original cells and could not be detected at ALI Day 14 by using this technique (as also seen 
before in Fig 4.7A), but was detectable at ALI Day 7 (Fig 4.11A). Batch to batch variation in 
the intensity of gene expression was noticed at various time points for Wt as well as Bpifa1-
/- mMECs. This inconsistency among batches may be indicative of the variability in the 
composition of cell types in the cultures.  
IFC microscopy of ALI Day 0 and Day 14 Bpifa1-/- mMECs indicated successful differentiation 
of cells at the proteomic level. Ciliated cells (FOXJ1) and goblet cells (MUC5B) were absent 
in the undifferentiated cells at ALI Day 0 (Fig 4.11C, E), but seen in clusters in differentiated 
ALI Day 14 cells (Fig 4.11D, F). This heterogeneous pattern of localisation was similar to that 
described previously for the Wt mMECs (Section 4.2.6, Fig 4.8). Absence of secreted and 
cytosolic BPIFA1 confirmed effective deletion of the gene (Fig 4.11B, D) 
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Figure 4.11 Pattern of expression of epithelial markers by Bpifa1-/- mMECs 
End-point RT-PCR comparing expression of selected secretory, mucin and ciliated cell genes between 
Wt and Bpifa1-/- mMECs. Expression profile of ALI Day 14 cells was similar to mMEC original cells for 
most genes (A). Absence of BPIFA1 in apical washes from differentiating Bpifa1-/- mMECs using 
western blotting technique when compared with transgenic BAL fluid from mice overexpressing 
BPIFA1 as a positive control (B). IFC images showing no staining of BPIFA1, MUC5B and FOXJ1 in 
undifferentiated ALI Day 0 Bpifa1-/- mMEC cultures (C, E). Differentiated mMEC ALI Day 14 Bpifa1-/- 
(D, F) cultures showing staining of FOXJ1 and MUC5B indicating successful differentiation but no 
staining of BPIFA1 indicating successful gene knockout (D). Scale bar =50μm. Data are representative 
of 3 independent batches of culture. 
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4.2.9 Bpifa1 deletion does not affect mRNA levels of other epithelial markers in 
differentiated mMEC cultures  
Variability in expression of epithelial genes across batches made it difficult to compare 
differences in expression between Wt and Bpifa1-/- mMECs using endpoint RT-PCR (Section 
4.2.8). To account for this and to detect lowly expressed genes such as Muc5ac with 
greater efficiency, quantification of epithelial gene expression at ALI Day 14 in Wt and 
Bpifa1-/- mMEC cultures was performed using RT-qPCR. Expression of target genes was 
normalized against three endogenous controls; Atp5b, Ppia and Cyc1, identified as the 
most stable controls for this experiments using the geNORM assay (Section 2.19.4). Data 
are presented as mean RQ± RQmin/max quantified by the ABI software.  
Bpifa1 deletion could be confirmed in Bpifa1-/- mMECs by average down regulation of 24 
fold (p=0.0004) compared to Wt mMECs. There was no difference in the expression of 
FoxJ1 (p=0.55), Muc5b (p=0.53), Muc5ac (p=0.64) and p63 (p=0.73) between mMECs from 
the two genotypes. (Fig 4.12). 
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Figure 4.12 Relative gene expression of epithelial markers in ALI Day 14 Bpifa1-/- mMECs compared 
to Wt mMECs  
Confirmation of Bpifa1 gene deletion in Bpifa1-/- mMECs (A). FoxJ1 expression (B), Muc5ac 
expression (C) Muc5b expression (D) and P63 expression (E) did not change significantly between 
genotypes (p>0.05). Data analysed using two tailed student’s t-test and represented as mean 
relative quantification (RQ) ± RQmin/max for three independent batches of cultures. ***p<0.005 
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4.2.10 Apical secretome of Bpifa1-/- mMECs 
Global proteomic analysis of apical ALI Day 14 secretions from Bpifa1-/- mMECs by Orbitrap 
MS, revealed a pattern very similar to that seen in Wt mMECs. Table 4.3 lists the 12 most 
abundant secreted proteins identified in apical washes from Bpifa1-/- mMECs, classified 
according to their emPAI score. Since this analysis was not performed at the same time as 
the Wt mMEC secretome analysis, comparisons between the levels of proteins expressed 
by the two cell types could not be quantified. However, the overall spectrum of proteins in 
the apical washes from the two genotypes was similar. The complete list of proteins 
identified is given in Appendix III, Table S6. 
 
Table 4.3: Most abundant secreted proteins identified in apical ALI Day 14 washes from Bpifa1-/- 
mMEC cultures 
Accession 
Number Protein 
Peptide 
count 
emPAI 
Score 
P08071 Lactotransferrin 47 247.93 
Q921I1 Serotransferrin  40 13.69 
O09049 Regenerating islet-derived protein 3-gamma  8 8.04 
P11672 Neutrophil gelatinase-associated lipocalin  9 5.66 
Q61147 Ceruloplasmin  55 4.58 
P10605 Cathepsin B 15 1.94 
Q61362 Chitinase-3-like protein 1 22 1.55 
LG3BP Galectin-3-binding protein  26 1.41 
P01027 Complement C3 111 1.32 
P50404 Pulmonary surfactant-associated protein D  23 1.3 
P08905 Lysozyme C-2  10 0.2 
Q9CQV3 Serpin B11 24 1.07 
NB- Accession numbers and biological functions from the UniProt database 
 
4.2.11 Expression of epithelial markers in Wt and Bpifa1-/- mNECs 
As a comparison to mMECs, I simultaneously cultured and assessed the expression of a 
limited number of epithelial markers in mNEC cultures at a transcriptional and proteomic 
level. Since the focus of the chapter was to develop a model of the mouse middle ear 
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epithelium, culture of mNECs was only used as preliminary evaluation and to confirm the 
successful differentiation of murine cells. 
Using RT-PCR, Bpifa1 was detectable in mNECs from ALI Day 3. Tekt1 and Muc5ac 
expression was delayed in Wt cultures (ALI Day 7) compared to knockout cultures (ALI Day 
3), but this observation was not consistent across the different batches tested. 
Nonetheless, the data indicates that the cells differentiated in culture from ALI Day 0 to ALI 
Day 14 and the pattern of expression in the differentiated cells was comparable to that of 
the original cells isolated from the nasal cavity (Fig 4.13A). 
This differentiation of Wt and Bpifa1-/- mNECs in culture was confirmed by IFC. Secretory 
cells (BPIFA1) and ciliated cells (FOXJ1) were absent in undifferentiated ALI Day 0 cultures 
(Fig4.13C, E).  Differentiated ALI Day 14 mNECs cells showed a uniform distribution of cilia 
throughout the culture (Fig 4.13D, F), rather than clusters as described previously in 
mMECs. Wt ALI Day 14 mNECs stained positive for BPIFA1 (Fig 4.13D) and their abundance 
was lower than that seen in differentiated mMECs, although this was not quantified. 
Absence of secreted (Fig 4.13B) and intracellular (Fig 4.13F) BPIFA1 at ALI Day 14 again 
confirmed successful deletion of the gene. 
Nuclear staining of cells with DAPI and Z-slice imaging using confocal microscopy 
demonstrated that mNECs formed a flat monolayer at ALI Day 0 (Fig 4.13G) and showed a 
homogenous organisation at ALI Day 14, with tightly organised single layer of cells (Fig 
4.13H). This morphology was contrasting to the combination of flat and elevated pseudo 
stratified type morphology noticed in mMECs. (Figures 4.8G, H). 
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Figure 4.13 Expression of epithelial markers by Bpifa1-/- mNECs 
End-point RT-PCR comparing expression of selected secretory, mucin and ciliated cell genes between 
Wt and Bpifa1-/- mNECs during differentiation. Expression profile of ALI Day 14 cells was similar to 
mNEC original cells for most genes (A). The absence of BPIFA1 in apical washes from 2 batches of ALI 
Day 14 Bpifa1-/- mNECs compared with 2 batches of ALI Day 14 Wt mNECs as a positive control (B). 
IFC images showing no expression of BPIFA1 and FOXJ1 in undifferentiated ALI Day 0 Wt (C) and 
Bpifa1-/- (E) mNECs. Differentiated mNEC ALI Day 14 Wt cells produces BPIFA1 and FOXJ1 (D) and 
Bpifa1-/- mNECs express FoxJ1 (F) indicating successful differentiation. Z-stack images of cross 
sections of nuclei stained with DAPI shows that ALI Day 0 and Day 14 cells form a relatively 
homogenous monolayer (G, H). Scale bar =50μm. Data are representative of 3 independent batches 
of culture.  
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The data up to this point indicate that I have developed an in vitro model of differentiated 
mouse middle ear cells that mimics the in vivo murine epithelium. Bpifa1 deletion does not 
affect the morphology and expression of epithelial markers in culture. Similarly, mNECs 
mimic the murine nasal epithelium and share many common features with middle ear cells; 
reinforcing the view that middle ear is physiologically similar to that of the URT. The next 
step was to evaluate the utility of mMECs for the study of host pathogen interactions as 
well as to assess the effect of Bpifa1 deletion on susceptibility to NTHi infection. Due to 
time constraints, comparison of the in vitro infections using mNECs was not performed.  
 
 
4.2.12 Susceptibility of Bpifa1-/- and Wt mMECs to NTHi infection  
4.2.12.1 Progression of infection 
In order to test the ability of the mMEC model to support the growth of otopathogens, Wt 
and Bpifa1-/- ALI Day 14 mMECs were infected with NTHi375SR-GFP at MOIs of 1:100 (1.2x107 
bacteria/ membrane) and 1:1000 (1.2x108 bacteria/membrane). Quantification of infection 
in the four central 10x fields indicated that the amount of infection increased in a time 
dependent manner at both the MOIs. Only a few bacteria were visible at 24 hpi but by 48 
hpi the infection rate had increased and the bacteria continued to spread laterally in 
culture, infecting the majority of cells by 72 hpi (Fig. 4.14 and 4.15). As expected, the 
amount of infection was higher for MOI 1:1000 (Fig. 4.15) compared to MOI 1:100 (Fig. 
4.14). Moreover, there was a suggestion of a higher infection in Bpifa1-/- mMECs than Wt 
mMECS, especially at 48 and 72 hpi at both MOIs. 
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Figure 4.14: Progression of NTHi infection at MOI 1: 100 
Low power IFC images showing progression of NTHi-375SR-GFP (MOI 1: 100) infection in ALI Day 14 Wt 
(A, B, C) and Bpifa1-/- (D, E, F) mMECs at 24 hpi (A, D), 48hpi (B, E) to 72 hpi (C, F). Each panel 
represents 4 central fields at 10x magnification spanning approximately 50% of the membrane. 
Amount of infection appears to be greater in Bpifa1-/- mMECs. Representative image for n=3 
independent batches. Scale bar = 200μm 
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Figure 4.15 Progression of NTHi infection at MOI 1: 1000 
Low power IFC images showing progression of NTHi-375SR-GFP (MOI 1: 1000) infection in ALI Day 14 
Wt (A, B, C) and Bpifa1-/- (D, E, F) mMECs at 24 hpi (A,D), 48hpi (B,E) to 72 hpi (C,F). Each panel 
represents 4 central fields at 10x magnification spanning approximately 50% of the membrane. 
Amount of infection appears to be higher in Bpifa1-/- mMECs. Representative image for n=3 
independent batches. Scale bar = 200μm. 
167  
4.2.12.2 Cellular damage based on nuclear fragmentation 
The pattern of infection was the same for both MOI 1:100 and MOI 1:1000. However, 
mMECs infected at MOI 1:1000 demonstrated high levels of cellular damage, indicated by 
nuclear fragmentation at 48 and 72 hpi compared to MOI 1:100. Here, the same batch of 
Wt mMECs infected at MOIs of 1:1000 (Fig 4.16A-F) and 1:100 (Fig 4.17A-F) respectively 
shows noticeably more nuclear disintegration for the higher dose, indicating more cell 
death. Therefore, M01 1:1000 was deemed too high a dose for infection studies and MOI of 
1:100 was selected for all further infection experiments. 
 
Figure 4.16 Nuclear fragmentation at MOI 1:1000 
IFC of NTHi infected Wt mMECs at MOI 1000 shows increase in infection from 24hpi, 48hpi to 72 hpi 
(A, B, C). DAPI staining for the corresponding nuclear sections (D, E, F) shows severely fragmented 
nuclei at 48hpi and 72 hpi (E, F). Examples of fragmented nuclei are shown with white arrows. Scale 
bar = 50μm 
 
A comparison between Wt and Bpifa1-/- mMECs at MOI 1:100, revealed intact nuclei at 
24hpi (Fig 4.17D, J). However, at 48hpi and 72hpi, Bpifa1-/- mMECs showed greater nuclear 
fragmentation (Fig 4.17K, L) compared to Wts (Fig 4.17E, F) indicating more severe 
infection and thus an enhanced susceptibility to NTHi.   
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Figure 4.17 Nuclear fragmentation at MOI 1:100 
IFC images NTHi infected Wt mMECs infected at MOI 100 shows increase in infection from 24hpi, 
48hpi to 72 hpi (A-C). Bpifa1-/- mMECs at MOI 100 also show progression in infection from 24hpi to 
72 hpi (G-I). DAPI staining for Wt (D-F) and Bpifa1-/- (J-L) nuclear sections at corresponding time 
points shows fragmented nuclei at 48hpi and 72 hpi (E, F, K, L).  However, amount of fragmentation 
appears higher in Bpifa1-/- mMECs compared to Wt mMECs. Examples of fragmented nuclei are 
shown with white arrows. Scale bar = 50μm 
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4.2.12.3 Quantification of NTHi infection in Bpifa1-/- and Wt mMECs 
Thus, the data so far suggested a higher level of infection in Bpifa1-/- mMECs than Wt 
mMECs. In order to confirm this observation, the amount NTHi375SR-GFP infection was 
quantified by measuring the green fluorescence in 3 individual batches of Wt and Bpifa1-/- 
mMECs. This indicated a clear progression of infection from 24hpi to 72hpi for both 
genotypes. The severity of infection was higher at 48 and 72 hpi in each batch of Bpifa1-/- 
mMECs compared to the corresponding batch of Wt mMECs. However, due to the variation 
in the intensity of infection between individual Wt and Bpifa1-/- batches, the difference in 
the mean fluorescence for the two genotypes did not reach statistical significance (Fig 
4.18A).  
In order to address this issue and obtain more tangible quantification data, I performed 
viable bacterial counts at 48 and 72hpi to determine the total number of bacteria 
associated with Wt and Bpifa1-/- mMECs. There was a significant increase in number of 
bacteria infecting Wt (p=0.021) as well as Bpifa1-/- (p=0.029) mMECs from 48hpi to 72 hpi, 
confirming progression of infection noted by IFC. However, there was no significant 
difference between the two genotypes (Fig 4.18B). 
 
4.2.13 BPIFA1 expressing cells are resistant to initial NTHi infection 
A more detailed analysis of multiple higher magnification images of infected ALI Day 14 Wt 
mMECs demonstrated a lack of co-localisation of NTHi with BPIFA1 positive cells at the 
24hpi time point. However, at 48hpi a few BPIFA1 positive cells were infected and by 72 hpi 
the infection spread laterally, affecting most cells including BPIFA1 expressing cells. Thus 
BPIFA1 positive cells appeared to be resistant to initial bacterial infection at 24hpi (Fig 
4.18C).  
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Since BPIFA1 expressing cells appeared to be resistant to initial infection, I sought to 
investigate if loss of Bpifa1 affects the initial association of NTHi with mMECs. ALI Day 14 
Wt and Bpifa1-/- mMECs were infected with NTHi375SR-GFP at MOI 1:100. Bacterial association 
was evaluated by washing unbound bacteria 1 hour after infection, lysing cells and 
enumerating CFUs/ml of serial dilutions, as a percentage of the initial inoculum.  However, 
there was no significant difference in the percentage of NTHi adhering to Wt and Bpifa1-/- 
mMECs after 1 hour (Fig 4.18G).  
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Figure 4.18 Quantification of NTHi infection in mMECs 
Increase in mean green fluorescence intensity in Wt and Bpifa1-/- mMECs infected at MOI 1: 100 
from 24hpi to 72hpi quantified using lower 10x IFC images. Each batch of Bpifa1-/- mMECs is infected 
at a higher rate that its corresponding Wt batch, infected at the same time. However, difference in 
mean infection intensity between Wt and Bpifa1-/- mMECs is not statistically significant (A). Viable 
counts show a significant increase in infection with time for both genotypes but no difference 
between genotypes (B). High magnification (60x) IFC images of Wt ALI Day 14 mMECs infected 24 
(C), 48 (D) and 72 hpi (E) showing an apparent decrease in BPIFA1 staining with time. Co-localisation 
of bacteria with BPIFA1 expressing cells can be seen at 48 and 72 hpi but not at 24 hpi. Control Wt 
ALI Day 14 mMECs MOCK infected for 72 hpi (F) Scale bar =50μm. There is no significant different 
between initial association of bacteria with Wt and Bpifa1-/- mMECs (G) Data quantified using one-
way ANOVA with Tukey’s post hoc test (A) and two tailed students t-tests (B, G) *p<0.05 n=3 
individual batches of culture. 
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4.2.14 BPIFA1 levels in Wt mMECs decreases following NTHi infection 
Along with a progression in infection (Sections 4.2.12.1 and 4.2.13), a decline in the amount 
of BPIFA1 staining was observed in NTHi infected Wt mMECs (Fig 4.18C). Intensity of red 
fluorescence, indicative of cytosolic BPIFA1, was quantified in five 60x fields per membrane 
for 3 individual batches of Wt mMEcs. This decrease from 24hpi to 72 hpi was not 
statistically significant (Fig4.19A). 
To investigate whether the apparent decrease in intracellular BPIFA1 with infection was 
due release of the protein, I examined the BPIFA1 levels in apical washes from infected 
mMECs and compared them to MOCK controls at the corresponding time point. Equal total 
protein concentrations tested using western blots revealed no difference at 24hpi, but the 
amount of BPIFA1 in the cell secretions was significantly lower in the infected washes at 
48hpi (p= 0.01) and 72hpi (p=0.006) compared to the MOCK infected controls. (Fig 4.19 B, 
C).  
To determine if the decrease in secreted BPIFA1 levels correlated with a decrease in Bpifa1 
mRNA levels, RT-qPCR was performed on NTHi infected and MOCK infected Wt mMECs. In 
keeping with the western blot data, mean Bpifa1 expression was lower in the infected 
samples than the MOCK samples (Fig 4.19D), particularly at 48hpi and 72hpi. The reduction 
in Bpifa1 reached statistical significance at 48hpi (p= 0.013) but not at 72hpi. A more 
careful analysis revealed decreased expression of Bpifa1 expression in each batch of 
infected sample compared to its respective MOCK sample, both at 48 and 72 hpi (Fig 
4.19E). However, batch variation in the levels of Bpifa1 expression was higher at 72hpi, 
thus affecting the overall significance levels. However, the data indicate that the expression 
of Bpifa1 in Wt mMECs decreases upon NTHi infection. 
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Figure 4.19 BPIFA1 decreases upon NTHi infection of Wt mMECs 
Decrease in mean fluorescence intensity of BPIFA1 staining following NTHi infection of Wt mMECs 
was non-significant (A). Secreted BPIFA1 decreased at 48hpi (**p<0.01) and 72 hpi (***p<0.005) 
compared to corresponding MOCK infected controls as seen by western blotting (B) and its 
quantification by densitometry (C). Mean genetic expression of Bpifa1 is significantly lower at 48hpi 
(*p<0.05) in infected samples compared to MOCK samples (D). Individual data points indicate 
reduction in Bpifa1 gene expression in each batch of infected mMECs compared to MOCK mMECs at 
48hpi and 72 hpi. Data presented at individual RQ values ± SEM (E). n=3 individual batches. 
Statistical significant measured using one-way ANOVA with Tukey’s post hoc test (A) and two tailed 
students t-tests (C, D, E). 
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4.2.15 Expression of pro-inflammatory and epithelial genes in Bpifa1-/- mMECs 
following NTHi infection. 
Having established a novel mMEC culture model that supports otopathogenic infection, I 
evaluated if Bpifa1 ablation resulted in an exacerbated pro-inflammatory response. 
Gene expression analysis of the pro-inflammatory chemokine Cxcl2/MIP2α and cytokine 
Tnfα was performed using RT-qPCR during progression of infection at 24hpi to 48hpi. The 
72hpi time point was excluded from this analysis due to the higher level of cellular damage 
and consequent RNA degradation. Cxcl2 was up regulated 85 fold at 24hpi and 63 fold 
48hpi in the infected Wt mMECs and 91 fold at 24 hpi and 158 fold in 48 hpi in infected 
Bpifa1-/- mMECs when compared to the respective MOCK samples at each time point (Fig 
4.20A p<0.0001). Tnfα was up regulated with infection by 4.3 fold at 24 hpi and by 3.1 fold 
in Wt mMECs, yet these increases were not significant. However, in Bpifa1-/- mMECs Tnfα 
was up regulated significantly at 24hpi (4.4 fold, p= 0.01) and 48hpi (2.6 fold, p= 0.05). 
Again, the responses exhibited a wide variation between individual batches (Fig 4.20B). 
Nevertheless, the data confirms that the mMEC model is capable of eliciting an 
inflammatory response. 
There was no difference between expression of Cxcl2 and Tnfα between Wt and Bpifa1-/- 
mMECs at either time points. (Fig 4.20A, B) 
I also analysed expression of the epithelial markers, Foxj1, Muc5b and Muc5ac in Wt and 
Bpifa1-/- mMECs following infection. Analysing this data was challenging due to the high 
level of batch variation in expression of these genes and no significant differences were 
seen either with genotype or infection (Fig 4.20C, D, E).  
The expression of target genes was normalized to three endogenous controls; Atp5b, Ppia 
and Cyc1 identified as most suitable controls for this experiment using the geNORM assay 
(Section 2.19.4). Here, I have presented all data as individual RQ values for each biological 
replicate ± SEM here in order to demonstrate the trend of upregulation of the pro-
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inflammatory cytokines in the infected samples, the degree of batch variation and its effect 
on statistical significance of means. 
  
176  
 
 
Figure 4.20 Relative gene expression of pro-inflammatory and epithelial markers in ALI Day 14 
Bpifa1-/- mMECs compared to Wt mMECs  
Significant up regulation of Cxcl2 in infected samples compared to MOCK samples, but no difference 
between genotypes ***p<0.0001 (A). Up regulation in Tnfα expression was significant only at 24hpi 
in the Bpifa1-/- mMECs with infection and not with genotype. (B), FoxJ1 expression (C) Muc5b 
expression (E) and Mu5cac expression (E) did not change significantly between with either infection 
or genotypes. Data were analysed using two-way ANOVA plus Tukey’s post Hoc test and represented 
as mean individual RQ values ± SEM for three independent batches of cultures.  
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4.3 Discussion 
4.3.1 Establishment of a novel model of the mouse middle ear epithelium 
In this chapter I have described the development of a novel model of the murine middle 
ear epithelium. The culture method that I have established was adapted from methods 
used for the ALI culture of murine TBE cells (Clarke et al 1992, Davidson et al 2000, Yamaya 
et al 1992, You et al 2002) and murine nasal epithelial cells (Woodworth et al 2007). The 
media supplements, epidermal growth factor, insulin, transferrin and cholera toxin 
enhance cell proliferation and ciliogeneisis whereas retinoic acid is important for 
differentiation of mucous cells (Lechner et al 1982, Wu et al 1997, You & Brody 2013, You 
et al 2002). Moreover, the ALI culture system mimics the in situ organization of airway 
epithelial cells and further promotes their differentiation.  
Normally, setting up ALI cultures requires a large number of animals in order to generate 
sufficient numbers of cells. The addition of ROCKi to the culture medium has been shown 
to enhance basal cell proliferation in airway epithelial cultures (Horani et al 2013). Using 
ROCKi, I could increase the number of transwell-cultures established from the limited 
number of cells isolated from the thin middle ear epithelium and nasal cavities without 
altering the ability of the cells to undergo differentiation; an observation that has been 
made in both human and mouse airway cells (Butler et al 2016, Horani et al 2013). Thus I 
was able to minimize the number of animals required and typically, 30 to 35 transwells 
were seeded from each batch of 6 mice. 
 
 
4.3.1.1 mMECs are an epithelial system 
mMEC cultures model the native middle ear epithelium as the cells exhibit characteristic 
epithelial features such as a cobble-stoned morphology, formation of tight junctions, 
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apical-basal polarisation, presence of desmosomes and apical microvilli. Following 
differentiation, the cultures contained a combination of single layered flatter polygonal 
cells and clusters of pseudostratified, dome shaped, elevated cells, with some of these 
demonstrating beating cilia. The dome shaped appearance of cells can be attributed to an 
active ion transport mechanism (Chun et al 2002, Nakamura et al 1991). An important and 
common problem identified in a number of previous attempts to grow middle ear epithelial 
cells was the contamination and overgrowth of fibroblasts in the cultures (Nakamura et al 
1991, Tsuchiya et al 2005, Vanblitterswijk et al 1986). By adding a differential adherence 
step, in which fibroblasts adhered to plastic in preference to the epithelial cells, I was able 
to eliminate fibroblasts from the cultures, generating a pure epithelial population, as 
shown by a lack of expression of the fibroblast marker, Vimentin, in ALI Day 14 mMEC 
cultures. 
 
 
4.3.1.2 mMECs express markers of the in vivo middle ear epithelium 
Another major limitation of previous middle ear epithelial culture models has been the lack 
of differentiation into distinct epithelial cell types. The middle ear epithelium, like the 
epithelium of the upper airways, is composed of ciliated cells, basal cells, goblet cells and 
other secretory cells. Previous studies highlighted difficulties in maintaining ciliated cells in 
culture (Nakamura et al 1991, Ueyama et al 2001). To my knowledge, the development of 
ciliated cells has only been described in one other report of human middle ear cultures 
(Choi et al 2002), a study in which cells were also grown at the ALI. mMEC cultures clearly 
showed the presence of actively beating cilia and also stained for nuclear FoxJ1 protein, a 
marker of motile cilia. The distribution of cilia in mMEC cultures partially mimicked that 
seen in the native middle ear epithelium by SEM. Parts of the middle ear epithelium were 
populated with tracts of dense cilia, parts with interspersed ciliated and non-ciliated cells 
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and some parts with a simple epithelium composed of flat non-ciliated polygonal cells. This 
distribution of cell types within the middle ear cavity is supported by previous studies (Lim 
1979, Thompson & Tucker 2013) which show that the native epithelium of the 
hypotympanum and towards the opening of the ET is densely packed with ciliated cells, 
whereas the mesotympanum contains ciliated islands amongst other non-ciliated cells. The 
epitympnaum is composed primarily of flat squamous cells, which may also contribute to 
the secretory defence system. On this basis, I believe that mMECs, which are a combination 
of flat non-ciliated, secretory and ciliated cells closely model the morphology of the native 
middle ear epithelium.   
Mucins are products of goblet cells, unique to the mucosal epithelia, and are essential for 
the maintenance of mucosal innate defence. A number of attempts have been described to 
utilise the existing middle ear models in order to study mucin gene expression at the 
transcriptional level (Kerschner et al 2010a, Liu et al 2016, Moon et al 2000, Tsuchiya et al 
2005). However, these studies were limited by the lack of production and localisation of 
detectable amounts of mucins at the protein level. Goblet cells (as shown by MUC5b 
positivity) were seen in the elevated pseudostratified clusters of ALI Day 14 mMEC cells, in 
close association with ciliated cells. It has previously been shown that in the native middle 
ear epithelium, the localisation of mucous secreting cells is in parallel to the distribution of 
ciliated cells, reiterating that the model mimics the in vivo middle ear epithelium (Lim et al 
1973). MUC5B is the predominant mucin in COM effusions (Preciado et al 2010). It has 
been shown to be indispensable for airway mucocilliary clearance and maintenance of 
mucosal homeostasis and Muc5b-/- mice develop OM (Roy et al 2014). The identification of 
Muc5b at readily detectable levels as demonstrated by IFC enables the mMEC model to be 
potentially utilised for further study of the role of mucins in the middle ear epithelium. 
Moreover, treating primary tracheal and bronchial epithelial cells grown at ALI with IL13 
has been shown to induce goblet cell hyperplasia (Atherton et al 2003, Kondo et al 2002). 
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The mMEC model therefore provides a platform to alter culture conditions to study middle 
ear mucous hypersecretory phenotypes of OM in vitro. The lack of MUC5AC or MUC5B 
detection in the MS analysis could be because of the loss of these high molecular weight 
glycoproteins during the sample processing and preparation. 
In addition to ciliated and goblet cells, the mMEC cultures also produced a range of other 
secretory cell products. We have previously shown that BPIFA1 is expressed abundantly in 
the middle ear epithelium (Sections 1.8.2 and 3.2.1). BPIFA1 constitutes a major proportion 
of secretions from TBE cells grown at ALI (Campos et al 2004) and is also strongly detected 
in primary nasal epithelial cells (Bingle & Bingle 2000). BPIFA1 was readily detectable in 
mMEC cultures and apical secretions from the cells. It localised to non-ciliated cells in the 
cultures, which is consistent with studies from the respiratory tract (Barnes et al 2008, Kim 
et al 2006, Musa et al 2012).  Bpifb1 mRNA, on the other hand, was detectable in the 
original cells, but not in the ALI Day 14 cultures and was absent from the list of proteins 
identified in the proteomic analysis performed using MS. BPIFB1 protein localises to goblet 
cells and minor glands associated with the ET, but its expression is limited in the middle ear 
epithelium (Mulay MSc thesis 2011). This observation suggests that the mMEC cultures 
model the middle ear epithelium rather than the ET epithelium.  
 
 
4.3.1.3 Evaluation of the mMEC secretome 
Unbiased, label-free proteomic MS analysis was used to identify a number of secretory 
proteins in the apical washes from the cells. The most abundant proteins comprised a 
variety of secretory host defence proteins with anti-microbial roles, proteins involved in 
cellular proliferation, wound repair, stress response, compliment activity and maintenance 
of cellular homeostasis. It is notable that the MS data contained a number of proteins also 
identified in a proteomic analysis of ear exudates from chronic OM patients such as 
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Lactotransferrin, BPIFA1, Lipocalin, Lysozyme and various cathespins and complement 
proteins (Val et al 2016). Lactotransferrin was by far the most abundant protein identified 
in this study. It is an antimicrobial protein secreted by airway mucosal surfaces and has 
been shown to play a role in maintenance of middle ear immunity (Bernstei.Jm et al 1974, 
Lim et al 2000, Moon et al 2002). Lactotransferrin prevents colonisation of mucosal 
surfaces by scavenging environmental iron, thus limiting its availability for bacterial growth. 
Human milk Lactotransferrin has been shown to attenuate the pathogenic potential of 
H.influenzae by proteolytically cleaving two important colonisation factors found on the 
bacterial surface (Hendrixson et al 2003) and the administration of Apolactoferrin has been 
shown to reduce bacterial counts in chinchilla middle ears with pneumococcal induced OM 
(Schachern et al 2010). SP-D was originally identified as a lung surfactant associated protein 
but is also expressed in the middle ear and the ET and has a suggested role in enhancing 
opsonisation and phagocytosis of bacteria (Lim et al 2000, van Rozendaal et al 2001, Wright 
1997). Reg3γ is C-type lectin produced by paneth cells and secreted into the intestinal 
lumen with a suggested bactericidal activity against Gram-positive bacteria by binding to 
peptidoglycan in the bacterial cell wall (Cash et al 2006). It has been shown to spatially 
regulate the separation of microbiota from the host small intestinal epithelium (Vaishnava 
et al 2011). Reg3γ-/- mice have an altered mucosal distribution and increased inflammatory 
response in the small intestine (Loonen et al 2014). Reg3γ has also been shown to be 
involved in pulmonary innate immunity as it is induced by Stat3 during methicillin resistant 
Staphalococcus aureus (MRSA) infection in lung and inhibits MRSA growth in vitro (Choi et 
al 2013). This is the first study reporting the expression of this protein in the middle ear and 
it is possible that Reg3γ performs a similar function in the middle ear.  
It was noticeable that the proteomic data unexpectedly contained many intracellular 
proteins. The presence of the membrane-tethered mucins Muc1, Muc4 and Muc18 was 
also detected (Table S1). These proteins can be reasoned to be the contents of secreted 
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exosomes or products released from damaged cells. Exosomes are small membrane bound 
units released by the fusion of endosomal microvesicular bodies with the apical plasma 
membrane. They have been suggested to be involved in stimulating immune responses, 
modulating secretory activities and engaging in cell communication by packaging and 
delivering microRNAs to other cells (Keller et al 2006, Valadi et al 2007). Exosomes are 
released by epithelial cells (Kapsogeorgou et al 2005, van Niel et al 2001), are found in BAL 
fluids (Admyre et al 2003) and are also present in the apical secretions from human TBE 
cultures (Kesimer et al 2009, Pillai et al 2014).  The presence of exosome-associated 
proteins in the mMEC secretome further adds to the potential utility of this model to study 
the role of exosomes in middle ear biology and OM pathogenesis. 
Thus I have developed a novel in vitro model that closely mimics the in situ middle ear 
epithelium and for the first time systematically characterised the epithelial cell types in the 
middle ear.  
 
 
4.3.2 Effect of loss of Bpifa1 on uninfected mMEC cultures 
Since BPIFA1 was localised to a large number of secretory cells in the middle ear epithelium 
and mMEC cultures, it was of interest to determine whether the ablation of Bpifa1 affected 
the morphology of mMECs or the expression of other epithelial markers. A study by (Liu et 
al 2013b) showed that Bpifa1-/- mice demonstrated decreased basal expression of Muc5ac, 
Muc5b and FoxJ1 in the lung tissue. Bpifa1-/- mMECs were morphologically and 
physiologically similar to Wt mMECs. Differences in expression of the epithelial genes could 
not be conclusively deduced using end point RT-PCR due to batch variability and lack of 
sensitivity of the technique in detecting subtle changes in expression. However, RT-qPCR 
analysis showed that loss of Bpifa1 did not affect the expression of any of the 
aforementioned genes in differentiated mMEC cultures. It is important to note that at this 
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point, I only quantified the expression levels of these markers in cultured cells but not in 
the original cells. Even though mMECs retain the characteristics of the native murine 
epithelium, there is a possibility that the culture conditions may modify the proportions of 
the different cell types. This issue is explored in detail in Chapter 5.  
The spectrum of proteins detected by MS in the apical secretome of the Bpifa1-/- mMECs 
was largely similar to that of the Wt cultures. Since the proteomic studies on Wt and 
Bpifa1-/- washes were not conducted simultaneously, it was not ideal to quantify the 
magnitude of difference in protein levels identified in the two secretomes. In this study, 
pooled ALI apical washes from 6 batches were used for MS analysis, due to the limited 
availability of samples. In future, individual apical washes from multiple batches Wt and 
Bpifa1-/- mMEC should be analysed in order to quantify differences between the two 
secretomes. 
 
 
4.3.3 mNECs are a comparator of the mMEC culture system 
The intra-nasal route is the biological route for the entry of bacteria into the middle ear and 
nasopharyngeal infections often precede OM development. The nasal passages of all 
animals consist of 4 major types of epithelia – squamous epithelium, transitional 
epithelium, respiratory epithelium and olfactory epithelium. The location of these epithelia 
within the nasal passages is highly strategic in order to effectively prevent entry of 
pathogens and irritants. The respiratory epithelium covers 46% of the nasal passages in 
rodents (Harkema et al 2006) and is similar to the epithelium of the remaining conducting 
airways. Previous studies in our lab have shown that BPIFA1 localises to the non-ciliated 
epithelial cells, in the respiratory epithelium of the nasal passages (Musa et al 2012). The 
method adopted for dissection of the nasal cavities (Woodworth et al 2007) along with the 
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highly specific growth medium used (You et al 2002) promoted the growth of the 
respiratory nasal epithelial cells.  
Since the middle ear can be considered to be an extension of the conducting airways, I 
postulated that mNECs are physiologically similar to mMECs and express common epithelial 
markers. Therefore, I cultured mNECs cells as a comparator cell type in order to ensure 
successful differentiation of mouse epithelial cells using the ALI technique. Similar to 
mMECs, mNECs displayed a cobble-stoned morphology, however the cultures appeared 
homogenous, with evenly distributed ciliated cells. Wt and Bpifa1-/- mNECs differentiated 
within 14 days at ALI, expressing ciliated and goblet cell markers and recapitulating the in 
vivo nasal epithelium. Wt mNECs demonstrated BPIFA1 staining in the non- ciliated cells 
consistent with the previously published in situ observations (Musa et al 2012). Thus, I have 
shown that middle ear cells and nasal respiratory cells express similar epithelial signatures. 
Due to time constraints I did not pursue further studies with mNEC cultures. However, the 
successful culture of this cell type in vitro at ALI provides an ideal platform to study cell 
biology of the nasal passages in conjunction with the middle ear, in order to develop a 
holistic understanding of the aetiology of OM. 
 
 
4.3.4 mMECs are an ototpathogenic model 
Since the advent of PCV-7 vaccine, NTHi has become the most common pathogen identified 
in OM effusions (Casey & Pichichero 2004). First and foremost, infection of mMECs using 
the human otopathogen, NTHi demonstrated that the mMEC culture system can be 
effectively utilised for the study of host pathogen interactions within the middle ear. NTHi 
initially infected or was associated with a small number of cells in culture and the infection 
spread laterally over time, indicating that mMECs are infected in a time dependent 
manner. Secondly, an elevation in expression of the pro-inflammatory molecules Cxcl2 and 
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Tnfα indicated that the model was responsive to infection. Both these aspects are 
discussed below along with the effect of ablation of Bpifa1 following infection. 
4.3.4.1 Evaluating the antimicrobial role of BPIFA1 
Based on the structural homology of BPIFA1 with BPI which binds LPS, and its expression in 
the proximal airways, an area of high pathogen contact, an antimicrobial role was originally 
suggested for this protein (Bingle & Craven 2002). As described in Chapter 3, a number of in 
vivo pulmonary infection models have suggested an increased susceptibility of Bpifa1 
deficient mice to bacterial challenges. In addition, a number of in vitro studies have 
highlighted the antimicrobial function of this protein. For example, Bpifa1 reduced biofilms 
formation by K.pneumoniae and P.aeruginosa on polarized human airway epithelial cells 
and nasal cells by increasing the surface tension at ALI (Gakhar et al 2010, Liu et al 2013a). 
BPIFA1 exerted bacteriostatic effects on B.cepacia and P.aeruginosa and the suggested 
mechanism in the later is by formation of small pores in the bacterial cell wall (Sayeed et al 
2013, Walton et al 2016). BPIFA1 inhibited growth of M.pneumoniae upon infection of HBE 
cells and has been suggested to decrease adhesion of M.pneumoniae to host cells (Chu et 
al 2007, Gally et al 2011). Purified chinchilla BPIFA1 exhibited bactericidal activity against 
NTHi in vitro (McGillivary & Bakaletz 2010). 
Therefore, I hypothesized that Bpifa1-/- mMECs would show increased susceptibility to NTHi 
infection in comparison to Wt cultures. BPIFA1 expressing cells appeared to be resistant to 
early infection at 24 hpi. However, there was no difference in the level of initial adhesion of 
NTHi between Wt and Bpifa1-/- mMECs at 1 hpi. The quantification of infection was 
challenging because of the batch variation seen in the cultures. Although each batch of 
Bpifa1-/- mMECs appeared to be infected to a greater degree than the Wts, as seen by IFC 
and also indicated by increased nuclear fragmentation in Bpifa1-/- mMECs, this difference 
did not reach of statistical significance. I also did not see a difference in the amount of 
infection at 48 and 72hpi by using viable counts, a more reliable method of quantification. 
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A possible reason for this observation may be that the viable counts were performed 
without washing the apical surfaces of cells with a view to compare the total associated 
bacteria. On the contrary, IFC was performed using cells whose apical surfaces had been 
washed and hence most bacteria detected were internalised bacteria. Perhaps, washing 
the cells before performing viable counts would give us a better comparison to the IFC 
data. However due to time constraints viable counts for analysing internalised bacteria 
could not be repeated. A previous study had reported a decrease in biofilm biomass of 
P.aeruginosa on incubation with recombinant BPIFA1 using a crystal violet biofilm assay but 
the researchers could not detect a reduction in CFU/ml using traditional viable counts 
methodology (Liu et al 2013a). They attributed this effect to the surfactant properties of 
BPIFA1, which helps in dispersing these matrix-encased bacterial communities, rather than 
to its antimicrobial properties. There is conflicting evidence on the formation of biofilms by 
NTHi and its relevance in OM. Several studies showed that culture negative effusions from 
patients showed presence of NTHi components and transcripts by PCR based methods 
(Bakaletz 2007, Swords 2012). We did not study the effect of BPIFA1 loss on NTHi biofilm 
formation in mMECs, however this avenue requires further investigation using the model 
system. 
 
 
4.3.4.2 Evaluating the immunomodulatory role of BPIFA1 upon NTHi infection 
In this chapter I have evaluated the expression levels of Cxcl2 and Tnfα alpha, two pro-
inflammatory mediators commonly upregulated during bacterial OM, during NTHi infection 
of mMECs. The chemokine Cxcl2/MIP2α is the murine homologue of human IL-8 and is a 
key mediator of overproduction of mucins and of neutrophil chemotaxis (Juhn et al 2008). 
NTHi infection is known to stimulate Cxcl2 upregulation in several murine tissues including 
the middle ear, lungs and the inner ear (Gaschler et al 2009, Lim et al 2007, Woo et al 
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2012). Moreover, Cxcl2 was identified as the most upregulated gene when mice were 
trans-tympanically injected with NTHi and on infection of the immortalized mouse middle 
ear epithelial cell line (mMEEC) with NTHi (Preciado et al 2013). TNFα is produced through 
a TLR-2 mediated response to NTHi. It results in infiltration of inflammatory cells as well as 
release of other pro-inflammatory cytokines through activation of the NFκB signalling 
cascade. Thus, it is a key early response cytokine and also plays an important role in OM 
sequelae (Larrick et al 1998, Moon et al 2006). TNFα was upregulated on NTHi infection of 
primary human middle ear cells (Moon et al 2008, Tong et al 2001). My data shows that 
Cxcl2 was significantly upregulated on NTHi infection of Wt as well as Bpifa1-/- mMECS after 
24 and 48 hours post infection in comparison to the respective MOCK controls. Tnfα, was 
also upregulated in the infected cultures of both genotypes, although this did not reach 
statistical significance. Taken together, the data suggests that the mMEC model responds 
to bacterial infection in a manner similar to the native middle ear epithelium. This opens up 
a new avenue to use the model for the study of the response of middle ear cells to 
different insults, injuries and infections. This will enable the study of interaction of host 
middle ear epithelial cells with a variety of bacterial as well as viral otopathogens.  
Based on the structural homology to BPI, which is an anti-inflammatory protein, several 
pulmonary infection studies have suggested a similar role for BPIFA1. Recombinant BPIFA1 
has shown to reduce IL-8 production in HBE cells upon M.pneumoniae infection (Chu et al 
2007). Moreover, BAL fluid from Bpifa1-/- mice showed higher levels of Cxcl2 amongst other 
cytokines during acute infection with infected with P.aeruginosa (Liu et al 2013b) whereas 
transgenic overexpression of BPIFA1 leads to decreased production of Tnfα (Lukinskiene et 
al 2011). We hypothesized that the loss of the anti-inflammatory function of BPIFA1 would 
lead to an increased Cxcl2 and Tnfα response in the Bpifa1-/- mMECS upon infection. 
However, expression of both markers was seen at similar levels in Wt and Bpifa1-/- mMECS 
and I did not observe an anti-inflammatory effect of Bpifa1 upon infection. The effect of 
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deletion of Bpifa1 on expression of a wider spectrum of cytokines in original mouse middle 
ear epithelial cells has been evaluated in Chapter 5. 
Epithelial remodelling, one of the most common features of OM and often a consequence 
of infection, is characterised by mucous metaplasia. There are several reports on induction 
of mucin genes upon NTHi infection as well as on TNFα treatment using the current in vitro 
middle ear models (Lim & Moon 2012, Nakamura et al 2013, Samuel et al 2008). (Liu et al 
2013b) showed that the decline in Muc5ac, Muc5b and FoxJ1 in Bpifa1-/- lungs persisted 
upon acute P.aeruginosa infection. Therefore, I evaluated expression of the mucin genes, 
Muc5ac and Muc5b and the ciliated cell marker, Foxj1 following infection and compared it 
between the two genotypes. Unfortunately, this study was particularly compromised by 
batch variation. I did not observe any clear trends or difference in the expression of 
epithelial genes, following NTHi infection or between the two genotypes. The lack of 
change in expression could also be because this study tested an acute response to NTHi 
infection whereas chronic persistence of infection may be needed to observe an obvious 
effect in the epithelial cell types. 
 
 
4.3.5 Regulation of BPIFA1 following NTHi infection 
BPIFA1 is expressed at high basal levels in the upper airways and the middle ear and it is 
tightly modulated during infection. The direction of modulation may vary with the type of 
pathogen. A number of studies such as pulmonary infections with M.pneumoniae and 
K.pneumoniae report increased levels of BPIFA1 in the BALF of mice upon infection (Chu et 
al 2007, Liu et al 2013a). Our own study saw an initial non-significant decline in the 
cytoplasmic levels of BPIFA1 staining with progression of NTHi infection using IFC. My initial 
assumption was that the decrease in cytoplasmic BPIFA1 might be accompanied by 
increase in secreted BPIFA1 in the apical washes. On the contrary, a significant decrease in 
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secreted BPIFA1 was observed at 48hpi and 72hpi. I reasoned that this decrease might be 
due to proteolytic cleavage of BPIFA1 during infection. A previous report has shown that 
BPIFA1 secreted by HBE cells is degraded when treated with neutrophil elastase (Jiang et al 
2013b). Another study showed that inhibiting proteinase activity during P.aeruginosa 
infection increased the levels of BPIFA1 in BAL fluids of mice (Jiang et al 2013a). However, 
the western blotting data did not show any obvious degradation bands in the infected 
samples compared to the MOCKs.  Another explanation for this observation could be that 
secreted BPIFA1 binds to NTHi present in the wash and is pelleted out during the 
centrifugation step of the protocol and hence the reduced levels in the supernatants. In 
future, bacterial pull down assays can be performed to detect BPIFA1 bound to NTHi. In 
order to test the decrease in BPIFA1 levels further, I quantified mRNA levels of Bpifa1 using 
RT-qPCR and found that there was indeed a decrease in every batch of infected sample 
compared to its corresponding MOCK control from the same batch. Although batch 
variation was observed, this decrease was statistically significant at 48 hpi. My observation 
is supported by the study by Britto et 2013, where the authors report a reduction in lung 
Bpifa1 mRNA and BPIFA1 protein in BAL fluids following acute infection with P. aeruginosa, 
S. pneumoniae, influenza A as well as LPS stimulation. The authors also replicated this 
observation in mTECs treated with LPS where they saw a reduction in Bpifa1 mRNA and 
protein at a similar time point used in this study. Thus, modulation in BPIFA1 levels 
functions as a biosensor of pathogenic insult, which may signal the host to mount an 
immune response against the pathogen. However, it is not clear if this decrease is a 
transcriptional downregulation of BPIFA1 promoter activity or a change in the phenotype 
of epithelial cells due to infection. 
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4.3.6 Potential for utilising mMECs as a model for studying OM pathogenesis 
A number of mouse models are available for the study of OM. These include mice deficient 
in innate immunity genes such as Evi1, Fbxo11, TLRs and Myd88, ciliary development genes 
such as Dnahc5 (Rye et al 2011a) and goblet cells (Roy et al 2014). It is known that primary 
cells cultured from CF and asthma patients maintain the disease phenotype in culture 
(Davies et al 2003, Matsui et al 1998). It will be interesting to investigate if the mMEC 
culture system can be utilised to reproduce the OM phenotype of these mouse mutants in 
vitro and enable comparative studies between unaffected and diseased cultures.  
OM often encompasses complex responses involving the middle ear epithelium, sub-
epithelial mesenchyme, inflammatory cells and middle ear effusion, making it challenging 
to identify epithelial cell-specific responses. The mMEC culture system provides us with the 
ability to isolate and assay responses of specific sub populations of epithelial cells. Our cell 
isolation method eliminates the influence of explants and excludes fibroblasts from culture, 
which were two of the most important confounding factors in previous models of primary 
middle ear epithelial cells. mMECs are a 3-dimentional model of the middle ear epithelium 
and hence mimics the in vivo physiology more closely compared to the available cell lines. 
Thus mMECs have several advantages over the currently available in vitro middle ear 
models. 
The possibility of replicating the phenotype of the genetic models of OM, the capacity to 
easily manipulate differentiation of cells by modifying culture conditions and the ability to 
infect cells with various otopathogens, makes the model applicable to the wider OM 
community.  
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4.3.7 Batch variation 
A major confounding factor throughout the studies outlined in this chapter was the 
variation among different batches of mMECs. Firstly, it is well known that primary cultures 
show substantial disparity between different batches, and the growth media used may 
influence this. Although the media used for mMEC cultures has been carefully optimised to 
promote growth of upper respiratory epithelial cells (You et al 2002), an influence of lot-to-
lot variation in media components such as serum and growth factors cannot be overlooked. 
Secondly only a small portion of the cells seeded was found to adhere to the membrane at 
day 3, which then proliferated and differentiated to establish an epithelial culture. 
Depending on the proportion of cells attached and their fate, the composition of the 
epithelium established in cultures can be variable, leading to a different proportion of 
goblet cells, secretory cells and ciliated cells in each batch of mMECs and hence the 
difference in the levels of various epithelial markers expressed.  
NTHi showed a heterogeneous pattern of infection in mMECs. Although each batch of 
Bpifa1-/- mMECs appeared to be infected at a greater level than Wt mMECs by IFC, the 
difference in levels of infection among batches made descriptive statistical evaluation of 
the results challenging. Owing to time constraints, an evaluation of susceptibility of the 
different cell types, other than BPIFA1 expressing cells, to NTHi infection was not possible. 
However, a variation in proportions of the different cell types being infected may partially 
be accountable for the discrepancy in levels of infection among different batches.  
Lastly, contamination of isolated RNA by components of the TRI reagent added to the 
variation seen among biological replicates in the RT-qPCR data. This aspect has been 
discussed in detail in the general discussion. However, despite the batch variation, I have 
presented individual data points where relevant in an attempt to describe any trends in 
data.  
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In future, this problem can be addressed by increasing the number of batches used for 
study in addition to using multiple wells from each batch. However, this was not feasible 
during this study due to the time period required for proliferation and differentiation of 
each batch of mMECs and sacrifice of wells from each batch for model validation and for 
confirmation of differentiation of cells. 
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4.4 Key experimental conclusions 
x  I have developed a novel in vitro model of mouse middle ear epithelial cells 
(mMECs) at the ALI, which recapitulates the characteristics of the native murine ME 
epithelium.  
x The various epithelial cell populations in differentiated mMECs were systematically 
characterised and compared to those seen within the native middle ear, using 
transcriptional and proteomic approaches.  
x  mMEC secretions included a multitude of innate defence proteins. 
x mMECs supported the growth of the otopathogen, NTHi and mounted a response 
to the infection by upregulation of Cxcl2, suggesting that the model can be 
successfully utilised to study host pathogen interactions in the middle ear. 
x Bpifa1-/- mMEcs were morphologically similar to Wt mMECs and did not show 
differences in expression of other epithelial markers.  
x Bpifa1-/- mMECs demonstrated slightly enhanced susceptibility to NTHi infection, 
albeit not statistically significant. However, Bpifa1 did not exhibit an overt anti-
inflammatory role during infection. 
x BPIFA1 was expressed at high basal levels in naïve Wt mMEC cultures. BPIFA1 
expressing cells appeared to be resistant to initial infection and the levels of Bpifa1 
reduced upon infection. These findings indicate a role for BPIFA1 in impeding early 
infection under steady state conditions and acting as a biosensor, signalling 
activation of a host immune response upon infection. However, whether the 
regulation is a result of an effect on BPIFA1 promoter activity or a phenotypic 
change in the epithelial cells needs to be investigated further. 
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CHAPTER 5:  ASSESSMENT OF THE EFFECTS OF BPIFA1 DELETION IN AN 
EXISTING MODEL OF OTITIS MEDIA 
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5.1.1 Introduction: 
The Evi1Jbo/+ mouse is a well-established model of chronic OM and conductive hearing loss. 
Evi1Jbo/+ mice spontaneously develop OM, characterised by accumulation of inflammatory 
fluid in the middle ear cavity and increase in middle ear mucosal thickness. The causative 
mutation in these mice is a SNP in the transcription factor; Evi1, which consists of two ZnF 
domains and a proline rich linker domain (Parkinson et al 2006). Each domain interacts with 
several co-activators and co-repressors and is thus involved in regulating multiple signalling 
pathways as described in Section 1.12.1.2. Of these, the interactions with the TGF-β 
signalling pathway via its first ZnF domain and the intermediate repressor domain are most 
widely studied (Izutsu et al 2001, Kurokawa et al 1998a, Kurokawa et al 1998b). The 
mutation in Evi1Jbo/+ mice is in the second ZnF domain, which has been recently shown to 
act as a negative feedback regulator of NF-κB signalling (Xu et al 2012). However, it is not 
known if this mutation also has an effect on the binding capacity of the first ZnF domain or 
the intermediate repressor domain. 
Several studies have identified components of both TGFβ and NFκB signalling pathways as 
candidate genes in susceptibility to OM development (MacArthur et al 2014, Rye et al 
2011a, Segade et al 2006). Fig 5.1 describes the potential involvement of the two signalling 
cascades in OM susceptibility in Evi1Jbo/+ mice. The transcription factor NFκB is a hetero or 
homo dimer of multiple REL proteins, the most common one being a heterodimer of REL 
A/p65 and p50 (Chen & Greene 2004). Under normal physiological conditions the p65/p50 
complex is maintained in an inactive state in the cytoplasm via the interaction with the 
inhibitor molecule IKK. However, an inflammatory stimulus leads to the degradation of IKK 
and translocation of the p65/p50 complex to the nucleus, where it binds to the target DNA 
sequences and activates several pro-inflammatory markers such as TNFα, IL1β, IL-10 as well 
as chemo attractants such as IL-8 (Cxcl2 in mice) which leads to infiltration of inflammatory 
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cells (Chen & Greene 2004). A recent study has shown that EVI1 which itself is induced by 
the inflammatory stimulus such as NTHi and TNFα and negatively regulates the NFκB 
signalling cascade by physically interacting with the p65 subunit of NFκB and preventing its 
acetylation (Xu et al 2012). Thus functional EVI1 acts as a negative feedback regulator of 
the NFκB signalling pathway and helps to prevent an excessive inflammatory response. 
Inflammatory stimuli also activate TGFβ signalling via induction of SMAD3, which in turn 
forms a complex with SMAD4. The SMAD3/SMAD4 complex translocates to the nucleus 
where it binds to and activates target genes involved in various regulatory processes such 
as cell proliferation, differentiation, wound repair and apoptosis (Kurokawa et al 1998a, 
Makinde et al 2007). EVI1 physically binds SMAD3 and thus alters DNA binding ability of the 
SMAD3/SMAD4. Thus by quenching SMAD3, it antagonizes TGFβ signalling (Rye et al 
2011a). Moreover, there is significant cross talk between the TGFβ and NFκB signalling 
pathways since the SMAD3/SMAD4 complex promotes acetylation of p65 (Ishinaga et al 
2007). Thus a mutation in Evi1 may cause a loss of its function to negatively regulate the 
NFκB and TGFβ signalling pathways leading to chronic inflammation in the middle ear and 
failure of proper resolution of this inflammation in Evi1Jbo/+ mice. 
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Figure 5.1 Potential role and interaction between NFκB and TGFβ signalling pathways in 
susceptibility to OM in Evi1Jbo/+ mice. 
EVI1 acts as a negative regulator of NFκB and TGFβ signalling pathways and thus a mutation in 
Evi1Jbo/+ mice may result in excess inflammation and failure of proper resolution of infection in. 
 
 
 
 
BPIFA1 is a major secretory product of the upper airway epithelium (Campos et al 2004) 
and is also abundantly expressed in the middle ear epithelium (Section 1.8.2). In Chapters 3 
and 4, I have mainly focussed on investigating the antimicrobial role of BPIFA1 by assessing 
the susceptibility of Bpifa1-/- mice and Bpifa1-/- mMECs to the ototpathogen NTHi. However, 
another important putative role for BPIFA1 in host defence is through an 
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immunomodulatory function, suggested on the basis of its structural similarity to the anti-
inflammatory protein, BPI (LeClair 2003). Several studies have supported an anti-
inflammatory role for BPIFA1 in the presence of an inflammatory stimulus. For example, 
Bpifa1 ablation was associated with exaggerated levels of pro-inflammatory mediators 
CXCL2, TNFα, IL1β and IL6 in BAL fluids after infection with K.pneumoniae and 
M.pneumoniae compared to Wt mice (Liu et al 2013a, Liu et al 2013b). On the other hand, 
treatment of human primary airway epithelial cultures with recombinant BPIFA1 reduced 
the mRNA levels of IL8 after infection with M.pneumoniae (Chu et al 2007) and transgenic 
mice overexpressing Bpifa1 showed lower levels of IL1β and CXCL2 in BAL fluids after 
exposure to P.aeruginosa compared to Wt control mice (Lukinskiene et al 2011). Moreover 
Bpifa1-/- mice showed increased neutrophilic infiltration in pulmonary infection models of 
M.pneumoniae, P.aeruginosa and K.pneumoniae and showed increased bacterial clearance 
(Gally et al 2011, Liu et al 2013a, Liu et al 2013b). 
Previous studies in our lab have suggested a decrease in staining intensity of BPIFA1 with 
OM progression in Evi1Jbo/+ mice and indicated partial proteolytic degradation of BPIFA1 in 
Evi1Jbo/+ ear exudates, suggesting an involvement or BPIFA1 in OM development in these 
mice (Section 1.13). Based on these data and the anti-inflammatory role of BPIFA1, I 
postulated that Bpifa1 deletion in the existing inflammatory microenvironment of Evi1Jbo/+ 
mice may lead to an exacerbation of the OM phenotype. This is the first study to report the 
use of compound Bpifa1 mutants. 
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5.1.2 Aims of this study 
The primary aim of this chapter was to ascertain if Bpifa1 ablation led to an exacerbation of 
the OM phenotype in Evi1Jbo/+ mice, an established model of chronic OM. Subsequently, the 
effect of Bpifa1 deletion on a repertoire of inflammatory, epithelial and sub-epithelial 
markers in the middle ear mucosa was evaluated, in order to uncover its role in aggravation 
of OM. Lastly, this chapter aimed to recapitulate the OM phenotype in vitro using the 
mMEC culture system. 
 
 
5.1.3 Study design 
Fig 5.2 gives a brief layout of the study plan for this chapter. Bpifa1-/-Evi1Jbo/+ compound 
mutants and their control genotypes were generated on the C3H/HeH background as 
described in Section 2.1.3. Viability of this line was assessed by analysing genotype ratios of 
the progeny (Section 5.2.1). It is known that Evi1Jbo/+ mice develop CSOM by P28 (Parkinson 
et al 2006). Morphometric analysis of middle ear mucosal thickness and presence of middle 
ear effusion was performed on Bpifa1-/-Evi1Jbo/+ mice at P21 and P28 in order to evaluate if 
loss of Bpifa1 leads to accelerated and exaggerated OM development (Section 5.2.2). 
Bpifa1-/-Evi1Jbo/+ mice between 7-10 weeks of age were analysed for body weights and 
persistence of OM in adulthood (Section 5.2.3 and Section 5.2.4). RT-qPCR for expression of 
inflammatory and epithelial genes was performed on isolated middle ear mucosal cells, in 
order to further investigate the OM phenotype (Section 5.2.5.1 and Section 5.2.5.2). The 
mMEC culture system (developed in Chapter 4) was utilised to attempt recapitulation of 
the OM phenotype in vitro. Expression of inflammatory and epithelial genes was compared 
between mMECs cultures from Bpifa1-/-Evi1Jbo/+ mice and the control genotypes at a 
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transcriptional as well as proteomic level (Section 5.2.6). Furthermore, the effect of Bpifa1 
ablation on the proliferative potential of mMECs and fibroblasts was analysed (Section 
5.2.7). Lastly, IHC was used in order to identify of the effect of Bpifa1 ablation on other 
epithelial and sub-epithelial proteins in vivo (Section 5.2.6).  
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Figure 5.2 Study plan for this chapter
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5.2 Results  
5.2.1 Genotype ratio analysis of the Bpifa1-/-Evi1Jbo/+ line 
The breeding strategy for generation of the compound mutants is described in detail in 
Section 2.1.3, Fig.2.2. Briefly, Bpifa1+/-  mice on a C57BL/6 background, were made congenic 
on the C3H/HeH background by recurrent backcrossing and then outcrossed with Evi1Jbo/+ 
mice (which are maintained on the C3H/HeH background), in order to produce Bpifa1+/-
Evi1Jbo/+ mice. To generate Bpifa1-/-Evi1Jbo/+ compound mutants and other control genotypes 
mentioned in Table 5.1, Bpifa1+/- mice were crossed with Bpifa1+/-Evi1Jbo/+ mice. The viability 
of the Bpifa1-/-Evi1Jbo/+ line, assessed by analysing genotype ratios of the progeny from this 
cross (Chi-square test) exhibited normal Mendelian ratios at weaning age, P21 (Table 5.1). 
All mice were inspected daily by ward technicians and no anomalies were observed in the 
general health and behaviour of Bpifa1-/-Evi1Jbo/+mice. 
 
 
Table 5.1: Numbers of live mice for the Bpifa1-/-Evi1Jbo/+ line  
Genotype Observed 
numbers 
% Observed  Expected 
numbers 
% Expected P-value 
Bpifa1+/-Evi1Jbo/+ 91 22.09 104 25 0.5329 
Bpifa1+/- 108 26.21 104 25  
Bpifa1-/-Evi1Jbo/+ 43 10.44 51 12.5  
Bpifa1-/- 48 11.65 51 12.5  
Evi1Jbo/+ 56 13.59 51 12.5  
Wt 67 16.02 51 12.5  
Total 412 100 412 100  
 
5.2.2 Loss of Bpifa1 exacerbates the OM phenotype of Evi1Jbo/+ mice.  
Morphometric analysis was performed on H&E stained middle ear sections from offspring 
of the Bpifa1-/-Evi1Jbo/+ line at P21 and P28. In order to determine if the loss of Bpifa1 
exacerbated the phenotype in an existing model of OM, Bpifa1-/-Evi1Jbo/+ mice were 
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compared with Evi1Jbo/+ mice. In addition, Bpifa1+/-Evi1Jbo/+ mice were used to assess 
whether haploinsufficiency of Bpifa1 resulted in a similar effect. In Chapter 3, I have shown 
that Bpifa1+/- and Bpifa1-/- mice do not develop spontaneous OM on a C57BL/6 background 
(Section 3.2.3). Here, the two genotypes were used as controls to test if the C3H/HeH 
background influenced OM development. Lastly, Wt mice were included in the study as the 
baseline comparison.  
Here, the two criteria used for assessment of the OM phenotype were:  
(i) The presence of middle ear exudate.  (ii) The thickness of the middle ear mucosa.  
 
5.2.2.1 OM development at P21 
Histological assessment of middle ear sections identified an OM phenotype in a proportion 
of Bpifa1-/-Evi1Jbo/+ and Evi1Jbo/+ at P21, characterised by the presence of middle ear fluids 
and thickening of the mucoperiosteum that was not present in the Bpifa1-/- and Wt mice. 
The middle ear fluids collected from both Bpifa1-/-Evi1Jbo/+ and Evi1Jbo/+ mice were either 
cellular or serous. Fig 5.3 shows representative images of the middle ear cavities from mice 
of the 4 genotypes.   
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Figure 5.3 H&E stained middle ear sections at P21 
Dorsal plane H&E sections from middle ears of Wt (A, B), and Bpifa1-/- (C, D) mice show no OM 
development. H&E sections from middle ears of Evi1Jbo/+ (E, F) and Bpifa1-/-Evi1Jbo/+ (G, H) mice 
demonstrate presence of an OM phenotype marked by mucosal thickening and presence of 
inflammatory ear fluids (asterisk). Mucosal thickening is a combination of epithelial 
hyperproliferation (i) and sup-epithelial mesenchyme expansion (ii). Mucosa of Bpifa1-/-Evi1Jbo/+ (H) is 
more thickened than Evi1Jbo/+ mice (F). Scale bar 500μm for low magnification images and 100μm for 
high magnification images. Wt ears (n=28), Bpifa1-/- ears (n=16), Evi1Jbo/+ ears (n=32) and Bpifa1-/-
Evi1Jbo/+ ears (n= 31). 
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OM can develop unilaterally or bilaterally. Hence development of OM in each ear was 
considered as an independent event for analysis. At this time point, the number of fluid 
containing Bpifa1-/-Evi1Jbo/+ middle ears (21/30) was higher than that for both Bpifa1+/-
Evi1Jbo/+ (16/31) and Evi1Jbo/+ (16/32) ears, however this difference was not statistically 
significant. 3/19 Bpifa1+/- and 4/28 Wt ears also showed middle ear fluid, however this was 
significantly lower compared to Bpifa1-/-Evi1Jbo/+ mice (p = 0.000006). None of the Bpifa1-/- 
mice (n=16 ears) displayed an OM phenotype (Fig 5.4). 
 
 
Figure 5.4 Percentage ears with middle ear fluids at P21 
The percentage of Bpifa1-/-Evi1Jbo/+ (n=30), Bpifa1+/-Evi1Jbo/+ (n=31), Evi1Jbo/+ (n=32), Wt (n=28), Bpifa1-
/- (n=16) and Bpifa1+/- (n=19) middle ears with inflammatory effusion at P21. The difference between 
Bpifa1-/-Evi1Jbo/+ and Evi1Jbo/+ mice was not significant at P21. Fishers exact test ****p<0.0001. 
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There were no sex related differences in the numbers of Bpifa1-/-Evi1Jbo/+ (n=13) Bpifa1+/-
Evi1Jbo/+ (n=10) and Evi1Jbo/+ (n=9) mice that had middle ear fluids (Fig 5.5 A). There were also 
no significant differences in the percentage of mice developing middle ear fluids in one ear 
versus the percentage of mice developing middle ear fluids in both ears (Fig 5.5 B).  
 
 
Figure 5.5 Analysis of mice with middle ear fluids at P21 
No sex related differences were seen between percentages of mice with middle ear fluids (A). No 
difference was seen between percentage of mice with unilateral and bilateral OM (B). Bpifa1-/-
Evi1Jbo/+ (n=13) Bpifa1+/-Evi1Jbo/+ (n=10) and Evi1Jbo/+ (n=9); Fishers exact test.   
 
Bpifa1-/-Evi1Jbo/+ middle ears (n=30) showed significantly more thickened mucosa compared 
to Evi1Jbo/+ ears (n= 32 p<0.01), Bpifa1+/-Evi1Jbo/+ ears (n=21, p<0.0001), Wt ears (n=28, 
p<0.0001), Bpifa1+/- ears (n=19, p<0.0001) and Bpifa1-/- ears (n=16, p<0.0001). However, at 
this point, there was no difference in the mucosal thickening in Bpifa1+/-Evi1Jbo/+ and  
Evi1Jbo/+ mice (Fig. 5.6). 
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Figure 5.6 Mucosal thicknesses at P21 
Mean mucosal thickness of Bpifa1-/-Evi1Jbo/+ (n=30) middle ears was significantly higher compared 
Bpifa1+/-Evi1Jbo/+ (n=31), Evi1Jbo/+ (n=32), Wt (n=28), Bpifa1-/- (n=16) and Bpifa1+/- (n=19) middle ears 
at P28. One-way ANOVA with Tukey’s posthoc test **p< 0.01; ****p< 0.0001. 
 
 
 
Overall, the data shows that a higher proportion of Bpifa1-/-Evi1Jbo/+ display an OM 
phenotype at P21, suggesting that the loss of Bpifa1 accelerates the development of OM in 
Evi1Jbo/+ mice. 
 
 
5.2.2.2 OM development at P28 
Bpifa1-/-Evi1Jbo/+ and Evi1Jbo/+ retained the OM phenotype at P28, evidenced by a thickened 
epithelial lining and fluid in the middle ear cavities. The middle ear fluids of both Bpifa1-/-
Evi1Jbo/+ and Evi1Jbo/+ were mostly cellular, but sometimes serous fluids were seen. Bpifa1-/- 
mice and Wt mice did not exhibit an OM phenotype. Fig 5.7 shows representative images 
of the middle ear cavities from these 4 genotypes of mice.   
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Figure 5.7 H&E stained middle ear sections at P28 
Dorsal plane H&E sections from middle ears of Wt (A, B), and Bpifa1-/- (C, D) mice show no OM 
development. H&E sections from middle ears of Evi1Jbo/+ (E, F) and Bpifa1-/-Evi1Jbo/+ (G, H) mice 
demonstrate presence of an OM phenotype marked by mucosal thickening and the presence of 
inflammatory ear fluids (asterisk). Mucosal thickening is a combination of epithelial 
hyperproliferation (i) and sup-epithelial mesenchyme expansion (ii). Mucosa of Bpifa1-/-Evi1Jbo/+ (H) is 
more thickened than Evi1Jbo/+ mice (F). Scale bar 500μm for low magnification images and 100μm for 
high magnification images. Wt ears (n=28), Bpifa1-/- ears (n=12), Evi1Jbo/+ ears (n=34) and Bpifa1-/-
Evi1Jbo/+ ears (n= 32).  
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As was mentioned previously, each ear was considered an independent sample for analysis 
for development of OM (Fig 5.8). At P28, the number of Bpifa1-/-Evi1Jbo/+ ears (30/32) that 
had middle ear exudate was significantly higher compared to Evi1Jbo/+ ears (23/34; 
p=0.0117). The increase in the number of fluid containing ears from P28 was significant for 
Bpifa1-/-Evi1Jbo/+ mice (p= 0.02) but not for Evi1Jbo/+ mice. The number of Bpifa1+/-Evi1Jbo/+ 
ears with fluids (26/34) was also higher than Evi1Jbo/+ mice (23/34), however this difference 
was not statistically significant. Only 4/28 Wt ears showed presence of fluid (this was very 
limited in volume), however this was significantly less compared to Bpifa1-/-Evi1Jbo/+ mice 
(p<0.0001). None of the Bpifa1+/- (n=14) and Bpifa1-/- (n=12) ears showed any fluid 
(p<0.0001)  
 
 
 
Figure 5.8 Percentage ears with middle ear fluids at P28 
The percentage of Bpifa1-/-Evi1Jbo/+ (n=32) middle ears with fluid was significantly higher compared to 
Evi1Jbo/+ (n=34), Wt (n=28), Bpifa1-/- (n=12) and Bpifa1+/- (n=14) middle ears but not compared to 
Bpifa1+/-Evi1Jbo/+ (n=31) middle ears at P28; Fishers exact test *p< 0.05; ****p< 0.0001. 
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All Bpifa1-/-Evi1Jbo/+ mice analysed (n=16) showed either unilateral or bilateral middle ear 
fluids. The percentage of Bpifa1-/-Evi1Jbo/+ developing bilateral OM (14/16) was significantly 
higher (p= 0.03) compared to both Bpifa1+/-Evi1Jbo/+ (10/16) and Evi1Jbo/+ mice (7/16) (Fig 
5.9A). No sex related differences were seen in the number of mice showing fluid 
development for either genotype (Fig 5.9B). 
 
Figure 5.9 Analysis of mice with middle ear fluids at P28 
The percentage of Bpifa1-/-Evi1Jbo/+ mice with bilateral OM was significantly higher than Bpifa1+/-
Evi1Jbo/+ and Evi1Jbo/+ mice (A). No sex related differences were seen between percentages of mice 
with middle ear fluids (B). n=16 mice of each genotype; Fishers exact test; *p< 0.05.  
 
Quantification of the mucosal thickness (Fig 5.10) revealed that Bpifa1-/-Evi1Jbo/+ ears (n=32) 
showed significantly thickened mucosa compared to Evi1Jbo/+ ears (n=34, p<0.0001) as well 
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as all the other control genotypes: Also, there was a significant difference in the mucosal 
thickening of Bpifa1+/-Evi1Jbo/+ ears (n=34) compared to Evi1Jbo/+ ears (p=0.036).  
The data confirms that the loss of Bpifa1 alone does not lead to spontaneous OM 
development on the C3H/HeH background, reiterating my observations on the C57BL/6 
(Section 3.2.3). However, the loss of Bpifa1 significantly exacerbates the OM phenotype in 
Evi1Jbo/+ mice. 
 
 
 
Figure 5.10 Mean middle ear mucosal thickness at P28 
Mean mucosal thickness of Bpifa1-/-Evi1Jbo/+ (n=32) middle ears was significantly higher compared 
Bpifa1+/-Evi1Jbo/+ (n=34), Evi1Jbo/+ (n=34), Wt (n=28), Bpifa1-/- (n=12) and Bpifa1+/- (n=14) middle ears 
middle ears at P28. Mean mucosal thickness of Bpifa1+/-Evi1Jbo/+ middle ears compared Evi1Jbo/+ 
middle ears was also significantly higher; One-way ANOVA with Tukey’s posthoc test **p< 0.01; 
****p< 0.0001. 
 
 
  
213  
To investigate if the difference in the OM phenotype of Bpifa1-/-Evi1Jbo/+ and Evi1Jbo/+ mice, 
was due to inherent differences between the middle ear epithelial cells between the two 
genotypes, I moved on to some in vitro studies. For this, cohorts of 7-10 week old Bpifa1-/-
Evi1Jbo/+, Evi1Jbo/+,  Bpifa1-/- and Wt mice were sent to University of Sheffield for cell 
isolations. The aim of the study was to investigate the potential differences in gene 
expression in freshly isolated middle ear mucosal cells of these mice as well as to use the 
mMEC model system developed in Chapter 4 in order to recapitulate the OM phenotype in 
vitro. Prior to performing these experiments, I analysed body weights and assessed OM 
status in these adult mice. 
 
 
5.2.3. Analysis of body weights 
Bpifa1-/-Evi1Jbo/+ mice appeared to be smaller in size compared to their Wt littermate 
controls. Therefore, I compared body weights of Bpifa1-/-Evi1Jbo/+, Evi1Jbo/+,  Bpifa1-/- and Wt 
mice between 7-9 weeks of age. Male Bpifa1-/-Evi1Jbo/+ mice weighed significantly less 
compared to male Wt (p=0.049) and Bpifa1-/- mice (p=0.035). Evi1Jbo/+ mice also weighed 
less, but this difference was not statistically significant (Fig 5.11A). Bpifa1-/-Evi1Jbo/+ as well 
as Evi1Jbo/+ females weighed significantly less compared to Wt (p= 0.016, 0.024 respectively) 
and Bpifa1-/- (p= 0.005, 0.01 respectively) females (Fig 5.11B).  
However, for both sexes, body weights did not differ between Bpifa1-/-Evi1Jbo/+ and Evi1Jbo/+ 
mice, indicating that the lowered body weight of the compound mutants was a result of 
the Evi1 mutation (Fig 5.11 A, B). This result also suggests that the loss of Bpifa1 alone does 
not cause a change in body weights on the C3H/HeH background, similar to that seen with 
the mutation on the C57BL/6 background (Section 3.2.2.2) 
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Figure 5.11 Body weight analyses of adult Bpifa1-/-Evi1Jbo/+ mice 
7-9 weeks old male Bpifa1-/-Evi1Jbo/+ mice (n=6) weigh significantly less than their Wt (n=6), Bpifa1-/- 
(n=10) and Evi1Jbo/+ (n=12) littermate controls (A) 7-9 weeks old female Bpifa1-/-Evi1Jbo/+ mice (n=6) 
and Evi1Jbo/+ (n=5) weigh significantly less than their Wt (n=5) and Bpifa1-/- (n=11) littermate controls 
(B). Data presented as box and whisker plots demonstrating minimum to maximum weights and 
horizontal line indicates median weight. Mean weights compared using One-way ANOVA with 
Tukey’s posthoc test; **p< 0.01; *p< 0.05.  
 
 
5.2.4. Persistence of OM in adult Bpifa1-/-Evi1Jbo/+ mice 
In order to assess the persistence of OM in adult mice (as the morphometric assessment 
described above was performed in 3-4 week old mice), I semi-quantitatively evaluated the 
Tm appearance in 7–10 week old Bpifa1+/-Evi1Jbo/+ mice and their Evi1Jbo/+, Bpifa1-/- and Wt 
littermate controls. Using a dissecting microscope, the Tm was scored as ‘cloudy’ or ‘clear’ 
based on the visibility of the malleus ossicle. (Fig 5.12 A, B). Mice with OM have a cloudy 
Tm due to fluid accumulation in the middle ear cavity. The penetrance of OM was higher in 
Bpifa1+/-Evi1Jbo/+ mice (88.6%, n=44 ears) compared to Evi1Jbo/+ (74%, n=54 ears). 
Statistically, the difference between the number of cloudy ears between these two 
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genotypes was borderline insignificant (p=0.058). Only 1/42 Bpifa1-/- ears and none of the 
Wt ears were cloudy (Fig 5.12 C). 
The volume of middle ear fluids sampled from cloudy ears displayed a large range. The 
average volume of middle ear fluids recovered from Bpifa1+/-Evi1Jbo/+ mice (0.63 µl) and that 
from Evi1Jbo/+ ears (0.56 µl) was not statistically significant (Fig 5.12 D). Due to the lack of 
time, a detailed analysis of the middle ear fluids could not be performed. However, a brief 
look at cytospun fluids from both Bpifa1+/-Evi1Jbo/+ and Evi1Jbo/+ revealed abundant 
neutrophils and a smaller proportion of macrophages (Fig 5.12 E, F) 
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Figure 5.12 Persistence of OM in adult Bpifa1-/-Evi1Jbo/+ mice 
Representative images showing a clear (A) and a cloudy (B) ear drum. Arrowhead shows the visibility 
of the malleus ossicle. The percentage of Bpifa1-/-Evi1Jbo/+ cloudy ears is higher than Evi1Jbo/+, Bpifa1-/- 
and Wt littermate controls, as calculated using One-way ANOVA with Tukey’s post hoc test; ****p< 
0.0001 (C) Volumes of ear fluids recovered do not differ between Bpifa1-/-Evi1Jbo/+ and Evi1Jbo/+ 
middle ears; two tailed t-test (D). Middle ear fluids from Bpifa1-/-Evi1Jbo/+ (E) and Evi1Jbo/+ mice (F) 
show the presence of neutrophils (i), macrophages (ii) and sloughed epithelial cells (iii). Bpifa1-/-
Evi1Jbo/+ (n=44), Evi1Jbo/+ (n=54), Bpifa1-/- (n=42), Wt (n=66). 
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5.2.5 Relative gene regulation in Bpifa1-/-Evi1Jbo/+ middle ear mucosal cells 
Both Bpifa1-/-Evi1Jbo/+and Evi1Jbo/+ mice demonstrated a thickened middle ear mucosa. I 
speculated that the mucosal thickening is a combined effect of remodelling of the middle 
ear epithelial cells as well as the underlying sub-epithelial layer, which includes fibroblasts. 
Therefore, I decided to evaluate the expression of inflammatory and epithelial genes in the 
middle ear mucosal lining, encompassing the epithelial cells as well as fibroblasts. To do 
this, middle ear cavities were dissected from 3 individual batches (each batch was 5-6 mice) 
of 7-10 week old Bpifa1-/-Evi1Jbo/+, Evi1Jbo/+, Bpifa1-/- and Wt mice and treated with Pronase 
overnight to strip off the mucosal layer, in accordance to the mMEC cell isolation protocol 
(Section 2.8.1.3). For RT-qPCR analysis of inflammatory and epithelial genes, a proportion 
of these freshly isolated cells were directly lysed in TRI reagent, without undergoing the 
differential fibroblast separation step. These cells will be referred to as mouse middle-ear 
mucosal cells (mMMCs) throughout this thesis.  
The remainder of the isolated cells underwent routine fibroblast separation using 
differential adherence to plastic and were then seeded on transwell membranes for culture 
and ALI differentiation according to the standard mMEC culture protocol. In doing this the 
aim was to model the OM phenotype in vitro. Experiments with cultured mMECs from the 
4 genotypes are described in Section 5.2.6 and Section 5.2.7.  
 
 
5.2.5.1 Expression of inflammatory genes in Bpifa1-/-Evi1Jbo/+ middle ear mucosa 
I was interested in evaluating if the exacerbation of the OM phenotype in Bpifa1-/-Evi1Jbo/+ 
mice was due to an enhanced inflammatory response, arising from the mucosal cells as a 
result of Bpifa1 ablation. In order to test this, gene expression analysis for a selected panel 
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of inflammatory markers was performed on mMMCs isolated from Bpifa1-/-Evi1Jbo/+, 
Evi1Jbo/+, Bpifa1-/- and Wt mice using RT-qPCR.  
The pro-inflammatory cytokines Cxcl2 (Fig 5.13A), Il1β (Fig 5.13B), Tnfα (Fig 5.13C) and the 
anti-inflammatory cytokine, Tgfβ (Fig 5.13D) were significantly upregulated in Evi1Jbo/+ and 
Bpifa1-/-Evi1Jbo/+ mMMCs compared to Wt and Bpifa1-/- mMMCs. Il6 was significantly 
upregulated in Bpifa1-/-Evi1Jbo/+ mMMCs compared to Wt mMMCs (Fig 5.13E). The 
statistically significant fold changes for all inflammatory genes analyzed in this study are 
detailed in Table 5.2. Thus, the middle ear mucosa of Evi1Jbo/+ and Bpifa1-/-Evi1Jbo/+ mice was 
severely inflamed. However, there was no significant difference in the expression levels for 
any of the markers between Wt and Bpifa1-/- mMMCs and Evi1Jbo/+ and Bpifa1-/-Evi1Jbo/+ 
mMMCs, suggesting that the loss of Bpifa1 did not aggravate the cytokine response. 
 
 
Table 5.2 Statistically significant fold changes in expression of inflammatory genes in Evi1Jbo/+ and 
Bpifa1-/-Evi1Jbo/+ mMMCs compared to Wt and Bpifa1-/- mMMCs 
Gene Genotype FC compared to Wt p-value 
FC compared to 
Bpifa1-/- p-value 
Cxcl2 
Evi1Jbo/+  52.18 0.0002 20.45 0.0023 
Bpifa1-/-Evi1Jbo/+  47.30 0.0005 18.54 0.0046 
Il1β 
Evi1Jbo/+  32.71 0.0001 17.26 0.0008 
Bpifa1-/-Evi1Jbo/+  24.27 0.0003 12.81 0.0023 
Tnfα 
Evi1Jbo/+  12.40 0.0002 4.88 0.0078 
Bpifa1-/-Evi1Jbo/+  15.53 0.0001 6.11 0.0035 
Tgfβ Evi1
Jbo/+  2.33 0.0002 2.11 0.0008 
Bpifa1-/-Evi1Jbo/+  2.18 0.0008 1.98 0.0033 
Il6 Bpifa1-/-Evi1Jbo/+  5.02 0.0287 
 
  
 
I also analysed the expression of Vegf, a marker of hypoxia, in mMMCs isolated from the 4 
genotypes of mice. Vegf expression was upregulated 2.7 fold in Bpifa1-/-Evi1Jbo/+ mice 
(p=0.016) and 2.3 fold in Evi1Jbo/+ mice (p=0.024) compared to Wt mice, suggesting the 
presence of a hypoxic environment in the inflamed mucosa of the Bpifa1-/-Evi1Jbo/+ and 
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Evi1Jbo/+ mice (Fig 5.13F). The upregulation compared to Bpifa1-/- mMMCs was not 
significant. Also, there there was no significant difference in Vegf expression levels 
between Wt and Bpifa1-/- mMMCs and between Evi1Jbo/+ and Bpifa1-/-Evi1Jbo/+ mMMCs. 
Expression of all target genes was normalized against three endogenous controls; Atp5b, 
Canx and Cyc1, identified using the geNORM assay (Section 2.19.4). Data is presented as 
individual RQ values for 3 biological replicates of each genotype ± SEM (Fig 5.13).  
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Figure 5.13 Gene expression of inflammatory markers in Bpifa1-/-Evi1Jbo/+ mMMCs 
Significant up regulation of Cxcl2 (A), Il1β (B), Tnfα (C) Tgfβ (D) in Bpifa1-/-Evi1Jbo/+ and Evi1Jbo/+ 
mMMCs compared to Wt and Bpifa1-/-  mMMCs. Significant upregulation of Il6 (E) in Bpifa1-/-Evi1Jbo/+ 
compared to Wt mMMCs and of Vegf (F) in Bpifa1-/-Evi1Jbo/+ and Evi1Jbo/+ mMMCs compared to Wt 
mMMCs. Overall, no effect of Bpifa1 deletion was seen on gene expression. Data were analysed 
using One-way ANOVA plus Tukey’s posthoc test and represented as individual RQ values ± SEM for 
three independent batches of freshly isolated mMMCs. ****p<0.0001, ***p<0.001, **p<0.01, 
*p<0.05 
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5.2.5.2 Expression of epithelial genes in Bpifa1-/-Evi1Jbo/+ middle ear mucosa 
Our preliminary studies had shown a decrease in BPIFA1 staining in the Evi1Jbo/+ middle ear 
compared to Wt mice using IHC (Section 1.13). In order to confirm if this was due to an 
inherent difference in gene expression, I compared expression of Bpifa1 in mMMCs 
isolated from Wt and Evi1Jbo/+ mice using RT-qPCR. This analysis showed that there was a 
significant down-regulation (3.18 fold, p= 0.0017) of Bpifa1 mRNA in Evi1Jbo/+ mMMCs (Fig 
5.14 A). 
I also evaluated levels of Evi1 expression between the 4 genotypes. There was a small but 
significant down-regulation in Evi1 in Evi1Jbo/+ and Bpifa1-/-Evi1Jbo/+ mMMCs compared to 
both Wt (1.56 fold, p=0.02 and 1.75-fold p=0.04 respectively) and Bpifa1-/- mMMCs (1.62 
fold, p=0.02 and 1.82-fold p=0.03 respectively) (Fig 5.14 B).  
Next, I compared expression of other epithelial markers, Foxj1, Muc5ac and Muc5b using 
RT-qPCR. The rationale behind this experiment was to evaluate if Bpifa1 ablation leads to 
an alteration of epithelial sub-populations in presence and absence of an inflammatory 
environment in the middle ear mucosa. The fold changes and significance levels for all 
epithelial genes analyzed are detailed in Table 5.3. The ciliated cell marker, Foxj1 was 
significantly downregulated in Evi1Jbo/+ and Bpifa1-/-Evi1Jbo/+ mMMCs compared to both Wt 
and Bpifa1-/- mMMCs (Fig 5.14 C). The goblet cell marker, Muc5ac was also down regulated 
significantly in Bpifa1-/-Evi1Jbo/+ mice compared to Wt mice and in both Bpifa1-/-Evi1Jbo/+ and 
Evi1Jbo/+ mice compared to Bpifa1-/-. Muc5ac was also down regulated 2.6 fold in Evi1Jbo/+ 
compared to Wt mice, although this difference did not reach statistical significance (Fig 
5.14 D). Muc5b expression was highly variable between individual batches and did not 
reach statistical significance (Fig 5.14 E). Expression of Foxj1, the mucin genes and Evi1 
appeared to be higher in Bpifa1-/- mice compared to Wt mice, but this did not reach 
statistically significance. Also, there was no difference in the level of expression of any of 
the markers between Evi1Jbo/+ and Bpifa1-/-Evi1Jbo/+ mice.  
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Table 5.3 Fold changes for expression of epithelial genes in Evi1Jbo/+ and Bpifa1-/-Evi1Jbo/+ mMMCs 
compared to Wt and Bpifa1-/- mMMCs 
Gene Genotype FC compared to Wt p-value 
FC compared to 
Bpifa1-/- p-value 
Bpifa1 Evi1Jbo/+ -3.18 0.0017 - - 
Foxj1 
Evi1Jbo/+  -2.95 0.0019 -3.65 0.0006 
Bpifa1-/-Evi1Jbo/+  -4.42 0.0003 -5.5 0.0001 
Muc5ac 
Evi1Jbo/+  -2.59 > 0.05 (ns) -6.94 0.007 
Bpifa1-/-Evi1Jbo/+  -4.73 0.022 -12.67 0.001 
Muc5b Evi1
Jbo/+  2.35 > 0.05 (ns) -1.38 > 0.05 (ns) 
Bpifa1-/-Evi1Jbo/+  1.81 > 0.05 (ns) -1.79 > 0.05 (ns) 
Evi1 Evi1
Jbo/+  -1.56  0.02 1.62 0.02 
Bpifa1-/-Evi1Jbo/+  -1.75 0.04 1.82 0.03 
         NB: p>0.05 (ns) = non significant 
 
 
 
Overall, the data indicate that Evi1Jbo/+ mice show epithelial cellular alterations marked by 
down regulation of Bpifa1, Foxj1 and Muc5ac. However, there is no added effect of Bpifa1 
deletion on alteration of epithelial genes.  
Expression of all target genes was normalized against three endogenous controls; Atp5b, 
Canx and Cyc1 identified using the geNORM assay (Section 2.19.4). Data is presented as 
individual RQ values for 3 biological replicates of each genotype ± SEM (Fig 5.14).  
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Figure 5.14 Expression of epithelial markers in Bpifa1-/-Evi1Jbo/+ mMMCs 
Significant downregulation of Bpifa1 in Evi1Jbo/+ mMMCs compared to Wt mMMCs (A) and of  Evi1 
(B) and Foxj1 (C) in Bpifa1-/-Evi1Jbo/+ and Evi1Jbo/+ mMMCs compared to Wt and Bpifa1-/- mMMCs. 
Significant downregulation of Muc5ac (D) in Bpifa1-/-Evi1Jbo/+ and Evi1Jbo/+ mMMCs (D). Muc5b 
expression was variable. Overall, no effect of Bpifa1 deletion was seen on expression of other 
epithelial genes. Data were analysed using One-way ANOVA plus Tukey’s posthoc test and 
represented as individual RQ values ± SEM for three independent batches of freshly isolated 
mMMCs. ****p<0.0001, ***p<0.001, **p<0.01, *p<0.05. 
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5.2.6 Modelling the OM phenotype of Bpifa1-/-Evi1Jbo/+ and Evi1Jbo/+ mice in vitro 
using the mMEC culture system 
In Chapter 4, I described the development of a novel model for the culture of mouse 
middle ear epithelial cells at ALI, which recapitulates the native murine middle ear 
epithelium in vitro. In order to evaluate whether I could utilise the mMEC culture system to 
model the OM phenotype in vitro, I isolated middle ear cells from 7-10 week old Bpifa1-/-
Evi1Jbo/+, Evi1Jbo/+, Bpifa1-/- and Wt mice using pronase treatment of dissected middle ear 
cavities. Fibroblasts were separated using differential adherence method and the epithelial 
cells (mMECs) were seeded on transwell membranes at an initial seeding density of 10,000 
cells/ well in the presence of ROCKi. The cells were then cultured using the routine mMEC 
culture protocol (Section 2.8.1.5) in submerged culture till confluence and differentiated at 
ALI for 14 days.  
 
 
5.2.6.1 Culture characteristics  
 The culture characteristics of mMECs from the 4 genotypes of mice were largely similar to 
those described for Wt and Bpifa1-/- cells on the C57BL/6 background in Chapter 4 (Section 
4.2.2.1, Table 4.1). Cells reached confluence within 8- 10 days submerged culture in 
presence of ROCKi and differentiated by Day 14 at ALI (Fig 5.15). This was evidenced by 
elevated clusters of cells with actively beating cilia. There were no gross differences 
between the mMECs cultured from the 4 genotypes except that Bpifa1-/-Evi1Jbo/+ and 
Evi1Jbo/+ cultures appeared to be more abundant in elevated clusters of cells compared to 
Wt and Bpifa1-/- cultures, when observed under the light microscope (personal 
observation).  
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Figure 5.15 Morphological characteristics of Bpifa1-/-Evi1Jbo/+ mMECs 
Phase contrast images showing Wt (A, E), Bpifa1-/- (B, F), Evi1Jbo/+ (C, G) and Bpifa1-/-Evi1Jbo/+ (D, H) 
mMECs in culture under 10x magnification. No difference is seen in the growth characteristics 
between the genotypes. Cells became confluent between 8-9 days in submerged culture (A, B, C, D) 
and differentiated by ALI Day 14 (E, F, G, H).  White arrowheads mark elevated cells with cilia and 
asterisk mark flatter polygonal cells. Scale bar = 200 μm. 
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5.2.6.2 Expression of epithelial and inflammatory genes in Bpifa1-/-Evi1Jbo/+ 
mMECs 
ALI day 14 mMECs from Bpifa1-/-Evi1Jbo/+, Evi1Jbo/+ Bpifa1-/- and Wt mice were analysed using 
RT-qPCR to evaluate differential expression of epithelial and inflammatory genes. The 
objective of this study was to investigate if the pattern of genetic alterations seen in the 
mucosal cells, mMMCs from OM affected mice (Section 5.2.5) was retained after culturing 
the cells in vitro. Expression of target genes was normalized against three endogenous 
controls; Atp5b, Ppia and Cyc1, identified using the geNORM assay (Section 2.19.4). Data is 
presented as individual RQ values for 3 biological replicates of each genotype ± SEM.  
The expression of Bpifa1 was 3.41 fold lower (p<0.0001; 2 tailed t-test) in Evi1Jbo/+ mMECs 
compared to Wt mMECs (Fig 5.16A). This finding was in line with our observation in 
mMMCs (Section 5.2.5.2) as well as in IHC data from our lab (Section 1.13,), confirming that 
the levels of Bpifa1 reduce with development of OM in Evi1Jbo/+ mice. 
I showed above that Foxj1 and Muc5ac expression was down regulated in the inflamed 
mucosa of Bpifa1-/-Evi1Jbo/+, Evi1Jbo/+ mice and expression of the ciliated and mucin gene 
markers did not vary with Bpifa1 ablation (Fig 5.14, Table 5.3). However, this expression 
pattern changed considerably when cells were cultured in vitro. Compared to Wt ALI Day 
14 mMECs, Foxj1 expression showed a small reduction of 1.4 fold in Bpifa1-/-Evi1Jbo/+ 
mMECs. This change was statistically significance(p=0.0076), probably due to the smaller 
variation seen between the batches for this particular marker. Foxj1 expression did not 
change in Evi1Jbo/+ mMECs (Fig 5.16B). Expression of Muc5ac and Muc5b did not differ 
between Wt, Evi1Jbo/+ and Bpifa1-/-Evi1Jbo/+ mMECs (Fig 5.16C, D). However, the expression 
of all the three genes was significantly lower in Bpifa1-/- mMECs compared to the other 
genotypes. FoxJ1 expression was reduced 1.8 fold (p<0.0001), Muc5ac was reduced 5.2 fold 
(p=0.0103) and Muc5b was reduced 7.5 fold (0.0002) in Bpifa1-/- mMECs compared to Wt 
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mMECs (Fig 5.16B-D). Expression of the basal cell marker, p63 did not differ between the 4 
genotypes (Fig 5.16E).  
Overall, the data indicates that although mMECs differentiate to express the different 
epithelial subtypes, they do not retain the expression pattern of majority of the genes seen 
in the native middle ear mucosa from Bpifa1-/-Evi1Jbo/+, Evi1Jbo/+ Bpifa1-/- and Wt mice. 
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Figure 5.16 Expression of epithelial markers in Bpifa1-/-Evi1Jbo/+ mMECs 
Significant downregulation of Bpifa1 in Evi1Jbo/+ mMECs compared to Wt mMECs. 2 tailed Student’s 
t-test (A). Expression pattern of Foxj1 (B) Muc5ac (C) and Muc5b (D) was altered in mMECs 
compared to that seen in mMMCs (Fig 5.13). p63 expression did not differ between the genotypes. 
Data were analysed using One-way ANOVA plus Tukey’s posthoc test and represented as mean 
individual RQ values ± SEM for three independent batches of cultured mMECs. ****p<0.0001, 
***p<0.001, **p<0.01, *p<0.05.  
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The expression of inflammatory genes was upregulated in the mucosal cells of Bpifa1-/-
Evi1Jbo/+ and Evi1Jbo/+ mice but their expression did not change additionally due to Bpifa1 
ablation (Section 5.2.5.1). I was interested in investigating whether cultured cells retained 
the elevated expression of these inflammatory genes. Cxcl2 was upregulated 6 fold 
(p=0.0012, Fig 5.17A), Tgfβ showed a small increase of 1.25 fold (p=0.02, Fig 5.17B) and Il6 
was upregulated 8.5 fold (p=0.002, Fig 5.17C) in Bpifa1-/-Evi1Jbo/+ mMECs compared to Wt 
mMECs, in line with our previous observation in freshly isolated mMMCs (Fig 5.13, Table 
5.2). However, the upregulation in Evi1Jbo/+ mMECs was not significant (Fig 5.17A-C). There 
was also a significant difference in the levels of Cxcl2 in Bpifa1-/- mMECs compared to Wt 
mMECs (p=0.0089, Fig 5.17A) and Il6 in Bpifa1-/-Evi1Jbo/+mMECs compared to 
Evi1Jbo/+mMECs (p=0.047, Fig 5.17C). Thus, my data indicates that although mMECs 
maintained expression of inflammatory genes, the pattern of expression differed widely to 
that seen in the native middle ear mucosa from Bpifa1-/-Evi1Jbo/+, Evi1Jbo/+, Bpifa1-/- and Wt 
mice. 
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Figure 5.17 Expression of epithelial markers in Bpifa1-/-Evi1Jbo/+ mMECs 
Significant upregulation of Cxcl2 (A), Tgfβ (B) and Il6 in Bpifa1-/-Evi1JbomMECs compared to Wt 
mMECs. The expression pattern of all three genes is altered in mMECs compared to that seen in 
mMMCs (Fig 5.12). Data were analysed using One-way ANOVA plus Tukey’s posthoc test and 
represented as individual RQ values ± SEM for three independent batches of cultured mMECs. 
**p<0.01, *p<0.05. 
 
 
 
 
5.2.6.3 Localisation of epithelial proteins in mMEC cultures using IFC microscopy 
IFC microscopy of ALI day 14 Bpifa1-/-Evi1Jbo/+, Evi1Jbo/+ Bpifa1-/- and Wt mMECs confirmed 
successful differentiation of cells at the proteomic level. BPIFA1 staining was localised to 
the non-ciliated cells and the intensity of staining appeared to be reduced in Evi1Jbo/+ 
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cultures compared to Wt cultures (Fig 5.18A, B). As expected BPIFA1 staining was absent in 
ALI day 14 Bpifa1-/- and Bpifa1-/-Evi1Jbo/+ mMECs (Fig 5.18C, D). Ciliated cells, marked by 
FOXJ1 and goblet cells marked by MUC5B were observed in clusters and localised to the 
elevated layers of cells (Fig 5.18E- H).  This is consistent with the observations in C57BL/6 
Wt and Bpifa1-/- mMECs (Sections 4.2.6 and 4.2.8). 
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Figure 5.18 Localisation of epithelial markers in Bpifa1-/-Evi1Jbo/+ mMECs 
Immunofluorescence confocal images (representative of three independent batches) showing BPIFA1 localisation in non-ciliated cells of ALI Day 14 Wt and Evi1Jbo/+ mMECs 
(A, C). BPIFA1 staining is absent in Bpifa1-/- and Bpifa1-/-Evi1Jbo/+mMECs (B, D). MUC5B and FOXJ1 localise to the elevated clusters of cells in ALI Day 14 Wt, Bpifa1-/-, Evi1Jbo/+ 
and Bpifa1-/-Evi1Jbo/+mMECs (E, F, G, H).  Scale bar =100μm
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In order to quantify the difference in the levels of these proteins between the 4 groups of 
mice, 8-10 20x fields, spanning one half of the transwell membrane were analysed from 3 
individual batches of ALI day 14 mMECs. The level of cytosolic BPIFA1 protein was 
significantly lower in Evi1Jbo/+ mMECs compared to Wt mMECs, as demonstrated by both 
the mean integrated fluorescence intensity for BPIFA1 staining (Fig 5.19A p=0.0105) as well 
as the percentage of BPIFA1 positive cells (Fig 5.19B p=0.0074). This supports our 
observation of reduced mRNA levels of Bpifa1 in Evi1Jbo/+ mMMCs (Section 5.2.5.2) and 
mMECs (Section 5.2.6.2).  
In contrast to a downregulation of Foxj1 seen by RT-qPCR analysis of mMMCs, the 
percentage of ciliated cells was higher in Evi1Jbo/+ and Bpifa1-/-Evi1Jbo/+ mMECs, although this 
did not reach statistical significance (Fig 5.19C). The percentage of MUC5B positive cells 
was highly variable in the Wt mMECs and did not differ between the 4 genotypes (Fig 
5.19D).  
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Figure 5.19 Quantification of epithelial sub-populations in mMMECs 
Mean integrated fluorescence intensity for BPIFA1 (A) and percentage of BPIFA1 positive cells (B) is 
significantly lower in ALI Day 14 Evi1Jbo/+ mMECs compared to ALI Day 14 Wt mMECs; 2 tailed t-test 
**p< 0.01, *p<0.05. There is no difference between percentage of Foxj1 and Muc5b positive cells 
between ALI Day 14 Wt, Bpifa1-/-, Evi1Jbo/+ and Bpifa1-/-Evi1Jbo/+ mMECs; One-way ANOVA with 
Tukey’s posthoc test. Data representative of three independent batches of mMECs. 
 
5.2.7 Proliferation rates of Bpifa1-/-Evi1Jbo/+ mMECs and fibroblasts 
I postulated that the thickening of the middle ear mucosa of Bpifa1-/-Evi1Jbo/+ and Evi1Jbo/+ 
mice, was a consequence of hyperproliferation of cells in the epithelial and sub-epithelial 
lining of the middle ear cavity. Since the average mucosal thickness in Bpifa1-/-Evi1Jbo/+ 
middle ears was significantly higher than that of Evi1Jbo/+ middle ears, I sought to investigate 
whether loss of Bpifa1 contributed to the enhanced proliferative capacity of the middle ear 
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mucosal cells. I seeded mMECs isolated from the middle ear cavities of Bpifa1-/-Evi1Jbo/+, 
Evi1Jbo/+ Bpifa1-/- and Wt mice at an initial density of 50,000 cells/transwell in absence of 
ROCKi to compare their population doubling times. Similarly, population doubling time for 
fibroblasts separated by differential adherence was also compared between the 4 
genotypes. No differences were seen between the doubling times of either mMECs (Fig 
5.20A) or fibroblasts (Fig 5.20B) cultured from the 4 genotypes, indicating that the cells 
proliferated at similar rates. 
 
Figure 5.20 Proliferation rates of mMECs and fibroblasts 
There was no significant difference between the population doubling times of Wt, Bpifa1-/-, Evi1Jbo/+ 
and Bpifa1-/-Evi1Jbo/+ mMECs (A) and fibroblasts (B) in culture. One-way ANOVA with Tukey’s posthoc 
test. 
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5.2.8 IHC for epithelial and sub-epithelial markers 
Since the exacerbated OM phenotype of Bpifa1-/-Evi1Jbo/+ mice is not a result of an increased 
strength in cytokine response and the OM phenotype could not be successfully replicated 
in vitro, I sought to investigate the changes in the native middle ear mucosa using IHC. The 
aim of this study was to identify the effects of Bpifa1 deletion on proteins of the middle ear 
epithelium and the sub-epithelial connective tissue, which may contribute to the increased 
mucosal thickening. Under my direction, a placement student in the lab, Catherine Russell, 
performed IHC on dorsal middle ear sections from P28 Bpifa1-/-Evi1Jbo/+, Evi1Jbo/+ Bpifa1-/- 
and Wt mice for this analysis. 
 
 
5.2.8.1 Intensity of BPIFA1 staining is reduced in Evi1Jbo/+ mice 
BPIFA1 was expressed strongly throughout the Wt middle ear epithelium (Fig 5.21A, E). The 
expression pattern was the same as described previously (Sections 1.8.2 and 3.2.2).  BPIFA1 
staining was also seen in the surface epithelium of Evi1Jbo/+ middle ears; however, the 
intensity of staining was reduced compared to Wt mice. The middle ear exudates stained 
positive for the BPIFA1. No staining was seen in the underlying sub-epithelial mesenchyme, 
except occasional staining in submucosal glands. (Fig 5.21C, G). This was consistent with my 
preliminary observations in Evi1Jbo/+ mice (Mulay MSc thesis 2011). This was also in line 
with my RT-qPCR data from isolated mMMCs and cultured mMECs. As expected, Bpifa1-/- 
(Fig 5.21B, F) and Bpifa1-/-Evi1Jbo/+ (Fig 5.21D, H) middle ears completely lacked positivity for 
BPIFA1. Also staining was absent in Wt negative control sections stained for the protein (Fig 
5.21I, J). 
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Figure 5.21 Localisation of BPIFA1 in P28 middle ears of Wt, Bpifa1-/-, Evi1Jbo/+ and Bpifa1-/-
Evi1Jbo/+mice.  
IHC analysis of middle ear sections showing abundant staining of BPIFA1 along the Wt middle ear 
epithelium (A, E) and reduction in staining intensity along Evi1Jbo/+ middle ear epithelium. BPIFA1 
staining is also seen in the middle ear effusion of Evi1Jbo/+ (C, G). BPIFA1 staining is completely absent 
in Bpifa1-/- (B, F) and Bpifa1-/-Evi1Jbo/+ (D, H) middle ears and in the Wt negative control (I , J).  Data is 
representative of n=3 mice for all genotypes. Scale bar: 500μm for 4x images and 50μm for 60x 
images. Arrowheads indicate positive staining 
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5.2.8.2 Intensity of Lactotransferrin staining increased with OM development  
Lacotransferrin intensely stained the thin middle ear epithelium of Wt and Bpifa1-/- mice. 
The staining was continuous throughout the middle ear cavity (Fig 5.22A-D). The mucosal 
lining of in Evi1Jbo/+ and Bpifa1-/-Evi1Jbo/+ middle ears was considerably thickened, and this 
thickening was seen both in the epithelial layer and the underlying mesenchyme. Unlike 
BPIFA1, Lactotransferrin staining was observed in both the surface epithelial cells as well as 
the underlying sub-epithelial layer. The amount of staining increased in the thickened 
middle ear mucosa (Fig 5.22E-H). Negative antibody controls from both Wt and Bpifa1-/-
Evi1Jbo/+ were completely devoid of Lactotransferrin staining (Fig 5.22I-L) 
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Figure 5.22 Localisation of Lactotransferrin in P28 middle ears of Wt, Bpifa1-/-, Evi1Jbo/+ and Bpifa1-/-
Evi1Jbo/+mice.  
IHC analysis of middle ear sections showing intense Lactotransferrin staining along the thin Wt (A, B) 
and Bpifa1-/- (C, D) middle ear epithelium. Staining intensity increased further in the inflamed and 
thickened mucosa of Evi1Jbo/+ (E, F) and Bpifa1-/-Evi1Jbo/+ (G, H) middle ear. Arrowheads indicate 
staining in middle ear epithelial cells and sub-epithelial mesenchyme. Lactotransferrin staining is 
completely absent in negative controls from Wt (I, J) and Bpifa1-/-Evi1Jbo/+ (K, L) middle ears. Data is 
representative of n=3 mice for all genotypes. Scale bar 500μm for 4x images and 50μm for 60x 
images.  
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5.2.8.3 Intensity of collagen staining increased with OM development 
Collagen fibres are an integral part of the extracellular matrix (ECM) of the sub-epithelial 
stroma. A thin layer of collagen staining (as shown by picro-sirus red staining) was observed 
underlying the epithelial cells in Wt and Bpifa1-/- middle ears (Fig 5.23A-D). Expansion of 
the sub-epithelial mesenchyme in Evi1Jbo/+ and Bpifa1-/-Evi1Jbo/+ middle ears was 
accompanied by an expansion of the collagen fibres throughout the mesenchyme as well as 
an increase in the intensity of staining (Fig 5.23E-H). 
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Figure 5.23 Collagen deposition in P28 middle ears of Wt, Bpifa1-/-, Evi1Jbo/+ and Bpifa1-/-
Evi1Jbo/+mice.  
Picrosirius red chemical staining showing collagen fibres in the sub-epithelial mesenchyme of Wt (A, 
B) and Bpifa1-/- (C, D) middle ear epithelium. Staining intensity increased in the inflamed and 
expanded mesenchyme of Evi1Jbo/+ (E, F) and Bpifa1-/-Evi1Jbo/+ (G, H) middle ear indicating increased 
deposition of collagen fibres. Arrowheads indicate positive staining. Scale bar 500μm for 4x images 
and 50μm for 60x images.  
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5.2.8.4 Intensity of α smooth muscle actin (α-SMA) staining increased with OM 
development 
α-SMA is a marker of terminally differentiated fibroblasts. Very little or no staining for α-
SMA was seen across all the Wt and Bpifa1-/- middle ears (Fig 5.24A-D). α-SMA strongly 
stained the thickened mesenchyme of Evi1Jbo/+ and Bpifa1-/-Evi1Jbo/+ middle ears, in a unique 
pattern. Unlike collagen which localised throughout the mesenchyme, α-SMA staining was 
only seen in the bottom half of the mesenchymal layer towards the bony cartilage of the 
bulla (Fig 5.24E-H). As expected, no staining was seen in the negative controls (Fig 5.24E-H) 
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Figure 5.24 Localisation of α-SMA in P28 middle ears of Wt, Bpifa1-/-, Evi1Jbo/+ and Bpifa1-/-
Evi1Jbo/+mice.  
IHC analysis of middle ear sections showing no α-SMA staining in the thin sub-epithelial 
mesenchyme of Wt (A, B) and Bpifa1-/- (C, D) middle ear epithelium. Intense α-SMA staining in the 
lower half of the expanded mesenchyme of Evi1Jbo/+ (E, F) and Bpifa1-/-Evi1Jbo/+ (G, H) middle ear. 
Arrowheads indicate positive staining. Data is representative of n=3 mice for all genotypes. Scale bar 
500μm for 4x images and 50μm for 60x images.  
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5.3 Discussion 
This is the first study to describe the effect of Bpifa1 deletion in a compound mutant 
model. Bpifa1-/-Evi1Jbo/+ compound mutants were generated for the experiments performed 
in this chapter in order to investigate the effect of the loss of Bpifa1 in an established 
model of genetic OM. Evi1Jbo/+ mice are routinely studied on the C3H/HeH background since 
previous studies in our lab have shown that OM susceptibility varies with the mouse strain 
(Bhutta 2012, Tyrer PhD thesis 2013). Generation of compound mutants therefore required 
the transfer of Bpifa1+/- mice from the original C57BL/6 background to the C3H/HeH 
background through repeated backcrossing with Wt C3H/HeH mice.  
 
 
5.3.1 Characterisation of Bpifa1-/-Evi1Jbo/+ mutants 
Bpifa1-/-Evi1Jbo/+ compound mutant mice did not exhibit any anomalies in viability and overt 
behaviour up to 3 months of age (the maximum time for which compound mutants were 
maintained for this study). However, adult Bpifa1-/-Evi1Jbo/+ and Evi1Jbo/+ mice had lower 
body weights compared to Wt mice. I did not observe a significant difference between the 
weights of Bpifa1-/-Evi1Jbo/+ and Evi1Jbo/+ or between Wt and Bpifa1-/- mice, suggesting that 
the smaller size was an effect of the Evi1 mutation. Through previous work in our lab, it is 
known that Evi1Jbo/+ mice are smaller in size compared to Wt mice (Parkinson et al 2006). 
Although Evi1Jbo/+ mice exhibit no respiratory distress or craniofacial abnormalities 
(Parkinson et al 2006), data from a previous PhD student’s work indicated that Evi1Jbo/+ 
lungs have reduced number of airways (Tyrer PhD thesis 2013). Evi1 has been suggested to 
be involved in the development of the airways and also in airway remodelling through its 
role in repression of the TGF-β signalling pathway (Duvernelle et al 2003, Perkins et al 
1991). Also a GWAS study identified Evi1 as a candidate gene for maintenance of 
pulmonary function (Soler Artigas et al 2011). Analysis of histological sections from Bpifa1-/-
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Evi1Jbo/+ and Evi1Jbo/+ lungs was out of the scope of this study. However, given the putative 
roles of both BPIFA1 and EVIi1 in the pulmonary innate immunity, this aspect warrants 
further evaluation. 
 
 
5.3.2 Loss of Bpifa1 leads to an exacerbation of the OM phenotype in Evi1Jbo/+ 
mice 
The Evi1Jbo/+ mouse is a powerful model of human OM, since disease development in these 
mice is non-syndromic i.e. the development of OM is not associated with any significant 
phenotype outside the middle ear, apart from formation of an extra digit(Parkinson et al 
2006). In SPF conditions, Evi1Jbo/+ mice develop mild spontaneous OM at P13. As shown in 
Chapter 3, the middle ear cavitates between P10-P15 (Section 3.2.1). Hence the 
development of OM in Evi1Jbo/+ mice is immediately following the formation of the middle 
ear cavity and the percentage of affected mice increases through P21 until the phenotype 
becomes chronic at P28 (Parkinson et al 2006).  
In this study, Bpifa1-/-Evi1Jbo/+ demonstrated greater penetrance of OM compared to 
Evi1Jbo/+ mice. This was evidenced by a significantly increased thickening of the middle ear 
mucosa at both P21 and P28 in Bpifa1-/-Evi1Jbo/+ mice and a higher incidence of middle ear 
fluids. The frequency of middle ear fluids in Evi1Jbo/+ bullae at P28 (67% ears) was consistent 
with the previously published literature (Parkinson et al 2006), whereas all  Bpifa1-/-Evi1Jbo/+ 
mice showed fluid development at this time point, with a significantly higher tendency for 
development of bilateral OM. 
 Mucosal thickening in affected mice was characterised by remodelling of the otherwise 
thin middle ear epithelium into a disorganised, multi-layered epithelium as well as 
expansion of the sub-epithelial mesenchyme. It is known that along with the inflammatory 
exudate within the middle ear cavity, OM is also associated with infiltration of the 
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mesenchymal tissue with inflammatory cells (Juhn et al 2008). Due to time constraints, I did 
not analyse the inflammatory cell populations in the middle ears of diseased mice. 
However, H&E sections of middle ears indicated that the exudate in Evi1Jbo/+ and Bpifa1-/-
Evi1Jbo/+ mice was largely purulent, albeit sometimes a serous exudate was also observed. 
Cytospun fluids from adult mice appeared to showed a larger proportion of neutrophils 
compared to macrophages. This is supported by previous studies in Evi1Jbo/+ mice which 
report the presence of a neutrophilic exudate, containing a smaller percentage of foamy 
macrophages and sloughed off epithelial cells (Cheeseman et al 2011, Parkinson et al 
2006). In future, IHC analysis for neutrophilic and macrophage markers such as Gr-1 and 
F4/80 as well as fluorescence associated cell sorting (FACS) analysis would provide a 
comparison of inflammatory sub-populations in the middle ears of Evi1Jbo/+ and Bpifa1-/-
Evi1Jbo/+ mice. The type of middle ear effusion has been suggested to be an indication of the 
stage of OM development and mucous effusions often point to a more severe disease in 
patients (Kubba et al 2000). Use of markers such as matrix mettaloproteinase-2 (MMP-2), 
which are specific to mucous effusions (Moon et al 2008) may provide further insight into 
the exacerbation of OM phenotype of Bpifa1-/-Evi1Jbo/+ mice. 
In order to maximise the potential for analysis, penetrance of OM was also assessed in 
adult Bpifa1-/-Evi1Jbo/+ mice that were transported to University if Sheffield for isolation of 
middle ear cells. The incidence of middle ear fluids was higher in Bpifa1-/-Evi1Jbo/+ mice 
compared to Evi1Jbo/+ as assessed by the appearance of the Tm. This result was borderline 
insignificant. However, it is important to note that such assessment of OM is only semi-
quantitative and is less powerful than histological analysis and it does not allow for analysis 
of the mucosal thickness. Also, these mice were analysed within an age range 7-9 weeks 
rather than at a single time point, which may add to phenotypic variation. Therefore, it is 
likely that Bpifa1-/-Evi1Jbo/+ retain the aggravated OM phenotype in adulthood and this 
aspect needs further exploration. 
247  
In line with my observations in C57BL/6 from Chapter 3, Bpifa1-/- mice on the C3H/HeH 
background did not demonstrate OM at any of the time points tested. Therefore, the data 
clearly indicated that loss of Bpifa1 alone does not lead to spontaneous development of 
OM irrespective of the genetic background. However, loss of Bpifa1 in a pre-existing 
inflammatory environment in Evi1Jbo/+ middle ears accelerates and worsens the OM 
phenotype.  
 
 
5.3.3 Loss of Bpifa1 does not lead to an exacerbated inflammatory cytokine 
response  
Several studies have suggested an anti-inflammatory role for BPIFA1. Bpifa1 ablation in 
mouse models showed higher levels of inflammatory compared to Wt mice upon bacterial 
infection and overexpression of the protein was accompanied by reduced in the levels of 
pro-inflammatory mediators (Liu et al 2013a, Liu et al 2013b, Lukinskiene et al 2011). In an 
allergic setting, Bpifa1 deficient mice stimulated with ovalbumin showed increased airway 
inflammation which was reversed by overexpression of Bpifa1 (Wright et al 2010).  In 
addition, preliminary IHC data from our lab suggested that that intensity of BPIFA1 staining 
in the Evi1Jbo/+ middle ear epithelium reduced with OM progression. BPIFA1 was detectable 
in Evi1Jbo/+ in middle ear exudates, however there was evidence of proteolytic degradation 
of the protein, suggesting that a reduction in levels or loss of the anti-inflammatory 
function of Bpifa1 may contribute to OM pathogenies (Mulay MSc thesis 2011). In Chapter 
4, I have shown that the loss of Bpifa1 alone did not lead to an enhanced pro-inflammatory 
response in mMECs following NTHi infection (Section 4.2.15). However, I speculated that 
Bpifa1 ablation in the pre-existing inflammatory environment of the Evi1Jbo/+ bullae might 
cause an exaggeration of the inflammatory response in vivo and this, in turn, may 
contribute to the exacerbated OM phenotype seen in Bpifa1-/-Evi1Jbo/+ mice.  
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Preliminary, semi-quantitative analysis of Evi1Jbo/+ ear exudates using mouse cytokine 
arrays in our lab indicated intense expression of IL1β and CXCL2 (Mulay MSc thesis 2011). 
Moreover gene expression analysis of Evi1Jbo/+ middle ear fluids compared with venous 
blood showed significant upregulation of a variety of  inflammatory markers, including Il1β, 
Cxcl2, Tnfα, Il6 and Tgfβ (Cheeseman et al 2011). A major limitation of analysing middle ear 
fluids is that Wt mice do not have effusions (or a middle ear lining fluid that can be 
sampled), thus impeding a direct comparison in the gene expression of Wt and 
Evi1Jbo/+middle ear contents. Analysis of middle ear fluids is also sub-optimal because they 
contain a mixture of inflammatory cells, bacterial remains and debris from sloughed off 
epithelial cells. Therefore, in order to provide a direct comparison between the mucosa of 
OM affected mice and normal mice, I isolated mMMCs from the Bpifa1-/-Evi1Jbo/+, Evi1Jbo/+, 
Bpifa1-/- and Wt mice. This provided the opportunity to study potential changes in the 
inflammatory gene repertoire of middle ear epithelial cells as well as the sub-epithelial 
stromal cells.  
My data show that all inflammatory genes studied were upregulated in mMMCs from 
Bpifa1-/-Evi1Jbo/+ mice. The neutrophil chemoattractant, Cxcl2, was the most differentially 
expressed gene in our study followed by Il1β, Tnfα, and Tgfβ and Il6. This elevation in 
expression was consistent with that seen in Evi1Jbo/+ exudates (when compared to venous 
blood) (Cheeseman et al 2011). However, expression of none of the inflammatory genes 
differed between Wt and Bpifa1-/- mMMCs and between Evi1Jbo/+ and Bpifa1-/-Evi1Jbo/+ 
mMMCs. Thus, it appears that Bpifa1 does not play an anti-inflammatory role in OM 
development.   
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 5.3.4 The inflamed mucosa of Evi1Jbo/+ and Bpifa1-/-Evi1Jbo/+ mice is hypoxic   
Previous studies in our lab have shown that the microenvironment of the inflamed Evi1Jbo/+ 
middle ear cavities is chronically hypoxic (Cheeseman et al 2011). Inflammatory cells in the 
middle ear fluids, the inflamed middle ear epithelium, as well as the sub-epithelial 
connective tissue of Evi1Jbo/+ mice, stained positive for markers of hypoxia and levels of 
Hif1α, Vegf and other Vegf signalling pathway genes are elevated in the ear fluids of 
Evi1Jbo/+ mice. Similarly, middle ear fluids from Tgif-/- and Fbxo11Jf/+ mice also showed high 
VEGF levels  (Cheeseman et al 2011, Tateossian et al 2013).  Vegf is a downstream 
signalling protein of the Hif1α signalling pathway and is involved in induction of 
angiogenesis, recruitment of inflammatory cells and vascular permeabilissation, thus 
contributing to fluid development within the middle ear (Cheeseman et al 2011). VEGF 
protein is also detectable in effusions from OM patients (Sekiyama et al 2011) .  
The Evi1Jbo/+ mutation is suggested to impact on TGFβ signalling (Kurokawa et al 1998b) and 
there is substantial crosstalk between the hypoxia and TGFβ signalling pathways. It has 
been shown that SMAD3 co-operates with HIF1α in presence of hypoxia to co-activate the 
transcription of VEGF (Sanchez-Elsner et al 2001). In this study, Vegf was significant 
upregulated in Evi1Jbo/+ and Bpifa1-/-Evi1Jbo/+ mMMCs compared to Wt and Bpifa1-/- mMMCs. 
Moreover, Il1β, Tnfα, which are known to regulate Hif1α (Frede et al 2007), were also 
upregulated. Thus the data confirms the presence of a hypoxic milieu in the inflamed 
middle ear mucosa and provides further support to the view that disruption in TGFβ 
signalling increases overall susceptibility to OM. In future, the presence of hypoxia can be 
further tested in Bpifa1-/-Evi1Jbo/+ mice via in intraperitoneal injection of pimonidazole, 
which is a marker of hypoxia and IHC on middle ear sections from these mice using anti-
pimonidazole antibodies (Cheeseman et al 2011). As seen with the other inflammatory 
genes such as Cxcl2, Il1β, Tnfα etc, loss of Bpifa1 did not influence the levels of Vegf.  
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It was interesting that elevation of Vegf was maintained in the inflamed mMMCs despite 
incubation in normoxic conditions during the overnight pronase cell isolation process. 
However, there is a possibility that this may have altered the true Vegf levels and a more 
careful analysis is required to identify differences in Vegf levels between Evi1Jbo/+ and 
Bpifa1-/-Evi1Jbo/+ mMMCs. Perhaps this type of analysis could be done by in situ gene 
analysis or through the use of gene expression in samples of mucosa isolated by laser 
capture microdissection. 
5.3.5 Cellular alterations in the inflamed mMMCs 
Along with the upregulation of inflammatory markers, I observed a downregulation of the 
ciliated cell marker, Foxj1 and goblet cell marker, Muc5ac in Evi1Jbo/+ and Bpifa1-/-Evi1Jbo/+ 
mMMCs compared to Wt mMMCs. My assumption is that this is the consequence of an 
altered cellular phenotype in the during inflammation. As shown in Fig 5.1, EVI1 is a 
transcriptional repressor of TGFβ/SMAD signalling via direct inhibition of SMAD3 
(Kurokawa et al 1998b). PAMPs such as those derived from NTHi and pro-inflammatory 
mediators such as TNFα, can signal through TLR2 or TLR4, which can lead to activation of 
the MAP kinase protein, p38 via MyD88 signalling. p38 regulates MUC5AC production and 
over activation of p38 is often implicated in diseases such as COPD (Fig 5.25). Activation of 
TGFβ signalling down regulates p38 activity via SMAD3 and thus prevents excessive 
MUC5AC production in the event of TLR2 mediated inflammation (Jono et al 2003). A 
mutation in the Evi1 locus may lead to over activation of TGFβ signalling leading to over-
suppression of MUC5AC, and thus impair mucocilliary clearance. This hypothesis is 
supported by the observation of reduced levels of Muc5ac in Evi1Jbo/+ and Bpifa1-/-Evi1Jbo/+ 
mMMCs. There is no published report on changes in genetic levels of ciliated cell markers 
in Evi1Jbo/+ mice, however reduction in the number of ciliated cells is often implicated in OM 
pathogenesis (Straetemans et al 2001).  
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Figure 5.25 TGFβ signalling downregulated MUC5AC production 
Activation of TGFβ signalling prevents over production of MUC5AC via inhibition of p38. Image 
reproduced from (Jono et al 2003), copyright American society for Biochemistry and Molecular 
biology. In Evi1Jbo/+ mice, over activation of TGFβ signalling can lead to increased suppression of 
Muc5ac production leading to mucociliary impairment. 
 
 
  
Expression of EVI1 is upregulated due to chromosomal rearrangements in myeloid 
leukaemia (Goyama & Kurokawa 2010, Hirai 1999, Kurokawa et al 2000). However, there is 
limited literature on the expression of Evi1 itself during OM in Evi1Jbo/+ mice. Evi1 mRNA was 
upregulated in middle ear fluids of Evi1Jbo/+ mice compared to venous blood (Cheeseman et 
al 2011). However, as mentioned before, analysis of ear exudates is sub-optimal due to the 
lack of an appropriate control in Wt mice. IHC for EVI1 showed that the protein localised to 
neutrophils in the exudates, basal epithelial cells and sub-epithelial fibroblasts of Evi1Jbo/+ 
middle ear at P13 and P21, before the onset of chronic OM, and was not seen in the 
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healthy, Wt middle ear (Parkinson et al 2006). It has also been shown that NTHi and TNFα 
lead to an up regulation of EVI1 in vitro and in vivo (Xu et al 2012). Therefore, I compared 
Evi1 expression specifically in the mucosal cells of adult mice and observed a small (<2 
fold), yet significant (probably due to less variation within batches compared), reduction its 
expression in the inflamed mMMCs from Evi1Jbo/+ and Bpifa1-/-Evi1Jbo/+ mice compared to Wt 
mice.  IHC analysis for EVI1 was not performed in this study. However, it is unclear if levels 
of EVI1 protein should be altered in Evi1Jbo/+ middle ear epithelium, since the causative 
mutation in these mice is a SNP. Perhaps the mutation causes a loss capacity of EVI1 to 
bind to its target co-repressors and a subsequent alteration in its function as a repressor of 
the Tgfβ and NfκB signalling pathways, thus setting in a feedback loop for activating these 
inflammatory pathways and leading to cellular alterations. 
 It is important to note that there was no added effect of deletion of Bpifa1 on the 
expression any of the epithelial genes analysed. This is contrast to a previously published 
study that suggested a downregulation of Foxj1 and Muc5ac in whole lung tissue of naïve 
Bpifa1-/- mice compared to Wt mice (Liu et al 2013a).  Analysis of cellular composition of 
the airways of mutant mice may help to resolve this discrepancy.  
I also observed a significant down regulation of Bpifa1 in Evi1Jbo/+ mMMCs compared to Wt 
mMMCs and this is discussed in detail in Section 5.3.8. Overall, my data suggests that the 
Evi1Jbo/+ mutation results in significant remodelling of middle ear epithelium, marked by 
downregulation of ciliated, goblet and Bpifa1 expressing cells, leading to dysregulation of 
the mucocilliary system and retention of fluid in the middle ear cavity. 
 
5.3.6 Lack of recapitulation of the OM phenotype in vitro 
I have shown that the loss of Bpifa1 did not increase the expression of cytokines in the 
original mucosal cells. I therefore postulated that Bpifa1 is involved in maintaining the 
stability of the middle ear epithelium, rather than serving an anti-inflammatory function 
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per se. In order to examine this in detail I cultured middle ear epithelial cells in vitro using 
the mMEC model established in Chapter 4. As with Wt cells, mMECs form the mutant mice 
differentiated into a variety of epithelial sub-types, both on a transcriptional and a protein 
level within 14 days of culture at the ALI. However, the majority of the epithelial and 
inflammatory markers did not retain the trends seen in the original mucosal cells 
(mMMCs). In addition, the pattern of expression of epithelial genes was also not consistent 
with that observed previously in C57BL/6 mMECs (Chapter4, Fig 4.12). There are two 
possible explanations for this failure to recapitulate the OM phenotype in vitro.  
The first reason might be the lack of the specific microenvironment of the inflamed middle 
ears of Evi1Jbo/+ and Bpifa1-/-Evi1Jbo/+ mice in mMECs. OM development is a collective 
outcome of the response to an insult to the middle ear epithelium and the isolated 
environment of the middle ear cavity. Development of hypoxia due to reduced ventilation 
in the middle ear space is an important contributing factor to the development of 
inflammation during OM pathogenesis (Corbeel 2007). Recent studies from our lab have 
highlighted the role of hypoxia and Vegf mediated signalling in development of OM in 
Evi1Jbo/+ mice (Cheeseman et al 2011). Elevation of Vegf in Evi1Jbo/+ and Bpifa1-/-Evi1Jbo/+ 
mMMCs in this study emphasizes the involvement of hypoxia in development of the OM 
phenotype. The absence of a hypoxia in mMEC cultures may be one of the reasons for the 
failure to recreate the microenvironment required for OM development. Use of hypoxia 
incubator chambers for the culture of Evi1Jbo/+ and Bpifa1-/-Evi1Jbo/+ mMECs may provide a 
more suitable environment for recapitulation of the native phenotype. As mentioned 
previously, EVI1 is predominantly localised to neutrophil leukocytes and fibroblasts in the 
Evi1Jbo/+ middle ear (Parkinson et al 2006). The absence of these cell types in our culture 
system may be another reason for the lack of the OM phenotype in vitro. The mucosal 
thickening observed in OM is due to combined expansion of both epithelial cells and the 
underlying mesenchymal tissue, indicating cross-talk between the two cell types. The 
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mMEC system models a pure population of epithelial cells. Lack of mesenchymal cells such 
as fibroblasts in culture may be another aspect contributing to the lack of the 
microenvironment required for OM development. Establishment of direct contact cultures 
by growing mMECs on one side of the transwell membrane and fibroblasts on the other 
may better mimic the organ morphology of the middle ear mucosa. 
The second reason for the lack of recapitulation of the OM phenotype in vitro may be a 
variation in the population of basal cells that initiate mMEC cultures. In Chapter 4, I have 
shown that only a small proportion of the seeded mMECs was found attached to the 
transwell membrane at submerged day 3 (Section 4.2.2.1). It is widely accepted that due 
abundant expression of junctional, cytosketal and adhesive proteins, basal cells easily 
anchor to the underlying matrix and act as initiators of in vitro cultures of airway epithelial 
cells (Rock et al 2010). Basal cells of the respiratory epithelium are adult stem cells that 
produce multipotent progenitor cells, which in turn give rise to ciliated cells, secretory cells 
and goblet cells of the respiratory epithelium (Rock et al 2009, Rock et al 2010). Therefore, 
depending on the fate of the initiator basal and progenitor cells attached to the membrane, 
the percentage of differentiated cell types can vary between the different batches of 
mMEC cultures and even between different transwells of the same batch of mMECs. 
Perhaps, a strategy to fractionate tagged basal cells using FACS prior to establishment of 
mMEC cultures may yield more uniform cultures. Moreover, depending on the 
microenvironment and type of stress, differentiated epithelial cells can transdifferentiate 
to then give rise to a new cell type, which is often the case in various pathological diseases 
in the airways. Lineage tracing experiments have led to seminal findings in the field of 
airway epithelial biology (Patel et al 2011, Rock et al 2009, Turner et al 2011). Extrapolating 
this reasoning to the middle ear epithelium, it is plausible that mMECs get reprogrammed 
once put into in vitro culture and establish a fresh epithelium irrespective of the genotype. 
In vivo lineage tracing of mouse middle ear epithelial sub-types may help to better 
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understand the origin and fate of the different epithelial sub-populations in mMEC 
cultures. Additionally, culture conditions can be modified to replicate specific disease 
phenotypes. For example, addition of IL13 to culture media has shown to promote 
differentiation into goblet cells (Kondo et al 2002, Turner et al 2011).  
 
 
5.3.7 Changes in the Evi1Jbo/+ and Bpifa1-/-Evi1Jbo/+ middle ear mucosa during 
chronic inflammation 
5.3.7.1 Changes in epithelial proteins  
IHC for BPIFA1 indicated a reduction in staining intensity for the protein in the epithelial 
cells of Evi1Jbo/+ middle ears, supporting the gene expression analysis of mMMCs. 
Regulation of Bpifa1 during OM in Evi1Jbo/+ mice has been discussed in further detail in 
Section 5.3.8. In Chapter 4, Lactotransferrin was identified as the most abundant protein in 
apical washes from ALI Day 14 mMEC cultures (Sections 4.2.5 and 4.2.10) and the intense 
staining for Lactotransferrin in the middle ear supports this finding. In order to monitor 
changes in the production of this protein during OM, IHC analysis on middle ear sections 
from the 4 genotypes of mice was performed. Lactotransferrin was strongly expressed in 
the thin mucoperiosteum of Wt and Bpifa1-/- mice, in line with our observation in mMECs. 
The staining intensity for Lactotransterrin increased further with inflammation in Evi1Jbo/+ 
and Bpifa1-/-Evi1Jbo/+ mice and the protein localised to epithelial cells, underlying 
mesenchyme and the inflammatory exudate in the middle ear cavity. Lactotransferrin, is an 
iron chelating protein produced by secretory cells of mucosal epithelia and is well-known 
for its anti-microbial host defence role in the middle ear (Lim et al 2000). It is also produced 
by PMN granules and therefore concentration of Lactotransferrin increases during 
inflammatory processes (Legrand et al 2005). Thus, localisation of Lactotransferrin to the 
sub-epithelial layer in the inflamed Evi1Jbo/+ and Bpifa1-/-Evi1Jbo/+ middle ears and an 
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increase in its staining intensity may be a result of its production by the inflammatory cells 
infiltrating this space. 
IHC was also performed for a range of other epithelial markers such as Reg3ϒ, MUC5B and 
p63 (basal cell marker) to investigate the effect of the loss of Bpifa1 on changes to the 
middle ear sub epithelial cell populations. However, it was challenging to interpret results 
from these experiments, due to lack of consistency of staining between individual mice. 
These issues could not be resolved in the time frame available.    
 
 
5.3.7.2 Fibrosis of Evi1Jbo/+ and Bpifa1-/-Evi1Jbo/+ middle ear mucosa 
Histological assessment demonstrated a thickened mucosa in Evi1Jbo/+ and Bpifa1-/-Evi1Jbo/+ 
middle ears, characterised by a multi-layered epithelium and expansion of the sub-
epithelial mesenchyme accompanied by infiltration of inflammatory cells. It would be 
expected that that very rapid expansion of the mucosal layer in the middle ears of the 
mutant mice would be accompanied by a significant cellular proliferation. The second ZnF 
domain of EVI1 has been shown to be involved in regulation of activator protein (AP)-1 
through transactivation of c-Fos. AP-1 is involved in control of cell proliferation, 
differentiation and apoptosis (Shaulian & Karin 2002, Tanaka et al 1994). The mucosal 
thickening was significantly greater in Bpifa1-/-Evi1Jbo/+ ears compared to Evi1Jbo/+ ears, 
which led me to speculate if the loss of Bpifa1 further enhances the proliferative capacity 
of the cells. However, proliferation rates of mMECs as well as fibroblasts cultured from Wt, 
Bpifa1-/-, Evi1Jbo/+ and Bpifa1-/-Evi1Jbo/+ mice did not differ significantly, perhaps due to the 
inability of mMECs to retain the OM phenotype in vitro. 
An interesting observation in this study was that mucosal thickening in the middle ears of 
Evi1Jbo/+ and Bpifa1-/-Evi1Jbo/+ mice was accompanied by increased deposition the ECM 
component, collagen and accumulation of myofibroblast marker, αSMA. This type of 
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epithelial remodelling in airways is a hallmark of fibrotic airways diseases such as IPF, and 
asthma (Makinde et al 2007, Selman & Pardo 2002). Although the presence of fibrosis in 
the middle ear epithelium during OM has been described before (Ishii et al 1980, Juhn et al 
2008), to my knowledge, there is no specific evidence on the role of myofibroblasts during 
OM disease development. Myofibroblasts originate from differentiation of mesenchymal 
fibroblasts at the site of injury and have an intermediate morphology between fibroblasts 
and smooth muscle cells (James et al 2006). They are involved in the production of ECM 
components such as collagen and fibronectin, under the influence of growth factors such as 
TGFβ, and help in wound contraction and airway remodelling which often follows 
inflammation as an epithelial repair response. Myofibroblasts are key contributors to sub-
epithelial fibrosis, which is characterised by elevated levels of TGFβ, enhanced 
accumulation of the repair proteins, collagen and fibronectin, increased proliferation of 
fibroblasts and reduced levels of apoptosis (Desmouliere et al 1993, Makinde et al 2007) 
Fibrosis is a a consequence of excessive remodelling and is associated with dysregulation of 
TGFβ signalling (Selman & Pardo 2002). Indeed the SMAD3/SMAD4 complex directly binds 
to and activates transcription of the gene, plasminogen activator inhibitor (PAI) gene 
(Kurokawa et al 1998b) which is elevated in fibrosis in various organs such as the lung, 
heart skin and kidneys (Ghosh & Vaughan 2012).  
The number of myofibroblasts correlates to the degree of sub epithelial thickening (Baum 
& Duffy 2011). In this study, mMECs from Evi1Jbo/+ and Bpifa1-/-Evi1Jbo/+ mice showed 
elevated levels of Tgfβ. TGFβ is secreted by inflammatory cells such as macrophages, mast 
cells, lymphocytes as well as structural cells of the mucosa such as epithelial cells and 
fibroblasts and diffuses across the different cell types to elicit specific functions and 
facilitate airway remodelling. This is suggestive of significant epithelial-mesenchymal cross 
talk (Makinde et al 2007). Bpifa1-/-Evi1Jbo/+ mucosa was significantly more thickened 
compared to Evi1Jbo/+ mice, suggesting that loss of Bpifa1 is responsible for exacerbation of 
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fibrosis in an existing inflammatory microenvironment. Perhaps the absence of Bpifa1 
further disrupts epithelial-mesenchymal cross talk and acts as a signal for an enhanced 
fibrotic response, preventing resolution of inflammation. There is one other report which 
showed that transgenic mice over expressing Bpifa1 demonstrated reduced levels of 
pulmonary fibrosis compared to Wt mice when challenged with sterile carbon nanotubules 
(Di et al 2013). However, the mechanism underlying such a function remains to be clarified 
 
 
5.3.8 Regulation of Bpifa1 during OM in Evi1Jbo/+ mice. 
BPIFA1 is abundantly produced by the non-ciliated cells of the Wt middle ear epithelium. 
There was significant down regulation Bpifa1 mRNA in mMMCs and a decrease in intensity 
of BPIFA1 staining in Evi1Jbo/+ middle ears compared to Wt middle ears. This reduction in 
BPIFA1 was also replicated in mMECs, where ALI Day 14 mMECs from Evi1Jbo/+ mice showed 
significantly lower levels of BPIFA1 on a transcriptional and proteomic level.  BPIFA1 is a 
secreted protein and has been identified in ear effusions of OME patients (Val et al 2016). 
Previous studies in our lab detected this protein in Evi1Jbo/+ exudates using western blots 
(Section 1.13). A recently performed proteomic analysis of Evi1Jbo/+ exudates at MRC, 
Harwell has identified abundant levels of BPIFA1 in the ear effusions (unpublished data).  
The severity and age of onset of OM in Evi1Jbo/+ mice is dependent on the air quality and 
microbiological status of their environment. In SPF conditions, which were used for housing 
the mice used in this study, Wt mice resolve middle ear fluids by weaning age whereas, 
Evi1Jbo/+ mice retain fluids, leading to the development of chronic non-syndromic OM by 
P28 (Parkinson et al 2006). It is interesting that Evi1Jbo/+ mice develop OM in gnotobiotic 
conditions as well, where the incidence of OM is unaltered but age of onset is shifted to 
P54 (Hood et al 2016, Rye et al 2011a). Thus, the Evi1Jbo/+ mouse is a genetic model of 
chronic OM, and the presence of endogenous bacteria is not a requisite for development of 
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OM. The inflammatory response in Evi1Jbo/+ mice may be triggered as a reaction to sterile 
irritants such as bedding particles. Several studies have shown that BPIFA1 levels decrease 
during irritant induced inflammation of the airways. For example, BPIFA1 secretion is 
reduced upon exposure to cigarette smoke (Britto & Cohn 2015). More importantly, BPIFA1 
protein levels were reduced in the nasal lavage fluids of perennial allergic rhinitis sufferers 
compared to sporadic allergic rhinitis suffers and healthy controls (Irander et al 2014) and 
in subjects with extended periods of exposure to occupational allergens (Fornander et al 
2013, Lindahl et al 2001). These studies indicate that presence of chronic inflammation 
induced by irritants can down-regulate levels of BPIFA1. This reasoning can be extrapolated 
to the reduction of BPIFA1 in Evi1Jbo/+ mice where a pre-existing existing chronic 
inflammatory condition leads to decreased levels of BPIFA1. It is plausible that the pre-
existing inflammation in Evi1Jbo/+ mice causes remodelling of the epithelium, leading to a 
reduction of BPIFA1secreting cells, perhaps through phenotypic changes in the epithelial 
cells such as mechanisms like epithelial-mesenchymal transition. The decrease in BPIFA1 
may thus act as a biosensor to signal the middle ear mucosa to enhance the defence 
response in the form of fibrosis. In case of the Bpifa1-/-Evi1Jbo/+ mutants, the complete 
absence of BPIFA1, coupled with the presence of a hypoxic, inflammatory 
microenvironment, may cause excessive fibrosis, thus adding to the viscous cycle of OM. 
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5.4 Key experimental conclusions 
x Bpifa1-/-Evi1Jbo/+ mice exhibit no differences in viability and overt behaviour 
compared to Wt mice. Bpifa1 deletion does not further lower body weights of 
Evi1Jbo/+ mice. 
x Bpifa1 ablation leads to an exacerbation of OM phenotype in Evi1Jbo/+ mice, 
characterised by increase in percentage of middle ears with fluid development and 
increase in thickness of the middle ear mucosa. 
x There is an up regulation of pro-inflammatory genes, Cxcl2, Tnfα, Il1β and Il6 and 
the anti-inflammatory gene, Tgfβ in the inflamed middle ear mucosa of Evi1Jbo/+ and 
Bpifa1-/-Evi1Jbo/+ mice 
x Exacerbation of OM in Bpifa1-/-Evi1Jbo/+ mice is not due to increase in the magnitude 
of this cytokine response. 
x Cellular alterations in Evi1Jbo/+ and Bpifa1-/-Evi1Jbo/+ middle ear mucosa are marked 
by decrease in levels of the ciliated cells marker, Foxj1 and the goblet cell marker, 
Muc5ac. However, there is no additive effect of Bpifa1 deletion. 
x The inflamed mucosa of Evi1Jbo/+ and Bpifa1-/-Evi1Jbo/+ mice is hypoxic.   
x There was a lack of recapitulation of the OM phenotype in vitro using the mMEC 
model system. 
x OM in Evi1Jbo/+ and Bpifa1-/-Evi1Jbo/+ mice is accompanied by mucosal fibrosis, 
characterised by hyper-proliferation of the epithelium, expansion of the sub-
epithelial mesenchyme, increased deposition of collagen and accumulation of 
myofibroblasts. Loss of Bpifa1 leads to an increase in the fibrotic phenotype of 
Evi1Jbo/+ mice. 
x Bpifa1 is expressed at high basal levels in Wt middle ear epithelial cells and an 
existing inflammatory environment in Evi1Jbo/+ mice is accompanied by reduction in 
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levels of BPIFA1. Fall in BPIFA1 may be due to phenotypic changes in the epithelial 
layer, and may act as a signal for exaggeration of the host fibrotic response. 
However, further studies are warranted to test this postulation. 
x This study underlines the necessity for investigation of mutations in Bpifa1 in 
combination with other inflammatory and allergic phenotypes in order to better 
understand aetiology of OM as well as other respiratory diseases. 
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CHAPTER 6:  GENERAL DISCUSSION  
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The overall aim of this thesis was to explore the role of the putative URT innate immunity 
molecule, BPIFA1 in the context of antimicrobial host defence of the middle ear epithelium 
and the effect of its loss on the development of OM. 
OM is the most prevalent paediatric disease and leading cause of childhood deafness. Due 
to the multifarious aetiology of OM, the main aim of the common treatment options is to 
eliminate infection and inflammation rather than targeting the pathological mechanisms 
underlying OM, thus making it the largest cause of antibiotic prescription (Daniel 2012). 
However, over recent years several candidate gene association studies as have been 
performed in order better understand the complex pathophysiology of the disease (Allen et 
al 2013, Casselbrant et al 2009, MacArthur et al 2014, Segade et al 2006). These studies, 
along with mouse models of OM have highlighted the role for innate immunity genes in 
OM susceptibility (Hardisty-Hughes et al 2006, Parkinson et al 2006, Rye et al 2011a, 
Tateossian et al 2013). A GWAS performed utilising the Western Australian Pregnancy 
Cohort demonstrated that polymorphisms in BPIFA1 are significantly associated with the 
OM phenotype (Rye et al 2012b). The cases recruited in this study were children between 
an average age of 1-3 years with OM characterised by bulging and scarred Tm, presence of 
tympanostomy tubes or rAOM. However, associations with BPIFA1 have not been 
replicated in other populations, primarily due to the lack of power and difference in 
phenotypes of patients recruited (Rye et al 2012b, Rye et al 2011b).  
Previous studies during my Masters project had shown that the middle ear epithelium of 
Wt mice demonstrates abundant levels of BPIFA1 and staining intensity for the protein was 
reduced in during OM development in the Evi1Jbo/+ model of chronic OM. The protein was 
also detected in ear exudates from these mice although it was partially degraded, most 
likely due to the action of proteases released by the inflammatory cells (Mulay MSc thesis 
2011). More recently, a study was published demonstrating that aged Bpifa1-/- mice show 
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enhanced susceptibility to OM (Bartlett et al 2015). Taken together, there was strong 
evidence to support my hypothesis that BPIFA1 is involved in protection of the middle ear 
and a loss of this protein may be associated with the development of OM. In order to test 
this hypothesis, I utilised Bpifa1-/- and Bpifa1-/-Evi1Jbo/+ mice as well as a novel in vitro model 
of the middle ear epithelium.  
 
Major findings and contributions to the field 
6.1 Expression of BPIFA1 in the murine middle ear 
BPIFA1 is one of the most highly expressed proteins in the epithelia of nasal passages, 
oropharynx, trachea and bronchi of humans and mice (Bingle & Bingle 2000, Bingle & 
Bingle 2011). It forms a major component of secretions from these sites such as in the nasal 
lavage, saliva, sputum and BAL fluids (Bingle & Bingle 2011, Campos et al 2004). In this 
thesis, a longitudinal study tracking the development of the middle ear cavity from P0 to 
P30, showed that BPIFA1 is present in the middle ear from the day of birth. It localises to 
the epithelial cells and submucosal glands and occasionally stains the mesenchymal 
material occupying the middle ear space till P15. After cavitation of the middle ear, BPIFA1 
localises to the non-ciliated cells and coats the middle ear epithelial surfaces and cilia. 
Bpifa1 gene expression had been reported in the chinchilla middle ear in 2010 (McGillivary 
& Bakaletz 2010) but the first report of the expression of BPIFA1 in the murine middle ear 
cavity was published by (Bartlett et al 2015). This report showed staining for the protein by 
IHC between 10-18months of age. As mentioned before the protein has also been detected 
in effusions of OM patients (Preciado et al 2010) and Evi1Jbo/+ mice (Mulay MSc thesis 
2011). High basal levels of BPIFA1 in the healthy murine middle ear throughout the life 
span suggest a role in initial protection of the middle ear epithelium. Taken together the 
data shows that the middle ear is a significant site of BPIFA1 expression and studies 
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focussing on the involvement of this protein in development of OM can provide further 
insight into the overall function of BPIFA1 in host defence of respiratory epithelia. 
 
6.2 Loss of Bpifa1 alone does not lead spontaneous development or induction of 
OM  
Using ABR assessments and histological analysis I have shown that the loss of Bpifa1 alone 
does not lead to the spontaneous development of OM in mice, irrespective of their genetic 
background. My data contradicts a recent report suggesting that aged Bpifa1-/- mice show 
increased susceptibility to OM (Bartlett et al 2015), albeit I did not study OM development 
in Bpifa1-/- mice beyond 6 months of age due to time limitations. It is important to note 
however that the penetrance of OM in Bpifa1-/- mice in the study by Bartlett and co-
workers was only 30% and did not differ significantly from that in Wt mice. Characterisation 
of OM was rather based on scoring criteria such as difference in mucosal thickness and 
amount of inflammatory cells and debris seen in the middle ear cavity. Also the mice were 
aged between 10-18 months of age, which is rather late in the timeline of what is almost 
exclusively a paediatric disease. It has been previously shown that mice over expressing 
BPIFA1 showed reduced levels lung fibrosis when exposed to the sterile irritant, single 
walled carbon nanotubules (Di et al 2013, Ghafouri et al 2003). Studies from our lab have 
shown that gnotobiotic Evi1Jbo/+ mice develop OM and their middle ear fluids sometimes 
contain foreign bodies suggesting that irritants such as bedding material can enter the 
middle ear space intranasally and trigger an inflammatory response (Hood et al 2016). 
Therefore, it is likely that the limited OM phenotype described by Bartlett et al in Bpifa1-/- 
mice may be a combined effect of the loss of Bpifa1, and an allergic response to inhaled 
irritants due to compromised immunity caused by their advanced age, rather than a 
specific effect of Bpifa1 deletion alone. However, in future our Bpifa1-/- mice within this age 
range must be studied to make a conclusive assessment. 
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This study is the first to attempt to induce OM in Bpifa1-/- mice. I found that IN challenge of 
Bpifa1-/- mice does not significantly increase the nasopharyngeal carriage of the 
otopathogen, NTHi into the middle ear. The importance of NTHi is as the causative 
pathogen in OM is growing since the advent of the PCV7 vaccine, with the bacterium being 
isolated from majority of the AOM and COME patients (Giebink 1991, Ngo et al 2016). The 
IN route of infection replicates the retrograde ascension of bacteria from the NP into the 
middle ear during OM pathogenesis. I believe that the major reason for low infection rates 
observed in the NTHi challenge experiments was the lack of a pre-existing fluid in the 
middle ear cavity of Bpifa1-/- mice. This is based on the observation from our lab that Wt 
middle ears very rarely show development of fluids or culture positivity on IN challenge 
with NTHi, whereas different mouse models of spontaneous OM such as Evi1Jbo/+, Fbxo11Jf/+ 
and Tgif-/-, all of which have pre-existing middle ear inflammation facilitate access of NTHi 
into the middle ears (Hood et al 2016). This suggests that in the absence of a craniofacial 
abnormality, an inflamed hypoxic microenvironment may promote bacterial entrance and 
survival in the middle ear cavity (Cheeseman et al 2011, Hood et al 2016). It is also plausible 
that the presence of fluid creates a pressure difference between the middle ear and the 
NP, promoting ascension of bacteria, although such pressure measurements have not been 
performed in Evi1Jbo/+. 
Although trans-bullar injection of bacteria has shown to guarantee middle ear colonisation 
in both mice and chinchillas (Sabirov & Metzger 2008), it is an artificial route that bypasses 
NP colonisation, a major site of BPIFA1 production. In humans, OM is often initiated by a 
viral URT infection that compromises the local mucosal immunity, leading to an ascension 
of bacteria into the middle ear (Bakaletz 2010). Indeed, studies in animal models have also 
shown that IN inoculation with a single dose of bacteria are often unsuccessful whereas co-
incident infection with respiratory viruses or repeated doses of bacterial infection (Bakaletz 
2009, Giebink 1981, Sabirov & Metzger 2008, Short et al 2013), promote middle ear 
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colonisation. Perhaps, as I have shown that Bpifa1-/- mice that do not spontaneously 
develop OM, this would be a better experimental strategy to more closely mimic the 
biological processes leading to infectious OM.  
A potentially important variable confounding the bacterial challenge studies I undertook in 
this thesis was the discrepancy between the genetic backgrounds of mice used for the 
experiments. Not only does genetic background influence development of spontaneous 
OM (Bhutta 2012), but it has also shown to affect the susceptibility of mice to 
nasopharyngeal carriage after IN inoculation with bacteria (McCool & Weiser 2004). Since 
transferring the Bpifa1-/- line from the original C57BL/6 to C3H/HeH background was a time 
consuming process, these experiments were performed within the initial phase of the 
transfer with mice that were readily available, potentially preventing a direct comparison 
between the results from the NTHi challenge experiments at the different time points used. 
The other variable confounding the bacterial challenge studies was the higher susceptibility 
of Bpifa1 mutants to the NTHi375SR strain compared to the NTHi162SR strain.  The two NTHi 
strains were obtained from a Finish pneumococcal vaccine study and contain structural 
modifications in their LPS side-chains (Cody et al 2003, Hood et al 1999). A previous study 
from our lab screened infection rates in Evi1Jbo/+ mice with 7 different NTHi strains in order 
to identify the most efficient strains for IN challenge (Hood et al 2016).  As described 
before, there is inconsistent evidence on the binding activity of BPIFA1 to LPS (Britto & 
Cohn 2015, Campos et al 2004). However, two recent studies from the same group, have 
identified the α4 helix of BPIFA1 as being important in LPS binding and bacteriostatic 
activity against the Gram-negative bacteria, P.aeruginosa and B.cepacia (Ahmad et al 2016, 
Walton et al 2016). Due to the low infection rates seen in Bpifa1-/- mice, an in vivo screen 
with different NTHi strains such as that performed in Evi1Jbo/+ mice would not be ethically 
justifiable. However, an in vitro study to compare LPS-binding activity of BPIFA1 to different 
269  
NTHi strains may provide a better foundation for testing the antimicrobial effect of BPIFA1 
in vivo. 
 
6.3 Exacerbation of the OM phenotype in Bpifa1-/- Evi1Jbo/+ mice 
The Evi1Jbo/+ mouse is a model of chronic OM, characterised by a thickening of the 
mucoperiosteum, presence of inflammatory exudate and chronic hypoxia in the middle ear 
(Cheeseman et al 2011, Parkinson et al 2006). These mice bear a SNP in the Evi1 gene, 
which functions a repressor of NFκB and TGFβ signalling pathways (Kurokawa et al 1998b, 
Xu et al 2012). Evi1Jbo/+ mice develop CSOM around P28. In order to study the effect of loss 
of Bpifa1 in an existing model of chronic OM, Bpifa1-/-Evi1Jbo/+ mice were generated. This is 
the first study to report the effect of Bpifa1 deletion in a compound mutant model. Bpifa1-/-
Evi1Jbo/+ middle ears demonstrated acceleration and exacerbation of the OM phenotype, 
characterised by significantly more thickened mucosa and very high incidence of middle ear 
fluids. All Bpifa1-/-Evi1Jbo/+ mice showed fluid development by P28. 
Gene expression in the middle ear epithelial cells of Evi1Jbo/+ has not been studied before, 
however previous studies of Evi1Jbo/+ exudates demonstrated elevation of inflammatory 
gene networks and hypoxia signalling genes compared to venous blood (Cheeseman et al 
2011). Wt mice do not have middle ear fluids making a direct comparison between OM 
affected and healthy middle ears challenging. In this study, I have demonstrated an up-
regulation of the pro-inflammatory mediators Cxcl2, Tnfα, Il1β and Il6; the anti-
inflammatory mediator, Tgfβ and the hypoxia marker, Vegf in the middle ear mucosa of 
Evi1Jbo/+ and Bpifa1-/-Evi1Jbo/+ mice. I have also shown that Evi1Jbo/+ and Bpifa1-/-Evi1Jbo/+ 
middle ears demonstrate epithelial cellular alterations characterised by significant down 
regulation of the ciliated cell marker, Foxj1 and the goblet cell marker, Muc5ac. Moreover, 
Evi1Jbo/+ mice also demonstrate reduced levels of Bpifa1.  Despite the exacerbated OM 
phenotype in Bpifa1-/-Evi1Jbo/+ mice, there was no additive effect of the loss of Bpifa1 on the 
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expression of any the inflammatory and epithelial markers. I also did not observe any 
differences between basal levels of cytokines and epithelial markers between Wt and 
Bpifa1-/- mice. These observations differ from previous reports suggesting that BPIFA1 has 
an anti-inflammatory function and serves to reduce levels of pro-inflammatory cytokines 
during bacterial infections and allergic inflammation (Britto & Cohn 2015, Liu et al 2013a, 
Liu et al 2013b, Lukinskiene et al 2011, Wright et al 2010). My findings also contradict the 
report suggesting that loss of Bpifa1 down regulates ciliated and goblet cell markers (albeit 
that this was in the airways not in the middle ear), at steady state and during infection, 
thus impairing mucociliary clearance (Liu et al 2013a). 
  
The middle ear mucosa of Evi1Jbo/+ and Bpifa1-/-Evi1Jbo/+ mice was highly thickened and this 
thickening was a result of an apparent hyper-proliferation of epithelial cells into multiple 
layers as well as expansion of the mesenchyme. As described previously in Evi1Jbo/+ mice, 
other factors including connective tissue oedema, dilation of lymphatics, blood vessels and 
infiltration of the sub-epithelial mesenchyme may contribute to this thickening (Parkinson 
et al 2006). Such vasodilation is also supported by high levels of Vegf in Evi1Jbo/+ and Bpifa1-
/-Evi1Jbo/+observed in this study, which may be contribute to the inflammatory cell 
infiltration and fluid build up in the middle ear cavity (Cheeseman et al 2011, Husseman et 
al 2012).  
An interesting feature observed in the the inflamed Evi1Jbo/+ and Bpifa1-/- middle ears was 
fibrosis of the sub-epithelial mesenchyme indicated by the increased staining for the 
myofibroblast marker, αSMA and by collagen deposition, a characteristic feature of fibrotic 
pulmonary diseases such as asthma, IPF (Akram et al 2013). Accumulation of 
myofibroblasts and collagen is indicative epithelial remodelling due to an over-active 
wound repair response following inflammation, suggesting  over-activation of the TGFβ 
signalling pathway (a target for EVI1) (Makinde et al 2007). The increased thickness of 
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Bpifa1-/-Evi1Jbo/+ mucoperiosteum compared to that of Evi1Jbo/+ mice suggests that the 
increased fibrosis due to loss of BPIFA1. This is an interesting suggestion since loss of 
BPIFA1 has been associated with an allergen-induced asthma-like phenotype in mice 
(Thaikoottathil et al 2012) and overexpression of BPIFA1 has been shown to protect against 
pulmonary fibrosis (Di et al 2013). However, the mechanism of such a role for BPIFA1 
remains to be elucidated. The development of OM in Evi1Jbo/+ mice in germ free conditions 
suggests that bacterial infection is not a pre-requisite for OM development in these mice, 
although infection does accelerate disease onset. Perhaps physical irritants such as bedding 
particles may initiate the development of AOM in Evi1Jbo/+ (Hood et al 2016). Patients with 
bronchial asthma mainly develop an allergic form of OM called Eosinophilic Otitis media 
(EOM) (Kanazawa et al 2015). However Evi1Jbo/+ middle ears do not have the phenotype of 
human EOM as they lack eosinophils and IgG levels are not different between Wt and 
Evi1Jbo/+ mice (Parkinson et al 2006). Nevertheless, given the suggested involvement of 
BPIFA1 in allergen induced asthma and the apparent increased in the fibrotic phenotype of 
Bpifa1-/-Evi1Jbo/+ ears, it may be useful the analyse of the inflammatory cell types in the 
Bpifa1-/-Evi1Jbo/+ exudates in detail and also to evaluate levels of TH2 cytokines such as IL-13, 
IL-4 and IL-5 in Bpifa1-/-Evi1Jbo/+ mice (Kanazawa et al 2015). 
 
 
6.4 The mMEC culture system   
The middle ear and its secretions play a key role in role in host defence and epithelial 
abnormalities are commonly implicated in OM development. Human middle ear tissue can 
be acquired only during surgical procedures and sampling of the mucosa is a terminal 
procedure in most animals. In vitro studies can enable maximum utilisation of the available 
sample, allow the effect of modifying culture conditions and also enable studies of host 
pathogenen interactions. Prior to my thesis there was a lack of a well-characterised in vitro 
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model of the middle ear epithelium that replicates the complex cellular composition of the 
middle ear. Primary cultures of middle ear epithelial cells are often contaminated and 
overgrown by fibroblasts (Nakamura et al 1991, Vanblitterswijk et al 1986). Currently the 
two most widely models used for in vitro study of OM are the normal human middle ear 
epithelial cell line (NHMEEC) and the mouse middle ear cell line (MMEEC), both 
immortalised cells lines from the middle ear (Chun et al 2002, Lim & Moon 2012, Tsuchiya 
et al 2005). However, there is a lack of complete differentiation into the various epithelial 
cell populations using these cell lines, especially at the proteomic level. Moreover, cell lines 
do not fully mimic the 3-dimentional physiology of middle ear cells and the different 
intracellular interactions. This has considerably limited our understanding of the different 
cell types in the middle ear epithelium and their involvement in OM pathophysiology. 
In this thesis, I have developed a novel in vitro model of mouse middle ear epithelial cells at 
ALI that recapitulates the characteristics of the native murine ME epithelium. The protocol 
used for the culture of mMECs was adopted from that used for the culture of mouse 
tracheal epithelial cells, mTECs (You et al 2002). (Lechner et al 1982, Wu et al 1997, You & 
Brody 2013, You et al 2002). Addition of ROCKi to the culture medium enhances the 
proliferation of basal cells (Butler et al 2016, Horani et al 2013) and thus increases number 
of transwells that can be generated for culture. I have demonstrated that mMECs undergo 
differentiation into the varied cell populations seen within the native middle ear. Proteomic 
analysis confirmed that the cultures secrete a multitude of innate defence proteins from 
their apical surface. Wt mMECs produced abundant amounts of BPIFA1 and secreted 
BPIFA1 was detected in the apical washes from the cells. I have shown that the mMECs 
supported the growth of the otopathogen, NTHi and also mounted an inflammatory 
response upon infection, suggesting that the model can be successfully utilised to study 
host pathogen interactions. Bpifa1-/- mMECs were morphologically similar to Wt mMECs 
and also did not differ in expression pattern of epithelial markers, contrary to the report 
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suggesting that loss of BPIFA1 results in down regulation of ciliated and goblet cells (Liu et 
al 2013a). Bpifa1-/- mMECs demonstrated slightly enhanced susceptibility to NTHi infection, 
however this did not reach statistical significance due batch variation. I was unable to 
perform biofilm dispersal assays (Ahmad et al 2016, Liu et al 2013a, Liu et al 2013b) to test 
the surfactant activity of BPIFA1. However, this is an avenue that should be explored in 
future. However, the mRNA and protein levels of BPIFA1 significantly decreased upon NTHi 
infection. 
I believe that the mMEC culture system has the potential to serve as a platform for 
validation of treatments designed to reverse aspects of epithelial remodelling underpinning 
OM development. I believe that these cells can be targets for genetic modulation studies. 
Previous studies have demonstrated successful gene silencing in primary HBE cells and 
mTECs using lentiviral transduction systems (Horani et al 2012, Vladar & Stearns 2007). 
More recently, the CRISPR/CAS9 genome editing system has been utilised in HBE cells and 
mouse tracheal organoid cultures (Gao et al 2015). The physiological similarities of mMEC 
cells with airway epithelial cells and the use of similar culture conditions for their growth 
means that the mMEC model might be amenable to gene editing studies in future.  
 
 
6.4.1 Limitations of the mMEC culture system 
6.4.1.1 Batch variation 
A confounding factor in the use of the mMEC culture system appears to be the variation 
among different batches of culture in terms of expression of markers as well as 
susceptibility to NTHi infection. Primary cultures are known to show considerable variability 
between different batches depending on the media components. However, I believe the 
major reason for the variation seen in mMEC cultures was the difference in the basal cell 
populations attaching to the membrane. Depending on the fate of the initiator basal cells 
274  
attached to the membrane, the percentage of differentiated cell types can vary between 
the different batches of mMEC cultures and even between different transwells from the 
same batch of mMECs, establishing a new epithelium each time. In order to reduce this 
issue tagged basal cells could be fractionated using FACS prior to the establishment of 
mMEC cultures in order to potentially yield more uniform cultures. 
Along with the difference in cell populations mentioned above, contamination of isolated 
RNA by components of the TRI reagent may have added to the variation seen among 
biological replicates in the RT-qPCR data. Cells were lysed in TRI reagent, which contains 
phenol and guanidinium thiocyanate prior to RNA extraction. The RNA was found to 
contaminated to variable degrees with phenol and guanidine salts leading incorrect 
absorbance ratios during RNA quantification. This problem was identified late in the 
project, because I performed all RT-qPCR experiments at MRC, Harwell towards the end of 
this study and appears to be more of a problem when RNA yields are low. In order to 
mitigate the problem, all RNA was cleaned of contaminants prior to the RT-qPCR 
experiments and a screen of 12 endogenous controls was performed to identify the 3 most 
stable controls for normalisation of target genes for each cell type analysed (details in the 
materials and methods section). Thus the variability between samples was reduced to the 
minimum possible level. However, it still meant that while larger differences in gene 
expression between samples could easily be detected, subtle differences sometimes did 
not reach statistical significance. In future a TRI-reagent free system should be utilised for 
RNA extraction of mMECs.  
 
 
6.4.1.2 Lack of recapitulation of the OM phenotype of in mMECs 
Although mMEC cultures from Evi1Jbo/+ and Bpifa1-/-Evi1Jbo/+ differentiated into epithelial 
sub-populations, they failed to retain the elevated expression of inflammatory cytokines 
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and epithelial cellular markers seen in the freshly isolated mMMCs. As mentioned above 
differences in adherence of specific populations of basal cells initiating the cultures and 
their cell fate may be one of the major reasons for limitation. Also depending on the 
environmental stress differentiated cells can transdifferentiate to give rise to a new cell 
types a process which is associated with  various pathological diseases in the airways 
(Turner et al 2011). In order to overcome this issue, lineage tagging specific basal cell 
populations or other cells of interest could be used to  identify the origin of the cells in 
culture (Patel et al 2011). Moreover, culture conditions can be modified to favour 
differentiation of a specific cell type in order to recapitulate a particular phenotype.  For 
example, addition of IL-13 to TBE cultures has been shown to promote differentiation of 
goblet cells (Kondo et al 2002). 
The second reason for the lack of recapitulation of the OM phenotype may be the absence 
of the specific microenvironment found in Evi1Jbo/+ and ears. The absence of a hypoxia in mMEC cultures may be one of the reasons for the failure to recreate the microenvironment required for OM development. OM development is due to a 
combination of the response to an insult to the middle ear epithelium and the isolated environment of the middle ear cavity. Also the absence of other cell types such as 
fibroblasts and neutrophils, from the cultures, which are the main sites of EVI1 expression 
in Evi1Jbo/+ mice (Parkinson et al 2006) may further prevent the recapitulation of the OM 
phenotype. 
In this work I have developed a novel system for the culture of murine middle ear cells that 
recapitulates the cell types in the native middle ear. Additional optimisation will be needed 
in order to replicate the OM phenotype in culture. However, the availability of this new 
model of the middle ear epithelium makes the mMEC model valuable to the wider OM 
community.  
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6.5 Regulation of BPIFA1 during infection and inflammation 
A consistent observation in this study was the down regulation of Bpifa1 in the middle ear 
epithelial cells upon infection with NTHi as well in the inflamed microenvironment of the 
Evi1Jbo/+ ears. NTHi infection of Wt mMECs led to a decrease in mRNA and cytosolic and 
secreted protein levels of BPIFA1 at 48hpi. mMMCs isolated from Evi1Jbo/+  mice showed 
reduced expression of Bpifa1, mirroring the decrease in the staining intensity for BPIFA1 
observed in the Evi1Jbo/+  middle ear epithelium by IHC. Reduced expression Bpifa1 was also 
seen in mMECs cultured from Evi1Jbo/+ mice. 
As discussed in the individual chapter discussions, several studies have shown that 
infection by bacterial pathogens as well as inflammatory cytokines regulate the levels of 
BPIFA1 and the direction of regulation is dependent on the type of stimulus and the type of 
tissue under study (Britto & Cohn 2015). However, there is no mechanistic data on the true 
transcriptional regulation of BPIFA1. Therefore, whether the fluctuations in levels of BPIFA1 
reflect a regulation of its promoter activity is highly debatable. I would like to draw the 
attention to two particular studies in this context. A study in ovalbumin-stimulated mice 
that develop allergic asthma–like phenotype demonstrated reduced levels of the epithelial 
reticulon 4B (NogoB). NogoB is expressed by airway epithelial and smooth muscle cells and 
is involved in controlling vascular injury and promoting wound healing during stress 
response (Wright et al 2010). The researchers showed that NogoB-/- mice displayed an 
exaggerated asthma phenotype and using genome-wide microarray analysis found that 
Bpifa1 was the most differentially expressed gene in these mice. While NogoB-/- mice 
demonstrated a marked reduction of expression of Bpifa1, mice overexpressing NogoB 
showed elevated levels of BPIFA1 and transgenic expression of Bpifa1 under the Clara-cell 
secretory promoter rescued the phenotype in NogoB-/- mice. The mechanism for such a 
proposed regulation of Bpifa1 by NogoB has not been elucidated. Another study showed 
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that LPS stimulation of human nasal epithelial cells increased the levels of BPIFA1, along 
with an increase in levels of phosphorylated JNK and cJun, and further treatment of cells 
with IL-13 attenuated the levels of BPIFA1 (Tsou et al 2015). The study thus suggests that 
BPIFA1 expression is regulated through the JNK pathway.   
Based on the observations in this thesis, I believe it is unlikely that such fluctuations in 
BPIFA1 levels are an indication of its true transcriptional regulation, but are rather a 
consequence of phenotypic changes in the cell types. For example, the up regulation of JNK 
and cJun in the above study (Tsou et al 2015) may be a consequence of activation of the 
JNK pathway due to infection, whereas the elevation in BPIFA1 may be a result of epithelial 
remodelling in the presence of this inflammation. Moreover, IL-13 is known to promote 
differentiation of goblet cells in cultures through MAP kinase regulation (Atherton et al 
2003). Since BPIFA1 is expressed by non-goblet cells (Bingle et al 2005), there may be 
reduction in the proportion of BPIFA1 expressing cells in culture.  
In my thesis, the down regulation of Bpifa1 observed in Wt mMECs upon NTHi infection 
and in Evi1Jbo/+ mice in the presence of the OM phenotype, may also be a result of an insult 
to the epithelium due to the presence of infection or inflammation, thus leading to 
phenotypic alterations in the cells. I believe that it is unlikely to be the primary cause for 
generation of an inflammatory response. It is possible that the changes seen in the middle 
ear epithelium of the Evi1Jbo/+ mice involve a loss of other cell types such as ciliated cells. 
This is indicated through a down-regulation of FoxJ1 mRNA in Evi1Jbo/+ mMMCs compared 
to Wt mMMCs. In future, this change can be confirmed at a protein level by staining Wt 
and Evi1Jbo/+ for FOXJ1 protein using IHC. Also, it will be of interest to test whether the 
downregulation of the epithelial markers is a result of denudation or loss of integrity of the 
epithelium itself, as a result of the extensive expansion of the sub-epithelial mesenchyme. 
This issue can be addressed by co-staining for secretory (BPIFA1), ciliated (FOXJ1) and 
goblet (MUC5B) cells with a more universal epithelial marker such as pan-cytokeratin.  
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6.5.1 Presence of an inflammatory stimulus is a pre-requisite for BPIFA1 function 
As discussed above the down regulation of Bpifa1 in this study may be a consequence of 
phenotypic changes in the epithelial cell populations in the presence of infection or 
inflammation rather than being a causal factor for initiation of an inflammatory response. 
This also explains why loss of Bpifa1 alone does not lead to the development of OM in 
Bpifa1-/- mice. Previous work has largely focused on evaluation of a role for BPIFA1 only the 
presence of an inflammatory or infectious stimulus. For example, in the presence of 
infection by bacterial and viral pathogens (Britto et al 2013, Gally et al 2011, Liu et al 2013a, 
Liu et al 2013b, Lukinskiene et al 2011, Zhou et al 2008); in case of chronic allergies such as 
rhino sinusitis (Irander et al 2014, Tsou et al 2015) and induction by allergic stimuli such as 
cigarette smoke or occupational irritants (Fornander et al 2013, Ghafouri et al 2003); in 
pre-existing pulmonary diseases such as CF and COPD (Bingle et al 2007, Di et al 2003) or 
other URT malignancies such as non-small cell carcinomas and nasopharyngeal carcinomas 
(Bingle & Bingle 2011). Indeed, existing studies with Bpifa1-/- mice did not report any 
phenotype or immunological abnormalities in the naïve Bpifa1-/- mice (Gally et al 2011, Liu 
et al 2013a). In this study, in addition to the absence of OM in Bpifa1-/-  mice, no anomalies 
were detected in 42 different tissues encompassing all the major organs of Bpifa1-/- mice. 
Thus, the presence of an infectious or inflammatory stimulus seems to be required to 
uncover functional roles of BPIFA1, suggesting that the high levels of BPIFA1 at steady state 
may be critical for initial protection against epithelial insults and pathogens and an 
alteration in its levels may exacerbate an existing inflammatory response. 
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6.6 Proposed role of BPIFA1 in the middle ear and development of Otitis media 
I have shown that BPIFA1 is secreted by the non-ciliated cells of the middle ear epithelium 
and it coats the surface of the middle ear epithelium. Similar to other sites in the URT, 
BPIFA1 is produced at high basal levels in the middle ear and these high levels of protein 
are involved in preventing initial infection in the middle ear. The exact role BPIFA1 plays in 
host defence remains incompletely understood. However, BPIFA1 decreases susceptibility 
against a wide range of bacteria and viruses. Recent studies in our lab have shown that 
Bpifa1-/- mice have increased susceptibility to pulmonary infection by Influenza A virus 
(Akram et al, unpublished data). In this study I have shown that loss of Bpifa1 increases 
susceptibility to a pre-existing inflammatory stimulus. The regulation of ENaC seems an 
unlikely role for BPIFA1 in the middle ear. The current hypothesis behind BPIFA1 regulation 
of ENaC is that BPIFA1 inhibits the activity of ENaC via the physical interaction through its 
N-terminus S18 peptide and blocks ENaC cleavage (Garcia-Caballero et al 2009). In CF lungs, 
loss of BPIFA1 activity due to low PH leads to hyperactivity of the ENaC channel and 
increased transport of sodium and water through the channel leading to dehydration of the 
airways and formation of mucous plugs (Garland et al 2013). ENaC is expressed by the 
middle ear epithelium (Choi et al 2006) and the presence of periciliary fluid has been 
described in the middle ear (Kubba et al 2000). Although fluid build-up in the ear is a result 
of vasodilation (inflammation and exudation), previously published literature shows that 
increased ENaC helps middle ear fluid clearance (Li et al 2005, Song et al 2012, Xu et al 
2015). According to the BPIFA1- mediated inhibition of ENaC hypothesis, the absence of 
BPIFA1 in this study might be expected to lead to dehydration of middle ear cavity, which is 
the opposite of the OM phenotype, characterised by fluid build-up within the middle ear 
cavity. Indeed, a condition called Pseudohypoaldosteronism, in which ENaC activity is 
severely diminished, leads to chronic rhinorrhea and increased bronchus secretions (Kerem 
et al 1999). However, disruption of the periciliary layer due to increased activity of ENaC 
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could still impact mucociliary clearance. It is unclear whether ENaC regulation by BPIFA1 is 
specific to the airways. Also, the N-terminus region of BPIFA1, (including the S18 region) is 
the most variable among primates and lower mammals, which may suggest that this 
function is restricted to primates (Bingle & Craven 2002).  
Taking account of all of the available data, I hypothesize that BPIFA1 is secreted into the 
surface lining fluid of the middle ear acts as a non-specific physical barrier to help maintain 
the homeostasis of the middle ear epithelium. It is known that the epithelium along with its 
secretions orchestrates various aspects of the inflammatory as well as wound repair 
response through cross-talk with ligands on the epithelial surface as well as with 
components of the sub-epithelial mesenchyme. The exact mechanism by which BPIFA1 
regulates these interactions and maintains homeostasis is unresolved. However, in the 
absence of an infection or insult to the epithelium, lack of BPIFA1 does not result in an 
inflammatory response and thus Bpifa1-/- mice do not show a phenotype under steady 
state conditions. However, absence of BPIFA1 superimposed on an insult to the epithelium 
in the form of infection or as a consequence of inflammation, may make the epithelium 
more susceptible to the initial injury and thus lead to an exacerbated host defence 
response and epithelial remodelling, as seen in the Bpifa1-/-Evi1Jbo/+ middle ears. This may 
be due to an alteration of the physical interaction of BPIFA1 with other components of the 
epithelium or due to a change in the composition of the secretions within the middle ear 
lining fluid, thus altering its biophysical properties such as surface tension. Further 
investigation is needed to explore the mechanistic role BPIFA1 in protection of the middle 
ear and its involvement in OM pathogenesis. 
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6.7 Future studies  
6.7.1 Studies with Bpifa1-/- mice 
In this thesis I have shown that Bpifa1-/- mice maintained in SPF conditions do not 
spontaneously develop OM, at least up to 6 months of age. The study by Bartlett and co-
workers suggests that Bpifa1-/- mice between 10-18 months of age develop low penetrance 
OM (Bartlett et al 2015). I believe the reason for this phenotype is the combined effect of 
loss of BPIFA1, the air quality in which the mice were housed and the compromised 
immunity due to advanced age. Therefore, in future the Bpifa1-/- line should be aged till 18 
months in SPF conditions and evaluated for spontaneous OM development. 
I have also shown that loss of Bpifa1 did not lead to increased ascension of NTHi from the 
NP into the middle ear. Due to the variability observed between NTHi375SR and NTHi162SR 
strains, a screen could be carried out to identify strains of NTHi which may infect Bpifa1-/- 
mice more effectively. 
6.7.2 Studies with Bpifa1-/-Evi1Jbo/+ mice 
In the preliminary experiment performed in this thesis, cytospun exudates from Evi1Jbo/+ 
and Bpifa1-/-Evi1Jbo/+ showed a high proportion of neutrophils and lower proportion of 
macrophages in the exudates. Previous studies have shown that Evi1Jbo/+ exudates are 
neutrophil rich (Cheeseman et al 2011, Parkinson et al 2006). However, FACs analysis of 
inflammatory cells should be carried out to identify the differences in proportions and 
types of inflammatory cells between Evi1Jbo/+ and Bpifa1-/-Evi1Jbo/+ mice. My studies have not 
confirmed if there is an increase in the fibrotic phenotype of Bpifa1-/-Evi1Jbo/+ mice 
compared to Evi1Jbo/+ mice. Analysis of TH2 cytokines such as IL-4, IL-5 and IL13 and 
quantification of myofibroblasts and cell proliferation will provide further insight into the 
phenotype of Bpifa1-/-Evi1Jbo/+ mice. 
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6.7.3 Lineage tracing experiments  
In order to establish more homogenous mMEC cultures and avoid variation between 
individual batches, basal cells could be tagged and FACs sorted prior to seeding them on 
transwell membranes. Also lineage tags for specific epithelial sub-types of interest, ciliated 
cells, BPIFA1 expressing cells, goblet cells, could be used to trace the origin and fate of 
trans differentiated cells. Also, a combination of epithelial and mesenchymal tags would 
allow for the study of changes in epithelial phenotype during remodelling of the middle ear 
epithelia.  
 
 
6.7.4 Recapitulation of the OM phenotype in mMECs 
In order to recapitulate the OM phenotype in vitro, mMECs from Evi1Jbo/+ and Bpifa1-/-
Evi1Jbo/+ could be established as direct contact cultures by growing mMECs on one side of 
the transwell membrane and fibroblasts on the other. This may better mimic the organ 
morphology of the middle ear mucosa. Also the cells may be cultured in hypoxic incubators 
in order to better recreate the microenvironment of Evi1Jbo/+ ears. Furthermore, a mucous 
phenotype could be induced by treating the cells with IL-13, a known inducer of goblet cells. 
 6.7.5 BPIFA1 deletion in other mouse models of OM  
This is the first report of deletion of BPIFA1 in combination with another genetic mutation.  
The generation of compound mutations enables the study of interaction between two 
genes in order to develop a better understanding of the pathophysiology of OM. Based on 
the data from my thesis, it will be interesting to know if deletion of Bpifa1 leads to an 
exacerbation of the phenotype in other models of OM. Fbxo11Jf/+ and Tgif-/- are two models 
of spontaneous OM at MRC Harwell and both have mutations which are implicated in the 
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TGFβ signalling pathway. Of these the Fbxo11Jf/+ mouse is particularly interesting because 
preliminary studies during my Masters project have identified expression of BPIFA1 in 
Fbxo11Jf/+ middle ear epithelium and exudates. The mutation in Fbxo11Jf/+ is implicated in 
regulation of phosphoSmad2 in epithelial cells of the airways, palatal shelves and eyelids 
(Rye et al 2011a, Tateossian et al 2015) and two studies have identified the association of 
this gene with OM susceptibility (Rye et al 2011b, Segade et al 2006). 
 
 
6.8 Conclusion 
Otitis media is the most prevalent paediatric disease, cause of paediatric surgery, antibiotic 
prescription and childhood conductive deafness. Identification of genes involved in OM 
susceptibility is key to understanding the complex pathophysiology of the disease and for 
development of better therapeutics. Through this thesis I have explored a role for the 
putative URT innate immunity protein, BPIFA1, in the protection of the middle ear and in 
the development of OM. BPIFA1 is expressed at high basal levels in the murine middle ear. 
Deletion of Bpifa1 alone does not lead to spontaneous development of OM and does not 
result in increased nasopharyngeal carriage of the human ototpathogen NTHi. However, 
deletion of Bpifa1 in Evi1Jbo/+ mice, a model of OM significantly exacerbates the OM 
phenotype. Through this study, I have also developed a novel in vitro model the murine 
middle ear epithelial cells that closely mimics the in situ middle ear epithelium and 
expresses markers for ciliated cells, goblet cells and secretory cells. The mMEC culture 
system can be applied as an effective tool to study the interaction between the ME 
epithelium and various otopathogens. Overall, the data from this thesis suggests that 
BPIFA1 may function as a non-specific mucosal defense protein that helps to maintain the 
homeostasis of the middle ear epithelium at high basal levels. Loss of BPIFA1 superimposed 
on an insult to the epithelium, in the form of infection or inflammation, increases the 
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susceptibility epithelium to injury leading to an exacerbated host defense response and 
excessive epithelial remodeling. This may be due to the uncoupling of its interaction with 
other components of the epithelium or the within the secretions of the middle ear lining 
fluid. Further investigation is required to explore the mechanistic role BPIFA1 in 
maintenance of the homeostasis of the middle ear.  
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Table S3: Solutions used for IHC 
Solution Constituents Amount 
Phosphate Buffered Saline 
(PBS) pH 7.5 
NaCl (Sigma-Aldrich) 
 
42.4 g 
Sodium phosphate (dibasic) 
(Fischer Scientific) 
 
7.12 g 
Potassium phosphate 
(monobasic) (Sigma , UK) 
1.25 g 
0.01 M Sodium Citrate Sodium Citrate (Sigma) 1.18 g 
Distilled water 400 ml 
Biotinylated Secondary 
antibody 
PBS 
 
10 ml 
100% normal goat serum 
 
150 µl 
 
Concentrated biotinylated 
secondary antibody 
50 µl 
VECTASTAIN Elite ABC reagent PBS 5 ml 
Reagent A 100 µl 
Reagent B 100 µl 
VECTOR Nova Red Coloring 
reagent 
Distilled water 5 ml 
Solution A 150 µl 
Solution B 100 µl 
Solution C 100 µl 
Solution D 100 µl 
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Table S4: Solutions used for Western blotting 
Solution Constituents Amount 
10  X Running Buffer 
Tris Base (Fischer Scientific) 30.3 g 
Glycine (Fischer Scientific) 190 g 
20 % SDS (Sigma-Aldrich) 50 mls 
 Distilled water Make up vol 1000 ml 
1 X Running Buffer 
10 X Running Buffer 100 ml 
Distilled water 900 ml 
1 X Transfer Buffer 
Tris Base (Fischer Scientific) 2.9 g 
Glycine (Fischer Scientific) 1.45 g 
20 % SDS (Sigma-Aldrich) 925 µl 
1 X TBS- TWEEN 
Tris HCl pH 8 (BioRad) 100 ml 
NaCl (Sigma-Aldrich Co) 97.3 g 
Tween – 20 (Fischer Scientific, 
UK) 5 ml 
Distilled water Make up vol 1000ml 
EZ- ECL  chemiluminescence 
reagent 
Solution A 1 ml  
Solution B 1ml 
2 X Lysis buffer 
1M DTT 1 ml 
20 % SDS (Sigma-Aldrich) 1ml 
Glycerol 2 ml 
Tris HCl 0.5M pH 6.8 (BioRad) 1.25 ml 
0.2 % Bromophenol blue 200 µl 
Protease inhibitor 1 tablet 
Distilled water 4.55 ml 
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Table S3: Solutions for Weigert’s Haematoxylin 
Solution Constituents Amount 
Weigert’s Solution A 
Haematoxylin (VWR) 1 g 
IDA (Genta) 100 ml 
Weigert’s Solution B 
30% aqueous ferric 
chloride(BDH) 4 ml 
Distilled water 100 ml 
Concentrated HCL (VWR) 1 ml 
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   APPENDIX II  
Table S4 A: Detailed histology screen for 6 month old Bpifa1-/- mice Part 1 (n=6) 
Mouse i.d SPLUNC-C3-IC/3.3D 3.3G 4.3C 4.3D 4.3F 6.2b 
Salivary gl lymphoid agg LA nad LA LA nad 
trachea thyroid 
para 
absent nad peri trach muscle sol 
focus myofiber 
regen 
trach thyroid nad 
parat absent 
trach thyroid 
nad parat 
absent 
 
LN nad absent absent absent nad nad 
skin nad absent absent  absent absent 
lung 1 sub pleural lymphoid agg. 1 peri bronch LA nad 1 peribronch LA 3 peribronch LA 1 peribronch LA 
heart nad nad nad nad nad nad 
tongue scatt mast cells scatt mast cells scatt mc scatt mc scatt mc scatt mc 
kidney nad nad nad nad nad sol focus mineraliz 
adrenal x zone vac, sub cap hyperpl x zone vac tang cut x zone vac, 
sub cap hyperpl 
cortex only sub cap 
hyperpl 
x zone vac, sub 
cap hyperpl 
x zone vac, sub cap 
hyperpl 
liver glycogen accumuation gly accum. gall 
bladder nad 
gly accum. gall 
bladder nad 
glycogen 
accumuation 
glycogen 
accumuation 
glyc and scatt fat 
accumuation 
LN nad nad absent pancreatic LN nad absent absent 
spleen consp. megakaryocytes consp. megakary. artef. Sub cap 
rarefaction 
red pulp congestion artef. Sub cap 
rarefaction 
artef. Sub cap rare 
and pigment 
macroph 
exoc pancreas scatt fat cells scatt fat cells scatt fat cells scatt fat cells focal autolysis nad 
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Mouse i.d SPLUNC-C3-IC/3.3D 3.3G 4.3C 4.3D 4.3F 6.2b 
islet nad 1 islet cavitated  nad nad nad nad 
thymus absent absent absent nad absent nad 
stomach nad nad nad nad nad nad 
SI nad nad nad nad nad nad 
LI nad apopt cells over 
Peyers patch 
nad nad nad nad 
islet nad nad nad nad nad nad 
exoc pancreas nad scatt fat cells artef degen + fat 
cells 
nad nad nad 
esophagus nad nad nad nad nad nad 
perineal skin nad nad nad nad nad nad 
vagina nad nad normal NLs nad normal NLs focal intraepith 
normal NLs 
uterus nad nad nad nad nad tangential sectins 
urinary bladder nad nad absent absent nad nad 
skin nad nad nad nad nad nad 
muscle nad nad nad nad nad nad 
eyes retinal degeneration RD nad nad nad RD 
optic nerve nad nad nad nad absent nad 
cerebell brain 
stem 
nad nad small sect. nad dark na dark na dark na 
thalamus cortex 
x2 
dark neuron artefact 1 focus perivasc 
mast cells 
dark na dark na dark na dark na 
rostral cortex nad dark na dark na dark na dark na dark na 
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Mouse i.d SPLUNC-C3-IC/3.3D 3.3G 4.3C 4.3D 4.3F 6.2b 
cord x3 dark neuron artefact dark na dark na dark na dark na dark na 
pituitary absent pars distalis only 
nad 
nad pars distalis and 
nervosa nad 
pd pi pn nad pd pi only nad 
nerve sciatic nad nad small sect. nad small sect. nad nad nad 
knee closed growth plate closed growth 
plate 
closed growth plate closed growth plate closed growth 
plate 
closed growth plate 
foc degen 
veterbra degen inter vert cartilage degen inter vert 
cartilage 
degen inter vert 
cartilage 
degen inter vert 
cartilage 
degen inter 
vert cartilage 
degen inter vert 
cartilage 
rostral snout nad nad ?orientation nad nad nad nad 
mid snout vm organ conspic blood 
vasculature 
nad fluid nasolacrymal 
tube 
nad nad nad 
caudal nasal 
passages 
nad includes harderian 
gland 
nad nad nad includes 
harderian gland 
nad  nad 
ovary nad nad nad one absent other 
nad 
nad nad 
tube nad nad nad nad nad nad 
ME unilat eosinophilic secretion 
few detach cells 
nad unilat eosinophilic 
secretion few 
detach cells 
unilat eosinophilic 
secretion few 
detach cells 
one bulla 
superfical cut 
nad 
nad 
oropharynx nad nad nad nad nad nad 
teeth nad nad nad nad nad nad 
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Table S4 B: Detailed histology screen for 6 month old Bpifa1-/- mice Part 1 (n=7) 
Mouse i.d 6.2F 1.7A 1.7B 4.3H 6.2J 6.2N 6.2K 
Salivary gl nad nad nad nad nad nad nad 
trachea thyroid 
para 
widely patent 
tracheal glands with 
ciliated epith, 
thyroid nad para 
absent 
conspicuous 
tracheal gland, 
thryroid nad 
nad para absent trachea thyroid 
para nad 
trachea 
thyroid para 
nad 
trachea 
thyroid nad 
trachea thyroid nad 
LN absent nad nad nad nad nad nad 
skin absent absent nad absent absent absent absent 
lung 1 sub pleural LA airway consp 
epithcell 
cytoplasm 
nad nad nad focal subcap 
lymphoid cells 
otherwise 
NAD 
  
heart nad nad nad nad nad nad nad 
tongue scatt mc scatt mc scatt mc scatt mc scatt mc scatt mc scatt mc 
kidney sol focus mineraliz nad nad nad tub vac nad tub vac nad tub vac nad tub vac 
adrenal x zone vac, sub cap 
hyperpl 
both tangential 
x zone vac, sub 
cap hyperpl 
both tangential x 
zone vac 
nad intra 
medul ?BV 
widely patent 
nad, 
tangential 
tangential, tangential 
liver glyc accum absent glyc accum nad nad glyc 
accumulation 
gall bladder 
nad 
glyc accumulation 
gall bladder nad 
LN nad nad absent nad absent nad nad 
spleen nad absent nad nad nad nad nad 
exoc pancreas nad nad scatt fat cells nad nad nad nad 
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Mouse i.d 6.2F 1.7A 1.7B 4.3H 6.2J 6.2N 6.2K 
islet scatt fat cells nad nad nad nad some have 
conspicuous 
capillaries 
some have 
conspicuous 
capillaries 
thymus nad nad nad nad nad absent nad 
stomach nad nad nad nad nad nad nad 
SI nad nad nad nad nad nad nad 
LI nad nad nad nad nad nad nad 
islet nad absent absent nad absnt absent absent 
exoc pancreas nad absent nad nad nad absent absent 
esophagus nad nad nad nad nad nad nad 
perineal skin nad nad absent MALE MALE MALE MALE 
vagina absent nad nad prostate, coag 
gl seminal ves 
nad 
vas defr, 
prostate, 
coag gl 
seminal ves 
nad 
vas defr, 
prostate focal 
dilation effete 
cells in lumen, 
coag gl 
seminal ves 
nad 
vas defr, prostate, 
coag gl seminal ves 
nad 
uterus nad nad nad edpidymis testis 
nad  
edpidymis 
testis nad  
edpidymis 
testis nad  
edpidymis nad testis 
occasional tubule 
degen cells 
multinucleates 
urinary bladder nad nad basophlic 
atrefact 
nad nad nad nad 
skin nad nad nad nad nad nad nad 
muscle nad altered focus nad nad nad nad nad 
eyes nad (1 only) nad rd nad rd nad rd 
308  
Mouse i.d 6.2F 1.7A 1.7B 4.3H 6.2J 6.2N 6.2K 
optic nerve absent nad rd nad rd tangential 
retina nad 
rd 
cerebell brain 
stem 
dark na dark na dark na dark na dark na dark na dark na 
thalamus cortex x2 dark na dark na dark na mineralization dark na dark na dark na 
rostral cortex focal cort cells focal cort cells dark na dark na dark na dark na dark na 
cord x3 dark na dark na dark na dark na dark na dark na dark na 
pituitary pd pi pn nad pd pi nad pn 
edge 
pd pi pn nad pd pi pn nad pd pi pn nad pd pi pn nad pd pi pn nad 
nerve sciatic artef frag nad nad nad nad nad nad nad 
knee closed growth plate  closed growth 
plate  
closed growth 
plate  
closed growth 
plate  
closed 
growth plate  
closed growth 
plate focal 
degen cart 
closed growth plate 
focal cart. Degen 
veterbra degen inter vert 
cartilage 
degen inter 
vert cartilage 
nad nad degen inter 
vert cartilage 
degen inter 
vert cartilage 
degen inter vert 
cartilage 
rostral snout few squames + NL nad nad  nad nad nad nad 
mid snout nad nad nad nad nad nad nad 
caudal nasal 
passages 
nad nad eosinophilic 
material 
nad nad nad nad  
ovary nad nad nad MALE MALE MALE   
tube absent nad nad         
ME nad nasopharynx 
nad 
nad 
nasopharynx 
nad 
nad  nad missing nad nad 
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oropharynx absent nad nad absent slide absent absent 
teeth absent nad nad nad   nad nad 
 
Abbreviations for histology analysis  
nad no abnormality detected  
dark na dark neurone artefact  
focal cortical cells  
tang cut tangential cut 
 x zone vac x zone vacuolatiion = female specific change 
sub cap hyp sub capsular hyperplasia 
degen inter vert cartilage degeneration of intervertebral cartilage 
 
pi pars intermedia 
pn pars nervosa 
pd pars distalis 
**Most of the abbreviations record that the concerned tissue was examined and nothing or only incidental non-pathological changes were noted. 
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Table S5 Top 500 proteins detected by MS analysis of Wt ALI Day mMEC washes 
Accession 
Number 
Protein Name (Wt ALI Day 14 mMECs) Gene name Peptide 
count 
emPAI 
P08071 Lactotransferrin  TRFL_MOUSE 47 202.53 
Q921I1 Serotransferrin  TRFE_MOUSE 40 29.58 
O09131 Glutathione S-transferase omega-1  GSTO1_MOUSE 17 28.64 
P60710 Actin, cytoplasmic 1  ACTB_MOUSE 23 24.63 
P50446 Keratin, type II cytoskeletal 6A  K2C6A_MOUSE 35 19.14 
P08074 Carbonyl reductase [NADPH] 2  CBR2_MOUSE 16 19.04 
Q9Z331 Keratin, type II cytoskeletal 6B  K2C6B_MOUSE 36 18.18 
P62806 Histone H4  H4_MOUSE 6 17.1 
P10107 Annexin A1  ANXA1_MOUSE 24 14.87 
P11679 Keratin, type II cytoskeletal 8  K2C8_MOUSE 33 14.67 
P19001 Keratin, type I cytoskeletal 19  K1C19_MOUSE 35 14.07 
Q61781 Keratin, type I cytoskeletal 14  K1C14_MOUSE 35 13 
O09049 Regenerating islet-derived protein 3-
gamma  
REG3G_MOUSE 8 11.38 
P35700 Peroxiredoxin-1  PRDX1_MOUSE 14 11.13 
Q06890 Clusterin  CLUS_MOUSE 22 10.47 
P11672 Neutrophil gelatinase-associated lipocalin  NGAL_MOUSE 9 10.45 
Q61147 Ceruloplasmin  CERU_MOUSE 55 10.1 
Q61414 Keratin, type I cytoskeletal 15  K1C15_MOUSE 32 9.92 
P17742 Peptidyl-prolyl cis-trans isomerase A  PPIA_MOUSE 14 9.81 
Q922U2 Keratin, type II cytoskeletal 5  K2C5_MOUSE 34 8.7 
Q9QWL7 Keratin, type I cytoskeletal 17  K1C17_MOUSE 33 7.76 
O08709 Peroxiredoxin-6  PRDX6_MOUSE 15 7.38 
P10649 Glutathione S-transferase Mu 1  GSTM1_MOUSE 18 6.68 
P07356 Annexin A2  ANXA2_MOUSE 23 6.63 
P52480 Pyruvate kinase PKM  KPYM_MOUSE 36 6.57 
P68372 Tubulin beta-4B chain  TBB4B_MOUSE 21 6.13 
Q6ZWY9 Histone H2B type 1-C/E/G  H2B1C_MOUSE 11 6.12 
Q8BND5 Sulfhydryl oxidase 1  QSOX1_MOUSE 43 6.1 
Q9DCV7 Keratin, type II cytoskeletal 7  K2C7_MOUSE 35 6.01 
P16858 Glyceraldehyde-3-phosphate 
dehydrogenase  
G3P_MOUSE 21 5.87 
Q61398 Procollagen C-endopeptidase enhancer 1  PCOC1_MOUSE 23 5.56 
P07744 Keratin, type II cytoskeletal 4  K2C4_MOUSE 31 5.43 
O35639 Annexin A3  ANXA3_MOUSE 24 5.16 
P68033 Actin, alpha cardiac muscle 1  ACTC_MOUSE 23 5.06 
P26040 Ezrin  EZRI_MOUSE 39 5.04 
P99024 Tubulin beta-5 chain  TBB5_MOUSE 21 4.94 
Q05816 Fatty acid-binding protein, epidermal  FABP5_MOUSE 9 4.92 
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P08249 Malate dehydrogenase, mitochondrial  MDHM_MOUSE 24 4.77 
P97361 BPI fold-containing family A member 1  BPIA1_MOUSE 9 4.74 
P01027 Complement C3  CO3_MOUSE 111 4.68 
Q8BGZ7 Keratin, type II cytoskeletal 75  K2C75_MOUSE 36 4.22 
P56480 ATP synthase subunit beta, mitochondrial  ATPB_MOUSE 30 4.18 
P62830 60S ribosomal protein L23  RL23_MOUSE 10 4.08 
P05784 Keratin, type I cytoskeletal 18  K1C18_MOUSE 32 3.99 
P50543 Protein S100-A11  S10AB_MOUSE 5 3.92 
P28654 Decorin  PGS2_MOUSE 23 3.86 
P40142 Transketolase  TKT_MOUSE 34 3.7 
Q9QUI0 Transforming protein RhoA  RHOA_MOUSE 13 3.7 
Q8VCT4 Carboxylesterase 1D  CES1D_MOUSE 27 3.69 
Q9Z2K1 Keratin, type I cytoskeletal 16  K1C16_MOUSE 35 3.64 
P57780 Alpha-actinin-4  ACTN4_MOUSE 61 3.61 
P17563 Selenium-binding protein 1  SBP1_MOUSE 31 3.49 
P17182 Alpha-enolase  ENOA_MOUSE 28 3.36 
P11499 Heat shock protein HSP 90-beta  HS90B_MOUSE 40 3.31 
P08730 Keratin, type I cytoskeletal 13  K1C13_MOUSE 31 3.29 
P14211 Calreticulin  CALR_MOUSE 27 3.28 
Q9D379 Epoxide hydrolase 1  HYEP_MOUSE 29 3.27 
P63017 Heat shock cognate 71 kDa protein  HSP7C_MOUSE 37 3.24 
Q00493 Carboxypeptidase E  CBPE_MOUSE 28 3.17 
P06797 Cathepsin L1  CATL1_MOUSE 12 3.11 
P62962 Profilin-1  PROF1_MOUSE 9 3.1 
P27773 Protein disulfide-isomerase A3  PDIA3_MOUSE 35 3.05 
P62908 40S ribosomal protein S3  RS3_MOUSE 19 3.05 
Q7TMM9 Tubulin beta-2A chain  TBB2A_MOUSE 21 3.03 
Q8VDD5 Myosin-9  MYH9_MOUSE 127 3.03 
P09103 Protein disulfide-isomerase  PDIA1_MOUSE 39 3.02 
P68368 Tubulin alpha-4A chain  TBA4A_MOUSE 22 2.99 
P68373 Tubulin alpha-1C chain  TBA1C_MOUSE 22 2.99 
Q8VED5 Keratin, type II cytoskeletal 79  K2C79_MOUSE 32 2.98 
Q61805 Lipopolysaccharide-binding protein  LBP_MOUSE 19 2.96 
Q9Z1Q5 Chloride intracellular channel protein 1  CLIC1_MOUSE 17 2.96 
Q07797 Galectin-3-binding protein  LG3BP_MOUSE 26 2.94 
Q61646 Haptoglobin  HPT_MOUSE 20 2.94 
Q7TPR4 Alpha-actinin-1  ACTN1_MOUSE 60 2.92 
P62821 Ras-related protein Rab-1A  RAB1A_MOUSE 18 2.9 
O88844 Isocitrate dehydrogenase [NADP] 
cytoplasmic  
IDHC_MOUSE 30 2.87 
P08228 Superoxide dismutase [Cu-Zn]  SODC_MOUSE 11 2.78 
P18760 Cofilin-1  COF1_MOUSE 12 2.72 
P19157 Glutathione S-transferase P 1  GSTP1_MOUSE 10 2.71 
Q9R0P5 Destrin  DEST_MOUSE 13 2.7 
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P06151 L-lactate dehydrogenase A chain  LDHA_MOUSE 23 2.62 
P20029 78 kDa glucose-regulated protein  GRP78_MOUSE 39 2.61 
P10126 Elongation factor 1-alpha 1  EF1A1_MOUSE 23 2.54 
Q60605 Myosin light polypeptide 6  MYL6_MOUSE 11 2.51 
Q62159 Rho-related GTP-binding protein RhoC  RHOC_MOUSE 11 2.5 
Q9D1G1 Ras-related protein Rab-1B  RAB1B_MOUSE 17 2.5 
P07901 Heat shock protein HSP 90-alpha  HS90A_MOUSE 39 2.47 
P10605 Cathepsin B  CATB_MOUSE 15 2.47 
P68040 Guanine nucleotide-binding protein 
subunit beta-2-like 1  
GBLP_MOUSE 22 2.47 
P97429 Annexin A4  ANXA4_MOUSE 22 2.4 
Q64669 NAD(P)H dehydrogenase [quinone] 1  NQO1_MOUSE 15 2.38 
O54974 Galectin-7  LEG7_MOUSE 10 2.33 
P33267 Cytochrome P450 2F2  CP2F2_MOUSE 29 2.3 
P47739 Aldehyde dehydrogenase, dimeric NADP-
preferring  
AL3A1_MOUSE 25 2.29 
Q61508 Extracellular matrix protein 1  ECM1_MOUSE 37 2.29 
Q9R0P3 S-formylglutathione hydrolase  ESTD_MOUSE 16 2.28 
P47738 Aldehyde dehydrogenase, mitochondrial  ALDH2_MOUSE 26 2.24 
P17751 Triosephosphate isomerase  TPIS_MOUSE 18 2.19 
P63038 60 kDa heat shock protein, mitochondrial  CH60_MOUSE 36 2.16 
Q61362 Chitinase-3-like protein 1  CH3L1_MOUSE 22 2.16 
P25785 Metalloproteinase inhibitor 2  TIMP2_MOUSE 14 2.08 
Q8BFZ3 Beta-actin-like protein 2  ACTBL_MOUSE 24 2.08 
Q9DCW4 Electron transfer flavoprotein subunit 
beta  
ETFB_MOUSE 14 2.08 
P63101 14-3-3 protein zeta/delta  1433Z_MOUSE 19 2.07 
Q03265 ATP synthase subunit alpha, 
mitochondrial  
ATPA_MOUSE 36 2.07 
Q62266 Cornifin-A  SPR1A_MOUSE 13 2.01 
P21956 Lactadherin  MFGM_MOUSE 23 1.99 
P15626 Glutathione S-transferase Mu 2  GSTM2_MOUSE 18 1.97 
Q9CQV3 Serpin B11  SPB11_MOUSE 24 1.97 
P63242 Eukaryotic translation initiation factor 5A-
1  
IF5A1_MOUSE 8 1.93 
P11276 Fibronectin  FINC_MOUSE 108 1.84 
P51881 ADP/ATP translocase 2  ADT2_MOUSE 21 1.84 
P05064 Fructose-bisphosphate aldolase A  ALDOA_MOUSE 23 1.82 
Q01853 Transitional endoplasmic reticulum 
ATPase  
TERA_MOUSE 45 1.82 
P70296 Phosphatidylethanolamine-binding 
protein 1  
PEBP1_MOUSE 9 1.81 
P21981 Protein-glutamine gamma-
glutamyltransferase 2  
TGM2_MOUSE 36 1.79 
P26043 Radixin  RADI_MOUSE 39 1.79 
P62245 40S ribosomal protein S15a  RS15A_MOUSE 11 1.76 
313  
Accession 
Number 
Protein Name (Wt ALI Day 14 mMECs) Gene name Peptide 
count 
emPAI 
Q6IFX2 Keratin, type I cytoskeletal 42  K1C42_MOUSE 33 1.75 
Q9DCD0 6-phosphogluconate dehydrogenase, 
decarboxylating  
6PGD_MOUSE 29 1.74 
P54116 Erythrocyte band 7 integral membrane 
protein  
STOM_MOUSE 17 1.71 
P26041 Moesin  MOES_MOUSE 40 1.7 
P18242 Cathepsin D  CATD_MOUSE 20 1.67 
Q923D2 Flavin reductase (NADPH)  BLVRB_MOUSE 13 1.65 
Q9R0Q7 Prostaglandin E synthase 3  TEBP_MOUSE 9 1.65 
P23492 Purine nucleoside phosphorylase  PNPH_MOUSE 19 1.64 
Q60932 Voltage-dependent anion-selective 
channel protein 1  
VDAC1_MOUSE 18 1.64 
Q9D051 Pyruvate dehydrogenase E1 component 
subunit beta, mitochondrial  
ODPB_MOUSE 18 1.63 
Q9WVA4 Transgelin-2  TAGL2_MOUSE 14 1.63 
P37040 NADPH--cytochrome P450 reductase  NCPR_MOUSE 35 1.6 
P61027 Ras-related protein Rab-10  RAB10_MOUSE 17 1.6 
P67778 Prohibitin  PHB_MOUSE 18 1.58 
P56382 ATP synthase subunit epsilon, 
mitochondrial  
ATP5E_MOUSE 4 1.56 
O88312 Anterior gradient protein 2 homolog  AGR2_MOUSE 10 1.53 
P24369 Peptidyl-prolyl cis-trans isomerase B  PPIB_MOUSE 15 1.51 
P50404 Pulmonary surfactant-associated protein 
D  
SFTPD_MOUSE 23 1.5 
P48678 Prelamin-A/C  LMNA_MOUSE 46 1.47 
P61750 ADP-ribosylation factor 4  ARF4_MOUSE 12 1.47 
Q61176 Arginase-1  ARGI1_MOUSE 18 1.47 
Q8BSL7 ADP-ribosylation factor 2  ARF2_MOUSE 12 1.45 
P62827 GTP-binding nuclear protein Ran  RAN_MOUSE 11 1.44 
P10810 Monocyte differentiation antigen CD14  CD14_MOUSE 16 1.41 
Q9CRB3 5-hydroxyisourate hydrolase  HIUH_MOUSE 7 1.41 
Q61598 Rab GDP dissociation inhibitor beta  GDIB_MOUSE 28 1.4 
P24549 Retinal dehydrogenase 1  AL1A1_MOUSE 23 1.39 
P38647 Stress-70 protein, mitochondrial  GRP75_MOUSE 43 1.39 
Q61468 Mesothelin  MSLN_MOUSE 29 1.38 
Q9QYB1 Chloride intracellular channel protein 4  CLIC4_MOUSE 17 1.38 
P24472 Glutathione S-transferase A4  GSTA4_MOUSE 12 1.36 
Q8BFU2 Histone H2A type 3  H2A3_MOUSE 7 1.36 
O35129 Prohibitin-2  PHB2_MOUSE 26 1.35 
O88569 Heterogeneous nuclear 
ribonucleoproteins A2/B1  
ROA2_MOUSE 19 1.33 
P47911 60S ribosomal protein L6  RL6_MOUSE 19 1.33 
Q9CPV4 Glyoxalase domain-containing protein 4  GLOD4_MOUSE 22 1.33 
Q9WV54 Acid ceramidase  ASAH1_MOUSE 21 1.33 
Q8BPB5 EGF-containing fibulin-like extracellular 
matrix protein 1  
FBLN3_MOUSE 27 1.31 
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Q8VDN2 Sodium/potassium-transporting ATPase 
subunit alpha-1  
AT1A1_MOUSE 53 1.27 
P97461 40S ribosomal protein S5  RS5_MOUSE 10 1.25 
Q60931 Voltage-dependent anion-selective 
channel protein 3  
VDAC3_MOUSE 17 1.25 
Q64433 10 kDa heat shock protein, mitochondrial  CH10_MOUSE 10 1.25 
Q62426 Cystatin-B  CYTB_MOUSE 6 1.24 
Q99LC5 Electron transfer flavoprotein subunit 
alpha, mitochondrial  
ETFA_MOUSE 23 1.24 
P47757 F-actin-capping protein subunit beta  CAPZB_MOUSE 20 1.22 
P51174 Long-chain specific acyl-CoA 
dehydrogenase, mitochondrial  
ACADL_MOUSE 24 1.21 
P08207 Protein S100-A10  S10AA_MOUSE 5 1.2 
P84228 Histone H3.2  H32_MOUSE 6 1.2 
Q9CR57 60S ribosomal protein L14  RL14_MOUSE 12 1.2 
P09411 Phosphoglycerate kinase 1  PGK1_MOUSE 29 1.18 
Q6IFZ6 Keratin, type II cytoskeletal 1b  K2C1B_MOUSE 39 1.18 
P62267 40S ribosomal protein S23  RS23_MOUSE 8 1.15 
Q91VR2 ATP synthase subunit gamma, 
mitochondrial  
ATPG_MOUSE 17 1.15 
Q9CQI6 Coactosin-like protein  COTL1_MOUSE 10 1.14 
Q9D8N0 Elongation factor 1-gamma  EF1G_MOUSE 27 1.14 
P10639 Thioredoxin  THIO_MOUSE 7 1.12 
P84084 ADP-ribosylation factor 5  ARF5_MOUSE 13 1.12 
P62264 40S ribosomal protein S14  RS14_MOUSE 6 1.11 
Q9ER10 Brain-specific serine protease 4  BSSP4_MOUSE 15 1.11 
Q91VI7 Ribonuclease inhibitor  RINI_MOUSE 27 1.1 
P62702 40S ribosomal protein S4, X isoform  RS4X_MOUSE 20 1.09 
P62717 60S ribosomal protein L18a  RL18A_MOUSE 14 1.09 
P97351 40S ribosomal protein S3a  RS3A_MOUSE 19 1.08 
Q99JY9 Actin-related protein 3  ARP3_MOUSE 21 1.08 
P17879 Heat shock 70 kDa protein 1B  HS71B_MOUSE 37 1.07 
P60766 Cell division control protein 42 homolog  CDC42_MOUSE 9 1.06 
O88342 WD repeat-containing protein 1  WDR1_MOUSE 37 1.05 
P08905 Lysozyme C-2  LYZ2_MOUSE 10 1.05 
P29758 Ornithine aminotransferase, 
mitochondrial  
OAT_MOUSE 23 1.05 
P15532 Nucleoside diphosphate kinase A  NDKA_MOUSE 12 1.03 
P48036 Annexin A5  ANXA5_MOUSE 25 1.03 
P51410 60S ribosomal protein L9  RL9_MOUSE 11 1.03 
Q61171 Peroxiredoxin-2  PRDX2_MOUSE 10 1.03 
Q01768 Nucleoside diphosphate kinase B  NDKB_MOUSE 12 1.02 
Q8K354 Carbonyl reductase [NADPH] 3  CBR3_MOUSE 20 1.02 
Q91XV3 Brain acid soluble protein 1  BASP1_MOUSE 10 1.02 
P62889 60S ribosomal protein L30  RL30_MOUSE 8 1.01 
P99029 Peroxiredoxin-5, mitochondrial  PRDX5_MOUSE 15 1.01 
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Q00612 Glucose-6-phosphate 1-dehydrogenase X  G6PD1_MOUSE 35 1.01 
P14152 Malate dehydrogenase, cytoplasmic  MDHC_MOUSE 21 1 
Q68FD5 Clathrin heavy chain 1  CLH1_MOUSE 95 0.99 
Q6ZWN5 40S ribosomal protein S9  RS9_MOUSE 14 0.99 
P60843 Eukaryotic initiation factor 4A-I  IF4A1_MOUSE 23 0.98 
Q60930 Voltage-dependent anion-selective 
channel protein 2  
VDAC2_MOUSE 16 0.98 
Q9WV32 Actin-related protein 2/3 complex subunit 
1B  
ARC1B_MOUSE 19 0.98 
P16110 Galectin-3  LEG3_MOUSE 10 0.97 
P35441 Thrombospondin-1  TSP1_MOUSE 70 0.97 
P05202 Aspartate aminotransferase, 
mitochondrial  
AATM_MOUSE 29 0.95 
P48962 ADP/ATP translocase 1  ADT1_MOUSE 22 0.95 
P58252 Elongation factor 2  EF2_MOUSE 52 0.95 
P62281 40S ribosomal protein S11  RS11_MOUSE 10 0.94 
P62874 Guanine nucleotide-binding protein 
G(I)/G(S)/G(T) subunit beta-1  
GBB1_MOUSE 13 0.94 
Q9WTY4 Aquaporin-5  AQP5_MOUSE 8 0.94 
Q9Z0K8 Pantetheinase  VNN1_MOUSE 23 0.94 
O70435 Proteasome subunit alpha type-3  PSA3_MOUSE 14 0.93 
P53994 Ras-related protein Rab-2A  RAB2A_MOUSE 15 0.93 
Q3UV17 Keratin, type II cytoskeletal 2 oral  K22O_MOUSE 39 0.93 
P35486 Pyruvate dehydrogenase E1 component 
subunit alpha, somatic form, 
mitochondrial  
ODPA_MOUSE 25 0.92 
P47791 Glutathione reductase, mitochondrial  GSHR_MOUSE 25 0.91 
Q9DAU7 WAP four-disulfide core domain protein 2  WFDC2_MOUSE 6 0.91 
P24452 Macrophage-capping protein  CAPG_MOUSE 14 0.9 
P62259 14-3-3 protein epsilon  1433E_MOUSE 18 0.9 
Q9CZM2 60S ribosomal protein L15  RL15_MOUSE 14 0.9 
P11214 Tissue-type plasminogen activator  TPA_MOUSE 31 0.89 
P62242 40S ribosomal protein S8  RS8_MOUSE 10 0.89 
Q8BG05 Heterogeneous nuclear ribonucleoprotein 
A3  
ROA3_MOUSE 20 0.89 
Q9WUU7 Cathepsin Z  CATZ_MOUSE 14 0.89 
P04104 Keratin, type II cytoskeletal 1  K2C1_MOUSE 35 0.88 
Q61581 Insulin-like growth factor-binding protein 
7  
IBP7_MOUSE 18 0.88 
P08113 Endoplasmin  ENPL_MOUSE 47 0.87 
Q3THE2 Myosin regulatory light chain 12B  ML12B_MOUSE 11 0.86 
Q6ZWV3 60S ribosomal protein L10  RL10_MOUSE 13 0.86 
P27659 60S ribosomal protein L3  RL3_MOUSE 22 0.85 
P62331 ADP-ribosylation factor 6  ARF6_MOUSE 9 0.85 
P63323 40S ribosomal protein S12  RS12_MOUSE 7 0.85 
P67984 60S ribosomal protein L22  RL22_MOUSE 6 0.85 
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Q80X90 Filamin-B  FLNB_MOUSE 146 0.85 
Q99LX0 Protein DJ-1  PARK7_MOUSE 13 0.85 
P06745 Glucose-6-phosphate isomerase  G6PI_MOUSE 32 0.84 
P16460 Argininosuccinate synthase  ASSY_MOUSE 25 0.84 
P48758 Carbonyl reductase [NADPH] 1  CBR1_MOUSE 19 0.84 
Q6ZWU9 40S ribosomal protein S27  RS27_MOUSE 5 0.83 
Q91YQ5 Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase subunit 1  
RPN1_MOUSE 40 0.83 
Q9CXW4 60S ribosomal protein L11  RL11_MOUSE 9 0.83 
O35640 Annexin A8  ANXA8_MOUSE 23 0.82 
P56395 Cytochrome b5  CYB5_MOUSE 8 0.82 
Q9CZ13 Cytochrome b-c1 complex subunit 1, 
mitochondrial  
QCR1_MOUSE 22 0.82 
O88593 Peptidoglycan recognition protein 1  PGRP1_MOUSE 10 0.81 
Q60854 Serpin B6  SPB6_MOUSE 23 0.81 
P14069 Protein S100-A6  S10A6_MOUSE 5 0.79 
P61358 60S ribosomal protein L27  RL27_MOUSE 6 0.79 
P62835 Ras-related protein Rap-1A  RAP1A_MOUSE 10 0.79 
P62880 Guanine nucleotide-binding protein 
G(I)/G(S)/G(T) subunit beta-2  
GBB2_MOUSE 13 0.79 
Q9QXC1 Fetuin-B  FETUB_MOUSE 17 0.79 
P11983 T-complex protein 1 subunit alpha  TCPA_MOUSE 35 0.78 
P14206 40S ribosomal protein SA  RSSA_MOUSE 15 0.78 
P62137 Serine/threonine-protein phosphatase 
PP1-alpha catalytic subunit  
PP1A_MOUSE 19 0.78 
P62911 60S ribosomal protein L32  RL32_MOUSE 8 0.77 
P70441 Na(+)/H(+) exchange regulatory cofactor 
NHE-RF1  
NHRF1_MOUSE 27 0.77 
P61514 60S ribosomal protein L37a  RL37A_MOUSE 6 0.75 
P61979 Heterogeneous nuclear ribonucleoprotein 
K  
HNRPK_MOUSE 27 0.75 
P63168 Dynein light chain 1, cytoplasmic  DYL1_MOUSE 5 0.75 
P68254 14-3-3 protein theta  1433T_MOUSE 18 0.75 
P0CG49 Polyubiquitin-B  UBB_MOUSE 28 0.74 
P40124 Adenylyl cyclase-associated protein 1  CAP1_MOUSE 30 0.74 
P62196 26S protease regulatory subunit 8  PRS8_MOUSE 28 0.74 
Q9CQV8 14-3-3 protein beta/alpha  1433B_MOUSE 17 0.74 
Q9Z2X1 Heterogeneous nuclear ribonucleoprotein 
F  
HNRPF_MOUSE 22 0.74 
O55234 Proteasome subunit beta type-5  PSB5_MOUSE 16 0.73 
P10630 Eukaryotic initiation factor 4A-II  IF4A2_MOUSE 23 0.73 
P47962 60S ribosomal protein L5  RL5_MOUSE 17 0.73 
P08752 Guanine nucleotide-binding protein G(i) 
subunit alpha-2  
GNAI2_MOUSE 20 0.72 
Q9CQQ7 ATP synthase F(0) complex subunit B1, 
mitochondrial  
AT5F1_MOUSE 18 0.72 
Q9DBH5 Vesicular integral-membrane protein LMAN2_MOUSE 21 0.72 
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VIP36  
P14602 Heat shock protein beta-1  HSPB1_MOUSE 12 0.71 
P99026 Proteasome subunit beta type-4  PSB4_MOUSE 11 0.71 
P80316 T-complex protein 1 subunit epsilon  TCPE_MOUSE 36 0.7 
P12970 60S ribosomal protein L7a  RL7A_MOUSE 16 0.69 
P51150 Ras-related protein Rab-7a  RAB7A_MOUSE 17 0.69 
P63330 Serine/threonine-protein phosphatase 2A 
catalytic subunit alpha isoform  
PP2AA_MOUSE 18 0.69 
P97494 Glutamate--cysteine ligase catalytic 
subunit  
GSH1_MOUSE 34 0.69 
Q8BTM8 Filamin-A  FLNA_MOUSE 143 0.69 
Q99KI0 Aconitate hydratase, mitochondrial  ACON_MOUSE 41 0.69 
O54734 Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase 48 kDa subunit  
OST48_MOUSE 22 0.68 
O70570 Polymeric immunoglobulin receptor  PIGR_MOUSE 38 0.68 
P47955 60S acidic ribosomal protein P1  RLA1_MOUSE 4 0.68 
Q8BP67 60S ribosomal protein L24  RL24_MOUSE 10 0.68 
Q91V41 Ras-related protein Rab-14  RAB14_MOUSE 15 0.68 
Q9D154 Leukocyte elastase inhibitor A  ILEUA_MOUSE 23 0.68 
Q9JII6 Alcohol dehydrogenase [NADP(+)]  AK1A1_MOUSE 23 0.68 
P60122 RuvB-like 1  RUVB1_MOUSE 22 0.66 
Q93092 Transaldolase  TALDO_MOUSE 23 0.66 
Q99020 Heterogeneous nuclear ribonucleoprotein 
A/B  
ROAA_MOUSE 14 0.66 
Q9D2Q8 Protein S100-A14  S10AE_MOUSE 8 0.66 
P09405 Nucleolin  NUCL_MOUSE 48 0.65 
P25444 40S ribosomal protein S2  RS2_MOUSE 22 0.65 
Q61503 5~-nucleotidase  5NTD_MOUSE 32 0.65 
Q6IME9 Keratin, type II cytoskeletal 72  K2C72_MOUSE 34 0.65 
Q9D1D4 Transmembrane emp24 domain-
containing protein 10  
TMEDA_MOUSE 10 0.65 
P30115 Glutathione S-transferase A3  GSTA3_MOUSE 14 0.64 
P54071 Isocitrate dehydrogenase [NADP], 
mitochondrial  
IDHP_MOUSE 31 0.64 
P80317 T-complex protein 1 subunit zeta  TCPZ_MOUSE 29 0.64 
Q64727 Vinculin  VINC_MOUSE 84 0.64 
Q9WTM5 RuvB-like 2  RUVB2_MOUSE 28 0.64 
Q9CZU6 Citrate synthase, mitochondrial  CISY_MOUSE 21 0.63 
P00405 Cytochrome c oxidase subunit 2  COX2_MOUSE 6 0.62 
Q61937 Nucleophosmin  NPM_MOUSE 16 0.62 
Q62186 Translocon-associated protein subunit 
delta  
SSRD_MOUSE 8 0.62 
Q69ZN7 Myoferlin  MYOF_MOUSE 131 0.62 
O55142 60S ribosomal protein L35a  RL35A_MOUSE 9 0.61 
P21107 Tropomyosin alpha-3 chain  TPM3_MOUSE 24 0.61 
P34884 Macrophage migration inhibitory factor  MIF_MOUSE 5 0.61 
318  
Accession 
Number 
Protein Name (Wt ALI Day 14 mMECs) Gene name Peptide 
count 
emPAI 
Q8VEM8 Phosphate carrier protein, mitochondrial  MPCP_MOUSE 21 0.61 
Q9Z2U1 Proteasome subunit alpha type-5  PSA5_MOUSE 11 0.6 
Q8BMS1 Trifunctional enzyme subunit alpha, 
mitochondrial  
ECHA_MOUSE 40 0.59 
O08756 3-hydroxyacyl-CoA dehydrogenase type-2  HCD2_MOUSE 16 0.58 
P35550 rRNA 2~-O-methyltransferase fibrillarin  FBRL_MOUSE 24 0.58 
P49312 Heterogeneous nuclear ribonucleoprotein 
A1  
ROA1_MOUSE 19 0.58 
O35737 Heterogeneous nuclear ribonucleoprotein 
H  
HNRH1_MOUSE 25 0.57 
O70456 14-3-3 protein sigma  1433S_MOUSE 19 0.57 
P60867 40S ribosomal protein S20  RS20_MOUSE 6 0.57 
P62315 Small nuclear ribonucleoprotein Sm D1  SMD1_MOUSE 5 0.57 
P62855 40S ribosomal protein S26  RS26_MOUSE 6 0.57 
Q9QUM9 Proteasome subunit alpha type-6  PSA6_MOUSE 13 0.57 
P08003 Protein disulfide-isomerase A4  PDIA4_MOUSE 43 0.56 
P0C0S6 Histone H2A.Z  H2AZ_MOUSE 6 0.56 
P61982 14-3-3 protein gamma  1433G_MOUSE 18 0.56 
P68510 14-3-3 protein eta  1433F_MOUSE 18 0.56 
Q8BP47 Asparagine--tRNA ligase, cytoplasmic  SYNC_MOUSE 30 0.56 
Q9JM76 Actin-related protein 2/3 complex subunit 
3  
ARPC3_MOUSE 12 0.56 
P45376 Aldose reductase  ALDR_MOUSE 20 0.55 
P50396 Rab GDP dissociation inhibitor alpha  GDIA_MOUSE 26 0.55 
P62754 40S ribosomal protein S6  RS6_MOUSE 13 0.55 
P62852 40S ribosomal protein S25  RS25_MOUSE 6 0.55 
Q78IK2 Up-regulated during skeletal muscle 
growth protein 5  
USMG5_MOUSE 3 0.55 
P12265 Beta-glucuronidase  BGLR_MOUSE 33 0.54 
P35980 60S ribosomal protein L18  RL18_MOUSE 9 0.54 
P50580 Proliferation-associated protein 2G4  PA2G4_MOUSE 24 0.54 
Q9R118 Serine protease HTRA1  HTRA1_MOUSE 21 0.54 
O54990 Prominin-1  PROM1_MOUSE 41 0.53 
P09803 Cadherin-1  CADH1_MOUSE 33 0.53 
P63001 Ras-related C3 botulinum toxin substrate 
1  
RAC1_MOUSE 9 0.53 
Q921F2 TAR DNA-binding protein 43  TADBP_MOUSE 17 0.53 
P14685 26S proteasome non-ATPase regulatory 
subunit 3  
PSMD3_MOUSE 39 0.52 
P62082 40S ribosomal protein S7  RS7_MOUSE 11 0.52 
Q8BFZ9 Erlin-2  ERLN2_MOUSE 24 0.52 
Q8BHN3 Neutral alpha-glucosidase AB  GANAB_MOUSE 51 0.52 
Q9D8W5 26S proteasome non-ATPase regulatory 
subunit 12  
PSD12_MOUSE 34 0.52 
O55143 Sarcoplasmic/endoplasmic reticulum 
calcium ATPase 2  
AT2A2_MOUSE 54 0.51 
Q60668 Heterogeneous nuclear ribonucleoprotein HNRPD_MOUSE 15 0.51 
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D0  
Q9R0Q3 Transmembrane emp24 domain-
containing protein 2  
TMED2_MOUSE 11 0.51 
O08807 Peroxiredoxin-4  PRDX4_MOUSE 16 0.5 
P29341 Polyadenylate-binding protein 1  PABP1_MOUSE 38 0.5 
P30412 Peptidyl-prolyl cis-trans isomerase C  PPIC_MOUSE 11 0.5 
Q99K51 Plastin-3  PLST_MOUSE 40 0.5 
Q9CYN9 Renin receptor  RENR_MOUSE 17 0.5 
P12032 Metalloproteinase inhibitor 1  TIMP1_MOUSE 12 0.49 
P14148 60S ribosomal protein L7  RL7_MOUSE 18 0.49 
P57776 Elongation factor 1-delta  EF1D_MOUSE 20 0.49 
P97430 Antileukoproteinase  SLPI_MOUSE 11 0.49 
Q99PT1 Rho GDP-dissociation inhibitor 1  GDIR1_MOUSE 14 0.49 
Q9DB20 ATP synthase subunit O, mitochondrial  ATPO_MOUSE 14 0.49 
Q9WU78 Programmed cell death 6-interacting 
protein  
PDC6I_MOUSE 52 0.49 
P10493 Nidogen-1  NID1_MOUSE 46 0.48 
P17225 Polypyrimidine tract-binding protein 1  PTBP1_MOUSE 22 0.48 
P28474 Alcohol dehydrogenase class-3  ADHX_MOUSE 20 0.48 
P62814 V-type proton ATPase subunit B, brain 
isoform  
VATB2_MOUSE 29 0.48 
P62849 40S ribosomal protein S24  RS24_MOUSE 7 0.48 
P14733 Lamin-B1  LMNB1_MOUSE 39 0.47 
P41105 60S ribosomal protein L28  RL28_MOUSE 11 0.47 
P47963 60S ribosomal protein L13  RL13_MOUSE 14 0.47 
P80315 T-complex protein 1 subunit delta  TCPD_MOUSE 37 0.47 
Q8BFR5 Elongation factor Tu, mitochondrial  EFTU_MOUSE 31 0.47 
Q9DC16 Endoplasmic reticulum-Golgi intermediate 
compartment protein 1  
ERGI1_MOUSE 13 0.47 
O70251 Elongation factor 1-beta  EF1B_MOUSE 14 0.46 
P14824 Annexin A6  ANXA6_MOUSE 49 0.46 
P14131 40S ribosomal protein S16  RS16_MOUSE 12 0.45 
P24270 Catalase  CATA_MOUSE 35 0.45 
P24527 Leukotriene A-4 hydrolase  LKHA4_MOUSE 39 0.45 
P42932 T-complex protein 1 subunit theta  TCPQ_MOUSE 39 0.45 
P53026 60S ribosomal protein L10a  RL10A_MOUSE 15 0.45 
Q791V5 Mitochondrial carrier homolog 2  MTCH2_MOUSE 14 0.45 
Q9CQX2 Cytochrome b5 type B  CYB5B_MOUSE 8 0.45 
Q9DBG6 Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase subunit 2  
RPN2_MOUSE 26 0.45 
Q9WTP7 GTP:AMP phosphotransferase AK3, 
mitochondrial  
KAD3_MOUSE 19 0.45 
P13745 Glutathione S-transferase A1  GSTA1_MOUSE 14 0.44 
P14869 60S acidic ribosomal protein P0  RLA0_MOUSE 18 0.44 
P49722 Proteasome subunit alpha type-2  PSA2_MOUSE 13 0.44 
P61079 Ubiquitin-conjugating enzyme E2 D3  UB2D3_MOUSE 5 0.44 
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Q61206 Platelet-activating factor acetylhydrolase 
IB subunit beta  
PA1B2_MOUSE 10 0.44 
Q9CVB6 Actin-related protein 2/3 complex subunit 
2  
ARPC2_MOUSE 22 0.44 
P14094 Sodium/potassium-transporting ATPase 
subunit beta-1  
AT1B1_MOUSE 16 0.43 
P61089 Ubiquitin-conjugating enzyme E2 N  UBE2N_MOUSE 11 0.43 
P61255 60S ribosomal protein L26  RL26_MOUSE 9 0.43 
P62334 26S protease regulatory subunit 10B  PRS10_MOUSE 27 0.43 
Q8K183 Pyridoxal kinase  PDXK_MOUSE 16 0.43 
Q921H8 3-ketoacyl-CoA thiolase A, peroxisomal  THIKA_MOUSE 22 0.43 
Q9D0S9 Histidine triad nucleotide-binding protein 
2, mitochondrial  
HINT2_MOUSE 11 0.43 
P06801 NADP-dependent malic enzyme  MAOX_MOUSE 32 0.42 
P16675 Lysosomal protective protein  PPGB_MOUSE 22 0.42 
Q62267 Cornifin-B  SPR1B_MOUSE 15 0.42 
Q8K2B3 Succinate dehydrogenase [ubiquinone] 
flavoprotein subunit, mitochondrial  
SDHA_MOUSE 36 0.42 
Q9JJI8 60S ribosomal protein L38  RL38_MOUSE 3 0.42 
P35979 60S ribosomal protein L12  RL12_MOUSE 11 0.41 
P62270 40S ribosomal protein S18  RS18_MOUSE 12 0.41 
Q8R081 Heterogeneous nuclear ribonucleoprotein 
L  
HNRPL_MOUSE 24 0.41 
Q9JJ00 Phospholipid scramblase 1  PLS1_MOUSE 13 0.41 
P45952 Medium-chain specific acyl-CoA 
dehydrogenase, mitochondrial  
ACADM_MOUSE 22 0.4 
P60335 Poly(rC)-binding protein 1  PCBP1_MOUSE 20 0.4 
P61939 Thyroxine-binding globulin  THBG_MOUSE 22 0.4 
Q08761 Vitamin K-dependent protein S  PROS_MOUSE 37 0.4 
Q61753 D-3-phosphoglycerate dehydrogenase  SERA_MOUSE 22 0.4 
Q9D8E6 60S ribosomal protein L4  RL4_MOUSE 27 0.4 
Q9WV55 Vesicle-associated membrane protein-
associated protein A  
VAPA_MOUSE 15 0.4 
Q9Z2U0 Proteasome subunit alpha type-7  PSA7_MOUSE 16 0.4 
O09167 60S ribosomal protein L21  RL21_MOUSE 9 0.39 
P63325 40S ribosomal protein S10  RS10_MOUSE 13 0.39 
Q8VEK3 Heterogeneous nuclear ribonucleoprotein 
U  
HNRPU_MOUSE 43 0.39 
Q922R8 Protein disulfide-isomerase A6  PDIA6_MOUSE 25 0.39 
Q9DB77 Cytochrome b-c1 complex subunit 2, 
mitochondrial  
QCR2_MOUSE 22 0.39 
P13597 Intercellular adhesion molecule 1  ICAM1_MOUSE 26 0.38 
P17710 Hexokinase-1  HXK1_MOUSE 57 0.38 
P70333 Heterogeneous nuclear ribonucleoprotein 
H2  
HNRH2_MOUSE 25 0.38 
Q02053 Ubiquitin-like modifier-activating enzyme 
1  
UBA1_MOUSE 55 0.38 
Q6URW6 Myosin-14  MYH14_MOUSE 126 0.38 
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Q9DBJ1 Phosphoglycerate mutase 1  PGAM1_MOUSE 15 0.38 
P26443 Glutamate dehydrogenase 1, 
mitochondrial  
DHE3_MOUSE 35 0.37 
P48771 Cytochrome c oxidase subunit 7A2, 
mitochondrial  
CX7A2_MOUSE 5 0.37 
P59999 Actin-related protein 2/3 complex subunit 
4  
ARPC4_MOUSE 13 0.37 
P70195 Proteasome subunit beta type-7  PSB7_MOUSE 12 0.37 
Q62425 Cytochrome c oxidase subunit NDUFA4  NDUA4_MOUSE 6 0.37 
Q9D6R2 Isocitrate dehydrogenase [NAD] subunit 
alpha, mitochondrial  
IDH3A_MOUSE 21 0.37 
Q9R1P0 Proteasome subunit alpha type-4  PSA4_MOUSE 14 0.37 
O55023 Inositol monophosphatase 1  IMPA1_MOUSE 17 0.36 
P42208 Septin-2  SEPT2_MOUSE 21 0.36 
Q8CAQ8 MICOS complex subunit Mic60  MIC60_MOUSE 55 0.36 
Q99JY0 Trifunctional enzyme subunit beta, 
mitochondrial  
ECHB_MOUSE 28 0.36 
P04186 Complement factor B  CFAB_MOUSE 42 0.35 
P13020 Gelsolin  GELS_MOUSE 34 0.35 
P25085 Interleukin-1 receptor antagonist protein  IL1RA_MOUSE 7 0.35 
P61211 ADP-ribosylation factor-like protein 1  ARL1_MOUSE 10 0.35 
P70124 Serpin B5  SPB5_MOUSE 22 0.35 
Q9QZ88 Vacuolar protein sorting-associated 
protein 29  
VPS29_MOUSE 11 0.35 
O08749 Dihydrolipoyl dehydrogenase, 
mitochondrial  
DLDH_MOUSE 26 0.34 
P47740 Fatty aldehyde dehydrogenase  AL3A2_MOUSE 21 0.34 
P97384 Annexin A11  ANX11_MOUSE 22 0.34 
P97449 Aminopeptidase N  AMPN_MOUSE 51 0.34 
P97807 Fumarate hydratase, mitochondrial  FUMH_MOUSE 32 0.34 
Q62465 Synaptic vesicle membrane protein VAT-1 
homolog  
VAT1_MOUSE 18 0.34 
Q99K48 Non-POU domain-containing octamer-
binding protein  
NONO_MOUSE 23 0.34 
Q9CQS8 Protein transport protein Sec61 subunit 
beta  
SC61B_MOUSE 6 0.34 
Q9DC53 Copine-8  CPNE8_MOUSE 33 0.34 
Q9JKR6 Hypoxia up-regulated protein 1  HYOU1_MOUSE 58 0.34 
O55022 Membrane-associated progesterone 
receptor component 1  
PGRC1_MOUSE 10 0.33 
Q07813 Apoptosis regulator BAX  BAX_MOUSE 10 0.33 
Q9CQW2 ADP-ribosylation factor-like protein 8B  ARL8B_MOUSE 12 0.33 
Q9DBS1 Transmembrane protein 43  TMM43_MOUSE 21 0.33 
P36536 GTP-binding protein SAR1a  SAR1A_MOUSE 11 0.32 
P46978 Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase subunit STT3A  
STT3A_MOUSE 36 0.32 
P80314 T-complex protein 1 subunit beta  TCPB_MOUSE 36 0.32 
Q7TMK9 Heterogeneous nuclear ribonucleoprotein HNRPQ_MOUSE 39 0.32 
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Q  
Q8BMF4 Dihydrolipoyllysine-residue 
acetyltransferase component of pyruvate 
dehydrogenase complex, mitochondrial  
ODP2_MOUSE 33 0.32 
Q8JZU2 Tricarboxylate transport protein, 
mitochondrial  
TXTP_MOUSE 17 0.32 
Q922B2 Aspartate--tRNA ligase, cytoplasmic  SYDC_MOUSE 38 0.32 
Q9CQN1 Heat shock protein 75 kDa, mitochondrial  TRAP1_MOUSE 50 0.32 
Q9DCN2 NADH-cytochrome b5 reductase 3  NB5R3_MOUSE 17 0.32 
O70503 Estradiol 17-beta-dehydrogenase 12  DHB12_MOUSE 18 0.31 
O88310 Intelectin-1a  ITL1A_MOUSE 17 0.31 
P05201 Aspartate aminotransferase, cytoplasmic  AATC_MOUSE 27 0.31 
P42669 Transcriptional activator protein Pur-alpha  PURA_MOUSE 15 0.31 
P62305 Small nuclear ribonucleoprotein E  RUXE_MOUSE 4 0.31 
Q02257 Junction plakoglobin  PLAK_MOUSE 44 0.31 
Q9D1Q6 Endoplasmic reticulum resident protein 44  ERP44_MOUSE 24 0.31 
Q9JKF1 Ras GTPase-activating-like protein IQGAP1  IQGA1_MOUSE 93 0.31 
Q9QWR8 Alpha-N-acetylgalactosaminidase  NAGAB_MOUSE 27 0.31 
Q9R1P1 Proteasome subunit beta type-3  PSB3_MOUSE 9 0.31 
P19253 60S ribosomal protein L13a  RL13A_MOUSE 17 0.3 
P27048 Small nuclear ribonucleoprotein-
associated protein B  
RSMB_MOUSE 14 0.3 
P35279 Ras-related protein Rab-6A  RAB6A_MOUSE 17 0.3 
P80313 T-complex protein 1 subunit eta  TCPH_MOUSE 33 0.3 
P80318 T-complex protein 1 subunit gamma  TCPG_MOUSE 38 0.3 
P97467 Peptidyl-glycine alpha-amidating 
monooxygenase  
AMD_MOUSE 51 0.3 
Q62167 ATP-dependent RNA helicase DDX3X  DDX3X_MOUSE 40 0.3 
Q8K3J9 G-protein coupled receptor family C group 
5 member C  
GPC5C_MOUSE 11 0.3 
Q9CQD1 Ras-related protein Rab-5A  RAB5A_MOUSE 14 0.3 
Q9ESW8 Pyroglutamyl-peptidase 1  PGPI_MOUSE 10 0.3 
Q9JIW9 Ras-related protein Ral-B  RALB_MOUSE 10 0.3 
Q9WUM5 Succinyl-CoA ligase [ADP/GDP-forming] 
subunit alpha, mitochondrial  
SUCA_MOUSE 15 0.3 
Q9Z0L8 Gamma-glutamyl hydrolase  GGH_MOUSE 17 0.3 
O08547 Vesicle-trafficking protein SEC22b  SC22B_MOUSE 13 0.29 
O70554 Small proline-rich protein 2B  SPR2B_MOUSE 5 0.29 
P00493 Hypoxanthine-guanine 
phosphoribosyltransferase  
HPRT_MOUSE 13 0.29 
P46638 Ras-related protein Rab-11B  RB11B_MOUSE 16 0.29 
Q07076 Annexin A7  ANXA7_MOUSE 23 0.29 
Q61879 Myosin-10  MYH10_MOUSE 125 0.29 
Q8K353 Cysteine-rich and transmembrane 
domain-containing protein 1  
CYTM1_MOUSE 2 0.29 
Q8VDW0 ATP-dependent RNA helicase DDX39A  DX39A_MOUSE 26 0.29 
Q9CYH2 Redox-regulatory protein FAM213A  F213A_MOUSE 14 0.29 
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Q9D103 Interferon-induced transmembrane 
protein 1  
IFM1_MOUSE 2 0.29 
Q9R112 Sulfide:quinone oxidoreductase, 
mitochondrial  
SQRD_MOUSE 32 0.29 
O54782 Epididymis-specific alpha-mannosidase  MA2B2_MOUSE 44 0.28 
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P08071 Lactotransferrin  TRFL_MOUSE 47 247.93 
Q921I1 Serotransferrin  TRFE_MOUSE 40 13.69 
O09049 Regenerating islet-derived protein 3-
gamma  
REG3G_MOUSE 8 8.04 
O09131 Glutathione S-transferase omega-1  GSTO1_MOUSE 17 6.64 
P11672 Neutrophil gelatinase-associated lipocalin  NGAL_MOUSE 9 5.66 
P60710 Actin, cytoplasmic 1  ACTB_MOUSE 23 5.11 
Q61147 Ceruloplasmin  CERU_MOUSE 55 4.58 
P08074 Carbonyl reductase [NADPH] 2  CBR2_MOUSE 16 4.36 
Q06890 Clusterin  CLUS_MOUSE 22 3.32 
P10649 Glutathione S-transferase Mu 1  GSTM1_MOUSE 18 3.22 
P50446 Keratin, type II cytoskeletal 6A  K2C6A_MOUSE 35 2.43 
Q8BND5 Sulfhydryl oxidase 1  QSOX1_MOUSE 43 2.42 
P10107 Annexin A1  ANXA1_MOUSE 24 2.39 
O35639 Annexin A3  ANXA3_MOUSE 24 2.36 
P11679 Keratin, type II cytoskeletal 8  K2C8_MOUSE 33 2.22 
P07356 Annexin A2  ANXA2_MOUSE 23 2.12 
Q922U2 Keratin, type II cytoskeletal 5  K2C5_MOUSE 34 2.11 
Q9DCV7 Keratin, type II cytoskeletal 7  K2C7_MOUSE 35 2.1 
Q9Z331 Keratin, type II cytoskeletal 6B  K2C6B_MOUSE 36 2.03 
Q61414 Keratin, type I cytoskeletal 15  K1C15_MOUSE 32 2 
P10605 Cathepsin B  CATB_MOUSE 15 1.94 
P19001 Keratin, type I cytoskeletal 19  K1C19_MOUSE 35 1.92 
P26040 Ezrin  EZRI_MOUSE 39 1.76 
P62962 Profilin-1  PROF1_MOUSE 9 1.74 
Q61398 Procollagen C-endopeptidase enhancer 1  PCOC1_MOUSE 23 1.73 
P24472 Glutathione S-transferase A4  GSTA4_MOUSE 12 1.66 
Q61646 Haptoglobin  HPT_MOUSE 20 1.63 
Q61362 Chitinase-3-like protein 1  CH3L1_MOUSE 22 1.55 
Q07797 Galectin-3-binding protein  LG3BP_MOUSE 26 1.41 
O08709 Peroxiredoxin-6  PRDX6_MOUSE 15 1.4 
P08249 Malate dehydrogenase, mitochondrial  MDHM_MOUSE 24 1.4 
P01027 Complement C3  CO3_MOUSE 111 1.32 
P35700 Peroxiredoxin-1  PRDX1_MOUSE 14 1.3 
P50404 Pulmonary surfactant-associated protein D  SFTPD_MOUSE 23 1.3 
P05213 Tubulin alpha-1B chain  TBA1B_MOUSE 22 1.26 
P17182 Alpha-enolase  ENOA_MOUSE 28 1.23 
P50543 Protein S100-A11  S10AB_MOUSE 5 1.22 
Q61781 Keratin, type I cytoskeletal 14  K1C14_MOUSE 35 1.18 
P08228 Superoxide dismutase [Cu-Zn]  SODC_MOUSE 11 1.14 
P47739 Aldehyde dehydrogenase, dimeric NADP-
preferring  
AL3A1_MOUSE 25 1.12 
Q9CQV3 Serpin B11  SPB11_MOUSE 24 1.07 
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Q9QWL7 Keratin, type I cytoskeletal 17  K1C17_MOUSE 33 1.06 
P28654 Decorin  PGS2_MOUSE 23 1.04 
P10126 Elongation factor 1-alpha 1  EF1A1_MOUSE 23 1 
Q8BGZ7 Keratin, type II cytoskeletal 75  K2C75_MOUSE 36 1 
P56480 ATP synthase subunit beta, mitochondrial  ATPB_MOUSE 30 0.98 
P30412 Peptidyl-prolyl cis-trans isomerase C  PPIC_MOUSE 11 0.97 
P05784 Keratin, type I cytoskeletal 18  K1C18_MOUSE 32 0.95 
P06797 Cathepsin L1  CATL1_MOUSE 12 0.94 
P08730 Keratin, type I cytoskeletal 13  K1C13_MOUSE 31 0.94 
P19157 Glutathione S-transferase P 1  GSTP1_MOUSE 10 0.93 
Q61176 Arginase-1  ARGI1_MOUSE 18 0.88 
P07744 Keratin, type II cytoskeletal 4  K2C4_MOUSE 31 0.86 
Q8VCT4 Carboxylesterase 1D  CES1D_MOUSE 27 0.86 
P47738 Aldehyde dehydrogenase, mitochondrial  ALDH2_MOUSE 26 0.85 
P40142 Transketolase  TKT_MOUSE 34 0.84 
P57780 Alpha-actinin-4  ACTN4_MOUSE 61 0.84 
Q8VED5 Keratin, type II cytoskeletal 79  K2C79_MOUSE 32 0.84 
P52480 Pyruvate kinase PKM  KPYM_MOUSE 36 0.83 
Q8BFZ3 Beta-actin-like protein 2  ACTBL_MOUSE 24 0.82 
Q6IFX2 Keratin, type I cytoskeletal 42  K1C42_MOUSE 33 0.77 
P63101 14-3-3 protein zeta/delta  1433Z_MOUSE 19 0.75 
Q62266 Cornifin-A  SPR1A_MOUSE 13 0.74 
Q61468 Mesothelin  MSLN_MOUSE 29 0.73 
O88844 Isocitrate dehydrogenase [NADP] 
cytoplasmic  
IDHC_MOUSE 30 0.72 
Q00493 Carboxypeptidase E  CBPE_MOUSE 28 0.71 
Q03265 ATP synthase subunit alpha, mitochondrial  ATPA_MOUSE 36 0.71 
P47791 Glutathione reductase, mitochondrial  GSHR_MOUSE 25 0.7 
P08207 Protein S100-A10  S10AA_MOUSE 5 0.69 
P24369 Peptidyl-prolyl cis-trans isomerase B  PPIB_MOUSE 15 0.69 
P17742 Peptidyl-prolyl cis-trans isomerase A  PPIA_MOUSE 14 0.67 
P33267 Cytochrome P450 2F2  CP2F2_MOUSE 29 0.67 
Q93092 Transaldolase  TALDO_MOUSE 23 0.66 
Q61508 Extracellular matrix protein 1  ECM1_MOUSE 37 0.64 
P17563 Selenium-binding protein 1  SBP1_MOUSE 31 0.62 
Q9DCD0 6-phosphogluconate dehydrogenase, 
decarboxylating  
6PGD_MOUSE 29 0.61 
P26043 Radixin  RADI_MOUSE 39 0.6 
P05202 Aspartate aminotransferase, 
mitochondrial  
AATM_MOUSE 29 0.59 
Q3UV17 Keratin, type II cytoskeletal 2 oral  K22O_MOUSE 39 0.58 
Q9WUU7 Cathepsin Z  CATZ_MOUSE 14 0.58 
P16110 Galectin-3  LEG3_MOUSE 10 0.57 
Q3TTY5 Keratin, type II cytoskeletal 2 epidermal  K22E_MOUSE 43 0.57 
O88593 Peptidoglycan recognition protein 1  PGRP1_MOUSE 10 0.56 
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P16858 Glyceraldehyde-3-phosphate 
dehydrogenase  
G3P_MOUSE 21 0.55 
P06151 L-lactate dehydrogenase A chain OS LDHA_MOUSE 23 0.54 
P14152 Malate dehydrogenase, cytoplasmic  MDHC_MOUSE 21 0.54 
Q9Z2K1 Keratin, type I cytoskeletal 16  K1C16_MOUSE 35 0.54 
Q61171 Peroxiredoxin-2  PRDX2_MOUSE 10 0.53 
P05064 Fructose-bisphosphate aldolase A  ALDOA_MOUSE 23 0.49 
P54116 Erythrocyte band 7 integral membrane 
protein  
STOM_MOUSE 17 0.49 
P27773 Protein disulfide-isomerase A3  PDIA3_MOUSE 35 0.48 
Q8BPB5 EGF-containing fibulin-like extracellular 
matrix protein 1  
FBLN3_MOUSE 27 0.48 
P11499 Heat shock protein HSP 90-beta  HS90B_MOUSE 40 0.47 
P23492 Purine nucleoside phosphorylase  PNPH_MOUSE 19 0.47 
Q8VDD5 Myosin-9  MYH9_MOUSE 127 0.47 
Q9Z0K8 Pantetheinase  VNN1_MOUSE 23 0.47 
Q6NXH9 Keratin, type II cytoskeletal 73  K2C73_MOUSE 37 0.46 
Q7TPR4 Alpha-actinin-1  ACTN1_MOUSE 60 0.45 
Q9ER10 Brain-specific serine protease 4  BSSP4_MOUSE 15 0.45 
P11276 Fibronectin  FINC_MOUSE 108 0.44 
P15626 Glutathione S-transferase Mu 2  GSTM2_MOUSE 18 0.44 
Q6IFZ6 Keratin, type II cytoskeletal 1b  K2C1B_MOUSE 39 0.44 
Q61805 Lipopolysaccharide-binding protein  LBP_MOUSE 19 0.43 
P08113 Endoplasmin  ENPL_MOUSE 47 0.41 
Q9JII6 Alcohol dehydrogenase [NADP(+)]  AK1A1_MOUSE 23 0.41 
P04104 Keratin, type II cytoskeletal 1  K2C1_MOUSE 35 0.4 
P18760 Cofilin-1  COF1_MOUSE 12 0.39 
Q571E4 N-acetylgalactosamine-6-sulfatase  GALNS_MOUSE 25 0.39 
P10810 Monocyte differentiation antigen CD14  CD14_MOUSE 16 0.38 
Q01853 Transitional endoplasmic reticulum 
ATPase  
TERA_MOUSE 45 0.38 
Q9DAU7 WAP four-disulfide core domain protein 2  WFDC2_MOUSE 6 0.38 
Q9QYB1 Chloride intracellular channel protein 4  CLIC4_MOUSE 17 0.38 
Q61581 Insulin-like growth factor-binding protein 
7  
IBP7_MOUSE 18 0.37 
P06745 Glucose-6-phosphate isomerase  G6PI_MOUSE 32 0.36 
P58252 Elongation factor 2  EF2_MOUSE 52 0.35 
Q9R0P3 S-formylglutathione hydrolase  ESTD_MOUSE 16 0.35 
P09803 Cadherin-1  CADH1_MOUSE 33 0.34 
P17751 Triosephosphate isomerase  TPIS_MOUSE 18 0.34 
Q60930 Voltage-dependent anion-selective 
channel protein 2  
VDAC2_MOUSE 16 0.34 
P35980 60S ribosomal protein L18  RL18_MOUSE 9 0.33 
Q9WV54 Acid ceramidase  ASAH1_MOUSE 21 0.33 
P09103 Protein disulfide-isomerase  PDIA1_MOUSE 39 0.32 
P0CG49 Polyubiquitin-B  UBB_MOUSE 28 0.32 
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P18242 Cathepsin D  CATD_MOUSE 20 0.32 
P05201 Aspartate aminotransferase, cytoplasmic  AATC_MOUSE 27 0.31 
P61027 Ras-related protein Rab-10  RAB10_MOUSE 17 0.31 
O70570 Polymeric immunoglobulin receptor  PIGR_MOUSE 38 0.3 
P14211 Calreticulin  CALR_MOUSE 27 0.3 
P23780 Beta-galactosidase  BGAL_MOUSE 28 0.3 
P97449 Aminopeptidase N  AMPN_MOUSE 51 0.3 
Q9DB20 ATP synthase subunit O, mitochondrial  ATPO_MOUSE 14 0.3 
P47963 60S ribosomal protein L13  RL13_MOUSE 14 0.29 
P21956 Lactadherin  MFGM_MOUSE 23 0.28 
P25785 Metalloproteinase inhibitor 2  TIMP2_MOUSE 14 0.28 
P61979 Heterogeneous nuclear ribonucleoprotein 
K  
HNRPK_MOUSE 27 0.28 
Q60692 Proteasome subunit beta type-6  PSB6_MOUSE 11 0.28 
Q61503 5~-nucleotidase  5NTD_MOUSE 32 0.28 
Q9CZU6 Citrate synthase, mitochondrial  CISY_MOUSE 21 0.28 
P35441 Thrombospondin-1  TSP1_MOUSE 70 0.27 
Q8BHL4 Retinoic acid-induced protein 3  RAI3_MOUSE 13 0.26 
Q9Z1Q5 Chloride intracellular channel protein 1  CLIC1_MOUSE 17 0.26 
P02535 Keratin, type I cytoskeletal 10  K1C10_MOUSE 28 0.25 
P20029 78 kDa glucose-regulated protein  GRP78_MOUSE 39 0.25 
Q6IME9 Keratin, type II cytoskeletal 72  K2C72_MOUSE 34 0.25 
P62259 14-3-3 protein epsilon  1433E_MOUSE 18 0.24 
O88968 Transcobalamin-2  TCO2_MOUSE 23 0.22 
P11214 Tissue-type plasminogen activator  TPA_MOUSE 31 0.22 
Q8K354 Carbonyl reductase [NADPH] 3  CBR3_MOUSE 20 0.22 
P48962 ADP/ATP translocase 1  ADT1_MOUSE 22 0.21 
Q61598 Rab GDP dissociation inhibitor beta  GDIB_MOUSE 28 0.21 
Q9D312 Keratin, type I cytoskeletal 20  K1C20_MOUSE 32 0.21 
Q9R118 Serine protease HTRA1  HTRA1_MOUSE 21 0.2 
P24549 Retinal dehydrogenase 1  AL1A1_MOUSE 23 0.19 
P38647 Stress-70 protein, mitochondrial  GRP75_MOUSE 43 0.19 
P48036 Annexin A5  ANXA5_MOUSE 25 0.19 
P97494 Glutamate--cysteine ligase catalytic 
subunit  
GSH1_MOUSE 34 0.19 
Q9JJ00 Phospholipid scramblase 1  PLS1_MOUSE 13 0.19 
P09405 Nucleolin  NUCL_MOUSE 48 0.18 
P37040 NADPH--cytochrome P450 reductase  NCPR_MOUSE 35 0.18 
Q61990 Poly(rC)-binding protein 2  PCBP2_MOUSE 18 0.18 
Q8VDN2 Sodium/potassium-transporting ATPase 
subunit alpha-1  
AT1A1_MOUSE 53 0.18 
Q9WU78 Programmed cell death 6-interacting 
protein  
PDC6I_MOUSE 52 0.18 
P29268 Connective tissue growth factor  CTGF_MOUSE 24 0.17 
Q8BG05 Heterogeneous nuclear ribonucleoprotein ROA3_MOUSE 20 0.17 
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A3  
Q8VEM8 Phosphate carrier protein, mitochondrial  MPCP_MOUSE 21 0.17 
Q99K85 Phosphoserine aminotransferase  SERC_MOUSE 27 0.17 
P06801 NADP-dependent malic enzyme  MAOX_MOUSE 32 0.16 
Q60854 Serpin B6  SPB6_MOUSE 23 0.16 
Q9WV32 Actin-related protein 2/3 complex subunit 
1B  
ARC1B_MOUSE 19 0.16 
O88342 WD repeat-containing protein 1  WDR1_MOUSE 37 0.15 
P07724 Serum albumin  ALBU_MOUSE 42 0.15 
P09411 Phosphoglycerate kinase 1  PGK1_MOUSE 29 0.15 
O35737 Heterogeneous nuclear ribonucleoprotein 
H  
HNRH1_MOUSE 25 0.14 
O54990 Prominin-1  PROM1_MOUSE 41 0.14 
P29758 Ornithine aminotransferase, mitochondrial  OAT_MOUSE 23 0.14 
Q8R2Y2 Cell surface glycoprotein MUC18  MUC18_MOUSE 34 0.14 
P21981 Protein-glutamine gamma-
glutamyltransferase 2  
TGM2_MOUSE 36 0.13 
P46664 Adenylosuccinate synthetase isozyme 2  PURA2_MOUSE 27 0.13 
Q91VI7 Ribonuclease inhibitor  RINI_MOUSE 27 0.13 
Q9D379 Epoxide hydrolase 1  HYEP_MOUSE 29 0.13 
O09159 Lysosomal alpha-mannosidase  MA2B1_MOUSE 47 0.12 
O54782 Epididymis-specific alpha-mannosidase  MA2B2_MOUSE 44 0.12 
P13597 Intercellular adhesion molecule 1  ICAM1_MOUSE 26 0.11 
P23953 Carboxylesterase 1C  EST1C_MOUSE 25 0.11 
P42932 T-complex protein 1 subunit theta  TCPQ_MOUSE 39 0.11 
P63038 60 kDa heat shock protein, mitochondrial  CH60_MOUSE 36 0.11 
Q68FD5 Clathrin heavy chain 1  CLH1_MOUSE 95 0.11 
P17879 Heat shock 70 kDa protein 1B  HS71B_MOUSE 37 0.1 
Q01279 Epidermal growth factor receptor  EGFR_MOUSE 66 0.1 
Q61490 CD166 antigen  CD166_MOUSE 29 0.1 
Q61656 Probable ATP-dependent RNA helicase 
DDX5  
DDX5_MOUSE 35 0.1 
Q69ZN7 Myoferlin  MYOF_MOUSE 131 0.1 
Q8K2I4 Beta-mannosidase  MANBA_MOUSE 49 0.1 
Q8R081 Heterogeneous nuclear ribonucleoprotein 
L  
HNRPL_MOUSE 24 0.1 
Q9DC53 Copine-8  CPNE8_MOUSE 33 0.1 
P12265 Beta-glucuronidase  BGLR_MOUSE 33 0.09 
Q8BHN3 Neutral alpha-glucosidase AB  GANAB_MOUSE 51 0.09 
Q8JZM8 Mucin-4  MUC4_MOUSE 115 0.09 
Q61851 Fibroblast growth factor receptor 3  FGFR3_MOUSE 35 0.08 
Q8VEK3 Heterogeneous nuclear ribonucleoprotein 
U  
HNRPU_MOUSE 43 0.08 
Q99K30 Epidermal growth factor receptor kinase 
substrate 8-like protein 2  
ES8L2_MOUSE 40 0.08 
P17710 Hexokinase-1  HXK1_MOUSE 57 0.06 
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P97467 Peptidyl-glycine alpha-amidating 
monooxygenase  
AMD_MOUSE 51 0.06 
P10493 Nidogen-1  NID1_MOUSE 46 0.05 
Q80X90 Filamin-B  FLNB_MOUSE 146 0.05 
Q8BTM8 Filamin-A  FLNA_MOUSE 143 0.05 
Q9JKF1 Ras GTPase-activating-like protein IQGAP1  IQGA1_MOUSE 93 0.03 
Q05793 Basement membrane-specific heparan 
sulfate proteoglycan core protein  
PGBM_MOUSE 151 0.02 
 
 
 
